Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
38 "Alcohol"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Original Articles
Trends in Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Survey in Korea
Junhyun Kwon, Hanbit Shin, Dae Ho Lee, Eunji Kim
Received July 24, 2025  Accepted October 15, 2025  Published online December 24, 2025  
DOI: https://doi.org/10.3803/EnM.2025.2578    [Epub ahead of print]
  • 659 View
  • 26 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The global burden of metabolic dysfunction-associated steatotic liver disease (MASLD), which is associated with higher risks of obesity, type 2 diabetes mellitus, cardiovascular disease, chronic kidney disease, and extrahepatic cancer, is increasing. This study aimed to examine the temporal trends in MASLD prevalence among Korean adults, with a focus on age-stratified patterns and related health conditions.
Methods
This secondary analysis of Korea National Health and Nutrition Examination Survey data included data of 90,912 adults aged ≥19 years from 2007 to 2023. MASLD was defined as having the presence of at least one cardiometabolic risk factor and no heavy alcohol consumption. Temporal trends in MASLD prevalence and associated cardiometabolic risk factors were examined across age groups using weighted prevalence estimates and log-linear regression models.
Results
The overall prevalence of MASLD increased from 25.0% in 2007–2009 to 31.0% in 2022–2023 (annual percent change [APC], 1.36%). The most substantial increase was observed in young adults aged 19–44 years (22.3% to 30.5%; APC=2.09%), particularly among men. Middle-aged (45–64 years) and older (≥65 years) adults showed relatively stable or modest increases over time. Among young adults with MASLD, chronic kidney disease prevalence increased from 2.1% to 5.7%.
Conclusion
This nationwide study revealed a significant and continuous increase in MASLD prevalence among Korean adults, particularly in younger age groups. The disproportionate burden in these populations, along with high rates of metabolic comorbidities, underscores an emerging public health concern that may place considerable strain on future healthcare systems.
Close layer
Diabetes, obesity and metabolism
Big Data Articles (National Health Insurance Service Database)
Associations of Alcohol Consumption with All-Cause and Cancer Mortalities in Patients with Type 2 Diabetes Mellitus: A Nationwide Population Cohort Study
Da Yeon Lee, Sun-Joon Moon, Kyung-Do Han, Ji-Hee Ko, Han-na Jang, Hye-Mi Kwon, Se-Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinol Metab. 2025;40(6):893-903.   Published online July 14, 2025
DOI: https://doi.org/10.3803/EnM.2024.2275
  • 2,855 View
  • 78 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
To investigate the impact of alcohol consumption on all-cause and cancer mortalities in patients with type 2 diabetes (T2D).
Methods
This nationwide cohort study included Korean patients with T2D aged >20 years from a national health exams cohort (2009 to 2012). Participants were categorized based on alcohol consumption: non, mild (<30 g/day), and heavy drinkers (≥30 g/day). Primary outcomes were all-cause and cancer mortality rates. Cox proportional hazard regression analyses were used to calculate adjusted hazard ratios (aHRs) with a 95% confidence interval (CI) with adjustments for age, sex, body mass index, smoking, exercise, comorbidities, diabetes duration, and medications.
Results
Among 2,642,359 participants (median follow-up, 7.8 years), 57.2%, 32.7%, and 10.1% were non, mild, and heavy drinkers, respectively. Compared to non-drinkers, mild alcohol consumption was associated with reduced all-cause mortality (aHR, 0.81; 95% CI, 0.80 to 0.82) and cancer mortality (aHR, 0.88; 95% CI, 0.86 to 0.89), while heavy drinking increased both all-cause (aHR, 1.06; 95% CI, 1.04 to 1.07) and cancer mortalities (aHR, 1.09; 95% CI, 1.06 to 1.11). Subgroup analyses revealed variations: in chronic kidney disease and older age groups, heavy drinkers showed lower risk of all-cause mortality compared to non-drinkers. Regarding cancer mortality, younger and middle-aged groups showed protective effects of alcohol even for heavy drinkers, while females showed linear association between alcohol consumption and cancer mortality.
Conclusion
This study indicates a J-shaped relationship between alcohol consumption and all-cause and cancer mortality risk in patients with T2D, with variations across subgroups. These findings suggest the need for personalized recommendations considering individual risk factors.

Citations

Citations to this article as recorded by  
  • Alcohol and the endocrine system: A critical review of disruptions, potential mechanisms, and health implications
    Patricia E. Molina, Liz Simon
    Alcohol, Clinical and Experimental Research.2026;[Epub]     CrossRef
  • High BMI-attributable female-specific cancers: a comprehensive analysis of the global disease burden and trends from 1990 to 2021 and projections to 2040
    Guangming Sun, Junmei Tang, Hao Chen, Yue Zhu, Pan Ren, Hanyue Gan, Wenbin Wu
    Frontiers in Oncology.2025;[Epub]     CrossRef
Close layer
Diabetes, obesity and metabolism
Fatty Liver Index Dynamics as a Predictor of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus and Non-Cirrhotic Livers
Eun-Hee Cho, Min Gu Kang, Chang Hun Lee, Shinyoung Oh, Chen Shen, Ha Ram Oh, Young Ran Park, Hyun Lee, Jong Seung Kim, Ji Hyun Park
Endocrinol Metab. 2025;40(6):883-892.   Published online May 29, 2025
DOI: https://doi.org/10.3803/EnM.2024.2286
  • 2,528 View
  • 107 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Type 2 diabetes mellitus (T2DM) is a significant risk factor for hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease; however, surveillance strategies for patients with T2DM, especially without cirrhosis, are inadequate. This study examined whether the fatty liver index (FLI) and its dynamic changes can effectively identify patients with T2DM at increased risk for HCC.
Methods
Data from 92,761 individuals with T2DM aged 40 to 79 who underwent two health screenings (2012 to 2015) were analyzed. The FLI, calculated using waist circumference, body mass index, triglycerides, and gamma-glutamyl transferase, was used to stratify patients by baseline FLI and FLI changes between screenings. HCC cases were identified via International Classification of Diseases codes and reimbursement records (2016 to 2020).
Results
Patients with baseline FLI of 30 to 59.9 had a 1.90-fold higher risk (P<0.01) and those with FLI ≥60 had a 2.94-fold higher risk (P<0.01) of developing HCC compared to those with FLI <30. An increase in FLI from <30 to ≥30 resulted in a 2.10-fold higher risk of HCC (P<0.01), while a reduction in FLI from ≥30 to <30 led to a 0.64-fold lower risk (P=0.03). Protective benefits of FLI reduction took approximately 3 years to manifest.
Conclusion
Baseline and dynamic monitoring of FLI effectively identified HCC risk in T2DM patients with non-cirrhotic livers, supporting early detection and intervention.
Close layer
Diabetes, obesity and metabolism
Sodium-Glucose Cotransporter-2 Inhibitor Enhances Hepatic Gluconeogenesis and Reduces Lipid Accumulation via AMPK-SIRT1 Activation and Autophagy Induction
Si Woo Lee, Hyunki Park, Minyoung Lee, Hyangkyu Lee, Eun Seok Kang
Endocrinol Metab. 2025;40(4):583-597.   Published online May 12, 2025
DOI: https://doi.org/10.3803/EnM.2024.2223
  • 3,591 View
  • 127 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Sodium-glucose cotransporter type 2 (SGLT2) inhibitors, such as dapagliflozin, are primarily used to lower glucose in type 2 diabetes. Recent studies suggest broader metabolic effects, particularly in the liver. This study explores the molecular mechanisms by which dapagliflozin influences hepatic glucose and lipid metabolism, hypothesizing that it activates the 5’-adenosine monophosphate-activated protein kinase (AMPK)-sirtuin 1 (Sirt1) pathway to promote gluconeogenesis and reduce lipid accumulation via autophagy.
Methods
HepG2 hepatocellular carcinoma cells were treated with dapagliflozin, and Western blotting, quantitative reverse transcription polymerase chain reaction, and fluorescence microscopy were used to assess gluconeogenic enzyme expression and autophagy. In vivo, mice with liver-specific autophagy related 7 (Atg7) deletion and those on a high-fat diet were used to evaluate glucose regulation, lipid metabolism, and autophagy.
Results
Dapagliflozin significantly increased expression of gluconeogenic enzymes like phosphoenolpyruvate carboxykinase (PEPCK) in HepG2 cells and enhanced autophagic flux, evidenced by increased light chain 3B (LC3B)-II levels and autophagosome formation. AMPK-Sirt1 activation was confirmed as the underlying mechanism. Additionally, dapagliflozin reduced fatty acid synthesis by suppressing enzymes such as acetyl-CoA carboxylase and fatty acid synthase, while promoting fatty acid degradation via carnitine palmitoyltransferase 1α (CPT1α) upregulation. In high-fat diet mice, dapagliflozin increased hepatic gluconeogenesis and reduced lipid accumulation, though serum cholesterol and triglyceride levels were unaffected.
Conclusion
Dapagliflozin enhances hepatic gluconeogenesis and reduces steatosis by activating the AMPK-Sirt1 pathway and promoting autophagy. These findings suggest that SGLT2 inhibitors could offer therapeutic benefits for managing hepatic lipid disorders, beyond glycemic control.

Citations

Citations to this article as recorded by  
  • Association of SGLT2 inhibitors use with a lower risk of biliary diseases in patients with type 2 diabetes mellitus: a retrospective cohort study
    Ming Gao, Qiuyu Lin, Kaiyue Hu, Bei Zhong, Tingyi Zhu, Zheng Gong, Kaini Zhang, Xiaoli Chen, Xinyu Chen, Ying Zhang, Yangyang Li, Shaowen Tang, Dongming Su, Xiubin Liang, Yu Liu
    Annals of Medicine.2026;[Epub]     CrossRef
  • Redefining SGLT2 inhibitors through cytoprotective mechanisms
    Sanja Stankovic, Zoran Miloradovic, Vladimir Petrovic, Milan Stoiljkovic
    European Journal of Pharmacology.2026; 1016: 178647.     CrossRef
  • Mechanism of swertiamarin and novel nitrogen-containing metabolites (R)-Gentiandiol and (S)-Gentiandiol in treating non-alcoholic fatty liver disease in rats: an untargeted metabolomics study based on UPLC-Q-TOF/MS
    Yidan Sun, Fuyan Cui, Shuhan Tang, Pengyu Li, Yaqi Xu, Hao Li, Yige Wang, Xintong Li, Minyue Zhang, Rong Ma, Xianna Li, Hongying Xu, Ying Wang, Hailong Zhang, Zhigang Wang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • The Emerging Therapeutic Promise of SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Wenjing Zhang, Huaidong Hu
    Digestive Diseases and Sciences.2025;[Epub]     CrossRef
  • SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration
    Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh
    Endocrinology and Metabolism.2025; 40(6): 851.     CrossRef
Close layer
Brief Report
Diabetes, obesity and metabolism
Characteristics of Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Risk for Hepatic Fibrosis in 476,124 Korean Adults: A Cross-Sectional Study
Da Yeon Lee, Ji-Hee Ko, Han-Na Jang, Sun Joon Moon, Hye-Mi Kwon, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Eun-Jung Rhee
Endocrinol Metab. 2025;40(4):648-652.   Published online March 27, 2025
DOI: https://doi.org/10.3803/EnM.2024.2281
  • 2,585 View
  • 83 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
As the new terminology of metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) has emerged, the clinical significance of MASLD is increasing. This cross-sectional study analyzed 476,124 health checkup participants (2002–2022) to compare hepatic fibrosis risks across MASLD, MetALD, non-alcoholic fatty liver disease (NAFLD), and metabolic dysfunction-associated fatty liver disease (MAFLD). Steatotic liver was identified via ultrasonography, and fibrosis risk was assessed using aspartate aminotransferase to platelet ratio index and NAFLD fibrosis score. The prevalence of NAFLD, MAFLD, MASLD, and MetALD was 30.1%, 32.3%, 29.8%, and 3.0%, respectively, with a 27.9% overlap among three conditions. Participants with steatotic liver were predominantly male, with higher glucose, lipids, liver enzymes, and homeostasis model assessment of insulin resistance levels. Three disease definitions largely overlapped, with MASLD and NAFLD being very similar, while participants with MAFLD and MetALD showed increased fibrosis risk (clinical trial registration number: 2024-11-050).

Citations

Citations to this article as recorded by  
  • Associations between steatotic liver disease subtypes and incident diabetes in young Korean adults: A nationwide cohort study
    Goh Eun Chung, Su Jong Yu, Jeayeon Park, Yoon Jun Kim, Jung‐Hwan Yoon, Kyungdo Han, Eun Ju Cho
    Diabetes, Obesity and Metabolism.2026; 28(3): 1947.     CrossRef
  • Epidemiology and characteristics of obesity in Koreans based on the 2024 Obesity Fact Sheet
    Eun-Jung Rhee
    Journal of the Korean Medical Association.2026; 69(1): 4.     CrossRef
  • Using an integrative multi-omics and in vitro approach to investigate the role of tris(2-butoxyethyl) phosphate in promoting hepatic steatosis
    Gang Zhou, Xihan Gu, Xinyao Zhou, Shuai Chen, Hanyang Liu, Jing Wang
    BMJ Open Gastroenterology.2026; 13(1): e002123.     CrossRef
Close layer
Review Article
Mineral, Bone & Muscle
Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia
Nobuaki Ito, Naoko Hidaka, Hajime Kato
Endocrinol Metab. 2024;39(2):255-261.   Published online March 11, 2024
DOI: https://doi.org/10.3803/EnM.2023.1908
  • 8,932 View
  • 262 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   ePub   
Fibroblast growth factor 23 (FGF23) is a pivotal humoral factor for the regulation of serum phosphate levels and was first identified in patients with autosomal dominant hypophosphatemic rickets and tumor-induced osteomalacia (TIO), the most common form of acquired FGF23-related hypophosphatemic rickets/osteomalacia (FGF23rHR). After the identification of FGF23, many other inherited and acquired forms of FGF23rHR were reported. In this review article, the detailed features of each acquired FGF23rHR are discussed, including TIO, ectopic FGF23 syndrome with malignancy, fibrous dysplasia/McCune-Albright syndrome, Schimmelpenning-Feuerstein-Mims syndrome/cutaneous skeletal hypophosphatemia syndrome, intravenous iron preparation-induced FGF23rHR, alcohol consumption-induced FGF23rHR, and post-kidney transplantation hypophosphatemia. Then, an approach for the differential diagnosis and therapeutic options for each disorder are concisely introduced. Currently, the majority of endocrinologists might only consider TIO when encountering patients with acquired FGF23rHR; an adequate differential diagnosis can reduce medical costs and invasive procedures such as positron emission tomography/computed tomography and venous sampling to identify FGF23-producing tumors. Furthermore, some acquired FGF23rHRs, such as intravenous iron preparation/alcohol consumption-induced FGF23rHR, require only cessation of drugs or alcohol to achieve full recovery from osteomalacia.

Citations

Citations to this article as recorded by  
  • Surgical management strategies and clinical outcomes of cutaneous skeletal hypophosphatemia syndrome: a case series
    Yi Qiao, Jin Dai, Ting Zhuang, Yicong Liu, Xiuzhi Ren
    Frontiers in Pediatrics.2026;[Epub]     CrossRef
  • Paraneoplastic endocrine syndromes: a contemporary overview
    Juan Eduardo Quiroz-Aldave, Jacsel Suarez-Rojas, Elman Rolando Gamarra-Osorio, Katia Rivera-Fabián, María Del Carmen Durand-Vásquez, Luis Alberto Concepción-Urteaga, José Paz-Ibarra, Marcio José Concepción-Zavaleta
    Expert Review of Endocrinology & Metabolism.2025; 20(1): 51.     CrossRef
  • Excess fibroblast growth factor 23 in alcoholic osteomalacia is derived from the bone
    Naoko Hidaka, Yuko Oyama, Minae Koga, Naoki Kondo, Yoichi Yasunaga, Taketoshi Shimakura, Noriaki Yamamoto, Hideaki E Takahashi, Yoichi Iwafuchi, So Watanabe, Soichiro Kimura, Yoshitomo Hoshino, Hajime Kato, Yuka Kinoshita, Hiroshi Kobayashi, Takeyuki Tana
    JBMR Plus.2025;[Epub]     CrossRef
  • X-linked hypophosphatemia and tumor-induced osteomalacia: a narrative review and expert opinion on the diagnostic and therapeutic challenges in the era of burosumab
    Maria Luisa Brandi, Cristina Eller Vainicher, Danilo Fintini, Andrea Giusti, Andrea Magnolato, Salvatore Minisola, Sandro Giannini
    Orphanet Journal of Rare Diseases.2025;[Epub]     CrossRef
  • Acquired hypophosphatemic osteomalacia: case series from a Peruvian referral center (1999–2023)
    José Paz-Ibarra, Sofía Sáenz-Bustamante, Manuel Inostroza-Fernández, Paola Sifuentes Hermenegildo, Liliana Ancajima Lescano, Marcio Concepción-Zavaleta, Alejandro Román-González, Alfredo Adolfo Reza-Albarrán
    Archives of Osteoporosis.2024;[Epub]     CrossRef
Close layer
Brief Report
Diabetes, obesity and metabolism
Performance of Simple Fibrosis Score in Non-Alcoholic Fatty Liver Disease with and without Type 2 Diabetes
Seung Min Chung, Min Kyu Kang, Jun Sung Moon, Jung Gil Park
Endocrinol Metab. 2023;38(2):277-281.   Published online March 13, 2023
DOI: https://doi.org/10.3803/EnM.2022.1635
  • 6,574 View
  • 146 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
This cross-sectional study enrolled 267 patients with metabolic risk factors and established non-alcoholic fatty liver disease in the prospective cohort. The performance of fibrosis-4 (FIB-4) score (≥1.3) to diagnose advanced fibrosis using transient elastography (liver stiffness measurement [LSM] ≥8 kPa) was analyzed. Comparing patients with type 2 diabetes (T2D, n=87) and without (n=180), not FIB-4, but LSM was significantly higher in T2D (P=0.026). The prevalence of advanced fibrosis was 17.2% in T2D and 12.8% in non-T2D. FIB-4 exhibited higher proportion of false negatives in T2D patients (10.9%) than those without (5.2%). The diagnostic performance of FIB-4 was suboptimal in T2D (area under curve [AUC], 0.653; 95% confidence interval [CI], 0.462 to 0.844) compared to that in non-T2D (AUC, 0.826; 95% CI, 0.724 to 0.927). In conclusion, patients with T2D might be beneficial to conduct transient elastography without screening to avoid missing advanced fibrosis.

Citations

Citations to this article as recorded by  
  • Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
    Xiaolong Qi, Jie Li, Cyrielle Caussy, Gao-Jun Teng, Rohit Loomba
    Hepatology.2026; 83(3): 661.     CrossRef
  • Hepatorenal vulnerability flagged by glomerular hyperfiltration in metabolic liver disease: a large health-screening cohort evidence
    Dae-Jeong Koo, Yun Tae Kim, Sun-Joon Moon, Hyemi Kwon, Se Eun Park, Sang Min Lee, Cheol-Young Park, Won-Young Lee, Sung Rae Cho, Eun-Jung Rhee
    Diabetology & Metabolic Syndrome.2026;[Epub]     CrossRef
  • The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease
    Rong Ren, Yanxia Pei, Lufei Kong, Yixin Shi
    Journal of Diabetes and its Complications.2025; 39(2): 108932.     CrossRef
  • Metabolic-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes: Mechanisms, Diagnostic Approaches, and Therapeutic Interventions
    Anastasia Ntikoudi, Anastasia Papachristou, Afroditi Tsalkitzi, Nikoletta Margari, Eleni Evangelou, Eugenia Vlachou
    Diabetology.2025; 6(4): 23.     CrossRef
  • DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus population
    Chuan Liu, Jie Shen, Jie Li, Zhihui Li, Ming-Hua Zheng, Hua Bian, Xiqiao Zhou, Wenjing Ni, Zhongji Meng, Jiaojian Lv, Yijun Tang, Xuan Liang, Min Li, Taolong Zhou, Heng Wan, Yuping Chen, Yuxia Qi, Yuli Ge, Yan Wang, Wen-Yue Liu, Mingxing Huang, Shanghao L
    Med.2025; 6(8): 100700.     CrossRef
  • Multiple Definitions of Fatty Liver Disease: Which One Most Accurately Predicts Diabetes?
    Eun-Jung Rhee
    Endocrinology and Metabolism.2024; 39(2): 397.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Prevalence of High and Moderate Risk of Liver Fibrosis Among Patients With Diabetes at a Noncommunicable Diseases (NCD) Clinic in a Primary Healthcare Center in Northern India
    Anubhav Mondal, Aninda Debnath, Ghurumourthy Dhandapani, Abhishek Sharma, Shveta Lukhmana, Geeta Yadav
    Cureus.2023;[Epub]     CrossRef
Close layer
Original Articles
Diabetes, Obesity and Metabolism
Big Data Articles (National Health Insurance Service Database)
Association among Current Smoking, Alcohol Consumption, Regular Exercise, and Lower Extremity Amputation in Patients with Diabetic Foot: Nationwide Population-Based Study
Yoon Jae Lee, Kyung-Do Han, Jun Hyeok Kim
Endocrinol Metab. 2022;37(5):770-780.   Published online October 12, 2022
DOI: https://doi.org/10.3803/EnM.2022.1519
  • 9,533 View
  • 263 Download
  • 13 Web of Science
  • 14 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
The present study investigates whether modifiable behavioral factors of current cigarette smoking, heavy alcohol consumption, and regular exercise are associated with risk of lower extremity amputation (LEA) in diabetic patients.
Methods
A total of 2,644,440 diabetic patients (aged ≥20 years) was analyzed using the database of the Korean National Health Insurance Service. Cox proportional hazard regression was used to assess adjusted hazard ratios (HRs) for the behavioral factors with risk of LEA under adjustment for potential confounders.
Results
The risk of LEA was significantly increased by current cigarette smoking and heavy alcohol consumption (HR, 1.436; 95% confidence interval [CI], 1.367 to 1.508 and HR, 1.082; 95% CI, 1.011 to 1.158) but significantly decreased with regular exercise (HR, 0.745; 95% CI, 0.706 to 0.786) after adjusting for age, sex, smoking, alcohol consumption, exercise, low income, hypertension, dyslipidemia, body mass index, using insulin or oral antidiabetic drugs, and diabetic duration. A synergistically increased risk of LEA was observed with larger number of risky behaviors.
Conclusion
Modification of behaviors of current smoking, heavy alcohol intake, and exercise prevents LEA and can improve physical, emotional, and social quality of life in diabetic patients.

Citations

Citations to this article as recorded by  
  • Fatores associados à amputação de membros inferiores em pacientes diabéticos: uma abordagem epidemiológica
    Edimar Chaves Junior, Ana Clara Paulino Queiroz, Arthur Felipe Vieira Bastos, Isadora Borges Toledo, Jessica Coelho Costa, Julien Barbosa, Lilian Nunes de Assis Lacerda, Marcos Bruno Couto Garcia, Maria Eduarda Avelina Bontempo, Maria Eduarda Mendes Reis,
    Caderno Pedagógico.2025; 22(1): e13493.     CrossRef
  • Are There Sex Differences in the Association of Alcohol Consumption With the Risk of Soft Tissue Sarcoma? A Nationwide Population-based Study in Korea
    Min Wook Joo, Kyungdo Han, Yoon Joo Cho, Nicholas Matthew Bernthal, Ye Bin Park
    Clinical Orthopaedics & Related Research.2025; 483(9): 1583.     CrossRef
  • Knowledge, attitudes, and practices among patients with diabetic foot ulcers towards disease management
    Liangxiao Xie, Changshun Wei, Liqun Chen, Huaqiang Zheng, Jiajia Dong, Jinzhi Wu
    Scientific Reports.2025;[Epub]     CrossRef
  • Diabetes‐Associated Major Limb Amputation in Solomon Islands: A National, 5‐Year Retrospective Study
    Dylan M. Bush, Adrian Garcia Hernandez, Anita Pickard, Thomas H. Fitzpatrick, Rooney Jagilly, Micky Olangi, Michael Buin, Johanna Roth, Hendrick Kaniki, Jones Ghabu, Tony Quity, Alexandra L. Martiniuk
    World Journal of Surgery.2025; 49(8): 2266.     CrossRef
  • The Severity of Diabetes and the Risk of Diabetic Foot Amputation: A National Cohort Study
    Jin Yu, Ji-Hyun Kim, Bongseong Kim, Kyungdo Han, Seung Hwan Lee, Mee Kyoung Kim
    Endocrinology and Metabolism.2025; 40(4): 574.     CrossRef
  • Nationwide study of income-based disparities in diabetic limb preservation in South Korea
    Yoon Jae Lee, Kyung-Do Han, Jun Hyeok Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Adjuvant effect of antimicrobial photodynamic therapy (aPDT) in the treatment of diabetic foot ulcers: A case series
    Rita de Cassia Ferreira, Rebeca Boltes Cecatto, Silvana Torres Perez, Raquel Agnelli Mesquita‐Ferrari, Sandra Kalil Bussadori, Cinthya Cosme Duran, Anna Carolina Tempestini Horliana, Kristianne Porta Santos Fernandes
    Journal of Biophotonics.2024;[Epub]     CrossRef
  • Factors associated with diabetic foot ulcers and lower limb amputations in type 1 and type 2 diabetes supported by real‐world data from the German/Austrian DPV registry
    Alexander J. Eckert, Stefan Zimny, Marcus Altmeier, Ana Dugic, Anton Gillessen, Latife Bozkurt, Gabriele Götz, Wolfram Karges, Frank J. Wosch, Stephan Kress, Reinhard W. Holl
    Journal of Diabetes.2024;[Epub]     CrossRef
  • Patients with diabetic foot ulcers: A qualitative study of patient knowledge, experience, and encountered obstacles
    Vahide Semerci Çakmak, Serap Çetinkaya Özdemir
    Journal of Tissue Viability.2024; 33(4): 571.     CrossRef
  • A randomized controlled trial of an app-based intervention on physical activity and glycemic control in people with type 2 diabetes
    Gyuri Kim, Seohyun Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
    BMC Medicine.2024;[Epub]     CrossRef
  • Influence of quitting smoking on diabetes-related complications: A scoping review with a systematic search strategy
    Magdalena Walicka, Arkadiusz Krysiński, Giusy Rita Maria La Rosa, Ang Sun, Davide Campagna, Agostino Di Ciaula, Tabinda Dugal, Andre Kengne, Phuong Le Dinh, Anoop Misra, Riccardo Polosa, Syed Abbas Raza, Cristina Russo, Roberta Sammut, Noel Somasundaram
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(5): 103044.     CrossRef
  • Visceral Adiposity as an Independent Risk Factor for Diabetic Peripheral Neuropathy in Type 2 Diabetes Mellitus: A Retrospective Study
    Rui-Ling Wu, Niyao Chen, Yanni Chen, Xiaohong Wu, Chih-Yuan Ko, Xiao-Yu Chen, Takayuki Masaki
    Journal of Diabetes Research.2024;[Epub]     CrossRef
  • Age Characteristics of Patients With Type 2 Diabetic Foot Ulcers and Predictive Risk Factors for Lower Limb Amputation: A Population‐Based Retrospective Study
    Yuanying Yao, Lei Chen, Yu Qian, Munmun Chattopadhyay
    Journal of Diabetes Research.2024;[Epub]     CrossRef
  • Investigating Diabetic Foot Pathophysiology and Amputation Prevention Strategies through Behavioral Modification
    Jun Hyeok Kim
    Journal of Wound Management and Research.2023; 19(3): 167.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018
Ji Cheol Bae, Lauren A. Beste, Kristina M. Utzschneider
Endocrinol Metab. 2022;37(3):455-465.   Published online June 21, 2022
DOI: https://doi.org/10.3803/EnM.2022.1434
  • 9,785 View
  • 175 Download
  • 19 Web of Science
  • 20 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We aimed to investigate the association of hepatic steatosis with liver fibrosis and to assess the interactive effects of hepatic steatosis and insulin resistance on liver fibrosis in a nationally representative sample of United States adults.
Methods
We conducted a cross-sectional analysis using data from National Health and Nutrition Examination Survey 2017 to 2018, which for the first time included transient elastography to assess liver stiffness and hepatic steatosis. We evaluated the association between hepatic steatosis (using controlled attenuation parameter [CAP]) and clinically significant liver fibrosis (defined as liver stiffness ≥7.5 kPa) using logistic regression with an interaction term for hepatic steatosis and insulin resistance (defined as homeostatic model assessment of insulin resistance ≥3.0).
Results
Among adults undergoing transient elastography (n=2,023), 45.9% had moderate or greater hepatic steatosis and 11.3% had clinically significant liver fibrosis. After adjustment for demographic and metabolic factors, the odds of significant liver fibrosis increased as CAP score rose (odds ratio, 1.35 per standard deviation increment; 95% confidence interval, 1.11 to 1.64). We detected a significant interaction effect between CAP score and insulin resistance on the probability of significant liver fibrosis (P=0.016 for interaction). The probability of significant liver fibrosis increased in the presence of insulin resistance with increasing CAP score, while those without insulin resistance had low probability of significant liver fibrosis, even with high CAP scores.
Conclusion
Individuals with hepatic steatosis had higher odds of fibrosis when insulin resistance was present. Our findings emphasize the importance of the metabolic aspects of the disease on fibrosis risk and suggest a need to better identify patients with metabolic associated fatty liver disease.

Citations

Citations to this article as recorded by  
  • Growth Differentiation Factor 15 (GDF-15) as a modulator of hepatic steatosis and fibrosis: insights from a 6-year retrospective cohort study
    Nicole Anna Dietzel, Maria Schmidt, Johannes Wiegand, Thomas Berg, Ronald Biemann, Ronny Baber, Michael Kluge, Kerstin Wirkner, Dirk Alexander Wittekind
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Appendicular skeletal muscle mass is associated with metabolic dysfunction-associated steatotic liver disease severity in young men: a cross-sectional and longitudinal study
    Jaejun Lee, Jinson So, Chang In Han, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Do Seon Song
    Hepatology International.2025; 19(1): 181.     CrossRef
  • Association between the triglyceride-glucose index and liver fibrosis in adults with metabolism-related fatty liver disease in the United States: a cross-sectional study of NHANES 2017–2020
    Yuou Ying, Yuan Ji, Ruyi Ju, Jinhan Chen, Mingxian Chen
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • The Value of TyG‐Related Indices in Evaluating MASLD and Significant Liver Fibrosis in MASLD
    Haoxuan Zou, Jiejie Xie, Xiaopu Ma, Yan Xie, Xingshun Qi
    Canadian Journal of Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
    Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
    Cells.2025; 14(6): 428.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease: The Role of Hepatic Steatosis in Insulin Resistance and Metabolic Health
    Ji Cheol Bae
    Endocrinology and Metabolism.2025; 40(2): 304.     CrossRef
  • NMR‐Based Metabolomics Reveals Metabolic Pathway Disruptions and Potential Biomarkers for Fibrosis
    Shreya Pandey, Deeksha Marwari, Jiya Mishra, Amit Goel, Ajay Kumar Mishra, Neeraj Sinha
    Magnetic Resonance in Chemistry.2025; 63(10): 836.     CrossRef
  • Association of insulin resistance indicators with hepatic steatosis and fibrosis in patients with metabolic syndrome
    Tzu-chia Kuo, Yang-bor Lu, Chieh-lun Yang, Bin Wang, Lin-xin Chen, Ching-ping Su
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • No More NAFLD: The Term Is Now MASLD
    Ji Cheol Bae
    Endocrinology and Metabolism.2024; 39(1): 92.     CrossRef
  • Insulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver Fibrosis
    Mohammad E. Khamseh, Mojtaba Malek, Soodeh Jahangiri, Sohrab Nobarani, Azita Hekmatdoost, Marieh Salavatizadeh, Samira Soltanieh, Haleh Chehrehgosha, Hoda Taheri, Zeinab Montazeri, Fereshteh Attaran, Faramarz Ismail-Beigi, Fariba Alaei-Shahmiri
    Digestive Diseases and Sciences.2024; 69(4): 1430.     CrossRef
  • The association of Neuromedin U levels and non-alcoholic fatty liver disease: A comparative analysis
    Murat Keskin, Sercan Avul, Aylin Beyaz, Nizameddin Koca
    Heliyon.2024; 10(5): e27291.     CrossRef
  • Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial
    Yuval Ishay, Joel Neutel, Yotam Kolben, Ram Gelman, Orly Sneh Arbib, Oliver Lopez, Helena Katchman, Rizwana Mohseni, Miriam Kidron, Yaron Ilan
    Gastro Hep Advances.2024; 3(3): 417.     CrossRef
  • Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease
    Mehwish Qamar, Abeer Fatima, Ambreen Tauseef, Muhammad I Yousufzai, Ibrahim Liaqat, Qanbar Naqvi
    Cureus.2024;[Epub]     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping
    Shahid Habib
    World Journal of Gastrointestinal Pathophysiology.2024;[Epub]     CrossRef
  • Greater Severity of Steatosis Is Associated with a Higher Risk of Incident Diabetes: A Retrospective Longitudinal Study
    Ji Min Han, Jung Hwan Cho, Hye In Kim, Sunghwan Suh, Yu-Ji Lee, Jung Won Lee, Kwang Min Kim, Ji Cheol Bae
    Endocrinology and Metabolism.2023; 38(4): 418.     CrossRef
  • Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis
    Byeong Chang Sim, Yea Eun Kang, Sun Kyoung You, Seong Eun Lee, Ha Thi Nga, Ho Yeop Lee, Thi Linh Nguyen, Ji Sun Moon, Jingwen Tian, Hyo Ju Jang, Jeong Eun Lee, Hyon-Seung Yi
    Cell Death & Disease.2023;[Epub]     CrossRef
  • Familial clustering of nonalcoholic fatty liver disease in first‐degree relatives of adults with lean nonalcoholic fatty liver disease
    Sorachat Niltwat, Chanin Limwongse, Natthinee Charatcharoenwitthaya, Duangkamon Bunditvorapoom, Wimolrak Bandidniyamanon, Phunchai Charatcharoenwitthaya
    Liver International.2023; 43(12): 2713.     CrossRef
  • Metabolic Score for Insulin Resistance Is Inversely Related to Incident Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
    Jun-Hyuk Lee, Yu-Jin Kwon, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Nutrients.2022; 14(15): 3039.     CrossRef
  • DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
    Ji Cheol Bae
    Endocrinology and Metabolism.2022; 37(6): 858.     CrossRef
Close layer
Review Article
Diabetes, Obesity and Metabolism
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Yongin Cho, Yong-ho Lee
Endocrinol Metab. 2022;37(1):38-52.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.102
  • 9,578 View
  • 316 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   ePub   
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, and non-alcoholic steatohepatitis (NASH), a subtype of NAFLD, can progress to cirrhosis, hepatocellular carcinoma, and death. Nevertheless, the current treatment for NAFLD/NASH is limited to lifestyle modifications, and no drugs are currently officially approved as treatments for NASH. Many global pharmaceutical companies are pursuing the development of medications for the treatment of NASH, and results from phase 2 and 3 clinical trials have been published in recent years. Here, we review data from these recent clinical trials and reports on the efficacy of newly developed antidiabetic drugs in NASH treatment.

Citations

Citations to this article as recorded by  
  • Impact of physical activities in metabolic dysfunction associated steatotic liver disease, sarcopenia, and cardiovascular disease
    Eugene Han, Sin Yung Woo, Justin Y. Jeon, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee, Yong-ho Lee
    Diabetes Research and Clinical Practice.2025; 224: 112209.     CrossRef
  • Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMJ.2024; 384: e076388.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Soyeon Shin, Jaeyoung Kim, Ju Yeon Lee, Jun Kim, Chang-Myung Oh
    Journal of Obesity & Metabolic Syndrome.2023; 32(4): 289.     CrossRef
  • Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study
    Jinyoung Kim, Kyungdo Han, Bongsung Kim, Ki-Hyun Baek, Ki-Ho Song, Mee Kyoung Kim, Hyuk-Sang Kwon
    Diabetes Research and Clinical Practice.2022; 194: 110187.     CrossRef
Close layer
Original Articles
Diabetes, Obesity and Metabolism
Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinol Metab. 2022;37(1):74-83.   Published online February 9, 2022
DOI: https://doi.org/10.3803/EnM.2021.1293
  • 9,750 View
  • 289 Download
  • 14 Web of Science
  • 16 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Dulaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), has been shown to reduce body weight and liver fat content in patients with type 2 diabetes. Family with sequence similarity 3 member A (FAM3A) plays a vital role in regulating glucose and lipid metabolism. The aim of this study was to determine the mechanisms by which dulaglutide protects against hepatic steatosis in HepG2 cells treated with palmitic acid (PA).
Methods
HepG2 cells were pretreated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM dulaglutide for 24 hours. Hepatic lipid accumulation was determined using Oil red O staining and triglyceride (TG) assay, and the expression of lipid metabolism-associated factor was analyzed using quantitative real time polymerase chain reaction and Western blotting.
Results
Dulaglutide significantly decreased hepatic lipid accumulation and reduced the expression of genes associated with lipid droplet binding proteins, de novo lipogenesis, and TG synthesis in PA-treated HepG2 cells. Dulaglutide also increased the expression of proteins associated with lipolysis and fatty acid oxidation and FAM3A in PA-treated cells. However, exendin-(9-39), a GLP-1R antagonist, reversed the expression of FAM3A, and fatty acid oxidation-associated factors increased due to dulaglutide. In addition, inhibition of FAM3A by siRNA attenuated the reducing effect of dulaglutide on TG content and its increasing effect on regulation of fatty acid oxidation.
Conclusion
These results suggest that dulaglutide could be used therapeutically for improving nonalcoholic fatty liver disease, and its effect could be mediated in part via upregulation of FAM3A expression through a GLP-1R-dependent pathway.

Citations

Citations to this article as recorded by  
  • Effect of Submaximal-Dose Semaglutide on MASLD Biopsy-Free Scoring Systems in Patients with Obesity
    Boris Focko, Martin Jozef Péč, Zuzana Miertová, Jakub Jurica, Andrej Miert, Lucia Kubíková, Peter Tudík, Norbert Nagy, Patrik Lecký, Ivana Ságová, Tomáš Bolek, Daniel Ján Havaj, Ľubomír Skladaný, Marián Mokáň, Matej Samoš
    Livers.2026; 6(1): 3.     CrossRef
  • Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research
    Xinyi Lu, Li Yang
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes
    Brandon Havranek, Rebecca Loh, Beatriz Torre, Rachel Redfield, Dina Halegoua-DeMarzio
    Scientific Reports.2025;[Epub]     CrossRef
  • Therapeutic effects and mechanisms of Xinmaitong formula for type 2 diabetes mellitus via GLP-1R signaling
    Weidong Pu, Yang Pan, Kang Yang, Jian Gao, Fen Tian, Jingrui Song, Yubing Huang, Yanmei Li
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Glucagon-like peptide-1 receptor agonists improve cholesterol metabolism by inhibiting SREBP-2 via SIRT6-AMPK pathway in HepG2 cells treated with palmitic acid
    Jinmi Lee, Eun-Jung Rhee, Yu-Mi Lim, Seok-Woo Hong, Won-Young Lee
    Cardiovascular Prevention and Pharmacotherapy.2025; 7(3): 61.     CrossRef
  • Tirzepatide and Obesity: A Narrative Review
    Arya Singh, Rahnuma Ahmad, Kona Chowdhury, Mahendra Narwaria, Mainul Haque
    Advances in Human Biology.2025;[Epub]     CrossRef
  • GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD
    Haoran Jiang, Linquan Zang
    Current Pharmaceutical Design.2024; 30(2): 100.     CrossRef
  • Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
    Tong Bu, Ziyan Sun, Yi Pan, Xia Deng, Guoyue Yuan
    Diabetes & Metabolism Journal.2024; 48(3): 354.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
    Salvatore Corrao, Chiara Pollicino, Dalila Maggio, Alessandra Torres, Christiano Argano
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study
    Toshitaka Sawamura, Ren Mizoguchi, Ai Ohmori, Mitsuhiro Kometani, Takashi Yoneda, Shigehiro Karashima
    Journal of Diabetes & Metabolic Disorders.2024; 23(2): 2105.     CrossRef
  • FABP1 induces lipogenesis by regulating the processing of SREBP1 in hepatocytes of large yellow croaker (Larimichthys crocea)
    Fan Chen, Tingting Hao, Qiang Chen, Yuning Sun, Yanan Shen, Zengqi Zhao, Jianlong Du, Yueru Li, Kangsen Mai, Qinghui Ai
    The FASEB Journal.2024;[Epub]     CrossRef
  • GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
    Riccardo Nevola, Raffaella Epifani, Simona Imbriani, Giovanni Tortorella, Concetta Aprea, Raffaele Galiero, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso
    International Journal of Molecular Sciences.2023; 24(2): 1703.     CrossRef
  • FAM3A mediates the phenotypic switch of human aortic smooth muscle cells stimulated with oxidised low-density lipoprotein by influencing the PI3K-AKT pathway
    Lei Yang, Baoshun Du, Shitao Zhang, Maode Wang
    In Vitro Cellular & Developmental Biology - Animal.2023; 59(6): 431.     CrossRef
  • ATP Secretion and Metabolism in Regulating Pancreatic Beta Cell Functions and Hepatic Glycolipid Metabolism
    Jing Li, Han Yan, Rui Xiang, Weili Yang, Jingjing Ye, Ruili Yin, Jichun Yang, Yujing Chi
    Frontiers in Physiology.2022;[Epub]     CrossRef
  • Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
    Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang
    Signal Transduction and Targeted Therapy.2022;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE−/−FXR−/− Mice
Yenna Lee, Bo-Rahm Kim, Geun-Hyung Kang, Gwan Jae Lee, Young Joo Park, Haeryoung Kim, Hak Chul Jang, Sung Hee Choi
Endocrinol Metab. 2021;36(6):1243-1253.   Published online December 28, 2021
DOI: https://doi.org/10.3803/EnM.2021.1100
  • 11,162 View
  • 189 Download
  • 29 Web of Science
  • 31 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Farnesoid X receptor (FXR), a bile acid–activated nuclear receptor, is a potent regulator of glucose and lipid metabolism as well as of bile acid metabolism. Previous studies have demonstrated that FXR deficiency is associated with metabolic derangements, including atherosclerosis and nonalcoholic fatty liver disease (NAFLD), but its mechanism remains unclear. In this study, we investigated the role of FXR in atherosclerosis and NAFLD and the effect of peroxisome proliferator-activated receptor (PPAR) agonists in mouse models with FXR deficiency.
Methods
En face lipid accumulation analysis, liver histology, serum levels of glucose and lipids, and mRNA expression of genes related to lipid metabolism were compared between apolipoprotein E (ApoE)−/− and ApoE−/−FXR−/− mice. The effects of PPARα and PPARγ agonists were also compared in both groups of mice.
Results
Compared with ApoE−/− mice, ApoE−/−FXR−/− mice showed more severe atherosclerosis, hepatic steatosis, and higher levels of serum cholesterol, low-density lipoprotein cholesterol, and triglycerides, accompanied by increased mRNA expression of FAS, ApoC2, TNFα, IL-6 (liver), ATGL, TGH, HSL, and MGL (adipocytes), and decreased mRNA expressions of CPT2 (liver) and Tfam (skeletal muscle). Treatment with a PPARα agonist, but not with a PPARγ agonist, partly reversed atherosclerosis and hepatic steatosis, and decreased plasma triglyceride levels in the ApoE−/−FXR−/− mice, in association with increased mRNA expression of CD36 and FATP and decreased expression of ApoC2 and ApoC3 (liver).
Conclusion
Loss of FXR is associated with aggravation of atherosclerosis and hepatic steatosis in ApoE-deficient mice, which could be reversed by a PPARα agonist through induction of fatty acid uptake, β-oxidation, and triglyceride hydrolysis.

Citations

Citations to this article as recorded by  
  • Evaluation of the causal effects of PFOS on atherosclerosis and its potential toxicological mechanisms: Integrated Mendelian randomization and network toxicology analysis
    Cong Yan, Ning Fang, Yongtai Gong
    Ecotoxicology and Environmental Safety.2026; 309: 119618.     CrossRef
  • PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPARα expression
    Yuan feng Cui, Xiao cui Chen, Tuoluonayi Mijiti, Abidan Abudurusuli, Li hui Deng, Xiang Ma, Bangdang Chen
    Scientific Reports.2025;[Epub]     CrossRef
  • Calycosin improves atherosclerosis by reshaping the interaction between the gut microbiome and bile acid metabolism
    Jiaqi Fu, Donghua Yu, Yuqin Liang, Xin Gao, Yunhe Shi, Yu Wang, Pingping Chen, Fang Lu, Shumin Liu
    Food Science and Human Wellness.2025; 14(4): 9250085.     CrossRef
  • Restoring FXR expression as a novel treatment strategy in liver cancer and other liver disorders
    Sosmitha Girisa, Babu Santha Aswani, Mukesh Kumar Manickasamy, Mangala Hegde, Mohammed S. Alqahtani, Mohamed Abbas, Gautam Sethi, Ajaikumar B. Kunnumakkara
    Expert Opinion on Therapeutic Targets.2025; 29(4-5): 193.     CrossRef
  • Targeted drug delivery systems for atherosclerosis
    Liangxing Tu, Zijian Zou, Ye Yang, Siying Wang, Banghuai Xing, Jianfang Feng, Yi Jin, Meng Cheng
    Journal of Nanobiotechnology.2025;[Epub]     CrossRef
  • Interplay of the pathophysiological mechanisms of non-alcoholic fatty liver disease, diabetes mellitus, and inflammation: A growing threat to public health
    Sharon Olabisoye Oladipupo, Emmanuel Henry Ezenabor, Adebola Busola Ojo, Akingbolabo Daniel Ogunlakin, Oluwafemi Adeleke Ojo
    Obesity Medicine.2025; 55: 100613.     CrossRef
  • Farnesoid X receptor‑driven metabolic plasticity: Bridging physiological adaptation and malignant transformation in lipid handling (Review)
    Yanning Sun, Kai Sun, Hongju Ling, Qinghua Xia
    International Journal of Molecular Medicine.2025; 56(1): 1.     CrossRef
  • Advances of exosome regulating‑FXR to repair inflammatory bowel disease (Review)
    Peter Muro, Caihong Jing, Yaru Qiao, Wenbing Wang, Bo Wang, Fei Mao
    International Journal of Molecular Medicine.2025; 56(3): 1.     CrossRef
  • Impact of smoking and physical activity on cardiovascular outcomes in type 2 diabetes across steatotic liver disease categories
    So Hyun Cho, Gyuri Kim, Kyu-na Lee, Rosa Oh, Ji Yoon Kim, Myunghwa Jang, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Kyungdo Han, Jae Hyeon Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Exercise in atherosclerosis: its beneficial effects and underlying mechanism
    Meng-ting Yin, Liang Guo
    Frontiers in Cell and Developmental Biology.2025;[Epub]     CrossRef
  • Investigating the Effects of Curcumin on Lipid Metabolism and Cell Viability in HepG2 Cells: Potential Therapeutic Implications for Nonalcoholic Fatty Liver Disease
    Faeze Qaleban, Javad Mohammadnejad, Amin Daemi, Gülüzar Özbolat, Yusuf Döğüş
    Drug Development Research.2025;[Epub]     CrossRef
  • Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions
    Mohammed A. Abdel-Rasol, Wael M. El-Sayed
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Effect of 3-hydroxyisobutyrate in vivo administration on cardiometabolic disease in ApoE-/- mouse model
    Viviana Casagrande, Luca Panarello, Alessio Lepri, Andrea Quatrana, Chiara Internò, Lorenzo Antonetti, Elena Bonanno, Ilaria Cicalini, Damiana Pieragostino, Andrea Gorgels, Vincenzo De Laurenzi, Claudia Goettsch, Marina Cardellini, Massimo Federici, Rosse
    Pharmacological Research.2025; 220: 107943.     CrossRef
  • Zhuriheng pills improve adipose tissue dysfunction and inflammation by modulating PPARγ to stabilize atherosclerotic plaques
    Qiong Zhai, Fangyuan Liang, Guanlin Yang, Zhimin Liu, Xin Dong, Ren Bu, Peifeng Xue, Shengsang Na, Xuan Zhang, Pengwei Zhao, Xiaoning Wang, Qiang Wei, Yuewu Wang, Jingkun Lu
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Analysis of the Correlation Between Cuproptosis and Instability of Atherosclerotic Plaques
    Muheremu Muhetaer, Tianwen He, Haoyan Zhu, Jiahe Wu, Jingjing Wan, Tong Zhang, Yushuang Hu, Zhibing Lu, Huanhuan Cai
    Biomedicines.2025; 13(12): 2983.     CrossRef
  • Evaluation of the hepatotoxicity of Psoralea corylifolia L. based on a zebrafish model
    Shu-Yan Gao, Jing-Cheng Zhao, Qing Xia, Chen Sun, Maimaiti Aili, Ainiwaer Talifu, Shi-Xia Huo, Yun Zhang, Zhi-Jian Li
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
    Yuxiao Jiang, Lili Wu, Xiaopeng Zhu, Hua Bian, Xin Gao, Mingfeng Xia
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease
    Milton Boaheng Antwi, Ariann Jennings, Sander Lefere, Dorien Clarisse, Anja Geerts, Lindsey Devisscher, Karolien De Bosscher
    npj Metabolic Health and Disease.2024;[Epub]     CrossRef
  • Monomethyl Branched‐Chain Fatty Acids Suppress M1 Macrophage Polarization via FABP4/PPAR‐γ Signaling Pathway
    Yuan He, Yu Zhang, Shuang Zhu, Yuan‐fa Liu, Sha Liu, Yong‐jiang Xu
    Molecular Nutrition & Food Research.2024;[Epub]     CrossRef
  • COL6A6 Peptide Vaccine Alleviates Atherosclerosis through Inducing Immune Response and Regulating Lipid Metabolism in Apoe−/− Mice
    Dongmei Tang, Yan Liu, Rui Duan, Run Lin, Zhonghao Li, Xianyan Liu, Jingrong Huang, Ming Zhao
    Cells.2024; 13(18): 1589.     CrossRef
  • Mitochondrial carnitine palmitoyltransferase-II dysfunction: A possible novel mechanism for nonalcoholic fatty liver disease in hepatocarcinogenesis
    Min Yao, Ping Zhou, Yan-Yan Qin, Li Wang, Deng-Fu Yao
    World Journal of Gastroenterology.2023; 29(12): 1765.     CrossRef
  • Emerging Roles of Gut Microbial Modulation of Bile Acid Composition in the Etiology of Cardiovascular Diseases
    Tess Yntema, Debby P. Y. Koonen, Folkert Kuipers
    Nutrients.2023; 15(8): 1850.     CrossRef
  • The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
    Alexandra C. Finney, Sandeep Das, Dhananjay Kumar, M. Peyton McKinney, Bishuang Cai, Arif Yurdagul, Oren Rom
    Frontiers in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • Targeting PPARs for therapy of atherosclerosis: A review
    Miao Miao, Xue Wang, Tian Liu, Yan-Jie Li, Wen-Qian Yu, Tong-Mei Yang, Shou-Dong Guo
    International Journal of Biological Macromolecules.2023; 242: 125008.     CrossRef
  • Cabernet sauvignon dry red wine ameliorates atherosclerosis in mice by regulating inflammation and endothelial function, activating AMPK phosphorylation, and modulating gut microbiota
    Xinlong Cheng, Xue Han, Liangfu Zhou, Yasai Sun, Qian Zhou, Xuan Lin, Zhe Gao, Jie Wang, Wen Zhao
    Food Research International.2023; 169: 112942.     CrossRef
  • Impacts of dietary lipids derived from animal or vegetable sources on healthy rats
    Mostafa M Dalal, Gamal M Edrees, Hanaa A Hassan, Mamdouh Abdel-Mogib, Mai Alaa El-Dein
    Egyptian Journal of Basic and Applied Sciences.2023; 10(1): 618.     CrossRef
  • Whey protein hydrolysate alleviated atherosclerosis and hepatic steatosis by regulating lipid metabolism in apoE-/- mice fed a Western diet
    Kai Wang, Zixin Fu, Xiaoyi Li, Hui Hong, Xin Zhan, Xiaohong Guo, Yongkang Luo, Yuqing Tan
    Food Research International.2022; 157: 111419.     CrossRef
  • Melatonin alleviates PM2.5‐induced glucose metabolism disorder and lipidome alteration by regulating endoplasmic reticulum stress
    Zhou Du, Junjie Hu, Lisen Lin, Qingqing Liang, Mengqi Sun, Zhiwei Sun, Junchao Duan
    Journal of Pineal Research.2022;[Epub]     CrossRef
  • Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
    Joon Ho Moon, Kyuho Kim, Sung Hee Choi
    Endocrinology and Metabolism.2022; 37(4): 575.     CrossRef
  • The role of the gut microbiota in health and cardiovascular diseases
    Lu Wang, Shiqi Wang, Qing Zhang, Chengqi He, Chenying Fu, Quan Wei
    Molecular Biomedicine.2022;[Epub]     CrossRef
Close layer
Review Article
Diabetes, Obesity and Metabolism
Serotonergic Regulation of Hepatic Energy Metabolism
Jiwon Park, Wooju Jeong, Chahyeon Yun, Hail Kim, Chang-Myung Oh
Endocrinol Metab. 2021;36(6):1151-1160.   Published online December 16, 2021
DOI: https://doi.org/10.3803/EnM.2021.1331
  • 13,398 View
  • 283 Download
  • 18 Web of Science
  • 18 Crossref
AbstractAbstract PDFPubReader   ePub   
The liver is a vital organ that regulates systemic energy metabolism and many physiological functions. Nonalcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease and end-stage liver failure. NAFLD is primarily caused by metabolic disruption of lipid and glucose homeostasis. Serotonin (5-hydroxytryptamine [5-HT]) is a biogenic amine with several functions in both the central and peripheral systems. 5-HT functions as a neurotransmitter in the brain and a hormone in peripheral tissues to regulate systemic energy homeostasis. Several recent studies have proposed various roles of 5-HT in hepatic metabolism and inflammation using tissue-specific knockout mice and 5-HT-receptor agonists/antagonists. This review compiles the most recent research on the relationship between 5-HT and hepatic metabolism, and the role of 5-HT signaling as a potential therapeutic target in NAFLD.

Citations

Citations to this article as recorded by  
  • The multiorgan crosstalk network of the liver-brain axis: From molecular mechanisms to emerging therapeutic targets
    Wen-Tao Wang, Yuan-Yuan Xin, Jun-Qiang Niu, Wei-Lin Jin
    Molecular Aspects of Medicine.2026; 108: 101460.     CrossRef
  • Repairing effect of total glucosides of Paeonia on deoxynivalenol-induced enterohepatic axis damage in weaned piglets
    Shuaiju Guo, Haiyan Li, Bangwang Peng, Zengxin Lv, Yingxuan Duan, Junlong Niu, Yongpeng Guo, Zhixiang Wang, Wei Zhang
    Ecotoxicology and Environmental Safety.2026; 311: 119876.     CrossRef
  • Perimenopause-induced insulin resistance via 5-HT dysregulation
    Yu Chen, Jingwen Yu, Chao Liu, Kun Wang, Yu Yang
    Clinical Science.2026; 140(3): 397.     CrossRef
  • Role of mitogens in normal and pathological liver regeneration
    Massoud Vosough, Bahare Shokouhian, Mohammad Amin Sharbaf, Roya Solhi, Zahra Heidari, Homeyra Seydi, Moustapha Hassan, Ezhilarasan Devaraj, Mustapha Najimi
    Hepatology Communications.2025;[Epub]     CrossRef
  • Transcriptomic Profiles of Rainbow Trout (Oncorhynchus mykiss) Selectively Bred for High and Low Fillet Yield
    Jamie L. Mankiewicz, Guangtu Gao, Timothy Leeds, Beth M. Cleveland
    Marine Biotechnology.2025;[Epub]     CrossRef
  • 5-Hydroxytryptamine mediated 5-HTR4-ILP axis orchestrates glucose utilization and glycogen storage in the Pacific oyster (Crassostrea gigas)
    Liting Ren, Ben Yang, Mengmeng Xu, Chengjun Zhi, Qi Li, Shikai Liu
    Food Bioscience.2025; 71: 107079.     CrossRef
  • Serotonin (5‐Hydroxytryptamine): Metabolism, Signaling, Biological Functions, Diseases, and Emerging Therapeutic Opportunities
    Yuxin Zhang, Nan Wang, Louqian Zhang, Yan Zhuang, Qilei Xin, Xiaosong Gu, Chunping Jiang, Junhua Wu
    MedComm.2025;[Epub]     CrossRef
  • Association of HTR1F with Prognosis, Tumor Immune Microenvironment, and Drug Sensitivity in Cancer: A Multi-Omics Perspective
    Yanjun Gao, Ziyue Zhang, Dafu Ye, Qingqing Li, Yingmei Wen, Shaowen Ma, Bo Zheng, Lei Chen, Yi Yao
    Biomedicines.2025; 13(9): 2238.     CrossRef
  • Maternal nutrient metabolism in the liver during pregnancy
    Hongxu Fang, Qingyang Li, Haichao Wang, Ying Ren, Leying Zhang, Ling Yang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Neural Stem Cell-based Regenerative Therapy: A New Approach to Diabetes Treatment
    Kajal Sharma, Nidhi Puranik, Dhananjay Yadav
    Endocrine, Metabolic & Immune Disorders - Drug Targets.2024; 24(5): 531.     CrossRef
  • The Influence of BMP6 on Serotonin and Glucose Metabolism
    Marina Milešević, Ivona Matić Jelić, Viktorija Rumenović, Natalia Ivanjko, Slobodan Vukičević, Tatjana Bordukalo-Nikšić
    International Journal of Molecular Sciences.2024; 25(14): 7842.     CrossRef
  • Exploring Endogenous Tryptamines: Overlooked Agents Against Fibrosis in Chronic Disease? A Narrative Review
    Hunter W. Korsmo
    Livers.2024; 4(4): 615.     CrossRef
  • Metabolic and Molecular Response to High-Fat Diet Differs between Rats with Constitutionally High and Low Serotonin Tone
    Petra Baković, Maja Kesić, Darko Kolarić, Jasminka Štefulj, Lipa Čičin-Šain
    International Journal of Molecular Sciences.2023; 24(3): 2169.     CrossRef
  • Roles of gut microbes in metabolic-associated fatty liver disease
    Chun-Yao Chen, Han-Chen Ho
    Tzu Chi Medical Journal.2023;[Epub]     CrossRef
  • Imidazoles as Serotonin Receptor Modulators for Treatment of Depression: Structural Insights and Structure–Activity Relationship Studies
    Kapil Kumar Goel, Somesh Thapliyal, Rajeev Kharb, Gaurav Joshi, Arvind Negi, Bhupinder Kumar
    Pharmaceutics.2023; 15(9): 2208.     CrossRef
  • Serotonin in the regulation of systemic energy metabolism
    Joon Ho Moon, Chang‐Myung Oh, Hail Kim
    Journal of Diabetes Investigation.2022; 13(10): 1639.     CrossRef
  • Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A
    Takashi Owaki, Kenya Kamimura, Masayoshi Ko, Itsuo Nagayama, Takuro Nagoya, Osamu Shibata, Chiyumi Oda, Shinichi Morita, Atsushi Kimura, Takeki Sato, Toru Setsu, Akira Sakamaki, Hiroteru Kamimura, Takeshi Yokoo, Shuji Terai
    Disease Models & Mechanisms.2022;[Epub]     CrossRef
  • Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines
    Anwesha Gangopadhyay, Radwa Ibrahim, Karli Theberge, Meghan May, Karen L. Houseknecht
    Frontiers in Neuroscience.2022;[Epub]     CrossRef
Close layer
Original Articles
Diabetes, Obesity and Metabolism
The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008–2011)
Hyun Min Kim, Yong-ho Lee
Endocrinol Metab. 2021;36(6):1232-1242.   Published online November 23, 2021
DOI: https://doi.org/10.3803/EnM.2021.1087
  • 8,301 View
  • 165 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The prevalence of non-alcoholic fatty liver disease (NAFLD) has rapidly increased worldwide. The aim of this study was to investigate whether there is an independent relationship between regional fat distribution, especially leg fat mass, and the presence of NAFLD using nationally representative data in Korea.
Methods
This cross-sectional study analyzed data from 14,502 participants in the Korea National Health and Nutrition Examination Survey 2008 to 2011. Total fat mass, leg fat mass, and appendicular skeletal muscle mass were measured by dual-energy X-ray absorptiometry. Validated NAFLD prediction models and scoring systems for hepatic fibrosis were used.
Results
The leg fat to total fat (LF/TF) ratio showed a negative relationship with many factors, including body mass index, waist circumference, blood pressure, fasting blood glucose, and liver enzyme levels. When the LF/TF ratio and indices of hepatic steatosis were stratified by quartiles, the LF/TF ratio showed a negative correlation with the scoring systems that were used. The LF/TF ratio showed better accuracy in predicting NAFLD than total fat mass or leg fat mass alone. After adjusting for various traditional and lifestyle factors, a low LF/TF ratio remained a risk factor for NAFLD. Among NAFLD subjects, the LF/TF ratio showed a negative relationship with hepatic fibrosis.
Conclusion
A lower LF/TF ratio was markedly associated with a higher risk of hepatic steatosis and advanced hepatic fibrosis using various predictive models in a Korean population. Therefore, the LF/TF ratio could be a useful anthropometric parameter to predict NAFLD or advanced hepatic fibrosis.

Citations

Citations to this article as recorded by  
  • Low leg fat mass is associated with low insulin sensitivity, inflammatory markers, and β-cell dysfunction in non-obese Japanese people
    Satomi Minato-Inokawa, Mari Honda, Ayaka Tsuboi-Kaji, Mika Takeuchi, Kaori Kitaoka, Miki Kurata, Bin Wu, Tsutomu Kazumi, Keisuke Fukuo
    Scientific Reports.2025;[Epub]     CrossRef
  • Body composition mediates the association between fatty acids and NAFLD risk: a prospective cohort study
    Qishan Yang, Xinming Xu, Yue Chen, Zhicheng Zhang, Berty Ruping Song, Liang Sun, Xiang Gao
    Journal of Health, Population and Nutrition.2025;[Epub]     CrossRef
  • Waistline to thigh circumference ratio as a predictor of MAFLD: a health care worker study with 2-year follow-up
    Xiaoyan Hao, Honghai He, Liyuan Tao, Wei Zhao, Peng Wang
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
    Asieh Mansour, Saeed Pourhassan, Hadis Gerami, Mohammad Reza Mohajeri‐Tehrani, Marziye Salahshour, Ali Abbasi, Elham Madreseh, Sayed Mahmoud Sajjadi‐Jazi
    Obesity Science & Practice.2024;[Epub]     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Adipose tissue insulin resistance index was inversely associated with gluteofemoral fat and skeletal muscle mass in Japanese women
    Satomi Minato-Inokawa, Mari Honda, Ayaka Tsuboi-Kaji, Mika Takeuchi, Kaori Kitaoka, Miki Kurata, Bin Wu, Tsutomu Kazumi, Keisuke Fukuo
    Scientific Reports.2024;[Epub]     CrossRef
  • A greater ratio of thigh subcutaneous fat to abdominal fat is associated with protection against non-alcoholic fatty liver disease
    Yebei Liang, Peizhu Chen, Siyu Chen, Dan Liu, Fusong Jiang, Zhijun Zhu, Keqing Dong, Li Wei, Xuhong Hou
    JHEP Reports.2023; 5(7): 100730.     CrossRef
  • Association between Alcohol Consumption and Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Alcohol Flushing Response in Men: The Korea National Health and Nutrition Examination Survey 2019–2021
    Dae Eon Kang, Si Nae Oh
    Nutrients.2023; 15(18): 3901.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Increased Risk of Nonalcoholic Fatty Liver Disease in Individuals with High Weight Variability
Inha Jung, Dae-Jeong Koo, Mi Yeon Lee, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinol Metab. 2021;36(4):845-854.   Published online August 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.1098
  • 9,774 View
  • 160 Download
  • 12 Web of Science
  • 13 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Weight loss through lifestyle modification is recommended for patients with nonalcoholic fatty liver disease (NAFLD). Recent studies have suggested that repeated loss and gain of weight is associated with worse health outcomes. This study aimed to examine the association between weight variability and the risk of NAFLD in patients without diabetes.
Methods
We examined the health-checkup data of 30,708 participants who had undergone serial examinations between 2010 and 2014. Weight variability was assessed using coefficient of variation and the average successive variability of weight (ASVW), which was defined as the sum of absolute weight changes between successive years over the 5-year period divided by 4. The participants were classified according to the baseline body mass index and weight difference over 4 years.
Results
On dividing the participants into four groups according to ASVW quartile groups, those in the highest quartile showed a significantly increased risk of NAFLD compared to those in the lowest quartile (odds ratio [OR], 1.89; 95% confidence interval [CI], 1.63 to 2.19). Among participants without obesity at baseline, individuals with high ASVW showed increased risk of NAFLD (OR, 1.80; 95% CI, 1.61 to 2.01). Participants with increased weight over 4 years and high ASVW demonstrated higher risk of NAFLD compared to those with stable weight and low ASVW (OR, 4.87; 95% CI, 4.29 to 5.53).
Conclusion
Regardless of participant baseline obesity status, high weight variability was associated with an increased risk of developing NAFLD. Our results suggest that further effort is required to minimize weight fluctuations after achieving a desirable body weight.

Citations

Citations to this article as recorded by  
  • Impact of Change, Fluctuation, or Variability in Weight on the Risk of Nonalcoholic Fatty Liver Disease in General Population: A Systematic Review and Meta‐Analysis
    Dorsa Alijanzadeh, Masoud Noroozi, Negin Rostami, Narges Norouzkhani, Mahdie ShojaeiBaghini, Saeed Zivari Lashkajani, Ali Mirzaei, Maryam Dianati, Maryam Salimi, Hamidreza Sadeghsalehi, Faezeh Jadidian, Sajjad Ghane Ezabadi, Mohammad Sadegh Fallahi, Mobin
    Health Science Reports.2025;[Epub]     CrossRef
  • Changes in Macronutrients during Dieting Lead to Weight Cycling and Metabolic Complications in Mouse Model
    Anouk Charlot, Anthony Bringolf, Léa Debrut, Joris Mallard, Anne-Laure Charles, Emilie Crouchet, Delphine Duteil, Bernard Geny, Joffrey Zoll
    Nutrients.2024; 16(5): 646.     CrossRef
  • Body weight variability and the risk of liver‐related outcomes in type 2 diabetes and steatotic liver disease: a cohort study
    Nathalie C. Leite, Claudia R. L. Cardoso, Cristiane A. Villela‐Nogueira, Gil F. Salles
    Obesity.2024; 32(6): 1210.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • A machine-learned model for predicting weight loss success using weight change features early in treatment
    Farzad Shahabi, Samuel L. Battalio, Angela Fidler Pfammatter, Donald Hedeker, Bonnie Spring, Nabil Alshurafa
    npj Digital Medicine.2024;[Epub]     CrossRef
  • Long-Term Yo-Yo Dieting Exaggerates Liver Steatosis and Lesions but Preserves Muscle Performance in Male Zebrafish
    Tzu-Chieh Hsu, Chun-Hsien Chiang, I-Hsuan Liu, Chih-Yun Wang, Ching-Yi Chen
    International Journal of Molecular Sciences.2024; 25(23): 13225.     CrossRef
  • Weight variability, physical functioning and incident disability in older adults
    Katie J. McMenamin, Tamara B. Harris, Joshua F. Baker
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(4): 1648.     CrossRef
  • Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
    Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
    Endocrinology and Metabolism.2022; 37(1): 74.     CrossRef
  • Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
    Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
    Obesity.2022; 30(6): 1279.     CrossRef
  • Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight
    Mohammed Eslam, Hashem B. El-Serag, Sven Francque, Shiv K. Sarin, Lai Wei, Elisabetta Bugianesi, Jacob George
    Nature Reviews Gastroenterology & Hepatology.2022; 19(10): 638.     CrossRef
  • Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study
    Ángel Arturo López-González, Bárbara Altisench Jané, Luis Masmiquel Comas, Sebastiana Arroyo Bote, Hilda María González San Miguel, José Ignacio Ramírez Manent
    Nutrients.2022; 14(14): 2795.     CrossRef
  • Higher Weight Variability Could Bring You a Fatty Liver
    Yeoree Yang, Jae-Hyoung Cho
    Endocrinology and Metabolism.2021; 36(4): 766.     CrossRef
  • Autonomic Imbalance Increases the Risk for Non-alcoholic Fatty Liver Disease
    Inha Jung, Da Young Lee, Mi Yeon Lee, Hyemi Kwon, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Won-Young Lee, Sung-Woo Park, Se Eun Park
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
Endocrinol Metab. 2021;36(4):823-834.   Published online August 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.1074
  • 9,448 View
  • 167 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. Type 2 diabetes mellitus (T2DM) is a risk factor that accelerates NAFLD progression, leading to fibrosis and cirrhosis. Thus, here we aimed to develop a simple model to predict the presence of NAFLD based on clinical parameters of patients with T2DM.
Methods
A total of 698 patients with T2DM who visited five medical centers were included. NAFLD was evaluated using transient elastography. Univariate logistic regression analyses were performed to identify potential contributors to NAFLD, followed by multivariable logistic regression analyses to create the final prediction model for NAFLD.
Results
Two NAFLD prediction models were developed, with and without serum biomarker use. The non-laboratory model comprised six variables: age, sex, waist circumference, body mass index (BMI), dyslipidemia, and smoking status. For a cutoff value of ≥60, the prediction accuracy was 0.780 (95% confidence interval [CI], 0.743 to 0.817). The second comprehensive model showed an improved discrimination ability of up to 0.815 (95% CI, 0.782 to 0.847) and comprised seven variables: age, sex, waist circumference, BMI, glycated hemoglobin, triglyceride, and alanine aminotransferase to aspartate aminotransferase ratio. Our non-laboratory model showed non-inferiority in the prediction of NAFLD versus previously established models, including serum parameters.
Conclusion
The new models are simple and user-friendly screening methods that can identify individuals with T2DM who are at high-risk for NAFLD. Additional studies are warranted to validate these new models as useful predictive tools for NAFLD in clinical practice.

Citations

Citations to this article as recorded by  
  • An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
    Zhuolin Zhou, Nan Gao, Jiaojiao Liu, Xuerong Ma, Zhijuan Ge, Cheng Ji
    Diabetes, Obesity and Metabolism.2026; 28(1): 122.     CrossRef
  • Prevalence, Sonographic Characteristics, and Metabolic Predictors of Nonalcoholic Fatty Liver Disease in Adults With Type 2 Diabetes in Tanzania
    Zubeir Zubeir, Zuhura Nkrumbih, Salama Ally, Yasser H. Hadi
    Dr. Sulaiman Al Habib Medical Journal.2025; 7(3): 180.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma
    Marcin Kosmalski, Agnieszka Śliwińska, Józef Drzewoski
    Biomedicines.2023; 11(4): 1097.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study
Sung-Woo Kim, Jae-Han Jeon, Jun Sung Moon, Mi Kyung Kim
Endocrinol Metab. 2021;36(4):800-809.   Published online August 20, 2021
DOI: https://doi.org/10.3803/EnM.2021.1040
  • 9,627 View
  • 190 Download
  • 10 Web of Science
  • 7 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Based on recent evidence on the importance of the presence of diabetes mellitus (DM) and fibrosis-4 (FIB-4) index in coronavirus disease 2019 (COVID-19) mortality, we analyzed whether these factors could additively predict such mortality.
Methods
This multicenter observational study included 1,019 adult inpatients admitted to university hospitals in Daegu. The demographic and laboratory findings, mortality, prevalence of severe disease, and duration of quarantine were compared between patients with and without DM and/or a high FIB-4 index. The mortality risk and corresponding hazard ratio (HR) were analyzed using the Kaplan-Meier method and Cox proportional hazard models.
Results
The patients with DM (n=217) exhibited significantly higher FIB-4 index and mortality compared to those without DM. Although DM (HR, 2.66; 95% confidence interval [CI], 1.63 to 4.33) and a high FIB-4 index (HR, 4.20; 95% CI, 2.21 to 7.99) were separately identified as risk factors for COVID-19 mortality, the patients with both DM and high FIB-4 index had a significantly higher mortality (HR, 9.54; 95% CI, 4.11 to 22.15). Higher FIB-4 indices were associated with higher mortality regardless of DM. A high FIB-4 index with DM was more significantly associated with a severe clinical course with mortality (odds ratio, 11.24; 95% CI, 5.90 to 21.41) than a low FIB-4 index without DM, followed by a high FIB-4 index alone and DM alone. The duration of quarantine and hospital stay also tended to be longer in those with both DM and high FIB-4 index.
Conclusion
Both DM and high FIB-4 index are independent and additive risk factors for COVID-19 mortality.

Citations

Citations to this article as recorded by  
  • The clinical features and outcomes of diabetes patients infected with COVID-19: a systematic review and meta-analysis comprising 192,693 patients
    Kai Liu, Shu Liu, Ting-ting Xu, Hong Qiao
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy
    Raffaele Galiero, Giuseppe Loffredo, Vittorio Simeon, Alfredo Caturano, Erica Vetrano, Giulia Medicamento, Maria Alfano, Domenico Beccia, Chiara Brin, Sara Colantuoni, Jessica Di Salvo, Raffaella Epifani, Riccardo Nevola, Raffaele Marfella, Celestino Sard
    PLOS ONE.2024; 19(5): e0296495.     CrossRef
  • COVID-19 and hepatic injury: Diversity and risk assessment
    Fares E M Ali, Mostafa K Abd El-Aziz, Mahmoud M Ali, Osama M Ghogar, Adel G Bakr
    World Journal of Gastroenterology.2023; 29(3): 425.     CrossRef
  • Differential Effects of COVID-19 Hospitalization on the Trajectory of Liver Disease Progression
    Dilara Hatipoğlu, Connor Mulligan, Jeffrey Wang, Juan Peticco, Reid Grinspoon, Sanjay Gadi, Camilla Mills, Jay Luther, Raymond T. Chung
    Gastro Hep Advances.2023; 2(4): 480.     CrossRef
  • Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis
    Gowthami Sai Kogilathota Jagirdhar, Rakhtan K Qasba, Harsha Pattnaik, Kaanthi Rama, Akshat Banga, Shiva Teja Reddy, Anna Carolina Flumignan Bucharles, Rahul Kashyap, Praveen Reddy Elmati, Vikas Bansal, Yatinder Bains, Theodore DaCosta, Salim Surani
    World Journal of Gastroenterology.2023; 29(21): 3362.     CrossRef
  • COVID-19 and Fatty Liver Disorders
    Maria Guarino, Valentina Cossiga, Francesco Cutolo, Maria Attanasio, Raffaele Lieto, Filomena Morisco
    Journal of Clinical Medicine.2023; 12(13): 4316.     CrossRef
  • Prevalence and Prognostic Significance of Liver Fibrosis in Patients With Aneurysmal Subarachnoid Hemorrhage
    Tiangui Li, Peng Wang, Xiao Gong, Weelic Chong, Yang Hai, Chao You, Juan Kang, Fang Fang, Yu Zhang
    Frontiers in Neurology.2022;[Epub]     CrossRef
Close layer
Clinical Study
Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes
Chi-Ho Lee, Wai-Kay Seto, Kelly Ieong, David T.W. Lui, Carol H.Y. Fong, Helen Y. Wan, Wing-Sun Chow, Yu-Cho Woo, Man-Fung Yuen, Karen S.L. Lam
Endocrinol Metab. 2021;36(1):134-145.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.887
  • 8,627 View
  • 158 Download
  • 9 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
In non-alcoholic fatty liver disease (NAFLD), transient elastography (TE) is an accurate non-invasive method to identify patients at risk of advanced fibrosis (AF). We developed a diabetes-specific, non-invasive liver fibrosis score based on TE to facilitate AF risk stratification, especially for use in diabetes clinics where TE is not readily available.
Methods
Seven hundred sixty-six adults with type 2 diabetes and NAFLD were recruited and randomly divided into a training set (n=534) for the development of diabetes fibrosis score (DFS), and a testing set (n=232) for internal validation. DFS identified patients with AF on TE, defined as liver stiffness (LS) ≥9.6 kPa, based on a clinical model comprising significant determinants of LS with the lowest Akaike information criteria. The performance of DFS was compared with conventional liver fibrosis scores (NFS, FIB-4, and APRI), using area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive and negative predictive values (NPV).
Results
DFS comprised body mass index, platelet, aspartate aminotransferase, high-density lipoprotein cholesterol, and albuminuria, five routine measurements in standard diabetes care. Derived low and high DFS cut-offs were 0.1 and 0.3, with 90% sensitivity and 90% specificity, respectively. Both cut-offs provided better NPVs of >90% than conventional fibrosis scores. The AUROC of DFS for AF on TE was also higher (P<0.01) than the conventional fibrosis scores, being 0.85 and 0.81 in the training and testing sets, respectively.
Conclusion
Compared to conventional fibrosis scores, DFS, with a high NPV, more accurately identified diabetes patients at-risk of AF, who need further evaluation by hepatologists.

Citations

Citations to this article as recorded by  
  • Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
    Chi‐Ho Lee, David Tak‐Wai Lui, Lung‐Yi Mak, Carol Ho‐Yi Fong, Kylie Sze‐Wing Chan, Jimmy Ho‐Cheung Mak, Chloe Yu‐Yan Cheung, Wing‐Sun Chow, Yu‐Cho Woo, Man‐Fung Yuen, Wai‐Kay Seto, Karen Siu‐Ling Lam
    Diabetes, Obesity and Metabolism.2025; 27(2): 574.     CrossRef
  • Moving diagnosis of liver fibrosis into the community
    Elisa Pose, Salvatore Piano, Maja Thiele, Núria Fabrellas, Emmanuel A. Tsochatzis, Pere Ginès
    Journal of Hepatology.2025; 83(1): 258.     CrossRef
  • Implementation of a liver health check in people with type 2 diabetes
    Kushala W M Abeysekera, Luca Valenti, Zobair Younossi, John F Dillon, Alina M Allen, Mazen Noureddin, Mary E Rinella, Frank Tacke, Sven Francque, Pere Ginès, Maja Thiele, Philip N Newsome, Indra Neil Guha, Mohammed Eslam, Jörn M Schattenberg, Saleh A Alqa
    The Lancet Gastroenterology & Hepatology.2024; 9(1): 83.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease
    Chi-Ho Lee, David Tak-Wai Lui, Raymond Hang-Wun Li, Michele Mae-Ann Yuen, Carol Ho-Yi Fong, Ambrose Pak-Wah Leung, Justin Chiu-Man Chu, Loey Lung-Yi Mak, Tai-Hing Lam, Jean Woo, Yu-Cho Woo, Aimin Xu, Hung-Fat Tse, Kathryn Choon-Beng Tan, Bernard Man-Yung
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review
    Luca Rinaldi, Chiara Giorgione, Andrea Mormone, Francesca Esposito, Michele Rinaldi, Massimiliano Berretta, Raffaele Marfella, Ciro Romano
    Viruses.2023; 15(8): 1730.     CrossRef
  • Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists?
    Chi-Ho Lee
    Primary Care Diabetes.2022; 16(2): 245.     CrossRef
  • Non‐alcoholic fatty liver disease and type 2 diabetes: An update
    Chi‐H Lee, David TW Lui, Karen SL Lam
    Journal of Diabetes Investigation.2022; 13(6): 930.     CrossRef
  • Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes
    Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
    Biomedicines.2022; 10(10): 2375.     CrossRef
Close layer
Review Article
Obesity and Metabolism
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Dae Ho Lee
Endocrinol Metab. 2020;35(2):243-259.   Published online June 24, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.2.243
  • 17,282 View
  • 342 Download
  • 24 Web of Science
  • 26 Crossref
AbstractAbstract PDFPubReader   ePub   
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver diseases and can progress to advanced fibrosis and end-stage liver disease. Thus, intensive research has been performed to develop noninvasive methods for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Currently, no single noninvasive tool covers all of the stages of pathologies and conditions of NAFLD, and the cost and feasibility of known techniques are also important issues. Blood biomarkers for NAFLD may be useful to select subjects who need ultrasonography (US) screening for NAFLD, and noninvasive tools for assessing fibrosis may be helpful to exclude the probability of significant fibrosis and to predict advanced fibrosis, thus guiding the decision of whether to perform liver biopsy in patients with NAFLD. Among various methods, magnetic resonance-based methods have been shown to perform better than other methods in assessing steatosis as well as in detecting hepatic fibrosis. Many genetic markers are associated with the development and progression of NAFLD. Further well-designed studies are needed to determine which biomarker panels, imaging studies, genetic marker panels, or combinations thereof perform well for diagnosing NAFLD, differentiating NASH and fibrosis, and following-up NAFLD, respectively.

Citations

Citations to this article as recorded by  
  • The value of ultrasonic attenuation parameters and serum indicators on MASLD patients with liver fat degenerationality
    Yan Liu, Wen Kang, Jingya Su, Yin Yang, Kui Li, Juntao Yang
    Journal of Radiation Research and Applied Sciences.2025; 18(3): 101647.     CrossRef
  • Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications
    Xuan Trong Truong, Dae Ho Lee
    Diabetes & Metabolism Journal.2025; 49(5): 964.     CrossRef
  • Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities, and Management of Non-alcoholic Fatty Liver Disorder
    Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin
    Current Drug Therapy.2024; 19(1): 20.     CrossRef
  • Intact ketogenesis predicted reduced risk of moderate-severe metabolic-associated fatty liver disease assessed by liver transient elastography in newly diagnosed type 2 diabetes
    Sejeong Lee, Jaehyun Bae, Seung Up Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,380 adults using serial echocardiography
    Gyuri Kim, Tae Yang Yu, Jae Hwan Jee, Ji Cheol Bae, Mira Kang, Jae Hyeon Kim
    Diabetes & Metabolism.2024; 50(3): 101534.     CrossRef
  • Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Monica A. Tincopa, Rohit Loomba
    Seminars in Liver Disease.2024; 44(03): 287.     CrossRef
  • A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
    Seung Joon Choi, Sungjin Yoon, Kyoung-Kon Kim, Doojin Kim, Hye Eun Lee, Kwang Gi Kim, Seung Kak Shin, Ie Byung Park, Seong Min Kim, Dae Ho Lee
    Diabetes & Metabolism Journal.2024; 48(4): 740.     CrossRef
  • Evaluating the role of IER3+ macrophages in the prognosis of liver fibrosis by bulk and single-cell transcriptional analyses
    Ling Chu, Junbo Zhang, Ruoyu Meng, Quan Zhuang
    iLIVER.2024; 3(4): 100132.     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Monica A Tincopa, Rohit Loomba
    The Lancet Gastroenterology & Hepatology.2023; 8(7): 660.     CrossRef
  • Hepatic Involvement across the Metabolic Syndrome Spectrum: Non-Invasive Assessment and Risk Prediction Using Machine Learning
    Adelaida Solomon, Călin Remus Cipăian, Mihai Octavian Negrea, Adrian Boicean, Romeo Mihaila, Corina Beca, Mirela Livia Popa, Sebastian Mihai Grama, Minodora Teodoru, Bogdan Neamtu
    Journal of Clinical Medicine.2023; 12(17): 5657.     CrossRef
  • Greater Severity of Steatosis Is Associated with a Higher Risk of Incident Diabetes: A Retrospective Longitudinal Study
    Ji Min Han, Jung Hwan Cho, Hye In Kim, Sunghwan Suh, Yu-Ji Lee, Jung Won Lee, Kwang Min Kim, Ji Cheol Bae
    Endocrinology and Metabolism.2023; 38(4): 418.     CrossRef
  • Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease
    Georgiana-Emmanuela Gîlcă-Blanariu, Daniela Simona Budur, Dana Elena Mitrică, Elena Gologan, Oana Timofte, Gheorghe Gh Bălan, Vasile Andrei Olteanu, Gabriela Ștefănescu
    Metabolites.2023; 13(11): 1115.     CrossRef
  • Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis
    Aron Park, Seung Joon Choi, Sungjin Park, Seong Min Kim, Hye Eun Lee, Minjae Joo, Kyoung Kon Kim, Doojin Kim, Dong Hae Chung, Jae Been Im, Jaehun Jung, Seung Kak Shin, Byung-Chul Oh, Cheolsoo Choi, Seungyoon Nam, Dae Ho Lee
    International Journal of Molecular Sciences.2022; 23(9): 5035.     CrossRef
  • Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
    Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
    Obesity.2022; 30(6): 1279.     CrossRef
  • The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018
    Ji Cheol Bae, Lauren A. Beste, Kristina M. Utzschneider
    Endocrinology and Metabolism.2022; 37(3): 455.     CrossRef
  • Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
    Moongi Ji, Yunju Jo, Seung Joon Choi, Seong Min Kim, Kyoung Kon Kim, Byung-Chul Oh, Dongryeol Ryu, Man-Jeong Paik, Dae Ho Lee
    Biomedicines.2022; 10(7): 1669.     CrossRef
  • Evaluation of Liver Changes in Type-2 Diabetes Mellitus Patients using Computed Tomography
    Nayyar Ashfaq, Akash John, Abid Ali, Amina Sharif Bhatti, Hateem Qaiser
    DIET FACTOR (Journal of Nutritional & Food Sciences).2022; : 14.     CrossRef
  • Accuracy of FIB-4 to Detect Elevated Liver Stiffness Measurements in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Referral Centers
    Mauro Viganò, Nicola Pugliese, Federica Cerini, Federica Turati, Vincenzo Cimino, Sofia Ridolfo, Simone Rocchetto, Francesca Foglio, Maria Terrin, Carlo La Vecchia, Maria Grazia Rumi, Alessio Aghemo
    International Journal of Molecular Sciences.2022; 23(20): 12489.     CrossRef
  • MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
    Ying-Xin Xian, Jian-Ping Weng, Fen Xu
    Chinese Medical Journal.2021; 134(1): 8.     CrossRef
  • Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review
    Jenny Lee, Yasaman Vali, Jerome Boursier, Rene Spijker, Quentin M. Anstee, Patrick M. Bossuyt, Mohammad H. Zafarmand
    Liver International.2021; 41(2): 261.     CrossRef
  • Serum syndecan‐4 is associated with nonalcoholic fatty liver disease
    Shu Jing Xia, Li Zhong Tang, Wen Hua Li, Zhao Shan Xu, Li Li Zhang, Feng Gan Cheng, Hong Xia Chen, Zi Hua Wang, Yu Cheng Luo, An Na Dai, Jian Gao Fan
    Journal of Digestive Diseases.2021; 22(9): 536.     CrossRef
  • Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
    Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
    Endocrinology and Metabolism.2021; 36(4): 823.     CrossRef
  • Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
    Suguru Ikeda, Takaaki Sugihara, Takuya Kihara, Yukako Matsuki, Takakazu Nagahara, Tomoaki Takata, Sonoko Kitao, Tsuyoshi Okura, Kazuhiro Yamamoto, Hajime Isomoto
    Diagnostics.2021; 11(12): 2316.     CrossRef
  • Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects
    Hwi Seung Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Chang Hee Jung, Joong-Yeol Park, Hong-Kyu Kim, Woo Je Lee
    Journal of Clinical Medicine.2021; 11(1): 41.     CrossRef
  • The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008–2011)
    Hyun Min Kim, Yong-ho Lee
    Endocrinology and Metabolism.2021; 36(6): 1232.     CrossRef
Close layer
Original Article
Clinical Study
Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis
Chan-Hee Jung, Eun-Jung Rhee, Hyemi Kwon, Yoosoo Chang, Seungho Ryu, Won-Young Lee
Endocrinol Metab. 2020;35(1):165-176.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.165
  • 11,876 View
  • 166 Download
  • 41 Web of Science
  • 46 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

We evaluated the association of visceral-to-subcutaneous fat ratio (VSR) with nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis degree based on noninvasive serum fibrosis markers in the general population with NAFLD.

Methods

This is a cross-sectional study, in 7,465 Korean adults who underwent health screening examinations. NAFLD was defined as fatty liver detected on ultrasonography, and visceral and subcutaneous abdominal fat was measured using computed tomography. We predicted fibrosis based on the fibrosis-4 (FIB-4) score and aspartate aminotransferase-to-platelet ratio index (APRI) and categorized the risk for advanced fibrosis as low, indeterminate, or high.

Results

The multivariable-adjusted prevalence ratios for indeterminate to high risk of advanced fibrosis based on FIB-4, determined by comparing the second, third, and fourth quartiles with the first quartile of VSR, were 3.38 (95% confidence interval [CI], 0.64 to 17.97), 9.41 (95% CI, 1.97 to 45.01), and 19.34 (95% CI, 4.06 to 92.18), respectively. The multivariable-adjusted prevalence ratios for intermediate to high degree of fibrosis according to APRI also increased across VSR quartiles (5.04 [95% CI, 2.65 to 9.59], 7.51 [95% CI, 3.91 to 14.42], and 19.55 [95% CI, 9.97 to 38.34], respectively). High VSR was more strongly associated with the prevalence of NAFLD in nonobese subjects than in obese subjects, and the associations between VSR and intermediate to high probability of advanced fibrosis in NAFLD were stronger in obese subjects than in nonobese subjects.

Conclusion

High VSR values predicted increased NAFLD risk and advanced fibrosis risk with NAFLD, and the predictive value of VSR for indeterminate to high risk of advanced fibrosis was higher in obese subjects than in nonobese subjects.

Citations

Citations to this article as recorded by  
  • Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: a prospective cohort study
    Chung-Yi Yang, Jian-Han Chen, Chung-Yen Chen, Cheng-Yi Kao, Shiu-Feng Huang, Wen-Yu Chang, Hung-Pin Tu, Jee-Fu Huang, Ming-Lung Yu, Chi-Ming Tai
    Surgery for Obesity and Related Diseases.2025; 21(5): 537.     CrossRef
  • The relationship between anthropometric indices and non-alcoholic fatty liver disease in adults: a cross-sectional study
    Mina Radmehr, Reza Homayounfar, Abolghasem Djazayery
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Nomogram for predicting severe abdominal adhesions prior to definitive surgery in patients with anastomotic fistula post-small intestine resection: a cohort study
    Zheng Yao, Weiwei Shang, Fan Yang, Weiliang Tian, Guoping Zhao, Xin Xu, Risheng Zhao MD, Tao Tian, Wuhan Li, Ming Huang, Yunzhao Zhao, Qian Huang
    International Journal of Surgery.2025; 111(2): 2046.     CrossRef
  • Clinical Significance and Therapeutic Approach Concerning Various Abdominal Adipose Tissue Irregularities in End‐Stage Liver Disease
    Qing Liu, Junling Liu, Chao Sun
    Obesity Reviews.2025;[Epub]     CrossRef
  • Pericardial fat pad detected on chest X-ray is closely associated with metabolic dysfunction-associated steatotic liver disease and visceral fat accumulation in patients with type 2 diabetes
    Kentaro Watanabe, Hidenori Nishioka, Masahiro Takubo, Minami Kosuda, Takeshi Yamamotoya, Taro Saigusa, Hisamitsu Ishihara
    Journal of Diabetes and its Complications.2025; 39(10): 109150.     CrossRef
  • Effect of six-week extracorporeal shockwave therapy in combination with aerobic exercise on body composition and serum lipids of obese women
    Hoda M. Fathy, Walaa K.H. Mohammed, Hala M. Hanafy , Hossam Al Din H.K. Salem, Marwa E. Hasanin
    Health, sport, rehabilitation.2025; 11(3): 90.     CrossRef
  • The role of adipose tissue in liver fat accumulation: a sex-specific analysis in an exploratory cross-sectional study
    Jana Hoffmann, Jochen Schmidt, Jens Thiele, Stefan Kwast, Roberto Falz, Timm Denecke, Martin Busse, Hans-Jonas Meyer
    Lipids in Health and Disease.2025;[Epub]     CrossRef
  • Associations between metabolic score for visceral fat and nonalcoholic fatty liver disease (NAFLD) in US adults: A cross-sectional study based on NHANES 2017–2020
    Juan Li, Shenglan Dai
    Medicine.2025; 104(46): e45082.     CrossRef
  • Visceral-to-subcutaneous fat ratio and risk of gallstones in Korean men: an observational study of 4,914 cases
    Hoonsub So, Young-Jee Jeon, Doo-Ho Lim
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Opportunistic Extraction of Quantitative CT Biomarkers: Turning the Incidental Into Prognostic Information
    Mohammad Nazri Md Shah, Raja Rizal Azman, Wai Yee Chan, Kwan Hoong Ng
    Canadian Association of Radiologists Journal.2024; 75(1): 92.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Association between obesity phenotypes and non-alcoholic fatty liver: a large population- based study
    Farid Najafi, Yahya Pasdar, Mehdi Moradi Nazar, Mitra Darbandi
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
    Asieh Mansour, Saeed Pourhassan, Hadis Gerami, Mohammad Reza Mohajeri‐Tehrani, Marziye Salahshour, Ali Abbasi, Elham Madreseh, Sayed Mahmoud Sajjadi‐Jazi
    Obesity Science & Practice.2024;[Epub]     CrossRef
  • Visceral to subcutaneous fat area ratio predicts severe abdominal adhesions in definitive surgery for anastomotic fistula after small intestine resection
    Fan Yang, Weiliang Tian, Shikun Luo, Wuhan Li, Guoping Zhao, Risheng Zhao, Tao Tian, Yunzhao Zhao, Zheng Yao, Qian Huang
    Scientific Reports.2024;[Epub]     CrossRef
  • Obesity. Reasons, features and prospects
    E. A. Bondareva, E. A. Troshina
    Obesity and metabolism.2024; 21(2): 174.     CrossRef
  • Differential association of abdominal, liver, and epicardial adiposity with anthropometry, diabetes, and cardiac remodeling in Asians
    Vivian Lee, Yiying Han, Desiree-Faye Toh, Jennifer A. Bryant, Redha Boubertakh, Thu-Thao Le, Calvin W. L. Chin
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Serum immunoglobulin A levels: Diagnostic utility in alcoholic liver disease and association with liver fibrosis in steatotic liver disease
    Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Kazuyoshi Nagata, Kenichi Sawa, Kazutaka Niiya, Kazuhiko Nakao
    Biomedical Reports.2024;[Epub]     CrossRef
  • Helicobacter pylori Infection Is Not Associated with Nonalcoholic Fatty Liver Disease: A Two-Year Cohort Study
    Huabo Zheng, Tangmeng Guo, Xiaofang Zhao, Kun Wang, Shengshuai Shan, Songpu Xie, Yichen Xu, Chengyun Liu, Weilin Lu
    Digestive Diseases.2024; : 1.     CrossRef
  • Association between Knowledge and Practice of Thermally Abused Cooking Oil, Serum Lipid Profile, Body Composition, and Waist Circumference of Hyperlipidemia Patients Running Title: Usage of Reused Cooking Oil on Health Parameters
    Siow Lean Yi, Divya Vanoh
    Malaysian Journal of Medicine and Health Sciences.2024; 20(4): 79.     CrossRef
  • Association between Knowledge and Practice of Thermally Abused Cooking Oil, Serum Lipid Profile, Body Composition, and Waist Circumference of Hyperlipidemia Patients Running Title: Usage of Reused Cooking Oil on Health Parameters
    Divya Vanoh, Siow Lean Yi
    Malaysian Journal of Medicine and Health Sciences.2024; 20(4): 79.     CrossRef
  • Positive Association Between the Chinese Visceral Adiposity Index and Nonalcoholic Fatty Liver Disease in Lean Adults
    Shuxia Shen, Hangkai Huang, Jinghua Wang, Zexi Tang, Chao Shen, Chengfu Xu
    Digestive Diseases and Sciences.2023; 68(2): 656.     CrossRef
  • Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis
    Wolhwa Song, Sung Hwan Yoo, Jinsun Jang, Su Jung Baik, Byoung Kwon Lee, Hyun Woong Lee, Jong Suk Park
    Gut and Liver.2023; 17(1): 130.     CrossRef
  • Using hyperhomocysteinemia and body composition to predict the risk of non-alcoholic fatty liver disease in healthcare workers
    Xiaoyan Hao, Honghai He, Liyuan Tao, Peng Wang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Visceral and subcutaneous fat, muscle mass, and liver volume as noninvasive predictors of the progress of non-alcoholic fatty liver disease
    Omar M. Mahmoud, Gehad Abd Elaziz Mahmoud, Haisam Atta, Wael A. Abbas, Hanan M. Ahmed, Mohamed A. A. Abozaid
    Egyptian Journal of Radiology and Nuclear Medicine.2023;[Epub]     CrossRef
  • Relationship between metabolic associated fatty liver disease and body fat ratio, visceral fat area, and resting metabolic rate estimated by bioelectrical impedance analysis
    Deng-Hua He, Yong-Zhan Zhang, Liang Xu, Jia-Jia Pei, Ying Zhang, Zhong-Fang Yan
    World Chinese Journal of Digestology.2023; 31(2): 56.     CrossRef
  • Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type 2 diabetes: Insights from Bayesian-network modelling
    T. Waddell, A. Namburete, P. Duckworth, A. Fichera, A. Telford, H. Thomaides-Brears, D. J. Cuthbertson, M. Brady
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Subcutaneous Fat Obesity in a High Body Mass Index Donor Is Not a Contraindication to Living Donor Hepatectomy
    Hirak Pahari, Amey Sonavane, Amruth Raj, Anup Kumar Agrawal, Ambreen Sawant, Deepak Kumar Gupta, Amit Gharat, Vikram Raut, Sorabh Kapoor
    Case Reports in Hepatology.2023; 2023: 1.     CrossRef
  • Comparison of cardiometabolic risk factors between obese and non-obese patients with nonalcoholic fatty liver disease
    Zahra Yari, Danial Fotros, Azita Hekmatdoost
    Scientific Reports.2023;[Epub]     CrossRef
  • Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
    Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
    Clinical and Molecular Hepatology.2023; 29(4): 987.     CrossRef
  • Visceral Adipose Tissue Inflammation and Radiographic Visceral-to-Subcutaneous Adipose Tissue Ratio in Patients with Cirrhosis
    Nghiem B. Ha, Soo-Jin Cho, Yara Mohamad, Dorothea Kent, Grace Jun, Randi Wong, Vivek Swarnakar, Shezhang Lin, Jacquelyn J. Maher, Jennifer C. Lai
    Digestive Diseases and Sciences.2022; 67(7): 3436.     CrossRef
  • The Influence of Obesity and Metabolic Health on Vascular Health
    Eun-Jung Rhee
    Endocrinology and Metabolism.2022; 37(1): 1.     CrossRef
  • The effect of combined exercises on the plasma levels of retinol-binding protein 4 and its relationship with insulin resistance and hepatic fat content in postmenopausal women with nonalcoholic fatty liver disease
    Masoumeh NOROUZPOUR, Sayyed M. MARANDI, Mohsen GHANBARZADEH, Abbasali ZARE MAIVAN
    The Journal of Sports Medicine and Physical Fitness.2022;[Epub]     CrossRef
  • The Perirenal Fat Thickness Was Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Yuxian Yang, Shuting Li, Yuechao Xu, Jing Ke, Dong Zhao
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1505.     CrossRef
  • Visceral adiposity is an independent risk factor for high intra-operative blood loss during living-donor liver transplantation; could preoperative rehabilitation and nutritional therapy mitigate that risk?
    Mahmoud Macshut, Toshimi Kaido, Siyuan Yao, Yosuke Miyachi, Mohamed Sharshar, Sena Iwamura, Masaaki Hirata, Hisaya Shirai, Naoko Kamo, Shintaro Yagi, Shinji Uemoto
    Clinical Nutrition.2021; 40(3): 956.     CrossRef
  • A review of non‐alcoholic fatty liver disease in non‐obese and lean individuals
    Mitra Ahadi, Kasra Molooghi, Negin Masoudifar, Ali Beheshti Namdar, Hassan Vossoughinia, Mohammadreza Farzanehfar
    Journal of Gastroenterology and Hepatology.2021; 36(6): 1497.     CrossRef
  • Quantification of abdominal fat from computed tomography using deep learning and its association with electronic health records in an academic biobank
    Matthew T MacLean, Qasim Jehangir, Marijana Vujkovic, Yi-An Ko, Harold Litt, Arijitt Borthakur, Hersh Sagreiya, Mark Rosen, David A Mankoff, Mitchell D Schnall, Haochang Shou, Julio Chirinos, Scott M Damrauer, Drew A Torigian, Rotonya Carr, Daniel J Rader
    Journal of the American Medical Informatics Association.2021; 28(6): 1178.     CrossRef
  • Hepatic Steatosis in Patients With Single Ventricle and a Fontan Circulation
    David A. Katz, Daniel Peck, Adam M. Lubert, Mathias Possner, Faizeen Zafar, Andrew T. Trout, Joseph J. Palermo, Nadeem Anwar, Jonathan R. Dillman, Adam W. Powell, Stavra A. Xanthakos, Alexander R. Opotowsky, Gruschen Veldtman, Tarek Alsaied
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Superficial vs Deep Subcutaneous Adipose Tissue: Sex-Specific Associations With Hepatic Steatosis and Metabolic Traits
    Tessa Brand, Inge Christina Lamberta van den Munckhof, Marinette van der Graaf, Kiki Schraa, Helena Maria Dekker, Leonardus Antonius Bernardus Joosten, Mihai Gheorghe Netea, Niels Peter Riksen, Jacqueline de Graaf, Joseph Henricus Wilhelmus Rutten
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): e3881.     CrossRef
  • Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study
    Dae-Jeong Koo, Mi Yeon Lee, Inha Jung, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee, Ming-Lung Yu
    PLOS ONE.2021; 16(8): e0255535.     CrossRef
  • Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
    Anne Flint, Grit Andersen, Paul Hockings, Lars Johansson, Anni Morsing, Mads Sundby Palle, Thomas Vogl, Rohit Loomba, Leona Plum‐Mörschel
    Alimentary Pharmacology & Therapeutics.2021; 54(9): 1150.     CrossRef
  • Effects of IL-33 on 3T3-L1 cells and obese mice models induced by a high-fat diet
    Yue Kai, Jingtao Gao, Hu Liu, Yubing Wang, Chenrui Tian, Sheng Guo, Ling He, Min Li, Zhongwei Tian, Xiangfeng Song
    International Immunopharmacology.2021; 101: 108209.     CrossRef
  • Lipid Accumulation Product as an Index for Visceral Obesity and Cardiovascular Risk among a Sample of Obese Egyptian Women
    Nayera E. Hassan, Sahar A. El-Masry, Gamila S. M. El-Saeed, Mohamed S. El Hussieny
    Open Access Macedonian Journal of Medical Sciences.2021; 9(B): 1229.     CrossRef
  • Combined Effects of Dyslipidemia and High Adiposity on the Estimated Glomerular Filtration Rate in a Middle-Aged Chinese Population
    Xichang Wang, Haoyu Wang, Jiashu Li, Xiaotong Gao, Yutong Han, Weiping Teng, Zhongyan Shan, Yaxin Lai
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 4513.     CrossRef
  • Determination of “indeterminate score” measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia
    Yasir Mohammed Khayyat
    World Journal of Hepatology.2021; 13(12): 2150.     CrossRef
  • Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population
    Dariusz Narankiewicz, Josefina Ruiz-Nava, Veronica Buonaiuto, María Isabel Ruiz-Moreno, María Dolores López-Carmona, Luis Miguel Pérez-Belmonte, Ricardo Gómez-Huelgas, María Rosa Bernal-López
    International Journal of Environmental Research and Public Health.2020; 17(10): 3518.     CrossRef
Close layer
Namgok Lecture 2019
Obesity and Metabolism
Impact of Skeletal Muscle Mass on Metabolic Health
Gyuri Kim, Jae Hyeon Kim
Endocrinol Metab. 2020;35(1):1-6.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.1
  • 25,373 View
  • 525 Download
  • 119 Web of Science
  • 120 Crossref
AbstractAbstract PDFPubReader   ePub   

Skeletal muscle is regarded as an endocrine and paracrine organ. Muscle-derived secretory proteins, referred to as myokines, mediate interactions between skeletal muscle mass and other organs such as the liver, adipose tissue, pancreas, bone, and the cardiovascular system. As individuals age, reduced levels of physical activity and sarcopenia (loss of skeletal muscle mass and strength) are associated with physical frailty and disability. Recently, several studies have suggested that the loss of skeletal muscle mass may contribute to metabolic disease. Therefore, herein, we focus on the relationships between skeletal muscle mass and metabolic diseases, including metabolic syndrome and non-alcoholic fatty liver disease.

Citations

Citations to this article as recorded by  
  • Muscle strength changes and physical activity during gender‐affirming hormone therapy: A systematic review
    Mathilde Kamp Nørlund, Louise Lehmann Christensen, Marianne Skovsager Andersen, Tine Taulbjerg Kristensen, Jan Frystyk, Jonas Mathiesen, Jakob Lindberg Nielsen, Dorte Glintborg
    Andrology.2026; 14(1): 303.     CrossRef
  • Prognostic significance of nutritional and muscular indices in immune checkpoint inhibitor therapy for metastatic urothelial carcinoma: A preliminary study
    Satoshi Yamamoto, Keita Higa, Koichiro Kurokawa, Hiroki Bamba, Sanji Kanaoka, Kazuyoshi Nakamura
    Nutrition.2026; 143: 113028.     CrossRef
  • Effects of exercise-based prehabilitation programs on sleep in patients with cancer undergoing surgery: a systematic review and meta-analysis
    Manuel Fernandez-Escabias, Benito Miron, Marta Flor-Alemany, Sofia Carrilho-Candeias, Andrea Orellana-Jaen, Rodrigo Fernandez-Escabias, Maria Tomas-Garcia, José Juan Jiménez-Moleón, Almudena Carneiro-Barrera, Francisco J. Amaro-Gahete
    European Journal of Surgical Oncology.2026; 52(2): 111314.     CrossRef
  • Body mass index and a body shape index: Individual and interactive predictors of all-cause and cardiovascular mortality risk in depression
    Shuwu Wei, Mingjun Xu, Xinyu Pan, Yao Xiao, Junping Wei
    Psychiatry Research.2026; 356: 116907.     CrossRef
  • Big bones mean big muscles: an MRI-based dataset of muscle-bone-body size relationships across 70 human muscles of the upper limb, trunk, and lower limb
    Lara Riem, Megan Pinette, Olivia DuCharme, Valeria Pabon, Jacob Morris, Ashley Coggins, Liza Harold, Kathryn Eve Costanzo, Matthew Cousins, Raina Hein, Matt Rhodes, Eline Lievens, Rajvi Shah, Xue Feng, Savannah Benusa, Tim Breeding, Michael D. Nelson, Wim
    Journal of Applied Physiology.2026; 140(1): 1.     CrossRef
  • Association Between Body Composition and Risk of Primary Open-Angle Glaucoma
    Jianqi Chen, Yue Xiao, Xiaohong Chen, Yingting Zhu, Zhidong Li, Shitong Huang, Hanyang Yu, Yehong Zhuo, Yunxia Leng
    American Journal of Ophthalmology.2026; 283: 256.     CrossRef
  • Impact of time‐restricted feeding on metabolic health and adipose tissue metabolism in aged female mice with high‐fat diet‐induced obesity
    Theresa Bushman, Hongming Su, Xiaoli Chen
    The Journal of Physiology.2026; 604(3): 1137.     CrossRef
  • In Vitro Study on the Effects of Rhododendron mucronulatum Branch Extract, Taxifolin-3-O-Arabinopyranoside and Taxifolin on Muscle Loss and Muscle Atrophy in C2C12 Murine Skeletal Muscle Cells
    Hyun Seo Lee, Hyeon Du Jang, Tae Hee Kim, Da Hyeon An, Ye Eun Kwon, Eun Ji Kim, Jae In Jung, Sangil Min, Hee Kyu Kim, Kwang-Hyun Park, Heesung Woo, Sun Eun Choi
    International Journal of Molecular Sciences.2026; 27(2): 570.     CrossRef
  • Polygenic risk score for lower limb skeletal muscle mass and its interaction with protein and vitamin D intake in older adults
    Meiling Liu, Sunmin Park
    Nutrition.2026; 145: 113100.     CrossRef
  • The Effects of Gamified Virtual Reality on Muscle Strength and Physical Function in the Oldest Old—A Pilot Study on Sarcopenia-Related Functional Outcomes
    Żaneta Grzywacz, Justyna Jaśniewicz, Anna Koziarska, Joanna Macierzyńska, Edyta Majorczyk
    Journal of Clinical Medicine.2026; 15(2): 621.     CrossRef
  • Metabolomic fingerprinting of soft tissues uncovers taxonomic, physiological, and ecological aspects of river fishes
    Benjamin Marie, Pierre Foucault, Sébastien Duperron, Catherine Quiblier
    Fish Physiology and Biochemistry.2026;[Epub]     CrossRef
  • Opposing effects of Gα12 and Gα13 loss on myotube size regulation via mTORC1 signaling
    Mai Kubota, Shuhei Fujita, Ryohei Kamata, Kazuma Tamura, Keiichiro Sugimoto, Tomoya Kitakaze, Naoki Harada, Ryoichi Yamaji
    Biochemical and Biophysical Research Communications.2026; 802: 153326.     CrossRef
  • Administration of Humulus scandens extract ameliorates cisplatin-induced muscle atrophy by attenuating inflammatory and oxidative stress responses in mice
    Shi Qi Xu, Wenchao Gong, Jing Li, Wenjie Qin, Yanming Yu, Dong-Hwa Chung, De Xin Dang
    Advances in Traditional Medicine.2026;[Epub]     CrossRef
  • Resistance training for the prevention and management of sarcopenia in older adults: Mechanisms, efficacy, and future applications
    Lan Lu, Caini Liu, Wei Wei
    Experimental Gerontology.2026; 216: 113085.     CrossRef
  • Dietary Calcium-to-Phosphorous Ratio, Metabolic Risk Factors and Lipid Accumulation Product, Skeletal Muscle Mass, and Visceral Fat Area Among Healthy Young Individuals
    Xuanshang Jin, Xiangchuan Jin, Wen Guan, Maolin Tang
    International Journal of Sport Nutrition and Exercise Metabolism.2025; 35(1): 43.     CrossRef
  • Risk factors for metabolic syndrome are associated with low handgrip strength in people with HIV
    Izabella Bernardes Araujo, Camila Ferreira Silva, Eduardo Vignoto Fernandes, Morganna Alves Siqueira, Marília Brasil Xavier, Luiz Fernando Gouvêa-e-Silva
    Sport Sciences for Health.2025; 21(1): 465.     CrossRef
  • Changes in muscle performance among older adults with myeloid malignancies engaging in a mobile health (mHealth) exercise intervention: a single arm pilot study
    Marielle Jensen-Battaglia, Po-Ju Lin, Chandrika Sanapala, Erin E. Watson, Jason H. Mendler, Jane Liesveld, Ying Wang, Elisabeth Hayward, Marissa LoCastro, Soroush Mortaz, Richard F. Dunne, Karen Mustian, Kah Poh Loh
    BMC Geriatrics.2025;[Epub]     CrossRef
  • The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
    Alan J. Sinclair, Ahmed H. Abdelhafiz
    Metabolites.2025; 15(1): 49.     CrossRef
  • Effects of 12-month physical and cognitive training on sarcopenia determinants in older adults: a subgroup analysis of a randomised clinical trial
    Onni Oskari Hämäläinen, Tiina Marketta Savikangas, Anna-Katriina Tirkkonen, Markku Juhani Alén, Arto Jorma Hautala, Sarianna Sipilä
    Aging Clinical and Experimental Research.2025;[Epub]     CrossRef
  • Preliminary Evidence Suggests That a 12-Week Treatment with Tirzepatide Plus Low-Energy Ketogenic Therapy Is More Effective than Its Combination with a Low-Calorie Diet in Preserving Fat-Free Mass, Muscle Strength, and Resting Metabolic Rate in Patients w
    Luigi Schiavo, Biagio Santella, Monica Mingo, Gianluca Rossetti, Marcello Orio, Luigi Cobellis, Attilio Maurano, Antonio Iannelli, Vincenzo Pilone
    Nutrients.2025; 17(7): 1216.     CrossRef
  • Effects of protein supplementation on muscle mass, muscle strength, and physical performance in older adults with physical inactivity: a systematic review and meta-analysis
    Liying Zhang, Gongxiang Liu, Xiaoli Huang, Fuqian He
    BMC Geriatrics.2025;[Epub]     CrossRef
  • Growth hormone–deficient Ames dwarf mice resist sarcopenia and exhibit enhanced endurance running performance at 24 months
    Matthew J. Johnston, Sharlene G. Rakoczy, LaDora V. Thompson, Holly M. Brown-Borg
    GeroScience.2025; 47(3): 4827.     CrossRef
  • Effects of a Combination of Morus bombycis Koidz. and Angelica keiskei Extracts on Muscle Atrophy in an Aging Mouse Model
    Hyun Hwangbo, Min Yeong Kim, Seon Yeong Ji, Da Hye Kim, Jae Hyun Yoon, Seong Un Jeong, Tae Hee Kim, Yung Hyun Choi
    Journal of the Korean Society of Food Science and Nutrition.2025; 54(3): 218.     CrossRef
  • Association between the skeletal muscle-to-visceral fat ratio and kidney stones: a cross-sectional study
    Yuan-Zhuo Du, Jia-Qing Yang, Jian Tang, Chi-Teng Zhang, Yi-Fu Liu
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Relationship between bmi and glomerular filtration rate in a large cohort initiating a weight loss program: differential contributions of fat mass, fat-free mass, and abdominal fat compartments
    Alessandro Leone, Francesca Menichetti, Laila Vignati, Federica Sileo, Ramona De Amicis, Andrea Foppiani, Simona Bertoli, Alberto Battezzati
    Nutrition Journal.2025;[Epub]     CrossRef
  • Sarcopenic obesity in the Asia-Pacific region: Epidemiology, risk factors, and management
    Chun-Feng Huang, Chih-Hsing Wu
    Osteoporosis and Sarcopenia.2025; 11(2): 40.     CrossRef
  • The relationship between cognitive function and muscle mass in older adults: a longitudinal study based on CLHLS
    Yin Shi, Yu Zhang, Xinyu Yang, Jiali Yang, Shilang Wang, YanFang Hong
    Frontiers in Psychiatry.2025;[Epub]     CrossRef
  • Dual energy X-ray absorptiometry-measured fat mass and lean mass indices and cardiometabolic diseases in elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study
    Katsuyasu Kouda, Yuki Fujita, Yuki Murakami, Kumiko Ohara, Takahiro Tachiki, Junko Tamaki, Jong-Seong Moon, Etsuko Kajita, Akemi Nitta, Nami Imai, Kazuhiro Uenishi, Masayuki Iki
    Environmental Health and Preventive Medicine.2025; 30: 59.     CrossRef
  • Combination of intermittent fasting and endurance exercise impedes the development of the musculoskeletal system in non-obese growing rats
    Zilin Wang, Wenduo Liu, Yu Gu, Jae Cheol Kim, Yoonjung Park, Sang Hyun Kim
    Nutrition Research and Practice.2025; 19(4): 483.     CrossRef
  • Characteristics, Prognosis, and European Society of Cardiology and European Respiratory Society Risk Stratification in Patients With Obesity and Pulmonary Arterial Hypertension
    Giulio Savonitto, Davide Barbisan, Pietro Ameri, Carlo Maria Lombardi, Mauro Driussi, Piero Gentile, Luke Howard, Matteo Toma, Matteo Pagnesi, Valentino Collini, Carolina Bauleo, Matteo Rugolotto, Giovanni Santi, Francesca Coppi, Gianluca Pagnoni, Pier Pa
    CHEST.2025; 168(3): 749.     CrossRef
  • Glucagon-like peptide-1 receptor agonists and muscle mass effects
    Alexandr Ceasovschih, Andreea Asaftei, Maria Giovanna Lupo, Stanislav Kotlyarov, Hana Bartušková, Anastasia Balta, Victorita Sorodoc, Laurentiu Sorodoc, Maciej Banach
    Pharmacological Research.2025; 220: 107927.     CrossRef
  • Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches
    Benson M. Hamooya, Lukundo Siame, Lweendo Muchaili, Sepiso K. Masenga, Annet Kirabo
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Differential impact of coffee quantity and sweetening on body composition parameters and inflammation
    Giuseppe Annunziata, Evelyn Frias-Toral, Francesco Campa, Maria Antonieta Touriz Bonifaz, Ludovica Verde, Martina Galasso, Silvia Savastano, Annamaria Colao, Antonio Paoli, Daniel Simancas-Racines, Giovanna Muscogiuri, Luigi Barrea
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Joint trajectories of skeletal muscle and fat mass in relation to glucose homeostasis: 6‐Year findings from adults aged ≥50 years
    Qiao Xiang, Yuxiao Li, Gregory Y. H. Lip, Daniel J. Cuthbertson, Wei Huang, Ziyi Zhong, Birong Dong, Jirong Yue, Masoud Isanejad
    Diabetes, Obesity and Metabolism.2025; 27(12): 7133.     CrossRef
  • Mediation of fasting blood glucose between relative muscle strength and hypertension: insights from two cohorts
    Pengyu Wang, Li Huang, Zhou Zhu, Xinyue Hu, Bingxin Wu, Xiaofang Yang
    Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
  • Muscle Mass Mediates the Effect of Physical Activity and Sedentary Behavior on Metabolic Syndrome, with Differences by Gender
    Jaehee Kim
    Healthcare.2025; 13(19): 2432.     CrossRef
  • Association between Cardiometabolic Index (CMI) with muscle mass and strength in US adults: A cross-sectional study
    Yuwen Shangguan, Shiqi Yu, Young-Je Sim, Kunyi Huang, Han Yuan, Yang Wang, Chen Chen, Zhenhao Lin, Zining Zhu
    Medicine.2025; 104(47): e46128.     CrossRef
  • Selective Mid-Wall Cardiac Dysfunction in Obesity: The Role of Muscle-to-Fat Balance
    Karolina Angela Sieradzka Uchnár, Ingrid Schusterová, Štefan Tóth, Tibor Porubän, Mariana Dvorožňáková, Pavol Fülöp
    Biomedicines.2025; 13(12): 3083.     CrossRef
  • Weight Loss and Adverse Events According to Baseline Skeletal Muscle Mass in Overweight Patients Treated with Gamitaeeumjowee-tang : A Retrospective Chart Review
    Jung-Mi Seok, Ji-Yeon Oh, Ji-Myung Ok
    Journal of Korean Medicine.2025; 46(4): 148.     CrossRef
  • Metabolic phenotypes of frailty and the course of type 2 diabetes mellitus
    L. A. Batrshina, S. V. Bulgakova, D. P. Kurmaev, E. V. Treneva, O. V. Kosareva, P. Ya. Merzlova, L. A. Sharonova, Yu. A. Dolgikh, N. A. Pervyshin, A. S. Bulgakov, E. A. Romanenko
    Experimental and Clinical Gastroenterology.2025; (3): 236.     CrossRef
  • Sex differences in the association between dual‐energy x‐ray absorptiometry‐measured body composition and periodontitis
    Peijun Zhu, An Li, Qingqing Cai, Yuntao Chen, Yang Liu, Harriët Jager‐Wittenaar, Geerten‐Has E. Tjakkes, Shulan Xu
    Journal of Periodontology.2024; 95(3): 219.     CrossRef
  • Advances in the treatment of functional male hypogonadism
    Giovanni Corona, Giulia Rastrelli, Clotilde Sparano, Linda Vignozzi, Alessandra Sforza, Mario Maggi
    Expert Review of Endocrinology & Metabolism.2024; 19(2): 163.     CrossRef
  • Heterogeneously elevated branched-chain/aromatic amino acids among new-onset type-2 diabetes mellitus patients are potentially skewed diabetes predictors
    Min Wang, Yang Ou, Xiang-Lian Yuan, Xiu-Fang Zhu, Ben Niu, Zhuang Kang, Bing Zhang, Anwar Ahmed, Guo-Qiang Xing, Heng Su
    World Journal of Diabetes.2024; 15(1): 53.     CrossRef
  • The Vicious Cycle of Type 2 Diabetes Mellitus and Skeletal Muscle Atrophy: Clinical, Biochemical, and Nutritional Bases
    Jose M. Lopez-Pedrosa, Maria Camprubi-Robles, German Guzman-Rolo, Andres Lopez-Gonzalez, Jose Manuel Garcia-Almeida, Alejandro Sanz-Paris, Ricardo Rueda
    Nutrients.2024; 16(1): 172.     CrossRef
  • FGF21 Induces Skeletal Muscle Atrophy and Increases Amino Acids in Female Mice: A Potential Role for Glucocorticoids
    Karlton R Larson, Devi Jayakrishnan, Karla A Soto Sauza, Michael L Goodson, Aki T Chaffin, Arik Davidyan, Suraj Pathak, Yanbin Fang, Diego Gonzalez Magaña, Benjamin F Miller, Karen K Ryan
    Endocrinology.2024;[Epub]     CrossRef
  • Sarcopenic Obesity and Cardiovascular Disease: An Overlooked but High-Risk Syndrome
    Saeid Mirzai, Salvatore Carbone, John A. Batsis, Stephen B. Kritchevsky, Dalane W. Kitzman, Michael D. Shapiro
    Current Obesity Reports.2024; 13(3): 532.     CrossRef
  • Mortality risk relationship using standard categorized BMI or knee-height based BMI – does the overweight/lower mortality paradox hold true?
    Nivetha Natarajan Gavriilidou, Mats Pihlsgård, Sölve Elmståhl, Henrik Ekström
    Aging Clinical and Experimental Research.2024;[Epub]     CrossRef
  • Gromwell (Lithospermum erythrorhizon) Attenuates High-Fat-Induced Skeletal Muscle Wasting by Increasing Protein Synthesis and Mitochondrial Biogenesis
    Ji-Sun Kim, Hyunjung Lee, Ahyoung Yoo, Hang Yeon Jeong, Chang Hwa Jung, Jiyun Ahn, Tae-Youl Ha
    Journal of Microbiology and Biotechnology.2024; 34(3): 495.     CrossRef
  • L-shaped association between lean body mass to visceral fat mass ratio with hyperuricemia: a cross-sectional study
    Longti Li, Ya Shao, Huiqin Zhong, Yu Wang, Rong Zhang, Boxiong Gong, Xiaoxv Yin
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Effect of COVID‐19 pandemic on bioimpedance health indicators in young adults
    Darina Falbová, Radoslav Beňuš, Simona Sulis, Lenka Vorobeľová
    American Journal of Human Biology.2024;[Epub]     CrossRef
  • Sex difference in skeletal muscle mass in relation to metabolic dysfunction-associated steatotic liver disease: a propensity score matching study
    Da-Hye Son, Yu-Jin Kwon, Jun-Hyuk Lee
    The Journal of nutrition, health and aging.2024; 28(6): 100270.     CrossRef
  • Critical variables regulating age-related anabolic responses to protein nutrition in skeletal muscle
    Colleen S. Deane, Jake Cox, Philip J. Atherton
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • Molecular mechanism of skeletal muscle loss and its prevention by natural resources
    Jin Tae Kim, Dong Hyeon Jeon, Hong Jin Lee
    Food Science and Biotechnology.2024; 33(15): 3387.     CrossRef
  • Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss
    Katharina Gross, Christian Brinkmann
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • The Effects of Blood Flow Restriction Aerobic Exercise on Body Composition, Muscle Strength, Blood Biomarkers, and Cardiovascular Function: A Narrative Review
    Chaeeun Cho, Sewon Lee
    International Journal of Molecular Sciences.2024; 25(17): 9274.     CrossRef
  • Low muscle mass is associated with efficacy of biologics in Crohn's disease
    Ye Fang, Luyan Fang, Mengqian Ye, Hanyue Jiang, Xinyu Long, Haoxuan Zhang, Qianqian Zhang, Daopo Lin, Xiaoxiao Shao
    Clinical Nutrition.2024; 43(10): 2354.     CrossRef
  • Pre-Transplant Dual-Energy X-ray Absorptiometry (DXA)-Derived Body Composition Measures as Predictors of Treatment Outcomes and Early Post-Transplant Complications in Patients with Multiple Myeloma (MM) Treated with Autologous Hematopoietic Stem Cell Tran
    Paula Jabłonowska-Babij, Diana Jędrzejuk, Maciej Majcherek, Agnieszka Szeremet, Magdalena Karasek, Bartłomiej Kuszczak, Krzysztof Kujawa, Milena Sitkiewicz, Marcin Landwójtowicz, Tomasz Wróbel, Maciej Tomasiewicz, Anna Czyż
    Journal of Clinical Medicine.2024; 13(19): 5987.     CrossRef
  • circAGO3 facilitates NF-κB pathway-mediated inflammatory atrophy in chicken skeletal muscle via the miR-34b-5p/TRAF3 axis
    Xiyu Zhao, Shuyue Tang, Zhenyu Lei, Xiaoxu Shen, Yao Zhang, Shunshun Han, Huadong Yin, Can Cui
    International Journal of Biological Macromolecules.2024; 283: 137614.     CrossRef
  • Analyzing body composition in living kidney donors: impact on post-transplant kidney function
    Evelien E. Quint, Lisa B. Westenberg, Gertrude J. Nieuwenhuijs-Moeke, Eva A. N. van den Broek, Marcel Zorgdrager, Alain R. Viddeleer, Stephan J. L. Bakker, Ija M. Nolte, Marco van Londen, Robert A. Pol
    Frontiers in Nephrology.2024;[Epub]     CrossRef
  • Eccentric Resistance Exercise Effects on Older Adults With Metabolic Syndrome
    Wafina Rohadhia, Christine Kudiarasu, Tomoko Koeda, Yoshihiro Katsura, Kazunori Nosaka, Favil Singh
    Journal of Clinical Exercise Physiology.2024; 13(4): 129.     CrossRef
  • Prevalence of adiposity-based chronic disease and its association with anthropometric and clinical indices: a cross-sectional study
    Luis E González-Salazar, Aurora E Serralde-Zúñiga, Adriana Flores-López, Juan P Díaz-Sánchez, Isabel Medina-Vera, Edgar Pichardo-Ontiveros, Rocío Guizar-Heredia, Karla G Hernández-Gómez, Ana Vigil-Martínez, Liliana Arteaga-Sánchez, Azalia Avila-Nava, Nata
    British Journal of Nutrition.2023; 130(1): 93.     CrossRef
  • Skeletal Muscle Myokine Expression in Critical Illness, Association With Outcome and Impact of Therapeutic Interventions
    Ilse Vanhorebeek, Jan Gunst, Michaël P Casaer, Inge Derese, Sarah Derde, Lies Pauwels, Johan Segers, Greet Hermans, Rik Gosselink, Greet Van den Berghe
    Journal of the Endocrine Society.2023;[Epub]     CrossRef
  • Effect of Circadian Rhythm Disturbance on the Human Musculoskeletal System and the Importance of Nutritional Strategies
    Norsham Juliana, Liyana Azmi, Nadia Mohd Effendy, Nur Islami Mohd Fahmi Teng, Izuddin Fahmy Abu, Nur Nabilah Abu Bakar, Sahar Azmani, Noor Anisah Abu Yazit, Suhaini Kadiman, Srijit Das
    Nutrients.2023; 15(3): 734.     CrossRef
  • Molecular mechanisms of post‐burn muscle wasting and the therapeutic potential of physical exercise
    Dorien Dombrecht, Ulrike Van Daele, Birgit Van Asbroeck, David Schieffelers, Pieter‐Jan Guns, Nick Gebruers, Jill Meirte, Eric van Breda
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(2): 758.     CrossRef
  • Metabolic Impact of Frailty Changes Diabetes Trajectory
    Alan J. Sinclair, Ahmed H. Abdelhafiz
    Metabolites.2023; 13(2): 295.     CrossRef
  • From Single- to Multi-organ-on-a-Chip System for Studying Metabolic Diseases
    Minjeong Jang, Hong Nam Kim
    BioChip Journal.2023; 17(2): 133.     CrossRef
  • INFLUENCE OF SARCOPENIA ON THE COURSE AND PROGNOSIS IN PATIENTS WITH CHRONIC HEART FAILURE
    Gulyaev N.I., Adamov A.A., Akhmetshin I.M.
    "Medical & pharmaceutical journal "Pulse".2023; : 124.     CrossRef
  • Frailty and the Interactions between Skeletal Muscle, Bone, and Adipose Tissue-Impact on Cardiovascular Disease and Possible Therapeutic Measures
    María Elena Soto, Israel Pérez-Torres, María Esther Rubio-Ruiz, Agustina Cano-Martínez, Linaloe Manzano-Pech, Verónica Guarner-Lans
    International Journal of Molecular Sciences.2023; 24(5): 4534.     CrossRef
  • Sarcoplasmic Reticulum Ca2+ Buffer Proteins: A Focus on the Yet-To-Be-Explored Role of Sarcalumenin in Skeletal Muscle Health and Disease
    Elena Conte, Giorgia Dinoi, Paola Imbrici, Annamaria De Luca, Antonella Liantonio
    Cells.2023; 12(5): 715.     CrossRef
  • Antarctic krill extracts enhance muscle regeneration and muscle function via mammalian target of rapamycin regulation
    Seongmin Lee, Mi-Ock Baek, Sana Abdul Khaliq, Amna Parveen, Sun Yeou Kim, Jin-Hyoung Kim, Il-Chan Kim, Mee-Sup Yoon
    Journal of Functional Foods.2023; 103: 105483.     CrossRef
  • Pharmacological and physiological roles of adipokines and myokines in metabolic-related dementia
    Archana Arjunan, Juhyun Song
    Biomedicine & Pharmacotherapy.2023; 163: 114847.     CrossRef
  • PRMT5 links lipid metabolism to contractile function of skeletal muscles
    Kun Ho Kim, Zhihao Jia, Madigan Snyder, Jingjuan Chen, Jiamin Qiu, Stephanie N Oprescu, Xiyue Chen, Sabriya A Syed, Feng Yue, Bruno T Roseguini, Anthony N Imbalzano, Changdeng Hu, Shihuan Kuang
    EMBO reports.2023;[Epub]     CrossRef
  • “Biqi” Bayberry Extract Promotes Skeletal Muscle Fiber Type Remodeling by Increasing Fast Myofiber Formation via the Akt/FoxO1 Pathway in Mice
    Jinjie Li, Yi Li, Xiangying Suo, Jiangtao Li, Da Huang, Guangning Kou
    Foods.2023; 12(13): 2471.     CrossRef
  • Effects of high-intensity interval training (HIIT) on skeletal muscle atrophy, function, and myokine profile in diabetic myopathy
    Yeşim Özçatal, Fırat Akat, Yakup Tatar, Hakan Fıçıcılar, Bilge Serdaroğlu, Ferda Topal Çelikkan, Metin Baştuğ
    Cytokine.2023; 169: 156279.     CrossRef
  • Impaired proteostatic mechanisms other than decreased protein synthesis limit old skeletal muscle recovery after disuse atrophy
    Jordan D. Fuqua, Marcus M. Lawrence, Zachary R. Hettinger, Agnieszka K. Borowik, Parker L. Brecheen, Marcelina M. Szczygiel, Claire B. Abbott, Frederick F. Peelor, Amy L. Confides, Michael Kinter, Sue C. Bodine, Esther E. Dupont‐Versteegden, Benjamin F. M
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(5): 2076.     CrossRef
  • Body physique rating as a factor to identify at-risk Mexicans for Metabolic Syndrome
    Oscar Herrera-Fomperosa, Sergio K. Bustamante-Villagomez, Sarahí Vazquez-Álvarez, Gabriela Vázquez-Marroquín, Leonardo M. Porchia, Enrique Torres-Rasgado, Ricardo Pérez-Fuentes, M. Elba Gonzalez-Mejia
    Human Nutrition & Metabolism.2023; 33: 200206.     CrossRef
  • Association between Fractional Oxygen Extraction from Resting Quadriceps Muscle and Body Composition in Healthy Men
    Rodrigo Yáñez-Sepúlveda, Jorge Olivares-Arancibia, Guillermo Cortés-Roco, Aldo Vasquez-Bonilla, Matías Monsalves-Álvarez, Ildefonso Alvear-Órdenes, Marcelo Tuesta
    Journal of Functional Morphology and Kinesiology.2023; 8(4): 149.     CrossRef
  • Correlations between Mental Health, Physical Activity, and Body Composition in American College Students after the COVID-19 Pandemic Lockdown
    Luis Torres, Manuela C. Caciula, Alin S. Tomoiaga, Carmen Gugu-Gramatopol
    International Journal of Environmental Research and Public Health.2023; 20(22): 7045.     CrossRef
  • Association between total body muscle percentage and prevalence of non-alcoholic fatty liver disease in Korean adults findings from an 18-year follow-up: a prospective cohort study
    Byoung Chan Ahn, Chul Yong Park, Jung Hee Hong, Ki Ook Baek
    Journal of Yeungnam Medical Science.2023; 40(Suppl): S47.     CrossRef
  • The independent and joint associations among muscle strength, abdominal obesity and cardiometabolic variables among adults
    Tiago Rodrigues de Lima, David Alejandro González‐Chica, Xuemei Sui, Diego Augusto Santos Silva
    European Journal of Sport Science.2022; 22(7): 1122.     CrossRef
  • Mentale Gesundheit und physische Aktivität
    Wolfgang Laube
    Manuelle Medizin.2022; 60(1): 13.     CrossRef
  • A new paradigm in sarcopenia: Cognitive impairment caused by imbalanced myokine secretion and vascular dysfunction
    Danbi Jo, Gwangho Yoon, Oh Yoen Kim, Juhyun Song
    Biomedicine & Pharmacotherapy.2022; 147: 112636.     CrossRef
  • Sarcopenia Is a Cause and Consequence of Metabolic Dysregulation in Aging Humans: Effects of Gut Dysbiosis, Glucose Dysregulation, Diet and Lifestyle
    James W. Daily, Sunmin Park
    Cells.2022; 11(3): 338.     CrossRef
  • Leveraging deep phenotyping from health check-up cohort with 10,000 Korean individuals for phenome-wide association study of 136 traits
    Eun Kyung Choe, Manu Shivakumar, Anurag Verma, Shefali Setia Verma, Seung Ho Choi, Joo Sung Kim, Dokyoon Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • Zika virus disrupts gene expression in human myoblasts and myotubes: Relationship with susceptibility to infection
    Ingo Riederer, Daniella Arêas Mendes-da-Cruz, Guilherme Cordenonsi da Fonseca, Mariela Natacha González, Otavio Brustolini, Cássia Rocha, Guilherme Loss, Joseane Biso de Carvalho, Mariane Talon Menezes, Lidiane Menezes Souza Raphael, Alexandra Gerber, Myr
    PLOS Neglected Tropical Diseases.2022; 16(2): e0010166.     CrossRef
  • Teil 1: Muskeldysfunktionen – mit Training gegen Schmerz
    Wolfgang Laube
    Manuelle Medizin.2022; 60(2): 84.     CrossRef
  • Transcription factors KLF15 and PPARδ cooperatively orchestrate genome-wide regulation of lipid metabolism in skeletal muscle
    Liyan Fan, David R. Sweet, Erica K. Fan, Domenick A. Prosdocimo, Annmarie Madera, Zhen Jiang, Roshan Padmanabhan, Saptarsi M. Haldar, Vinesh Vinayachandran, Mukesh K. Jain
    Journal of Biological Chemistry.2022; 298(6): 101926.     CrossRef
  • An Overview of the TRP-Oxidative Stress Axis in Metabolic Syndrome: Insights for Novel Therapeutic Approaches
    Mizael C. Araújo, Suzany H. S. Soczek, Jaqueline P. Pontes, Leonardo A. C. Marques, Gabriela S. Santos, Gisele Simão, Laryssa R. Bueno, Daniele Maria-Ferreira, Marcelo N. Muscará, Elizabeth S. Fernandes
    Cells.2022; 11(8): 1292.     CrossRef
  • Effects of a 10-Week Physical Activity Intervention on Asylum Seekers’ Physiological Health
    Matheus Guerra, Danilo Garcia, Maryam Kazemitabar, Erik Lindskär, Erica Schütz, Daniel Berglind
    Brain Sciences.2022; 12(7): 822.     CrossRef
  • Low muscle mass and mortality risk later in life: A 10-year follow-up study
    Cristina Camargo Pereira, Valéria Pagotto, Cesar de Oliveira, Erika Aparecida Silveira, Kiyoshi Sanada
    PLOS ONE.2022; 17(7): e0271579.     CrossRef
  • Independent and joint associations of weightlifting and aerobic activity with all-cause, cardiovascular disease and cancer mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
    Jessica Gorzelitz, Britton Trabert, Hormuzd A Katki, Steven C Moore, Eleanor L Watts, Charles E Matthews
    British Journal of Sports Medicine.2022; 56(22): 1277.     CrossRef
  • Handgrip Strength Cutoff Value Among Korean Adolescents with Metabolic Syndrome Components: Korean National Health and Nutrition Examination Survey Data 2014–2017
    Chang Hoon Lee, Jun Hyeok Lee, Yong Whi Jeong, Hong Koh, Yunkoo Kang
    Metabolic Syndrome and Related Disorders.2022; 20(10): 584.     CrossRef
  • Physical activity level, sitting time, and skeletal muscle mass between esports players and non-esports players
    Zhi H. SEE, Mohamad S. ABDUL HAMID
    Gazzetta Medica Italiana Archivio per le Scienze Mediche.2022;[Epub]     CrossRef
  • Impact of the Nutrition–Inflammation Status on the Functionality of Patients with Chronic Kidney Disease
    Ángel Nogueira, Graciela Álvarez, Guillermina Barril
    Nutrients.2022; 14(22): 4745.     CrossRef
  • Does Timing Matter? A Narrative Review of Intermittent Fasting Variants and Their Effects on Bodyweight and Body Composition
    Alan A. Aragon, Brad J. Schoenfeld
    Nutrients.2022; 14(23): 5022.     CrossRef
  • Sex- and region-specific associations of skeletal muscle mass with metabolic dysfunction-associated fatty liver disease
    Pei Xiao, Pu Liang, Panjun Gao, Jinyi Wu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Donor Skeletal Muscle Quality Affects Graft Mortality After Living Donor Liver Transplantation- A Single Center, Retrospective Study
    Takahiro Tomiyama, Noboru Harada, Takeo Toshima, Yuki Nakayama, Katsuya Toshida, Akinari Morinaga, Yukiko Kosai-Fujimoto, Takahiro Tomino, Takeshi Kurihara, Kazuki Takeishi, Yoshihiro Nagao, Kazutoyo Morita, Shinji Itoh, Tomoharu Yoshizumi
    Transplant International.2022;[Epub]     CrossRef
  • Handgrip Strength Is Associated with Metabolic Syndrome and Insulin Resistance in Children and Adolescents: Analysis of Korea National Health and Nutrition Examination Survey 2014–2018
    Hae Woon Jung, Jieun Lee, Jaehyun Kim
    Journal of Obesity & Metabolic Syndrome.2022; 31(4): 334.     CrossRef
  • Diet quality and a traditional dietary pattern predict lean mass in Australian women: Longitudinal data from the Geelong Osteoporosis Study
    Jessica A. Davis, Mohammadreza Mohebbi, Fiona Collier, Amy Loughman, Nitin Shivappa, James R. Hébert, Julie A. Pasco, Felice N. Jacka
    Preventive Medicine Reports.2021; 21: 101316.     CrossRef
  • Association between serum FGF21 level and sarcopenia in older adults
    Hee-Won Jung, Jin Hoon Park, Da Ae Kim, Il-Young Jang, So Jeong Park, Jin Young Lee, Seungjoo Lee, Jeoung Hee Kim, Hyon-Seung Yi, Eunju Lee, Beom-Jun Kim
    Bone.2021; 145: 115877.     CrossRef
  • Benchside to the bedside of frailty and cardiovascular aging: Main shared cellular and molecular mechanisms
    Sandra Maria Barbalho, Ricardo José Tofano, Eduardo Federigui Baisi Chagas, Cláudia Rucco Penteado Detregiachi, Ricardo de Alvares Goulart, Uri Arian Princ Flato
    Experimental Gerontology.2021; 148: 111302.     CrossRef
  • Effect of CCL11 on In Vitro Myogenesis and Its Clinical Relevance for Sarcopenia in Older Adults
    Da Ae Kim, So Jeong Park, Jin Young Lee, Jeoung Hee Kim, Seungjoo Lee, Eunju Lee, Il-Young Jang, Hee-Won Jung, Jin Hoon Park, Beom-Jun Kim
    Endocrinology and Metabolism.2021; 36(2): 455.     CrossRef
  • Sarcopenic obesity as a determinant of cardiovascular disease risk in older people: a systematic review
    Katherine Evans, Dima Abdelhafiz, Ahmed H Abdelhafiz
    Postgraduate Medicine.2021; 133(8): 831.     CrossRef
  • Decreased continuous sitting time increases heart rate variability in patients with cardiovascular risk factors
    Natsuki Nakayama, Masahiko Miyachi, Koji Tamakoshi, Toshio Hayashi, Koji Negi, Koji Watanabe, Makoto Hirai, Sharon Mary Brownie
    PLOS ONE.2021; 16(6): e0253399.     CrossRef
  • Muskeltraining – ein universelles Medikament
    Wolfgang Laube
    Manuelle Medizin.2021; 59(3): 179.     CrossRef
  • The Effects of Oxytocin on Appetite Regulation, Food Intake and Metabolism in Humans
    Liya Kerem, Elizabeth A. Lawson
    International Journal of Molecular Sciences.2021; 22(14): 7737.     CrossRef
  • Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss
    David McCarthy, Aloys Berg
    Nutrients.2021; 13(7): 2473.     CrossRef
  • Association of FGF‐19 and FGF‐21 levels with primary sarcopenia
    Rabia Bag Soytas, Veysel Suzan, Pinar Arman, Tugce Emiroglu Gedik, Damla Unal, Mahir Cengiz, Ibrahim Murat Bolayirli, Deniz Suna Erdincler, Alper Doventas, Hakan Yavuzer
    Geriatrics & Gerontology International.2021; 21(10): 959.     CrossRef
  • Der Muskulatur mehr Aufmerksamkeit schenken!
    Wolfgang Laube
    Manuelle Medizin.2021; 59(4): 302.     CrossRef
  • Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: A review
    Antti Tolonen, Tomppa Pakarinen, Antti Sassi, Jere Kyttä, William Cancino, Irina Rinta-Kiikka, Said Pertuz, Otso Arponen
    European Journal of Radiology.2021; 145: 109943.     CrossRef
  • Waist and hip circumference are independently associated with the risk of liver disease in population‐based studies
    Oscar Danielsson, Markku J. Nissinen, Antti Jula, Veikko Salomaa, Satu Männistö, Annamari Lundqvist, Markus Perola, Fredrik Åberg
    Liver International.2021; 41(12): 2903.     CrossRef
  • Understanding of sarcopenia: from definition to therapeutic strategies
    Jee Won Kim, Ryuni Kim, Hyerim Choi, Sang-Jin Lee, Gyu-Un Bae
    Archives of Pharmacal Research.2021; 44(9-10): 876.     CrossRef
  • Muscle strength and its association with cardiometabolic variables in adolescents: does the expression of muscle strength values matter?
    Tiago Rodrigues de Lima, Xuemei Sui, Luiz Rodrigo Augustemak de Lima, Diego Augusto Santos Silva
    World Journal of Pediatrics.2021; 17(6): 597.     CrossRef
  • Musclin Is Related to Insulin Resistance and Body Composition, but Not to Body Mass Index or Cardiorespiratory Capacity in Adults
    Yeliana L. Sánchez, Manuela Yepes-Calderón, Luis Valbuena, Andrés F. Milán, María C. Trillos-Almanza, Sergio Granados, Miguel Peña, Mauricio Estrada-Castrillón, Juan C. Aristizábal, Raúl Narvez-Sanchez, Jaime Gallo-Villegas, Juan C. Calderón
    Endocrinology and Metabolism.2021; 36(5): 1055.     CrossRef
  • Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications
    Sandra Maria Barbalho, Uri Adrian Prync Flato, Ricardo José Tofano, Ricardo de Alvares Goulart, Elen Landgraf Guiguer, Cláudia Rucco P. Detregiachi, Daniela Vieira Buchaim, Adriano Cressoni Araújo, Rogério Leone Buchaim, Fábio Tadeu Rodrigues Reina, Piero
    International Journal of Molecular Sciences.2020; 21(10): 3607.     CrossRef
  • Prevalence of Metabolic Syndrome and Association with Grip Strength in Older Adults: Findings from the HOPE Study


    Reshma Aziz Merchant, Yiong Huak Chan, Jia Yi Lim, John E Morley
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 2677.     CrossRef
  • Lower Serum n-3 Fatty Acid Level in Older Adults with Sarcopenia
    Il-Young Jang, Hee-Won Jung, Jin Hoon Park, Jeoung Hee Kim, Seungjoo Lee, Eunju Lee, Jin Young Lee, So Jeong Park, Da Ae Kim, Su Jung Kim, Hyun Ju Yoo, Beom-Jun Kim
    Nutrients.2020; 12(10): 2959.     CrossRef
  • Advances in understanding of health‐promoting benefits of medicine and food homology using analysis of gut microbiota and metabolomics
    Minmin Yang, Tao Yan, Meng Yu, Jie Kang, Ruoxi Gao, Peng Wang, Yuhuan Zhang, Huafeng Zhang, Lin Shi
    Food Frontiers.2020; 1(4): 398.     CrossRef
  • The association of circulating kynurenine, a tryptophan metabolite, with frailty in older adults
    Il-Young Jang, Jin Hoon Park, Jeoung Hee Kim, Seungjoo Lee, Eunju Lee, Jin Young Lee, So Jeong Park, Da Ae Kim, Mark W. Hamrick, Beom-Jun Kim
    Aging.2020; 12(21): 22253.     CrossRef
  • Sarcopenia and Muscle Aging: A Brief Overview
    Tam Dao, Alexander E. Green, Yun A Kim, Sung-Jin Bae, Ki-Tae Ha, Karim Gariani, Mi-ra Lee, Keir J. Menzies, Dongryeol Ryu
    Endocrinology and Metabolism.2020; 35(4): 716.     CrossRef
Close layer
Review Article
Obesity and Metabolism
Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
Eun-Jung Rhee
Endocrinol Metab. 2019;34(3):226-233.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.226
  • 17,042 View
  • 368 Download
  • 83 Web of Science
  • 88 Crossref
AbstractAbstract PDFPubReader   ePub   

Nonalcoholic fatty liver disease (NAFLD) is thought to stem from the body's inability to store excess energy in adipocytes; as such, it is commonly viewed as the hepatic manifestation of metabolic syndrome. The pathogenesis of NAFLD involves ectopic fat accumulation, which also takes place in the liver, muscle and visceral fat. NAFLD is rapidly becoming more widespread in Korea, with an estimated prevalence of 30% in adults. Type 2 diabetes mellitus (T2DM) and NAFLD share insulin resistance as a common pathophysiological mechanism, and each of these two diseases affects the development of the other. Recent studies have suggested that NAFLD is often present as a comorbidity in T2DM patients. The mutual interrelationship between these conditions is shown by findings suggesting that T2DM can exacerbate NAFLD by promoting progression to nonalcoholic hepatosteatosis or fibrosis, while NAFLD causes the natural course of diabetic complications to worsen in T2DM patients. It remains unknown whether one disease is the cause of the other or vice versa. In this review, I would like to discuss current epidemiological data on the associations between NAFLD and T2DM, and how each disease affects the course of the other.

Citations

Citations to this article as recorded by  
  • HMG-CoA Reductase Inhibitors (Statins) May Preserve Hepatic Function and Reduce Portal-Systemic Shunting in Compensated Advanced Chronic Liver Disease: Results From the SHUNT-V Study
    Robert S. Rahimi, Edward Mena, Kathryn J. Lucas, Michael P. McRae, John Kittelson, Joanne C. Imperial, Alastair D. Smith, Gregory T. Everson
    Clinical and Translational Gastroenterology.2026;[Epub]     CrossRef
  • Noninvasive Assessment of the Severity of Liver Fibrosis in MASLD Patients with Long-Standing Type 2 Diabetes
    Farooq Khan, Stafny Dsouza, Amar Hassan Khamis, Fatima Abdul, Muhammad Hamed Farooqi, Fatima Sulaiman, Fahad Mulla, Fatheya Al Awadi, Mohammed Hassanein, Riad Bayoumi
    Journal of General Internal Medicine.2025; 40(10): 2309.     CrossRef
  • Association between diabetes prevalence and weekend warrior activity patterns
    Zihao Chen, Junqiang Jia, Jiayuan Tu, Yuehui Zhao, Xiaoming Li
    Public Health.2025; 240: 97.     CrossRef
  • Antiobesity medications in adult and pediatric obesity and metabolic dysfunction–associated steatotic liver disease
    Natalie Rodriguez, Phillipp Hartmann
    Pharmacological Reviews.2025; 77(4): 100058.     CrossRef
  • Navigating New Frontiers: Approaches to Diabetes Care Through Perimenopause and Menopause
    Brian Burroughs, Angie Clinton, Laura Knudsen
    ADCES in Practice.2025;[Epub]     CrossRef
  • Association between perceived stress and MAFLD partially mediated by smoking and drinking
    Yan Gong, Shengshu Wang, Jianan Jiang, Qiang Zeng, Weimin Wang, Yansong Zheng, Wenping Lv
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • The relationship between tobacco and non-alcoholic fatty liver disease incidence: a systematic review and meta-analysis of observational studies
    Jianxiang Jin, Yuping Zhang, Yiping Huang
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Sugar-sweetened beverage consumption predicts metabolic associated fatty liver disease in patients with type 2 diabetes mellitus
    Zhenjun Yu, Mengdie Chen, Shicheng Gu, Chaohui Wang, Ping Feng, Gang Lin
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Quantitative evaluation of myocardial work in patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver by noninvasive pressure-strain loop
    Min Tian, Xuanning Hou, Zihan Wang, Xiuxiu Cui, Meng Jing, Xingxiang Ren, Weiwei Ping, Kefeng LI, Xiaoyan Wang
    BMC Cardiovascular Disorders.2025;[Epub]     CrossRef
  • Prevalence, Sonographic Characteristics, and Metabolic Predictors of Nonalcoholic Fatty Liver Disease in Adults With Type 2 Diabetes in Tanzania
    Zubeir Zubeir, Zuhura Nkrumbih, Salama Ally, Yasser H. Hadi
    Dr. Sulaiman Al Habib Medical Journal.2025; 7(3): 180.     CrossRef
  • Recent advances and potentiality of postbiotics in the food industry: Composition, inactivation methods, current applications in metabolic syndrome, and future trends
    Yujie Zhong, Tao Wang, Ruilin Luo, Jiayu Liu, Ruyi Jin, Xiaoli Peng
    Critical Reviews in Food Science and Nutrition.2024; 64(17): 5768.     CrossRef
  • Effect of exercise intervention on clinical parameters in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
    Yu Zeng, Xuemei Zhang, Wenling Luo, Yunjian Sheng
    European Journal of Gastroenterology & Hepatology.2024; 36(1): 1.     CrossRef
  • Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis
    Sven M. Francque, Alexander Hodge, Jerome Boursier, Ziad H. Younes, Gerardo Rodriguez-Araujo, Grace S. Park, Naim Alkhouri, Manal F. Abdelmalek
    Hepatology Communications.2024;[Epub]     CrossRef
  • Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients
    Young-Hwan Park, Minji Sohn, So Yeon Lee, Soo Lim
    Diabetes & Metabolism Journal.2024; 48(2): 253.     CrossRef
  • Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver Disease
    强江 郭
    Advances in Clinical Medicine.2024; 14(03): 561.     CrossRef
  • Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe
    Maria Eleni Chondrogianni, Ioannis Kyrou, Theodoros Androutsakos, Christina-Maria Flessa, Evangelos Menenakos, Kamaljit Kaur Chatha, Yekaterina Aranan, Athanasios G. Papavassiliou, Eva Kassi, Harpal S. Randeva
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Obeticholic Acid and Insulin Sensitivity in Overweight Patients with Prediabetes
    H. Amer, M. Nesim, H. Mansour, E. Nasr, N. Ahmed
    Obesity and metabolism.2024; 21(2): 161.     CrossRef
  • Multiple Definitions of Fatty Liver Disease: Which One Most Accurately Predicts Diabetes?
    Eun-Jung Rhee
    Endocrinology and Metabolism.2024; 39(2): 397.     CrossRef
  • The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes
    Morteza Aghajanpoor, Mehrzad Gholampourdehaki, Reza Mosaed, Iraj Mirzaii-Dizgah, Afsaneh Vosughi
    Annals of Military and Health Sciences Research.2024;[Epub]     CrossRef
  • Higher habitual intakes of flavonoids and flavonoid-rich foods are associated with a lower incidence of type 2 diabetes in the UK Biobank cohort
    Alysha S. Thompson, Amy Jennings, Nicola P. Bondonno, Anna Tresserra-Rimbau, Benjamin H. Parmenter, Claire Hill, Aurora Perez-Cornago, Tilman Kühn, Aedín Cassidy
    Nutrition & Diabetes.2024;[Epub]     CrossRef
  • Associations of sex-related and thyroid-related hormones with risk of metabolic dysfunction-associated fatty liver disease in T2DM patients
    Weihong Lu, Shangjian Li, Yuhua Li, Jingqi Zhou, Kai Wang, Ning Chen, Zhibin Li
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • Diagnostic role of SPP1 and collagen IV in a rat model of type 2 diabetes mellitus with MASLD
    Shan Xiao, Xiao Bei Wang, Ye Yang, Qin Wang
    Scientific Reports.2024;[Epub]     CrossRef
  • Impact of dietary fiber intake on non-alcoholic fatty liver disease risk in Korean patients with obesity and type 2 diabetes mellitus
    Ji-Sook Park, Hina Akbar, Young-Seol Kim, Jung-Eun Yim
    Journal of Nutrition and Health.2024; 57(3): 282.     CrossRef
  • Clinical cohort of nonalcoholic fatty liver disease in a primary care setting
    Julia R. Gips, Lisa Yanek, Jiajun Wu, James P. Hamilton, Tinsay A. Woreta, Jeanne M. Clark
    Journal of Family Medicine and Primary Care.2024; 13(8): 2958.     CrossRef
  • Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
    Sultan Alfawaz, Abdulhadi Burzangi , Ahmed Esmat
    Cureus.2024;[Epub]     CrossRef
  • Povara bolii ficatului steatozic
    Felicia Darii, Olga Tagadiuc
    Akademos.2024; (2(73)): 91.     CrossRef
  • Honey preparation in complex therapy of metabolically associated fatty liver disease
    V. P. Gomonova, A. Yu. Baranovsky, I. S. Sakeian
    Experimental and Clinical Gastroenterology.2024; (10): 195.     CrossRef
  • Utility of Indices Obtained during Medical Checkups for Predicting Fatty Liver Disease in Non-obese People
    Naoya Otsubo, Tatsuya Fukuda, Genhin Cho, Fumiaki Ishibashi, Tetsuya Yamada, Koshiro Monzen
    Internal Medicine.2023; 62(16): 2307.     CrossRef
  • Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs
    Yan Zhao, Wenli Zhao, Huaien Bu, Maeda Toshiyoshi, Ye Zhao
    Medicine.2023; 102(6): e32892.     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Metabolomics analysis reveals serum biomarkers in patients with diabetic sarcopenia
    Yuwei Tan, Xiaosong Liu, Yinping Yang, Baoying Li, Fei Yu, Wenqian Zhao, Chunli Fu, Xin Yu, Zhenxia Han, Mei Cheng
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Antagonizing apolipoprotein J chaperone promotes proteasomal degradation of mTOR and relieves hepatic lipid deposition
    Shuangdi Duan, Nong Qin, Jiayi Pi, Pei Sun, Yating Gao, Lamei Liu, Zenghui Li, Ya Li, Liyang Shi, Qiang Gao, Ye Qiu, Songqing Tang, Chun-Hsiang Wang, Tzu-Ying Chen, Sin-Tian Wang, Kung-Chia Young, Hung-Yu Sun
    Hepatology.2023; 78(4): 1182.     CrossRef
  • The Influence of Metabolic Factors in Patients with Chronic Viral Hepatitis C Who Received Oral Antiviral Treatment
    Oana Irina Gavril, Radu Sebastian Gavril, Florin Mitu, Otilia Gavrilescu, Iolanda Valentina Popa, Diana Tatarciuc, Andrei Drugescu, Andrei Catalin Oprescu, Andreea Gherasim, Laura Mihalache, Irina Mihaela Esanu
    Metabolites.2023; 13(4): 571.     CrossRef
  • The bidirectional relationship between NAFLD and type 2 diabetes: A prospective population-based cohort study
    Minzhen Wang, Yanan Zhao, Yingqian He, Lulu Zhang, Jing Liu, Shan Zheng, Yana Bai
    Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(8): 1521.     CrossRef
  • Visceral fat: A key mediator of NAFLD development and progression
    Savita Bansal, Meenakshi Vachher, Taruna Arora, Bhupender Kumar, Archana Burman
    Human Nutrition & Metabolism.2023; 33: 200210.     CrossRef
  • Greater Severity of Steatosis Is Associated with a Higher Risk of Incident Diabetes: A Retrospective Longitudinal Study
    Ji Min Han, Jung Hwan Cho, Hye In Kim, Sunghwan Suh, Yu-Ji Lee, Jung Won Lee, Kwang Min Kim, Ji Cheol Bae
    Endocrinology and Metabolism.2023; 38(4): 418.     CrossRef
  • The role of TRIM family in metabolic associated fatty liver disease
    Jingyue Zhang, Yingming Zhang, Ze Ren, Dongmei Yan, Guiying Li
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Non-alcoholic fatty liver disease and diabetic retinopathy: Is there an association?
    Mathew Jacob, Mary Joseph, Jyothi Idiculla
    Journal of Family Medicine and Primary Care.2023; 12(9): 2028.     CrossRef
  • Camel whey protein improves diabetic liver injury by targeting ACMSD and promoting de novo NAD+ synthesis
    Zhihua Dou, Huaibin Yao, Yutong Xie, Ying Liu, Yang Gao, Jie Yang
    Journal of Functional Foods.2023; 110: 105835.     CrossRef
  • Gut microbiota and nonalcoholic fatty liver disease
    Boyeon Kim, Bukyung Kim
    Kosin Medical Journal.2023; 38(3): 169.     CrossRef
  • Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
    E.G. Mankieva, E.I. Kukhareva
    Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 103.     CrossRef
  • Body Fat Distribution, Glucose Metabolism, and Diabetes Status Among Older Adults: The Multiethnic Cohort Adiposity Phenotype Study
    Gertraud Maskarinec, Phyllis Raquinio, Bruce S. Kristal, Adrian A. Franke, Steven D. Buchthal, Thomas M. Ernst, Kristine R. Monroe, John A. Shepherd, Yurii B. Shvetsov, Loïc Le Marchand, Unhee Lim
    Journal of Epidemiology.2022; 32(7): 314.     CrossRef
  • Evaluation of the reciprocal interaction between hepatic steatosis and type 2 diabetes: a comparative analysis with respect to anti-diabetic treatment, glycemic control, renal and hepatic function
    Teslime Ayaz, Hatice Beyazal Polat, Bilgesah Kilictas
    International Journal of Diabetes in Developing Countries.2022; 42(3): 421.     CrossRef
  • Glycemic control, the unconsidered outcome in the treatment of nonalcoholic fatty liver disease
    Diego García-Compeán, Emanuela Orsi, Tsutomu Nishida, Ramesh Kumar
    Annals of Hepatology.2022; 27(1): 100648.     CrossRef
  • Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999–2016
    Pegah Golabi, James M. Paik, Michael Harring, Elena Younossi, Khaled Kabbara, Zobair M. Younossi
    Clinical Gastroenterology and Hepatology.2022; 20(12): 2838.     CrossRef
  • The Influence of Obesity and Metabolic Health on Vascular Health
    Eun-Jung Rhee
    Endocrinology and Metabolism.2022; 37(1): 1.     CrossRef
  • Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials
    Xiaojuan Peng, Juan Li, Hailiang Zhao, Junlong Lai, Junqin Lin, Shaohui Tang
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018
    Ji Cheol Bae, Lauren A. Beste, Kristina M. Utzschneider
    Endocrinology and Metabolism.2022; 37(3): 455.     CrossRef
  • Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
    Eun-Jung Rhee
    Endocrinology and Metabolism.2022; 37(3): 415.     CrossRef
  • Structurally‐engineered fatty acid 1024 (SEFA‐1024) improves diet‐induced obesity, insulin resistance, and fatty liver disease
    Jordon D. Secor, Bennet S. Cho, Lumeng J. Yu, Amy Pan, Victoria H. Ko, Duy T. Dao, Michael Feigh, Lorenzo Anez‐Bustillos, Gillian L. Fell, David A. Fraser, Kathleen M. Gura, Mark Puder
    Lipids.2022; 57(4-5): 241.     CrossRef
  • Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study
    Ángel Arturo López-González, Bárbara Altisench Jané, Luis Masmiquel Comas, Sebastiana Arroyo Bote, Hilda María González San Miguel, José Ignacio Ramírez Manent
    Nutrients.2022; 14(14): 2795.     CrossRef
  • Captopril and Spironolactone can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting ABCA1 and microRNA-33
    Tina Ghaffari, Nariman Moradi, Elham Chamani, Zahra Ebadi, Reza Fadaei, Shahin Alizadeh-Fanalou, Sahar Yarahmadi, Soudabeh Fallah
    Current Pharmaceutical Design.2022; 28(16): 1367.     CrossRef
  • Elevated serum γ-glutamyl transferase is associated with low muscle function in adults independent of muscle mass
    Seunghyun Lee, Dawon Song, Sungjae Shin, Namki Hong, Yumie Rhee
    Nutrition.2022; 103-104: 111813.     CrossRef
  • Cross-sectional association between prolactin levels and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a retrospective analysis of patients from a single hospital in China
    Yuanyuan Zhang, Huaizhen Liu
    BMJ Open.2022; 12(10): e062252.     CrossRef
  • Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients : what do we know so far ?
    Q Binet, A Loumaye, V Preumont, J-P Thissen, M.P. Hermans, N Lanthier
    Acta Gastro Enterologica Belgica.2022; 85(2): 346.     CrossRef
  • Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
    Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
    Nutrients.2022; 14(23): 4994.     CrossRef
  • Correlation between Component Factors of Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Nurses: An Observational and Cross-Sectional Study
    Wen-Pei Chang, Yu-Pei Chang
    International Journal of Environmental Research and Public Health.2022; 19(23): 16294.     CrossRef
  • Holistic analysis of hepatosteatosis literature: a scientometric study of global hepatosteatosis publications between 1980 and 2019
    Fatih ESKİN, Engin ŞENEL
    Journal of Medicine and Palliative Care.2022; 3(4): 300.     CrossRef
  • Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
    Pengyu Yao, Yajuan Liu
    Molecules.2022; 28(1): 272.     CrossRef
  • Association of Non-Alcoholic Fatty Liver Dis-ease and Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: a Cross-Sectional Study
    Zahra Heidari, Zahra Sharafi
    Iranian South Medical Journal.2022; 25(1): 30.     CrossRef
  • Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review
    Kiarash Riazi, Mark G. Swain, Stephen E. Congly, Gilaad G. Kaplan, Abdel-Aziz Shaheen
    Nutrients.2022; 14(21): 4556.     CrossRef
  • MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
    Ying-Xin Xian, Jian-Ping Weng, Fen Xu
    Chinese Medical Journal.2021; 134(1): 8.     CrossRef
  • Factors associated with elevated alanine aminotransferase in employees of a German chemical company: results of a large cross-sectional study
    Matthias Claus, Christoph Antoni, Bernd Hofmann
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Treatment potential of LPCN 1144 on liver health and metabolic regulation in a non-genomic, high fat diet induced NASH rabbit model
    P. Comeglio, E. Sarchielli, S. Filippi, I. Cellai, G. Guarnieri, A. Morelli, G. Rastrelli, E. Maseroli, S. Cipriani, T. Mello, A. Galli, B. J. Bruno, K. Kim, K. Vangara, K. Papangkorn, N. Chidambaram, M. V. Patel, M. Maggi, L. Vignozzi
    Journal of Endocrinological Investigation.2021; 44(10): 2175.     CrossRef
  • Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis
    Chien-Yu Lin, Pratik Adhikary, Kun Cheng
    Advanced Drug Delivery Reviews.2021; 174: 127.     CrossRef
  • Trend for Clinical Use of Metabolic Associated Fatty Liver Disease (MAFLD)
    Hiroshi Bando
    Asploro Journal of Biomedical and Clinical Case Reports.2021; 4(2): 99.     CrossRef
  • Prediction of Cardiovascular Risk Using Nonalcoholic Fatty Liver Disease Scoring Systems
    Ye-Na Kweon, Hae-Jin Ko, A-Sol Kim, Hye-In Choi, Ji-Eun Song, Ji-Yeon Park, Sung-Min Kim, Hee-Eun Hong, Kyung-Jin Min
    Healthcare.2021; 9(7): 899.     CrossRef
  • Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice
    Yongxiang Yu, Dongru Chen, Yuhua Zhao, Jianjun Zhu, Xiaohui Dong
    International Journal of Immunopathology and Pharmacology.2021;[Epub]     CrossRef
  • Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus
    Jaskamal Padda, Khizer Khalid, Anwar Khedr, Fahriba Tasnim, Ola A Al-Ewaidat, Ayden Charlene Cooper, Gutteridge Jean-Charles
    Cureus.2021;[Epub]     CrossRef
  • Nonalcoholic fatty liver disease and the risk of insulin-requiring gestational diabetes
    Sang Youn You, Kyungdo Han, Seung-Hawn Lee, Mee Kyoung Kim
    Diabetology & Metabolic Syndrome.2021;[Epub]     CrossRef
  • Serum syndecan‐4 is associated with nonalcoholic fatty liver disease
    Shu Jing Xia, Li Zhong Tang, Wen Hua Li, Zhao Shan Xu, Li Li Zhang, Feng Gan Cheng, Hong Xia Chen, Zi Hua Wang, Yu Cheng Luo, An Na Dai, Jian Gao Fan
    Journal of Digestive Diseases.2021; 22(9): 536.     CrossRef
  • Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
    Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
    Endocrinology and Metabolism.2021; 36(4): 823.     CrossRef
  • Grape pomace reduces the severity of non-alcoholic hepatic steatosis and the development of steatohepatitis by improving insulin sensitivity and reducing ectopic fat deposition in mice
    Tehila Daniel, Michaella Ben-Shachar, Elyashiv Drori, Sharleen Hamad, Anna Permyakova, Elad Ben-Cnaan, Joseph Tam, Zohar Kerem, Tovit Rosenzweig
    The Journal of Nutritional Biochemistry.2021; 98: 108867.     CrossRef
  • The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease
    Sylwia Ziolkowska, Agata Binienda, Maciej Jabłkowski, Janusz Szemraj, Piotr Czarny
    International Journal of Molecular Sciences.2021; 22(20): 11128.     CrossRef
  • The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008–2011)
    Hyun Min Kim, Yong-ho Lee
    Endocrinology and Metabolism.2021; 36(6): 1232.     CrossRef
  • Tip 2 Diyabet Modeli Ratların Karaciğer Dokularında Kodlanan Genlerin İfade Düzeyleri
    Lütfiye ÖZPAK, Ayfer PAZARBAŞI
    Ankara Sağlık Bilimleri Dergisi.2021; 10(1): 25.     CrossRef
  • Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
    Judith Aron-Wisnewsky, Chloé Vigliotti, Julia Witjes, Phuong Le, Adriaan G. Holleboom, Joanne Verheij, Max Nieuwdorp, Karine Clément
    Nature Reviews Gastroenterology & Hepatology.2020; 17(5): 279.     CrossRef
  • Non-alcoholic fatty liver disease and primary care physicians
    Ludovico Abenavoli, Anna C. Procopio, Milica Medić-Stojanoska, Francesco Luzza
    Minerva Gastroenterologica e Dietologica.2020;[Epub]     CrossRef
  • The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
    Hideki Fujii, Norifumi Kawada
    International Journal of Molecular Sciences.2020; 21(11): 3863.     CrossRef
  • Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway
    Yuanyuan Liu, Mengjie Wang, Wei Xu, Hongman Zhang, Weihe Qian, Xiang Li, Xingbo Cheng
    Life Sciences.2020; 241: 117086.     CrossRef
  • Serum lipoprotein(a) levels and insulin resistance have opposite effects on fatty liver disease
    Inha Jung, Hyemi Kwon, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee
    Atherosclerosis.2020; 308: 1.     CrossRef
  • The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus
    Xueyang Zhang, Ran Bai, Yong Jia, Junwei Zong, Yongbo Wang, Yanan Dong
    International Journal of Diabetes in Developing Countries.2020; 40(4): 491.     CrossRef
  • Association between Thyroid Function and Nonalcoholic Fatty Liver Disease in Euthyroid Type 2 Diabetes Patients
    Bin Huang, Shengju Yang, Shandong Ye
    Journal of Diabetes Research.2020; 2020: 1.     CrossRef
  • The Absence of NLRP3-inflammasome Modulates Hepatic Fibrosis Progression, Lipid Metabolism, and Inflammation in KO NLRP3 Mice during Aging
    Paloma Gallego, Beatriz Castejón-Vega, José A. del Campo, Mario D. Cordero
    Cells.2020; 9(10): 2148.     CrossRef
  • Prevalence of people at risk of developing type 2 diabetes mellitus and the involvement of community pharmacies in a national screening campaign: a pioneer action in Brazil
    Cassyano J. Correr, Wendel Coura-Vital, Josélia C. Q. P. Frade, Renata C. R. M. Nascimento, Lúbia G. Nascimento, Eliete B. Pinheiro, Wesley M. Ferreira, Janice S. Reis, Karla F. S. Melo, Roberto Pontarolo, Mônica S. A. Lenzi, José V. Almeida, Hermelinda C
    Diabetology & Metabolic Syndrome.2020;[Epub]     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
  • Elevated TPOAb is a Strong Predictor of Autoimmune Development in Patients of Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Case–Control Study


    Chenyi Wang, Qianglong Niu, Haihong Lv, Qian Li, Yuping Ma, Jiaojiao Tan, Chunhua Liu
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 4369.     CrossRef
  • Sarcopoterium spinosum Inhibited the Development of Non-Alcoholic Steatosis and Steatohepatitis in Mice
    Ayala Wollman, Tehila Daniel, Tovit Rosenzweig
    Nutrients.2019; 11(12): 3044.     CrossRef
Close layer
Original Articles
Clinical Study
Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults
Sang Bae Lee, Min Kyung Kim, Shinae Kang, Kahui Park, Jung Hye Kim, Su Jung Baik, Ji Sun Nam, Chul Woo Ahn, Jong Suk Park
Endocrinol Metab. 2019;34(2):179-186.   Published online May 20, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.2.179
  • 13,477 View
  • 220 Download
  • 126 Web of Science
  • 124 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Recently, the triglyceride glucose (TyG) index has been considered a surrogate marker of insulin resistance which is a well-known pathogenic factor in nonalcoholic fatty liver disease (NAFLD). However, few studies have investigated the relationship between the TyG index and NAFLD. Thus, we investigated the relationship between the TyG index and NAFLD and the effectiveness of the TyG index compared with the homeostasis model assessment of insulin resistance (HOMA-IR) in identifying NAFLD in Korean adults.

Methods

Participants of 4,986 who underwent ultrasonography in a health promotion center were enrolled. The TyG index was calculated as ln [fasting triglycerides (mg/dL)×fasting glucose (mg/dL)/2], and HOMA-IR was estimated. NAFLD was diagnosed by ultrasonography.

Results

Significant differences were observed in metabolic parameters among the quartiles of the TyG index. The prevalence of NAFLD significantly increased with increment in the TyG index. After adjusting for multiple risk factors, a logistic regression analysis was performed. When the highest and lowest quartiles of the TyG index and HOMA-IR were compared, the odds ratios for the prevalence of NAFLD were 2.94 and 1.93 (95% confidence interval, 2.32 to 3.72 and 1.43 to 2.61; both P for trend <0.01), respectively. According to the receiver operating characteristic analysis, the TyG index was superior to HOMA-IR in predicting NAFLD.

Conclusion

The TyG index and prevalence of NAFLD were significantly related and the TyG index was superior to HOMA-IR in predicting NAFLD in Korean adults.

Citations

Citations to this article as recorded by  
  • Índice metabólico como marcador predictivo no invasivo de esteatosis hepática en pacientes con enfermedad del hígado graso no alcohólico
    Julio Lara-Riegos, Luis Alberto Chi-Cervera, Iaarah Montalvo-Gordon, Hugo Azcorra-Pérez, Julio Torres-Romero, Víctor Arana-Argáez, Mario Ramírez-Camacho, María Eugenia Icaza-Chávez
    Medicina Clínica.2026; 166(1): 107268.     CrossRef
  • The predictive potential of surrogate indicators of insulin resistance for type 2 diabetic kidney disease
    Qiuhui Tian, Yu Liu, Qiumei Cao, Meixu Zhang, Fengying Zhu, Yukai He, Xiaoling Zhu
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Comparison of the triglyceride-glucose index and triglyceride-glucose-body mass index for predicting non-alcoholic fatty liver disease in elderly diabetic patients
    Gaohui Zhu, Yihui Qu, Kanan Chen, Dingfa He, Jing Wang, Ziwei Tang, Xinyi Wang, Minqiao Zhang, Peilan Jiang, Ruijie Zhang, Kedan Cai, Qian Wu
    PLOS One.2026; 21(2): e0341109.     CrossRef
  • Metabolic index a non-invasive predictive marker of liver steatosis in patients with non-alcoholic fatty liver disease
    Julio Lara-Riegos, Luis Alberto Chi-Cervera, Iaarah Montalvo-Gordon, Hugo Azcorra-Pérez, Julio Torres-Romero, Víctor Arana-Argáez, Mario Ramírez-Camacho, María Eugenia Icaza-Chávez
    Medicina Clínica (English Edition).2026; 166(1): 107268.     CrossRef
  • Association between the C-reactive protein-triglyceride glucose index and erectile dysfunction in US males: results from NHANES 2001–2004
    Yangyang Mei, Yangmeina Li, Bo Zhang, Renfang Xu, Xingliang Feng
    International Journal of Impotence Research.2025; 37(8): 612.     CrossRef
  • Triglyceride-glucose index as a marker for visceral obesity in patients with gastric cancer
    Junbo Zuo, Zhenhua Huang, Yan Ge, Xin Ding, Xiuhua Wang, Yan Huang
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • The Prognostic Value of the Triglyceride-Glucose and Fibrosis-4 Indices in Patients Undergoing Coronary Angiography: A Retrospective Cohort Analysis
    Amir Aker, Tom Tarchitzky, Yuval Avidan, Barak Zafrir
    CJC Open.2025; 7(4): 465.     CrossRef
  • Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus
    Mengmeng Hu, Jingyu Yang, Beibei Gao, Zhoulu Wu, Ying Wu, Dandan Hu, Qiong Shen, Lei Chen
    Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
  • Predictive Value of the Triglyceride-Glucose Index for Metabolic-Associated Fatty Liver Disease in Individuals with Different Metabolic Obese Phenotypes
    Dan Lv, Zepu Wang, Huanxin Liu, Cuiqiao Meng
    Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 125.     CrossRef
  • Use of the FHTHWA Index as a Novel Approach for Predicting the Incidence of Diabetes in a Japanese Population Without Diabetes: Data Analysis Study
    Jiao Wang, Jianrong Chen, Ying Liu, Jixiong Xu
    JMIR Medical Informatics.2025; 13: e64992.     CrossRef
  • The predictive value of triglyceride-glucose-high density lipoprotein-body mass index (TGH-BMI) for different degrees of hepatic steatosis and liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD)
    Ying Li, Tianrong Pan, Yue Wang, Guojuan Wang, Fang Wang
    Clinical Nutrition ESPEN.2025; 66: 290.     CrossRef
  • Comparison of SPISE and METS-IR and Other Markers to Predict Insulin Resistance and Elevated Liver Transaminases in Children and Adolescents
    Kyungchul Song, Eunju Lee, Hye Sun Lee, Hana Lee, Ji-Won Lee, Hyun Wook Chae, Yu-Jin Kwon
    Diabetes & Metabolism Journal.2025; 49(2): 264.     CrossRef
  • The Value of TyG‐Related Indices in Evaluating MASLD and Significant Liver Fibrosis in MASLD
    Haoxuan Zou, Jiejie Xie, Xiaopu Ma, Yan Xie, Xingshun Qi
    Canadian Journal of Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Association of triglyceride-glucose index with bone mineral density and fracture: a systematic review
    Maryam Yousefiasl, Arezou Soltanattar, Ali Ezzatollahi Tanha, Pouria Azami, Maryam Alaei, Amir Ali Alamdari, Farhad Esmailsorkh, Amirhossein Habibzadeh, Shaghayegh Khanmohammadi
    Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
  • The triglyceride glucose-waist circumference is the best indicator for screening non-alcoholic fatty liver disease in middle-aged and elderly people
    Yin Yang, Yuan Luo, Jinchun Shi, Yunyu Yin, Xiangyu Du, Jia Guo, Hua Zhuang
    Nutrición Hospitalaria.2025;[Epub]     CrossRef
  • Triglyceride-glucose index is independently associated with fatty pancreas disease in Chinese elderly
    Weinuo Mi, Yuzhi Zhang, Qifeng Wang, Wenbo Ding, Xiaodong Mao, Yu Sun, Xingjia Li, Chao Liu, Shuhang Xu
    BMC Endocrine Disorders.2025;[Epub]     CrossRef
  • Comparison of triglyceride glucose index and other insulin resistance indexes in children with overweight and obesity
    Derya Kalyoncu, Melis Kavrak Kursun
    BMC Endocrine Disorders.2025;[Epub]     CrossRef
  • Comparison of the predictive value of TyG index and METS-IR for OSA combined with NAFLD: a retrospective observational study based on a physical examination population
    Min Li, Yujing Wan, Ziyue Wei, Weihong Lin
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Association of Triglyceride-Glucose (TyG) Index With Severe Acute Pancreatitis: A Systematic Review and Meta-Analysis
    Roshan K Mahat, Vedika Rathore, Ravindra Saxena
    Cureus.2025;[Epub]     CrossRef
  • Triglyceride-glucose parameters as predictors of diabetes mellitus incidence in Korean adults: a secondary analysis of a Prospective Cohort Study
    Yu Jin Park, Miseon Shin, Hyun Seon Jeon, Eun Hee Yang
    Journal of Korean Academy of Nursing.2025; 55(2): 205.     CrossRef
  • Potential utility of the triglyceride-glucose index as a predictor of erectile dysfunction and its severity: a cross-sectional, case–control study
    Huseyin Aytac Ates, Taha Burak Bulut
    Scientific Reports.2025;[Epub]     CrossRef
  • Relationship between triglyceride-glucose index and stroke risk in middle-aged and older Chinese population: a national longitudinal study based on explainable machine learning
    Ying Gao, Meihui Zhang, Chen Xu, Birong Wu, Shan Qiao, Yong Cai, Fan Hu
    Diabetes Research and Clinical Practice.2025; 227: 112414.     CrossRef
  • Gender differences in the association between the triglyceride-glucose index and peripheral artery disease in vascular surgery inpatients aged 50 and above: a retrospective cross-sectional study
    Zhi-wei Li, Peng Zhou, Bei-hao Shi, Ya-qin Gong, Ke Lu, Jian Zhu
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Impact of genotyping (PTPN2, rs2542151) and (MBOAT7, rs641738) in prediction of fibrosis in Metabolic dysfunction- associated steatotic liver disease’ patients
    Shimaa Abdelsattar, Hiba S. Al-Amodi, Hala F. M. Kamel, Zeinab A. Kasemy, Ehab Darwish, Asmaa Mosbeh, Ayman A. Sakr, Hanaa M. Elgazzar, Mervat Abdelkareem, Mai Abozeid, Shimaa K. Zewain, Hanan M. Bedair, Sabry M. Abdelmageed
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Associations of triglyceride-glucose index with N-terminal pro-B-type natriuretic peptide and mortality in middle-aged and elderly individuals
    Haitao Xie, Le Shen, Jianghong Li, Chuxin Lv, Tong Sun, Peng Yu, Xiaohu Chen, Shuhua Tang
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Association between the TyG index and MAFLD and its subtypes: a population-based cross-sectional study
    Cui’e Liu, Chaochen Li, Jia Fu, Long Bai, Man Wang, Pei Song, Meng Zheng
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Novel surrogate markers of insulin resistance in patients with metabolic dysfunction-associated steatosis liver disease: Associations with dietary and lifestyle inflammatory scores in the large cross-sectional study
    Yusuf Yilmaz, Behrad Saeedian, Nastaran Babajani, Sara Ashtari, Fereshteh Ghorat, Ehsaneh Taheri
    Clinical Nutrition ESPEN.2025; 70: 204.     CrossRef
  • Landscape and research trends of triglyceride-glucose index with health: a bibliometric analysis
    Jia Liu, Song Hu, Shan Wang, Tongxiao Luan, Yuting Duan, Nina An, Jing Zhou, Li Jia, Yongjun Mao
    Discover Medicine.2025;[Epub]     CrossRef
  • The Predictive Role of the Triglyceride/High-Density Lipoprotein Ratio and the Triglyceride–Glucose Index, Along with Anthropometric Measurements, in Diagnosing Non-Alcoholic Fatty Liver Disease in Obese Kids and Juveniles, and the Evaluation of Novel Car
    Emrah Çığrı, Funda Çatan İnan, Sedat Gülten, Mehmet Akif Bildirici, Ayşe Ece Gökkaya, Metin Asıleren, Mustafa Koyun, Bahadır Reis, Merve Esen
    Children.2025; 12(11): 1439.     CrossRef
  • Associations of longitudinal trajectories of triglyceride-glucose index combined with classical and novel obesity indices and cardiovascular disease: evidence from a nationwide prospective cohort study in China
    Chao Wang, Shiming He, Guobo Xie, Shuhua Zhang, Zhiyu Xiong, Hengcheng Lu, Qun Wang, Lin Xie, Wei Wang, Yang Zou, Xue Li
    Cardiovascular Diabetology.2025;[Epub]     CrossRef
  • High triglyceride-glucose index is associated with diabetes mellitus in people with HIV in Southwest China
    Liangjia Wei, Chunxing Tao, Xinju Huang, Ruby Congjiang Wang, Jianhua Che, Aidan Nong, Rongye Huang, Zhiman Yan, Lijing Huang, Jiao Qin, Lincong Chen, Sanqi An, Junjun Jiang, Lixian Xiong, Hao Liang, Lijuan Bao, Bingyu Liang, Li Ye
    AIDS.2025; 39(15): 2295.     CrossRef
  • Assessing the role of the Triglyceride-glucose related indices in identifying metabolic syndrome risk across body mass index categories
    Chengcheng Qian, Liling Mao, Yu Liu, Xinxin Zhao, Jin Li, Fei Sheng, Haoming Song
    Endocrine.2025;[Epub]     CrossRef
  • Comparison of the TyG index, TyG-traditional obesity indices, and TyG-novel obesity indices: does increased complexity help in predicting cardiometabolic multimorbidity?
    Fanzhi Zhang, Bin Zhang, Xinfang Huang, Zhenyu Wang, Juan Wang, Houhui Lan, Guobo Xie, Wei Wang, Yang Zou, Chao Wang
    Lipids in Health and Disease.2025;[Epub]     CrossRef
  • Triglyceride-glucose body mass index predicts prognosis in patients with ST-elevation myocardial infarction
    Ming Liu, Jianyuan Pan, Ke Meng, Yuwei Wang, Xueqing Sun, Likun Ma, Xiaofan Yu
    Scientific Reports.2024;[Epub]     CrossRef
  • Triglyceride-glucose index is capable of identifying metabolically obese, normal-weight older individuals
    Bokun Kim, Keisuke Taniguchi, Tomonori Isobe, Sechang Oh
    Journal of Physiological Anthropology.2024;[Epub]     CrossRef
  • Comparison of triglyceride/glucose index and related parameters with Indian Diabetes Risk Score assessment in non-diabetic individuals visiting primary healthcare centre—A community-based cross-sectional study
    Sivapragasam Ramalingam, Amlan Kumar Kar, Rajini Senthil
    Journal of Family Medicine and Primary Care.2024; 13(1): 235.     CrossRef
  • Insulin resistance in NSCLC: unraveling the link between development, diagnosis, and treatment
    Shizhang Zhan, Liu Wang, Wenping Wang, Ruoran Li
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • The association between the triglyceride–glucose index and prognosis in postoperative renal cell carcinoma patients: a retrospective cohort study
    Guoliang Qin, Zhuang Sun, Yuxiang Jin, Xiangguo Ren, Zhaocun Zhang, Shuo Wang, Guanwen Zhou, Kun Huang, Haifeng Zhao, Xianzhou Jiang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Profiling triglyceride-glucose index in Filipinos with type 2 diabetes mellitus: a single-center study
    Chastene Christopher Flake, Madonna Morales-Valenzuela, Raphael Enrique Tiongco, Annalyn Navarro
    The Egyptian Journal of Internal Medicine.2024;[Epub]     CrossRef
  • Diagnostic Performance of Insulin Resistance Indices for Identifying Metabolic Dysfunction–Associated Fatty Liver Disease
    A. Lum Han, Hee Kyung Lee, Sae Ron Shin
    Metabolic Syndrome and Related Disorders.2024; 22(5): 402.     CrossRef
  • Metabolic profiling of galectin-1 and galectin-3: a cross-sectional, multi-omics, association study
    Emanuel Fryk, Vagner Ramon Rodrigues Silva, Lena Strindberg, Robin Strand, Håkan Ahlström, Karl Michaëlsson, Joel Kullberg, Lars Lind, Per-Anders Jansson
    International Journal of Obesity.2024; 48(8): 1180.     CrossRef
  • A Study of the Relationship Between the Triglyceride-Glucose Index and Skeletal Muscle Mass in a General Chinese Population
    Yue Liu, Hongwei Chen, Ziyi Wei, Tingting Han, Ningxin Chen, Yurong Weng, Yaomin Hu
    Clinical Medicine Insights: Endocrinology and Diabetes.2024;[Epub]     CrossRef
  • Triglyceride–glucose–alanine aminotransferase index: A noninvasive serum predictor for identifying the severity of pediatric nonalcoholic fatty liver disease
    Eu-Seon Noh, Il Tae Hwang
    Medicine.2024; 103(26): e38241.     CrossRef
  • Triglyceride glucose index as a predictor for non-alcoholic fatty liver disease: insights from a longitudinal analysis in non-obese individuals
    Qi Ning, Keyang Zheng, Jiafu Yan, Chao Zhu
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • The nutritional metabolic risk index as a predictor of all-cause and cardiovascular mortality: A national cohort study
    Chuanwei Zhao, Yane Yang, Conghao Duan, Chenxuan Gao, Yansi Wang, Huan Ni, Lanping Zhou, Yunfang Xiang, MeiJu Li, Zhao Xu
    Clinical Nutrition ESPEN.2024; 63: 391.     CrossRef
  • Triglyceride Glucose Index is Associated with Ultrasonographic Fatty Liver Indicator in Children and Adolescents with Non-alcoholic Fatty Liver Disease
    Bitgyeol Kim, Hye Young Jin, Jong Seo Yoon, Eu Seon Noh, Il Tae Hwang
    Journal of Clinical Research in Pediatric Endocrinology.2024;[Epub]     CrossRef
  • Triglyceride-glucose index and combined indicators: effective indicators for screening NAFLD in snoring patients
    Yuqing Cai, Jia Chen, Xiaoyu Deng, Biying Wang, Jiefeng Huang, Ningfang Lian
    BMC Pulmonary Medicine.2024;[Epub]     CrossRef
  • Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis
    Sandeep Samethadka Nayak, Dona Kuriyakose, Lakshmi D. Polisetty, Anjali Avinash Patil, Daniyal Ameen, Rakshita Bonu, Samatha P. Shetty, Pubali Biswas, Micheal T. Ulrich, Negin Letafatkar, Arman Habibi, Mohammad-Hossein Keivanlou, Sara Nobakht, Abdulhadi A
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Relationship between triglyceride-glucose index and endometriosis: a cross-sectional analysis
    Yue Cao, Qian Yang, Qiqing Mai, Jianxiong Wuliu, Kaixian Deng
    BMC Women's Health.2024;[Epub]     CrossRef
  • Association Between Triglyceride-Glucose Index and Lung Function Parameters in the General Population Undergoing Health Examinations
    Yu Yang, Shuqi Wang, Boying Jia, Shuchun Chen
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 4031.     CrossRef
  • Association of HOMA-IR Versus TyG Index with Diabetes in Individuals Without Underweight or Obesity
    Bokun Kim, Gwon-Min Kim, Up Huh, Juhyun Lee, Eunji Kim
    Healthcare.2024; 12(23): 2458.     CrossRef
  • The Triglyceride-Glucose Index is Associated with Vitamin D Status in Metabolic-Associated Fatty Liver Disease
    Zhiping Liu, Wensha Zhang, Zhiwei Zhao, Wenhao Li, Jinhua Zhang
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2651.     CrossRef
  • The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose–response meta-analysis
    Qin Ling, Jiawei Chen, Xiao Liu, Yi Xu, Jianyong Ma, Peng Yu, Kai Zheng, Fuwei Liu, Jun Luo
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Triglyceride–Glucose Index as a Potential Indicator of Sarcopenic Obesity in Older People
    Bokun Kim, Gwonmin Kim, Yongkook Lee, Keisuke Taniguchi, Tomonori Isobe, Sechang Oh
    Nutrients.2023; 15(3): 555.     CrossRef
  • Association of insulin resistance with bone mineral density in a nationwide health check-up population in China
    Ming Zhuo, Ze Chen, Mao-Lin Zhong, Fang Lei, Juan-Juan Qin, Shuhua Liu, Ye-Mao Liu, Tao Sun, Xiao-Jing Zhang, Lihua Zhu, Jingjing Cai, Jun-Ming Ye, Erping Yang
    Bone.2023; 170: 116703.     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Comparison of the prognostic value of a comprehensive set of predictors in identifying risk of metabolic-associated fatty liver disease among employed adults
    Ze Yang, Bin Yu, Zihang Wang, Zhitao Li, Bo Yang, Honglian Zeng, Shujuan Yang
    BMC Public Health.2023;[Epub]     CrossRef
  • The triglyceride glucose index and CDKAL1 gene rs10946398 SNP are associated with NAFLD in Chinese adults
    Jun ZHU, Dujuan XU, Ruihua YANG, Min LIU, Ying LIU
    Minerva Endocrinology.2023;[Epub]     CrossRef
  • PNPLA3 rs738409 risk genotype decouples TyG index from HOMA2-IR and intrahepatic lipid content
    Ákos Nádasdi, Viktor Gál, Tamás Masszi, Anikó Somogyi, Gábor Firneisz
    Cardiovascular Diabetology.2023;[Epub]     CrossRef
  • Baseline level and change trajectory of the triglyceride-glucose index in relation to the development of NAFLD: a large population-based cohort study
    Yaqin Wang, Jiangang Wang, Lei Liu, Pingting Yang, Shuwen Deng, Xuelian Liu, Linlin Zhao, Changfa Wang, Ying Li
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Assessing temporal differences in the predictive power of baseline TyG-related parameters for future diabetes: an analysis using time-dependent receiver operating characteristics
    Maobin Kuang, Ruijuan Yang, Xin Huang, Chao Wang, Guotai Sheng, Guobo Xie, Yang Zou
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • Metabolic Score for Insulin Resistance (METS-IR) Predicts Adverse Cardiovascular Events in Patients with Type 2 Diabetes and Ischemic Cardiomyopathy
    Xuehe Zhang, Fen Liu, Wenling Li, Jixin Zhang, Tong Zhang, Xiaolin Yu, Junyi Luo, Qian Zhao, Jinyu Zhang, Binbin Fang, Yining Yang, Xiaomei Li
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 1283.     CrossRef
  • Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease Among Hospital Staff
    Daya Zhang, Lijun Zhang, Shiju Chen, Runxiang Chen, Xiaodong Zhang, Feihu Bai
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 1221.     CrossRef
  • The metabolic score of insulin resistance is positively correlated with bone mineral density in postmenopausal patients with type 2 diabetes mellitus
    Peng Gu, Bin Pu, Qiao Xin, Dan Yue, LieLiang Luo, JiaSheng Tao, HaiShan Li, Ming Chen, MingHua Hu, XiaoRong Hu, XiaoHui Zheng, ZhanPeng Zeng
    Scientific Reports.2023;[Epub]     CrossRef
  • Prevalence estimates of the insulin resistance and associated prevalence of heart failure among United Status adults
    Xiaozhong Li, Jihong Wang, Liyan Niu, Ziqi Tan, Jianyong Ma, Ling He, Peng Yu, Xiao Liu, Juxiang Li
    BMC Cardiovascular Disorders.2023;[Epub]     CrossRef
  • From NAFLD to HCC: Advances in noninvasive diagnosis
    Qinchen Xu, Maoxiao Feng, Yidan Ren, Xiaoyan Liu, Huiru Gao, Zigan Li, Xin Su, Qin Wang, Yunshan Wang
    Biomedicine & Pharmacotherapy.2023; 165: 115028.     CrossRef
  • Usefulness of two-dimensional shear wave elastography in the assessment of non-alcoholic fatty liver disease in children and adolescents
    Jong Seo Yoon, Kyoung Ja Lim, Il Tae Hwang
    Scientific Reports.2023;[Epub]     CrossRef
  • A non-linear relationship between triglyceride glucose waist circumference and nonalcoholic fatty liver disease in a Japanese population: a secondary analysis
    Xiaojie He, Xinyue Huang, Yafang Qian, Ting Sun
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Neck Circumference as a Predictor of Insulin Resistance in People with Non-alcoholic Fatty Liver Disease
    Da-Hye Son, Jee Hye Han, Jun-Hyuk Lee
    Journal of Obesity & Metabolic Syndrome.2023; 32(3): 214.     CrossRef
  • Prediction and Validation of Metabolic Dysfunction-Associated Fatty Liver Disease Using Insulin Resistance-Related Indices in the Japanese Population
    Kengo Moriyama, Nagamu Inoue, Jin Imai, Yumi Masuda, Chizumi Yamada, Noriaki Kishimoto, Shinji Takashimizu, Akira Kubo, Yasuhiro Nishizaki
    Metabolic Syndrome and Related Disorders.2023; 21(9): 489.     CrossRef
  • Application value of triglyceride-glucose index and triglyceride-glucose body mass index in evaluating the degree of hepatic steatosis in non-alcoholic fatty liver disease
    Mengyuan Wang, Mingxing Chang, Peipu Shen, Wei Wei, Huayao Li, Guifang Shen
    Lipids in Health and Disease.2023;[Epub]     CrossRef
  • Homeostatic Model Assessment of Insulin Resistance as a Potential Screening Test for Non-Alcoholic Fatty Liver Disease in Korean Adults without Diabetes
    Hyejung Lee, Jae-Ho Lee
    Korean Journal of Family Practice.2023; 13(4): 233.     CrossRef
  • Comparison of the Triglyceride Glucose Index and Modified Triglyceride Glucose Indices to Predict Nonalcoholic Fatty Liver Disease in Youths
    Kyungchul Song, Goeun Park, Hye Sun Lee, Myeongseob Lee, Hae In Lee, Han Saem Choi, Junghwan Suh, Ahreum Kwon, Ho-Seong Kim, Hyun Wook Chae
    The Journal of Pediatrics.2022; 242: 79.     CrossRef
  • The triglyceride-glucose index as a clinical useful marker for metabolic associated fatty liver disease (MAFLD): a population-based study among Iranian adults
    Ehsaneh Taheri, Mohammad Amin Pourhoseingholi, Alireza Moslem, Amir Hossein Hassani, Alireza Mousavi Jarrahi, Hamid Asadzadeh Aghdaei, Mohammad Reza Zali, Behzad Hatami
    Journal of Diabetes & Metabolic Disorders.2022; 21(1): 97.     CrossRef
  • Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome
    Da-Hye Son, Hye Sun Lee, Yong-Jae Lee, Jun-Hyuk Lee, Jee-Hye Han
    Nutrition, Metabolism and Cardiovascular Diseases.2022; 32(3): 596.     CrossRef
  • Triglycerides/Glucose Index Is Associated with Sperm Parameters and Sperm DNA Fragmentation in Primary Infertile Men: A Cross-Sectional Study
    Federico Belladelli, Luca Boeri, Edoardo Pozzi, Giuseppe Fallara, Christian Corsini, Luigi Candela, Walter Cazzaniga, Daniele Cignoli, Luca Pagliardini, Alessia D’Arma, Paolo Capogrosso, Eugenio Ventimiglia, Francesco Montorsi, Andrea Salonia
    Metabolites.2022; 12(2): 143.     CrossRef
  • Association of triglyceride-glucose index and stroke recurrence among nondiabetic patients with acute ischemic stroke
    Xiaomeng Yang, Guangyao Wang, Jing Jing, Anxin Wang, Xiaoli Zhang, Qian Jia, Xia Meng, Xingquan Zhao, Liping Liu, Hao Li, Yongjun Wang, Yilong Wang
    BMC Neurology.2022;[Epub]     CrossRef
  • The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients
    Benjamin Rivière, Audrey Jaussent, Valérie Macioce, Stéphanie Faure, Nicolas Builles, Patrick Lefebvre, Philippe Géraud, Marie-Christine Picot, Sandra Rebuffat, Eric Renard, Valérie Paradis, Marie-Dominique Servais, Nathalie de Preville, David Nocca, Anne
    Diabetes & Metabolism.2022; 48(4): 101345.     CrossRef
  • Association of triglyceride-glucose with cardiac hemodynamics in type 2 diabetes
    Chenxi Wang, Zhicong Zhao, Xia Deng, Zhensheng Cai, Tian Gu, Lian Li, Chang Guo, Dong Wang, Ling Yang, Li Zhao, Guoyue Yuan
    Diabetes and Vascular Disease Research.2022;[Epub]     CrossRef
  • Comparison of the Modified TyG Indices and Other Parameters to Predict Non-Alcoholic Fatty Liver Disease in Youth
    Kyungchul Song, Hae Won Lee, Han Saem Choi, Goeun Park, Hye Sun Lee, Su Jin Kim, Myeongseob Lee, Junghwan Suh, Ahreum Kwon, Ho-Seong Kim, Hyun Wook Chae
    Biology.2022; 11(5): 685.     CrossRef
  • Triglyceride-Glucose Index for Early Prediction of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of 121,975 Individuals
    Azizullah Beran, Hazem Ayesh, Mohammed Mhanna, Waseem Wahood, Sami Ghazaleh, Ziad Abuhelwa, Wasef Sayeh, Nameer Aladamat, Rami Musallam, Reem Matar, Saif-Eddin Malhas, Ragheb Assaly
    Journal of Clinical Medicine.2022; 11(9): 2666.     CrossRef
  • Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome
    Anca Maria Amzolini, Mircea-Cătălin Forțofoiu, Anca Barău Alhija, Ionela Mihaela Vladu, Diana Clenciu, Adina Mitrea, Maria Forțofoiu, Daniela Matei, Magdalena Diaconu, Marinela Sinziana Tudor, Elena Simona Micu
    Journal of Clinical Medicine.2022; 11(11): 3043.     CrossRef
  • Triglyceride glucose index is superior biomarker for predicting type 2 diabetes mellitus in children and adolescents
    Jong Seo Yoon, Hye Jin Lee, Hwal Rim Jeong, Young Suk Shim, Min Jae Kang, Il Tae Hwang
    Endocrine Journal.2022; 69(5): 559.     CrossRef
  • Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
    Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
    Obesity.2022; 30(6): 1279.     CrossRef
  • Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
    Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
    Journal of General Internal Medicine.2022; 37(16): 4153.     CrossRef
  • The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications
    Rossella Palma, Annamaria Pronio, Mario Romeo, Flavia Scognamiglio, Lorenzo Ventriglia, Vittorio Maria Ormando, Antonietta Lamazza, Stefano Pontone, Alessandro Federico, Marcello Dallio
    Journal of Clinical Medicine.2022; 11(13): 3649.     CrossRef
  • Comparison of the diagnostic value between triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio in metabolic-associated fatty liver disease patients: a retrospective cross-sectional study
    Zhi Liu, He He, Yuzhao Dai, Lidan Yang, Shenling Liao, Zhenmei An, Shuangqing Li
    Lipids in Health and Disease.2022;[Epub]     CrossRef
  • Insulin Resistance Markers to Detect Nonalcoholic Fatty Liver Disease in a Male Hispanic Population
    Maritza Pérez-Mayorga, Jose P. Lopez-Lopez, Maria A. Chacon-Manosalva, Maria G Castillo, Johanna Otero, Daniel Martinez-Bello, Diego Gomez-Arbelaez, Daniel D. Cohen, Patricio Lopez-Jaramillo, Federico Ravaioli
    Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1.     CrossRef
  • Risk factors and prediction model for nonalcoholic fatty liver disease in northwest China
    Danting Li, Meiyu Zhang, Shengli Wu, Huiwen Tan, Nong Li
    Scientific Reports.2022;[Epub]     CrossRef
  • The triglyceride glucose index is associated with the cerebral small vessel disease in a memory clinic population
    Jiayu Zhang, Ming Hu, Yanqiu Jia, Shicong Zhao, Peiyuan Lv, Mingyue Fan, Yuanyuan Shi, Wei Jin
    Journal of Clinical Neuroscience.2022; 104: 126.     CrossRef
  • Integrating experimental model, LC-MS/MS chemical analysis, and systems biology approach to investigate the possible antidiabetic effect and mechanisms of Matricaria aurea (Golden Chamomile) in type 2 diabetes mellitus
    Yassin Ismail, Dina M. Fahmy, Maivel H. Ghattas, Mai M. Ahmed, Walaa Zehry, Samy M. Saleh, Dina M. Abo-elmatty
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Laboratory data clustering in defining population cohorts: Case study on metabolic indicators
    Ivan Pavicevic, Goran Miljus, Olgica Nedic
    Journal of the Serbian Chemical Society.2022; 87(9): 1025.     CrossRef
  • Association of triglyceride glucose-body mass index with non-small cell lung cancer risk: A case-control study on Chinese adults
    Feifei Wang, Ting He, Guoliang Wang, Tuo Han, Zhongqiang Yao
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Association Between Triglyceride-Glucose Index and Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Cohort Study
    Ru Zhang, Qing Guan, Mengting Zhang, Yajie Ding, Zongzhe Tang, Hongliang Wang, Wei Zhang, Yue Chen, Rong Jiang, Yan Cui, Jie Wang
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 3167.     CrossRef
  • Association between the triglyceride-glucose (TyG) index and increased blood pressure in normotensive subjects: a population-based study
    Dong-Hwa Lee, Jong Eun Park, So Young Kim, Hyun Jeong Jeon, Jong-Hyock Park
    Diabetology & Metabolic Syndrome.2022;[Epub]     CrossRef
  • Fructose consumption correlates with triglyceride-glucose index and glycemic status in healthy adults
    Eda Keskin, Havvanur Yoldas Ilktac
    Clinical Nutrition ESPEN.2022; 52: 184.     CrossRef
  • Associations Between Type 2 Diabetes Subtypes and Complications: Analysis of the Malaysia National Diabetes Registry
    Rasa Kazlauskaite, Nathan Ellermeier, Carrie Ngongo, Arunah Chandran, Pankaja Desai, Ethan Ritz, Rachel Nugent, Feisul Idzwan Mustapha
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • Independent and combined effects of triglyceride-glucose index on prehypertension risk: a cross-sectional survey in China
    Hong Xie, Jian Song, Liangliang Sun, Xinxin Xie, Yehuan Sun
    Journal of Human Hypertension.2021; 35(3): 207.     CrossRef
  • Association of Triglyceride-Glucose Index with Bone Mineral Density in Non-diabetic Koreans: KNHANES 2008–2011
    Jee Hee Yoon, A Ram Hong, Wonsuk Choi, Ji Yong Park, Hee Kyung Kim, Ho-Cheol Kang
    Calcified Tissue International.2021; 108(2): 176.     CrossRef
  • Triglyceride‐Glucose Index (TyG) is associated with erectile dysfunction: A cross‐sectional study
    Mehmet Yilmaz, Mustafa Karaaslan, Senol Tonyali, Mecit Celik, Tuncay Toprak, Oner Odabas
    Andrology.2021; 9(1): 238.     CrossRef
  • Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity
    Mohammad E. Khamseh, Mojtaba Malek, Rowshanak Abbasi, Hoda Taheri, Maryam Lahouti, Fariba Alaei-Shahmiri
    Metabolic Syndrome and Related Disorders.2021; 19(3): 167.     CrossRef
  • Triglyceride and glucose index and the risk of gestational diabetes mellitus: A nationwide population-based cohort study
    Jung A Kim, Jinsil Kim, Eun Roh, So-hyeon Hong, You-Bin Lee, Sei Hyun Baik, Kyung Mook Choi, Eunjin Noh, Soon Young Hwang, Geum Joon Cho, Hye Jin Yoo
    Diabetes Research and Clinical Practice.2021; 171: 108533.     CrossRef
  • Association of the triglyceride and glucose index with low muscle mass: KNHANES 2008–2011
    Jung A. Kim, Soon Young Hwang, Ji Hee Yu, Eun Roh, So-hyeon Hong, You-Bin Lee, Nam Hoon Kim, Hye Jin Yoo, Ji A. Seo, Nan Hee Kim, Sin Gon Kim, Sei Hyun Baik, Kyung Mook Choi
    Scientific Reports.2021;[Epub]     CrossRef
  • The triglycerides and glucose index is strongly associated with hepatic steatosis in children with overweight or obesity
    Luis E. Simental-Mendía, César Javier Ortega-Pacheco, Elvira García-Guerrero, María Alejandra Sicsik-Aragón, Fernando Guerrero-Romero, Gerardo Martínez-Aguilar
    European Journal of Pediatrics.2021; 180(6): 1755.     CrossRef
  • Triglyceride-glucose index and the risk of stroke and its subtypes in the general population: an 11-year follow-up
    Anxin Wang, Guangyao Wang, Qian Liu, Yingting Zuo, Shuohua Chen, Boni Tao, Xue Tian, Penglian Wang, Xia Meng, Shouling Wu, Yongjun Wang, Yilong Wang
    Cardiovascular Diabetology.2021;[Epub]     CrossRef
  • Association Between Triglyceride Glucose Index and Non-Small Cell Lung Cancer Risk in Chinese Population
    Xin Yan, Yujuan Gao, Jingzhi Tong, Mi Tian, Jinghong Dai, Yi Zhuang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Triglyceride Glucose Index Is Associated With Arterial Stiffness and 10-Year Cardiovascular Disease Risk in a Chinese Population
    Wen Guo, Wenfang Zhu, Juan Wu, Xiaona Li, Jing Lu, Pei Qin, Cheng Zhu, Nianzhen Xu, Qun Zhang
    Frontiers in Cardiovascular Medicine.2021;[Epub]     CrossRef
  • An Analysis of the Potential Relationship of Triglyceride Glucose and Body Mass Index With Stroke Prognosis
    Zongyi Hou, Yuesong Pan, Yindong Yang, Xiaofan Yang, Xianglong Xiang, Yilong Wang, Zixiao Li, Xingquan Zhao, Hao Li, Xia Meng, Yongjun Wang
    Frontiers in Neurology.2021;[Epub]     CrossRef
  • Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review
    Raquel Cano, José Pérez, Lissé Dávila, Ángel Ortega, Yosselin Gómez, Nereida Valero-Cedeño, Heliana Parra, Alexander Manzano, Teresa Véliz Castro, María Albornoz, Gabriel Cano, Joselyn Rojas-Quintero, Maricarmen Chacín, Valmore Bermúdez
    International Journal of Molecular Sciences.2021; 22(9): 4807.     CrossRef
  • Triglyceride glucose (TyG) index and the progression of liver fibrosis: A cross-sectional study
    Helda Tutunchi, Fatemeh Naeini, Majid Mobasseri, Alireza Ostadrahimi
    Clinical Nutrition ESPEN.2021; 44: 483.     CrossRef
  • Newly proposed insulin resistance indexes called TyG-NC and TyG-NHtR show efficacy in diagnosing the metabolic syndrome
    M. Mirr, D. Skrypnik, P. Bogdański, M. Owecki
    Journal of Endocrinological Investigation.2021; 44(12): 2831.     CrossRef
  • Association Between the Triglyceride–Glucose Index and Outcomes of Nonalcoholic Fatty Liver Disease: A Large-Scale Health Management Cohort Study
    Jing Liu, Liying Guan, Meng Zhao, Qihang Li, An Song, Ling Gao, Haiyan Lin, Jiajun Zhao
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 2829.     CrossRef
  • Association between triglyceride-glucose index and thyroid function in euthyroid adults: The Korea National Health and Nutritional Examination Survey 2015
    Wonsuk Choi, Ji Yong Park, A. Ram Hong, Jee Hee Yoon, Hee Kyung Kim, Ho-Cheol Kang, Sun Young Lee
    PLOS ONE.2021; 16(7): e0254630.     CrossRef
  • Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus
    Mojtaba Malek, Mohammad E. Khamseh, Haleh Chehrehgosha, Sohrab Nobarani, Fariba Alaei-Shahmiri
    Endocrine.2021; 74(3): 538.     CrossRef
  • The association between triglyceride-glucose index, cardio-cerebrovascular diseases, and death in Korean adults: A retrospective study based on the NHIS-HEALS cohort
    Joungyoun Kim, Sang-Jun Shin, Hee-Taik Kang, Claudio Passino
    PLOS ONE.2021; 16(11): e0259212.     CrossRef
  • A population-based study of TyG index distribution and its relationship to cardiometabolic risk factors in children and adolescents
    Jong Seo Yoon, Young Suk Shim, Hae Sang Lee, Il Tae Hwang, Jin Soon Hwang
    Scientific Reports.2021;[Epub]     CrossRef
  • Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China
    Jingrui Wang, Zhenzhen Su, Yijin Feng, Ruihan Xi, Jiamin Liu, Peixi Wang
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • The value of the triglyceride-glucose index in the diagnosis of insulin resistance in early forms of non-alcoholic fatty liver disease
    A. A. Shipovskaya, N. A. Larina, I. V. Kurbatova, O. P. Dudanova
    Experimental and Clinical Gastroenterology.2021; (10): 43.     CrossRef
  • Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects
    Hwi Seung Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Chang Hee Jung, Joong-Yeol Park, Hong-Kyu Kim, Woo Je Lee
    Journal of Clinical Medicine.2021; 11(1): 41.     CrossRef
  • Homeostasis model assessment of insulin resistance and lobular inflammation in nondiabetic patients with nonalcoholic fatty liver disease: methodological considerations
    Denis Monneret, Dominique Bonnefont-Rousselot
    European Journal of Gastroenterology & Hepatology.2020; 32(4): 542.     CrossRef
  • Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome
    Chen Chen, Caiyun Zhang, Xuelin Wang, Feijuan Zhang, Ze Zhang, Pengchai Ma, Shuzhi Feng
    European Journal of Gastroenterology & Hepatology.2020; 32(7): 857.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
  • The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults
    Wen Guo, Jing Lu, Pei Qin, Xiaona Li, Wenfang Zhu, Juan Wu, Nianzhen Xu, Qun Zhang
    Lipids in Health and Disease.2020;[Epub]     CrossRef
  • Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese Chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study
    Yaling Li, Rui Zheng, Jie Li, Shuyi Feng, Li Wang, Zhiming Huang
    Lipids in Health and Disease.2020;[Epub]     CrossRef
Close layer
Clinical Study
Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
Dug-Hyun Choi, Chan-Hee Jung, Ji-Oh Mok, Chul-Hee Kim, Sung-Koo Kang, Bo-Yeon Kim
Endocrinol Metab. 2018;33(3):387-394.   Published online September 18, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.3.387
  • 9,069 View
  • 137 Download
  • 40 Web of Science
  • 43 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are expected to improve the liver function of patients with non-alcoholic fatty liver disease (NAFLD) combined type 2 diabetes mellitus (T2DM) by its characteristic mechanism. This study was designed to investigate the effect of dapagliflozin, one of the SGLT2i, on the liver function of T2DM with NAFLD when combined with metformin.

Methods

Among patients who received dual oral hypoglycemic agents within the 3 months of diagnosing NAFLD, patients who had abnormal alanine aminotransferase (ALT) level (>40 IU/L) were included. Patients were divided into two groups: metformin+dapagliflozin group and metformin+dipeptidyl peptidase-4 inhibitors (DPP4i) group. Demographic data, biochemical data and the clinical and treatment histories of all patients were reviewed.

Results

A total of 102 patients were included (dapagliflozin group, n=50; DPP4i group, n=52). Dapagliflozin group showed more weight loss and more ALT decline than DPP4i group (−2.9 kg vs. −0.4 kg, P=0.005; −21.1 U/L vs. −9.5 U/L, P=0.008, respectively) and the proportion of patients with ALT normalization after treatment was also significantly higher in the dapagliflozin group (80.0% vs. 61.5%, P=0.041). The effect of dapagliflozin with metformin on ALT normalization remained significant after adjustment for confounding variables including body weight loss (odds ratio, 3.489; P=0.046).

Conclusion

ALT improvement was statistically significant in the dapagliflozin than the DPP4i when combined with metformin and the result was consistent after adjustment for confounding variables including body weight loss.

Citations

Citations to this article as recorded by  
  • Treatment Modalities for Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Review Article
    Varun Damle, Akarshan Sharma, Brijendra Kumar Srivastava, Arkiath Veettil Raveendran, Krishna G. Seshadri, Viswanathan Mohan
    Journal of Diabetology.2026;[Epub]     CrossRef
  • Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study
    Vicente Pallarés-Carratalá, Antonio Ruiz-García, Adalberto Serrano-Cumplido, Antonio Segura Fragoso, Verónica Fernández-Pascual, Beatriz Sánchez-Sánchez, María Inmaculada Cervera-Pérez, Francisco Javier Alonso-Moreno, Ezequiel Arranz-Martínez, Alfonso Bar
    Clínica e Investigación en Arteriosclerosis.2025; 37(1): 100724.     CrossRef
  • The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
    Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari,
    Journal of Clinical Medicine.2025; 14(2): 428.     CrossRef
  • Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study
    Vicente Pallarés-Carratalá, Antonio Ruiz-García, Adalberto Serrano-Cumplido, Antonio Segura Fragoso, Verónica Fernández-Pascual, Beatriz Sánchez-Sánchez, María Inmaculada Cervera-Pérez, Francisco Javier Alonso-Moreno, Ezequiel Arranz-Martínez, Alfonso Bar
    Clínica e Investigación en Arteriosclerosis (English Edition).2025; 37(1): 100724.     CrossRef
  • Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis
    Xingyu Fan, Yueyue Wang, Yue Wang, Hao Duan, Yijun Du, Tianrong Pan, Xing Zhong
    BMC Pharmacology and Toxicology.2025;[Epub]     CrossRef
  • Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials
    Samuel Dinerman, Yan Shu
    International Journal of Translational Medicine.2025; 5(1): 7.     CrossRef
  • Role of sodium-glucose cotransporter 2 inhibitors in liver diseases
    Prajna Anirvan, Suprabhat Giri, Sayan Malakar, Dibya Lochan Praharaj
    World Journal of Experimental Medicine.2025;[Epub]     CrossRef
  • The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
    Maria Zachou, Pagona Flevari, Narjes Nasiri-Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva Kassi, Theodoros Androutsakos
    European Journal of Clinical Pharmacology.2024; 80(1): 127.     CrossRef
  • Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis
    Hirokazu Takahashi, Keiko Asakawa, Yoshinori Kosakai, Takumi Lee, Mitsuhiro Rokuda
    Diabetes, Obesity and Metabolism.2024; 26(3): 997.     CrossRef
  • Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes
    Xiuying Gao, Chuanming Zhu, Wei Zhu, Lin Wang
    Biomedical Reports.2024;[Epub]     CrossRef
  • Targeted use of hepatoprotectors for the treatment of various stages of non-alcoholic fatty liver disease (fatty degeneration of the liver according to ICD 10) and associated comorbid conditions; tables for medical use
    L. B. Lazebnik, S. V. Turkina, E. V. Golovanova
    Experimental and Clinical Gastroenterology.2024; (10): 11.     CrossRef
  • Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
    Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, Erica Vetrano, Giulia Medicamento, Carlo Acierno, Luca Rinaldi, Aldo Marrone, Teresa Salvatore, Marcellino Monda, Celestino Sardu, Raffaele Marfella, Ferdinando Carlo Sasso
    Biomedicines.2023; 11(2): 322.     CrossRef
  • Swimming exercise ameliorates insulin resistance and nonalcoholic fatty liver by negatively regulating PPARγ transcriptional network in mice fed high fat diet
    Yong Zhang, Jie Xu, Di Zhou, Tingting Ye, Puqing Zhou, Zuofeng Liu, Xinyuan Liu, Zinan Wang, Tianmiao Hua, Zhenghao Zhang, Qingyan Sun
    Molecular Medicine.2023;[Epub]     CrossRef
  • Association between Obstructive Sleep Apnea and Heart Failure in Adults—A Systematic Review
    Agnieszka Polecka, Natalia Olszewska, Łukasz Danielski, Ewa Olszewska
    Journal of Clinical Medicine.2023; 12(19): 6139.     CrossRef
  • Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
    Iryna Kostitska, Nadia Protas, Liliia Petrovska
    Diabetes Obesity Metabolic Syndrome.2023; (5): 8.     CrossRef
  • Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
    Mazhar Hussain, Muhammad Zafar Majeed Babar, Saba Tariq, Muhammad Irfan Ahmad, Lubna Akhtar
    International Journal of Diabetes in Developing Countries.2022; 42(2): 290.     CrossRef
  • The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis
    Manqiu Mo, Zichun Huang, Yuzhen Liang, Yunhua Liao, Ning Xia
    Digestive and Liver Disease.2022; 54(4): 461.     CrossRef
  • Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation
    Reem M. Hazem, Ahmed Z. Ibrahim, Dina A. Ali, Yasser M. Moustafa
    International Immunopharmacology.2022; 104: 108503.     CrossRef
  • SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
    Theodoros Androutsakos, Narjes Nasiri-Ansari, Athanasios-Dimitrios Bakasis, Ioannis Kyrou, Efstathios Efstathopoulos, Harpal S. Randeva, Eva Kassi
    International Journal of Molecular Sciences.2022; 23(6): 3107.     CrossRef
  • Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
    Panshuang Qiao, Yingli Jia, Ang Ma, Jinzhao He, Chen Shao, Xiaowei Li, Shuyuan Wang, Baoxue Yang, Hong Zhou
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial
    Yumie Takeshita, Masao Honda, Kenichi Harada, Yuki Kita, Noboru Takata, Hiromasa Tsujiguchi, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Eishiro Mizukoshi, Hiroyuki Nakamura, Shuichi Kaneko, Toshinari Takamura
    Diabetes Care.2022; 45(9): 2064.     CrossRef
  • Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes
    Vincenzo Maria Monda, Sandro Gentile, Francesca Porcellati, Ersilia Satta, Alessandro Fucili, Marcello Monesi, Felice Strollo
    Advances in Therapy.2022; 39(11): 4837.     CrossRef
  • Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms
    Hager H. Shaaban, Ibrahim Alzaim, Ahmed El-Mallah, Rania G. Aly, Ahmed F. El-Yazbi, Ahmed Wahid
    Life Sciences.2022; 308: 120956.     CrossRef
  • The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
    Lampros Chrysavgis, Alkistis‐Maria Papatheodoridi, Antonios Chatzigeorgiou, Evangelos Cholongitas
    Journal of Gastroenterology and Hepatology.2021; 36(4): 893.     CrossRef
  • Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
    Chloe Wong, Clyve Yu Leon Yaow, Cheng Han Ng, Yip Han Chin, Yi Fen Low, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Chin Meng Khoo
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
    Francisca dos Santos Coelho, Marta Borges‐Canha, Madalena von Hafe, João Sérgio Neves, Catarina Vale, Ana Rita Leite, Davide Carvalho, Adelino Leite‐Moreira
    Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
  • Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
    Elizabeth M. Lamos, Megan Kristan, Maka Siamashvili, Stephen N. Davis
    Expert Review of Clinical Pharmacology.2021; 14(7): 837.     CrossRef
  • Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
    Won Euh, Soo Lim, Jin-Wook Kim
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway
    Jingyi Luo, Pengbo Sun, Yangyang Wang, Yang Chen, Yaoyun Niu, Yipei Ding, Naihan Xu, Yaou Zhang, Weidong Xie
    European Journal of Pharmacology.2021; 907: 174304.     CrossRef
  • The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease
    Susrichit Phrueksotsai, Kanokwan Pinyopornpanish, Juntima Euathrongchit, Apinya Leerapun, Arintaya Phrommintikul, Supawan Buranapin, Nipon Chattipakorn, Satawat Thongsawat
    Journal of Gastroenterology and Hepatology.2021; 36(10): 2952.     CrossRef
  • Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
    Vincenzo Maria Monda, Francesca Porcellati, Felice Strollo, Alessandro Fucili, Marcello Monesi, Ersilia Satta, Sandro Gentile
    Advances in Therapy.2021; 38(8): 4195.     CrossRef
  • Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B
    Lilian Yan Liang, Vincent Wai‐Sun Wong, Vicki Wing‐Ki Hui, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Grace Chung‐Yan Lui, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong
    GastroHep.2021; 3(4): 261.     CrossRef
  • Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels
    Kanokwan Pinyopornpanish, Apinya Leerapun, Kanokporn Pinyopornpanish, Nipon Chattipakorn
    Gut and Liver.2021; 15(6): 827.     CrossRef
  • The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
    F. Anthony Romero, Christopher T. Jones, Yingzi Xu, Martijn Fenaux, Randall L. Halcomb
    Journal of Medicinal Chemistry.2020; 63(10): 5031.     CrossRef
  • SGLT2 Inhibitors in Liver Patients
    John Chen Hsiang, Vincent Wai-Sun Wong
    Clinical Gastroenterology and Hepatology.2020; 18(10): 2168.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
  • Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
    Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
    Metabolism.2019; 92: 82.     CrossRef
  • Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
    Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, Cheol-Young Park
    Diabetes & Metabolism Journal.2019; 43(2): 127.     CrossRef
  • Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet
    Fan Zheng, Ying Cai
    Lipids in Health and Disease.2019;[Epub]     CrossRef
  • The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
    Chan-Hee Jung, Ji-Oh Mok
    Journal of Obesity & Metabolic Syndrome.2019; 28(1): 18.     CrossRef
  • Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
    Niki Katsiki, Nikolaos Perakakis, Christos Mantzoros
    Metabolism.2019; 98: iii.     CrossRef
  • Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
    Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
    Molecular and Cellular Endocrinology.2019; 498: 110539.     CrossRef
  • Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
    A.J. Scheen
    Diabetes & Metabolism.2019; 45(3): 213.     CrossRef
Close layer
Review Articles
Obesity and Metabolism
Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease
Chrysoula Boutari, Nikolaos Perakakis, Christos Socrates Mantzoros
Endocrinol Metab. 2018;33(1):33-43.   Published online March 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.1.33
  • 14,979 View
  • 179 Download
  • 137 Web of Science
  • 133 Crossref
AbstractAbstract PDFPubReader   ePub   

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease affecting 30% of the general population and 40% to 70% of obese individuals. Adipose tissue plays a crucial role in its pathogenesis, as it produces and secretes pro- and anti-inflammatory cytokines called adipokines. Adiponectin and leptin have well-determined actions in terms of NAFLD pathophysiology. Adiponectin deficiency is associated with a pro-inflammatory condition, as it is observed in obesity and other metabolic disorders. On the other hand, increased leptin levels, above the normal levels, act as a pro-inflammatory stimulus. Regarding other adipokines (resistin, visfatin, chemerin, retinol-binding protein 4, irisin), data about their contribution to NAFLD pathogenesis and progression are inconclusive. In addition, pharmacological agents like thiazolidinediones (pioglitazone and rosiglitazone), that are used in the management of NAFLD exert favourable effects on adipokine levels, which in turn may contribute to the improvement of liver function. This review summarizes the current knowledge and developments in the association between adipokines and NAFLD and discusses possible therapeutic implications targeting the modulation of adipokine levels as a potential tool for the treatment of NAFLD.

Citations

Citations to this article as recorded by  
  • Insights into causal associations between type 2 diabetes and common human diseases: a phenotype-wide bi-directional Mendelian randomization analysis
    Wenxi Sun, Hongbao Cao, Dongming Liu, Ancha Baranova, Xiaobin Zhang, Fuquan Zhang
    Nutrition, Metabolism and Cardiovascular Diseases.2026; 36(2): 104371.     CrossRef
  • Modulatory Role of Traditional Chinese Medicine in Gut–Liver and Adipose–Liver Axis Dysfunction in MASLD
    Sampat Singh Tanwar, Seema Sharma
    Pharmacological Research - Modern Chinese Medicine.2026; 18: 100743.     CrossRef
  • The effect of Cornus mas L. fruit extract supplementation on glycemic control, insulin resistance, and adiponectin levels in patients with metabolic dysfunction-associated steatotic liver disease: a double-blind randomized controlled clinical trial
    Zohreh Sadat Sangsefidi, Abbas Ali Sangouni, Faezeh Yarhosseini, Mahdieh Hosseinzadeh, Mohsen Akhondi-Meybodi, Alimohammad Ranjbar, Farzan Madadizadeh, Hassan Mozaffari-Khosravi
    Journal of Health, Population and Nutrition.2026;[Epub]     CrossRef
  • The Role of Kupffer Cells and Liver Macrophages in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ioannis Tsomidis, Angeliki Tsakou, Argyro Voumvouraki, Elias Kouroumalis
    Biomedicines.2026; 14(1): 151.     CrossRef
  • Glucolipid Metabolic Disorders and Helicobacter pylori Infection
    Jing Yuan, Pingjie Xiong, Zhipeng Zhou, Jiali Wu, Baihua Wu, Bin Wang, Jiao Guo, Suraiya Saleem
    International Journal of Endocrinology.2026;[Epub]     CrossRef
  • Adiponectin and Adiponectin Receptors in Atherosclerosis
    Ioanna Gianopoulos, Christos S Mantzoros, Stella S Daskalopoulou
    Endocrine Reviews.2025; 46(1): 1.     CrossRef
  • A comparative study on the effect of melatonin and orlistat combination versus orlistat alone on high fat diet-induced hepatic changes in the adult male albino rats (a histological and morphometric study)
    Sayed M. El-Sayed, Gehan A. El-Sayed, Mansour M.A, Enas Haridy Ahmed, Sherif A. Kamar
    Ultrastructural Pathology.2025; 49(1): 20.     CrossRef
  • Higher Circulating Resistin Levels Linked to Increased Sarcopenia Risk in Older Adults
    Mi Kyung Kwak, Ji Yeon Baek, So Jeong Park, Hee-Won Jung, Eunju Lee, Il-Young Jang, Eunhye Ji, Eun-Gyoung Hong, Yunju Jo, Dongryeol Ryu, Beom-Jun Kim
    The Journal of Clinical Endocrinology & Metabolism.2025; 110(9): e2994.     CrossRef
  • Characterization of liver, adipose, and fecal microbiome in obese patients with MASLD: links with disease severity and metabolic dysfunction parameters
    Katherine J. P. Schwenger, Julia K. Copeland, Yasaman Ghorbani, Lina Chen, Elena M. Comelli, David S. Guttman, Sandra E. Fischer, Timothy D. Jackson, Allan Okrainec, Johane P. Allard
    Microbiome.2025;[Epub]     CrossRef
  • Adipokines regulate the development and progression of MASLD through organellar oxidative stress
    Ke Zhao, Heng Zhang, Wenyu Ding, Xiaoshuai Yu, Yanli Hou, Xihong Liu, Xinhua Li, Xiaolei Wang
    Hepatology Communications.2025;[Epub]     CrossRef
  • Higher serum resistin levels and increased frailty risk in older adults: Implications beyond metabolic function
    Beom-Jun Kim, Yunju Jo, Ji Yeon Baek, So Jeong Park, Hee-Won Jung, Eunju Lee, Il-Young Jang, Hyuk Sakong, Dongryeol Ryu
    The Journal of nutrition, health and aging.2025; 29(5): 100521.     CrossRef
  • Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis
    Thendo I. Mabuda, Nicole R. S. Sibuyi, Adewale O. Fadaka, Mervin Meyer, Abram M. Madiehe, Kwazikwakhe B. Gabuza
    Reviews in Endocrine and Metabolic Disorders.2025; 26(6): 955.     CrossRef
  • Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Muhammad Moseeb Ali Hashim, Muhammad Aizaz Mohsin Khan, Muhammad Usama Ashraf, Saniya Mohsin, Kamran Zahoor, Javeria Niazi, Aiza Khan, Sania Muzaffar, Madiha Makhdumi, Omar Ahmed Ibad, Talha Kamran Khan, Sohaib Khalid
    Cureus.2025;[Epub]     CrossRef
  • Insulin resistance as a mediator of the association between obesity, high-intensity binge drinking, and liver enzyme abnormalities in young and middle-aged adults: a cross-sectional study
    Jiayi Zhu, Yinglong Duan, Ying Li, Yi Zhou, Zitong Lu, Nandan Chen, Juan Luo, Xingxing Wang, Xiaoqian Dong, Andy S. K. Cheng, Yuan Liu
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Associations Between Inflammatory Adipokines, Liver Steatosis, and Fibrosis in Patients with Different Degrees of Adiposity with or Without Metabolic Syndrome
    Karynne Grutter Lopes, Maria das Graças Coelho de Souza, Fernanda de Azevedo Marques Lopes, Vicente Lopes da Silva Junior, Carlos Antonio Terra, Ana Teresa Pugas Carvalho, Eliete Bouskela, Luiz Guilherme Kraemer-Aguiar
    Hormone and Metabolic Research.2025; 57(09): 529.     CrossRef
  • Effects of a polypill on circulating levels of resistin and visfatin in men with non-alcoholic fatty liver disease: A five-year clinical trial
    Mahdieh Nazari-Robati, Tania Dehesh, Beydolah Shahouzehi, Gholamreza Roshandel, Hossein Poustchi, Solaleh Emamgholipour, Aleksandra Klisic
    PLOS One.2025; 20(10): e0331121.     CrossRef
  • Mechanistic Insights into N-Oleoylethanolamide-Mediated Hepatoprotection via PPAR-α
    Darya Ivashkevich, Arina Ponomarenko, Igor Manzhulo, Inessa Dyuizen
    BIOCELL.2025; 49(4): 607.     CrossRef
  • Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction
    Wasitha P. D. W. Thilakarathna, H. P. Vasantha Rupasinghe
    Molecules.2024; 29(3): 709.     CrossRef
  • The role of novel adipokines and adipose-derived extracellular vesicles (ADEVs): Connections and interactions in liver diseases
    Lijun Xie, Huiying Wang, Jinying Hu, Zhuoying Liu, Fang Hu
    Biochemical Pharmacology.2024; 222: 116104.     CrossRef
  • The association between healthy eating index-2015 with anthropometric, cardiometabolic and hepatic indices among patients with non-alcoholic fatty liver disease
    Seyed Ahmad Hosseini, Ali Akbar Shayesteh, Seyed Jalal Hashemi, Zahra Rahimi, Nader Saki, Hossein Bavi Behbahani, Bahman Cheraghian, Meysam Alipour
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity
    Chrysoula Boutari, Konstantinos Stefanakis, Stamatia Simati, Valentina Guatibonza-García, Laura Valenzuela-Vallejo, Ioanna A. Anastasiou, Margery A. Connelly, Alexander Kokkinos, Christos S. Mantzoros
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population
    Chenbing Liu, Nan Li, Di Sheng, Yahong Shao, Lihong Qiu, Chao Shen, Zhong Liu
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Association of Fatty Liver with Severity and Clinical Outcomes in Patients with Acute Pancreatitis: A Prospective Study from a Tertiary Care Center in South India
    Naveen Chand Make, Rohan Yewale, G. Parthasarathy, Babu Vinish Doraiswami, Kayalvizhi Jayaraman, D. Karthikeyan, Balakrishnan S. Ramakrishna
    Gastroenterology, Hepatology and Endoscopy Practice.2024; 4(3): 87.     CrossRef
  • Non-Invasive Markers for the Detection of Gastric Precancerous Conditions
    Marcin Romańczyk, Malgorzata Osmola, Alexander Link, Amaury Druet, Caroline Hémont, Jerome Martin, Nicolas Chapelle, Tamara Matysiak-Budnik
    Cancers.2024; 16(12): 2254.     CrossRef
  • The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review
    Cristina Elena Negroiu, Robertina Iulia Tudoraşcu , Maria Cristina Beznă , Adrian Ionuţ Ungureanu , Sorina Octavia Honţaru , Suzana Dănoiu
    Romanian Journal of Morphology and Embryology.2024; 65(2): 159.     CrossRef
  • Regional gray matter changes in steatotic liver disease provide a neurobiological link to depression: A cross-sectional UK Biobank cohort study
    Dominic Arold, Stefan R. Bornstein, Nikolaos Perakakis, Stefan Ehrlich, Fabio Bernardoni
    Metabolism.2024; 159: 155983.     CrossRef
  • Prevalence and impact of metabolic associated fatty liver disease in non-metastatic breast cancer women at initial diagnosis: a cross-sectional study in China
    Zhi-yu Jiang, Xin-yu Liang, Lei Hu, Liang Ran, Rui-ling She, Chen-yu Ma, Jun-han Feng, Jing-yu Song, Zhao-xing Li, Xiu-quan Qu, Bai-qing Peng, Kai-nan Wu, Ling-quan Kong
    Clinical and Translational Oncology.2024; 27(4): 1586.     CrossRef
  • Diabetes as a risk factor for MASH progression
    Sofiya Gancheva, Michael Roden, Laurent Castera
    Diabetes Research and Clinical Practice.2024; 217: 111846.     CrossRef
  • Correlation between portal hypertension and somatic constitution: rationale behind the concept
    Yury O. Zharikov, Ilia A. Voloshin, Roman V. Maslennikov, Aida N. Gadzhiakhmedova, Tatiana S. Zharikova, Vladimir N. Nikolenko
    Science and Innovations in Medicine.2024; 9(4): 251.     CrossRef
  • Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases
    Nikolaos Perakakis, Hani Harb, Benjamin G Hale, Zsuzsanna Varga, Charlotte Steenblock, Waldemar Kanczkowski, Vasileia Ismini Alexaki, Barbara Ludwig, Peter Mirtschink, Michele Solimena, Nicole Toepfner, Sebastian Zeissig, Manuel Gado, Irene Alma Abela, Fe
    The Lancet Diabetes & Endocrinology.2023; 11(9): 675.     CrossRef
  • Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice
    Kyung Eun Kim, Jaewoong Lee, Hyun Joo Shin, Eun Ae Jeong, Hye Min Jang, Yu Jeong Ahn, Hyeong Seok An, Jong Youl Lee, Meong Cheol Shin, Soo Kyoung Kim, Won Gi Yoo, Won Ho Kim, Gu Seob Roh
    Hepatology.2023; 77(3): 888.     CrossRef
  • Effect of Dietary Intervention, with or without Cointerventions, on Inflammatory Markers in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Renate L. Hall, Elena S. George, Audrey C. Tierney, Anjana J. Reddy
    Advances in Nutrition.2023; 14(3): 475.     CrossRef
  • The Anti-Obesity and Anti-Steatotic Effects of Chrysin in a Rat Model of Obesity Mediated through Modulating the Hepatic AMPK/mTOR/lipogenesis Pathways
    Ghaleb Oriquat, Inas M. Masoud, Maher A. Kamel, Hebatallah Mohammed Aboudeya, Marwa B. Bakir, Sara A. Shaker
    Molecules.2023; 28(4): 1734.     CrossRef
  • Association between caffeine intake and liver biomarkers in non-alcoholic fatty liver disease
    Kübra UÇAR, Evrim KAHRAMANOĞLU, Zeynep GÖKTAŞ
    Cukurova Medical Journal.2023; 48(1): 177.     CrossRef
  • Changes in liver enzymes are associated with changes in insulin resistance, inflammatory biomarkers and leptin in prepubertal children with obesity
    Rosario Valle-Martos, Luis Jiménez-Reina, Ramón Cañete, Rosario Martos, Miguel Valle, María Dolores Cañete
    Italian Journal of Pediatrics.2023;[Epub]     CrossRef
  • The key role of inflammation in the pathogenesis and management of obesity and CVD
    Chrysoula Boutari, Michael A. Hill, Claudio Procaccini, Giuseppe Matarese, Christos S. Mantzoros
    Metabolism.2023; 145: 155627.     CrossRef
  • Obesity and diabetes
    Chrysoula Boutari, Antea DeMarsilis, Christos S. Mantzoros
    Diabetes Research and Clinical Practice.2023; 202: 110773.     CrossRef
  • Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages
    Weiwei He, Yinxiang Huang, Xiulin Shi, Qingxuan Wang, Menghua Wu, Han Li, Qiuhong Liu, Xiaofang Zhang, Caoxin Huang, Xuejun Li
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • The emerging significance of mitochondrial targeted strategies in NAFLD treatment
    Tao Zhang, Yingli Nie, Jiliang Wang
    Life Sciences.2023; 329: 121943.     CrossRef
  • Association between leptin and NAFLD: a two-sample Mendelian randomization study
    Ziwei Guo, Hongbo Du, Yi Guo, Qian Jin, Ruijia Liu, Zhangjun Yun, Jiaxin Zhang, Xiaoke Li, Yong’an Ye
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • Liver fat as risk factor of hepatic and cardiometabolic diseases
    Münevver Demir, Stefan R. Bornstein, Christos S. Mantzoros, Nikolaos Perakakis
    Obesity Reviews.2023;[Epub]     CrossRef
  • Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study
    Laura Valenzuela-Vallejo, Pavlina Chrysafi, Matina Kouvari, Valentina Guatibonza-Garcia, Sophia C. Mylonakis, Angeliki Katsarou, Ornella Verrastro, Georgios Markakis, Mohammed Eslam, Georgios Papatheodoridis, Geltrude Mingrone, Jacob George, Christos S. M
    Metabolism.2023; 148: 155694.     CrossRef
  • Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-α/AMPK and Nrf-2/HO-1 signaling pathways
    P. Tamilmani, V. V. Sathibabu Uddandrao, P. Chandrasekaran, G. Saravanan, Parim Brahma Naidu, S. Sengottuvelu, S. Vadivukkarasi
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(10): 102231.     CrossRef
  • Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease
    Niketa Sharma, Swarupa Chakole, Bhushan Wandile
    Cureus.2023;[Epub]     CrossRef
  • Fetal programming by androgen excess impairs liver lipid content and PPARg expression in adult rats
    Aimé Florencia Silva, Giselle Adriana Abruzzese, María José Ferrer, María Florencia Heber, Silvana Rocío Ferreira, Gloria Edith Cerrone, Alicia Beatriz Motta
    Journal of Developmental Origins of Health and Disease.2022; 13(3): 300.     CrossRef
  • Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19
    Adryana Cordeiro, Amanda Ribamar, Andrea Ramalho
    Clinics and Research in Hepatology and Gastroenterology.2022; 46(3): 101807.     CrossRef
  • Comparison of bioelectrical impedance analysis, mass index, and waist circumference in assessing risk for non-alcoholic steatohepatitis
    Katherine J.P. Schwenger, Alexander Kiu, Maryam AlAli, Amnah Alhanaee, Sandra E. Fischer, Johane P. Allard
    Nutrition.2022; 93: 111491.     CrossRef
  • Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease
    Juan Moreno-Vedia, Josefa Girona, Daiana Ibarretxe, Lluís Masana, Ricardo Rodríguez-Calvo
    Biomedicines.2022; 10(1): 197.     CrossRef
  • Predictive and Diagnostic Value of Serum Adipokines in Pregnant Women with Intrahepatic Cholestasis
    Nazan Yurtcu, Canan Soyer Caliskan, Huri Guvey, Samettin Celik, Safak Hatirnaz, Andrea Tinelli
    International Journal of Environmental Research and Public Health.2022; 19(4): 2254.     CrossRef
  • Symposium review: Adipose tissue endocrinology in the periparturient period of dairy cows
    Susanne Häussler, Hassan Sadri, Morteza H. Ghaffari, Helga Sauerwein
    Journal of Dairy Science.2022; 105(4): 3648.     CrossRef
  • Rodent models and metabolomics in non-alcoholic fatty liver disease: What can we learn?
    Maria Martin-Grau, Vannina G Marrachelli, Daniel Monleon
    World Journal of Hepatology.2022; 14(2): 304.     CrossRef
  • Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients – a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown
    Simona Alexandra Iacob, Diana Gabriela Iacob
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease
    Baran Ghezelbash, Nader Shahrokhi, Mohammad Khaksari, Gholamreza Asadikaram, Maryam Shahrokhi, Sara Shirazpour
    Chinese Journal of Integrative Medicine.2022; 28(6): 531.     CrossRef
  • The pathophysiological mechanism between hypopituitarism and nonalcoholic fatty liver disease
    Xinhe Zhang, Haoyu Tian, Yiling Li
    iLIVER.2022; 1(1): 65.     CrossRef
  • Correlation of Adiponectin Gene Polymorphisms rs266729 and rs3774261 With Risk of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yong-Tian Zheng, Tian-Mei Xiao, Chan-Xian Wu, Jin-Yan Cheng, Le-Yu Li
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • An Overview of the TRP-Oxidative Stress Axis in Metabolic Syndrome: Insights for Novel Therapeutic Approaches
    Mizael C. Araújo, Suzany H. S. Soczek, Jaqueline P. Pontes, Leonardo A. C. Marques, Gabriela S. Santos, Gisele Simão, Laryssa R. Bueno, Daniele Maria-Ferreira, Marcelo N. Muscará, Elizabeth S. Fernandes
    Cells.2022; 11(8): 1292.     CrossRef
  • Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex
    Yoosun Cho, Yoosoo Chang, Seungho Ryu, Hyun‐Suk Jung, Chan‐won Kim, Hyungseok Oh, Mi Kyung Kim, Won Sohn, Hocheol Shin, Sarah H. Wild, Christopher D. Byrne
    Hepatology Communications.2022; 6(9): 2238.     CrossRef
  • The Perirenal Fat Thickness Was Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Yuxian Yang, Shuting Li, Yuechao Xu, Jing Ke, Dong Zhao
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1505.     CrossRef
  • Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena
    Aamir Bashir, Ajay Duseja, Arka De, Manu Mehta, Pramil Tiwari
    Liver Research.2022; 6(2): 72.     CrossRef
  • Relationship between Liver Stiffness and Steatosis in Obesity Conditions: In Vivo and In Vitro Studies
    Francesca Baldini, Mohamad Khalil, Alice Bartolozzi, Massimo Vassalli, Agostino Di Ciaula, Piero Portincasa, Laura Vergani
    Biomolecules.2022; 12(5): 733.     CrossRef
  • Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
    Eleftheria Galatou, Elena Mourelatou, Sophia Hatziantoniou, Ioannis S. Vizirianakis
    Antioxidants.2022; 11(6): 1060.     CrossRef
  • The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study
    Osama Hamid, Ahmed Eltelbany, Abdul Mohammed, Khaled Alsabbagh Alchirazi, Sushrut Trakroo, Imad Asaad
    Annals of Hepatology.2022; 27(5): 100727.     CrossRef
  • Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles
    Romelia Pop, Alexandru-Flaviu Tăbăran, Andrei Paul Ungur, Andrada Negoescu, Cornel Cătoi
    Pharmaceutics.2022; 14(7): 1463.     CrossRef
  • Traumatic brain injury alters the gut-derived serotonergic system and associated peripheral organs
    Natosha M. Mercado, Guanglin Zhang, Zhe Ying, Fernando Gómez-Pinilla
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2022; 1868(11): 166491.     CrossRef
  • Detangling the interrelations between MAFLD, insulin resistance, and key hormones
    Shreya C. Pal, Mohammed Eslam, Nahum Mendez-Sanchez
    Hormones.2022; 21(4): 573.     CrossRef
  • Historical Changes in Weight Classes and the Influence of NAFLD Prevalence: A Population Analysis of 34,486 Individuals
    Benjamin Kai Yi Nah, Cheng Han Ng, Kai En Chan, Caitlyn Tan, Manik Aggarwal, Rebecca Wenling Zeng, Jieling Xiao, Yip Han Chin, Eunice X. X. Tan, Yi Ping Ren, Douglas Chee, Jonathan Neo, Nicholas W. S. Chew, Michael Tseng, Mohammad Shadab Siddiqui, Arun J.
    International Journal of Environmental Research and Public Health.2022; 19(16): 9935.     CrossRef
  • Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?
    Vera Francisco, Maria Jesus Sanz, José T. Real, Patrice Marques, Maurizio Capuozzo, Djedjiga Ait Eldjoudi, Oreste Gualillo
    Biology.2022; 11(8): 1237.     CrossRef
  • Fatty Liver/Adipose Tissue Dual‐Targeting Nanoparticles with Heme Oxygenase‐1 Inducer for Amelioration of Obesity, Obesity‐Induced Type 2 Diabetes, and Steatohepatitis
    Juhyeong Hong, Yong‐Hee Kim
    Advanced Science.2022;[Epub]     CrossRef
  • Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH
    Susanna C. Larsson, Karl Michaëlsson, Marina Mola-Caminal, Jonas Höijer, Christos S. Mantzoros
    Metabolism.2022; 137: 155329.     CrossRef
  • Gender differences in the ideal cutoffs of visceral fat area for predicting MAFLD in China
    Pingping Yu, Huachao Yang, Xiaoya Qi, Ruixue Bai, Shouqin Zhang, Jianping Gong, Ying Mei, Peng Hu
    Lipids in Health and Disease.2022;[Epub]     CrossRef
  • Apelin and chemerin receptors are G protein-coupled receptors involved in metabolic as well as reproductive functions: Potential therapeutic implications?
    Anthony Estienne, Alice Bongrani, Pascal Froment, Joëlle Dupont
    Current Opinion in Endocrine and Metabolic Research.2021; 16: 86.     CrossRef
  • Metformin dose increase versus added linagliptin in non‐alcoholic fatty liver disease and type 2 diabetes: An analysis of the J‐LINK study
    Yasuji Komorizono, Kaori Hosoyamada, Naoko Imamura, Shoko Kajiya, Yasuhiro Hashiguchi, Norio Ueyama, Hirohiko Shinmaki, Nobuyuki Koriyama, Masako Tsukasa, Tetsuro Kamada
    Diabetes, Obesity and Metabolism.2021; 23(3): 832.     CrossRef
  • Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population
    I-Ting Lin, Mei-Yueh Lee, Chih-Wen Wang, Da-Wei Wu, Szu-Chia Chen
    International Journal of Environmental Research and Public Health.2021; 18(3): 857.     CrossRef
  • Leptin in Leanness and Obesity
    Nikolaos Perakakis, Olivia M. Farr, Christos S. Mantzoros
    Journal of the American College of Cardiology.2021; 77(6): 745.     CrossRef
  • Severe insulin resistance syndromes
    Angeliki M. Angelidi, Andreas Filippaios, Christos S. Mantzoros
    Journal of Clinical Investigation.2021;[Epub]     CrossRef
  • Liver Enzymes Correlate With Metabolic Syndrome, Inflammation, and Endothelial Dysfunction in Prepubertal Children With Obesity
    Rosario Valle-Martos, Miguel Valle, Rosario Martos, Ramón Cañete, Luis Jiménez-Reina, María Dolores Cañete
    Frontiers in Pediatrics.2021;[Epub]     CrossRef
  • From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
    Marta Flisiak-Jackiewicz, Anna Bobrus-Chociej, Natalia Wasilewska, Dariusz Marek Lebensztejn
    Journal of Clinical Medicine.2021; 10(5): 924.     CrossRef
  • Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives
    Christina-Maria Flessa, Ioannis Kyrou, Narjes Nasiri-Ansari, Gregory Kaltsas, Athanasios G. Papavassiliou, Eva Kassi, Harpal S. Randeva
    Current Obesity Reports.2021; 10(2): 134.     CrossRef
  • Role of Insulin Resistance in MAFLD
    Yoshitaka Sakurai, Naoto Kubota, Toshimasa Yamauchi, Takashi Kadowaki
    International Journal of Molecular Sciences.2021; 22(8): 4156.     CrossRef
  • Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis
    Nikolaos Perakakis, Konstantinos Stefanakis, Michael Feigh, Sanne S. Veidal, Christos S. Mantzoros
    Liver International.2021; 41(8): 1853.     CrossRef
  • Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
    Hyunmi Kim, Da Som Lee, Tae Hyeon An, Hyun-Ju Park, Won Kon Kim, Kwang-Hee Bae, Kyoung-Jin Oh
    International Journal of Molecular Sciences.2021; 22(9): 4495.     CrossRef
  • Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
    Oriol Juanola, Sebastián Martínez-López, Rubén Francés, Isabel Gómez-Hurtado
    International Journal of Environmental Research and Public Health.2021; 18(10): 5227.     CrossRef
  • Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis
    Abdulrahman Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Dan L. Dumitrascu
    Journal of Clinical Medicine.2021; 10(14): 3029.     CrossRef
  • Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents
    Farah D.R. Al-Baiaty, Aziana Ismail, Zarina Abdul Latiff, Khairul Najmi Muhammad Nawawi, Raja Affendi Raja Ali, Norfilza Mohd Mokhtar
    Frontiers in Pediatrics.2021;[Epub]     CrossRef
  • Adipokines in Insulin Resistance: Current Updates
    Utpal Jagdish Dongre
    Biosciences Biotechnology Research Asia.2021; 18(2): 357.     CrossRef
  • Metabolic Effects of Gastrectomy and Duodenal Bypass in Early Gastric Cancer Patients with T2DM: A Prospective Single-Center Cohort Study
    Young Ki Lee, Eun Kyung Lee, You Jin Lee, Bang Wool Eom, Hong Man Yoon, Young-Il Kim, Soo Jeong Cho, Jong Yeul Lee, Chan Gyoo Kim, Sun-Young Kong, Min Kyong Yoo, Yul Hwangbo, Young-Woo Kim, Il Ju Choi, Hak Jin Kim, Mi Hyang Kwak, Keun Won Ryu
    Journal of Clinical Medicine.2021; 10(17): 4008.     CrossRef
  • Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
    Fateme Kooshki, Fardin Moradi, Arash Karimi, Hamid Reza Niazkar, Manouchehr Khoshbaten, Vahid Maleki, Bahram Pourghassem Gargari
    European Journal of Gastroenterology & Hepatology.2021; 33(10): 1298.     CrossRef
  • Specificities of lipotoxicity of free fatty acids and cytokine profile in patients with chronic diffuse liver diseases
    V. I. Didenko, I. A. Klenina, О. M. Tatarchuk, O. I. Hrabovska, O. P. Petishko
    Regulatory Mechanisms in Biosystems.2021; 13(1): 3.     CrossRef
  • Markers of progression of liver fibrotic changes in patients with chronic toxic drug-induced hepatitis
    V.I. Didenko, O.M. Tatarchuk, O.P. Petishko, I.S. Konenko, S.L. Melanich
    GASTROENTEROLOGY.2021; 55(2): 91.     CrossRef
  • Long-term abuse of a high-carbohydrate diet is as harmful as a high-fat diet for development and progression of liver injury in a mouse model of NAFLD/NASH
    Simona Pompili, Antonella Vetuschi, Eugenio Gaudio, Alessandra Tessitore, Roberta Capelli, Edoardo Alesse, Giovanni Latella, Roberta Sferra, Paolo Onori
    Nutrition.2020; 75-76: 110782.     CrossRef
  • Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD
    Stergios A Polyzos, Nikolaos Perakakis, Chrysoula Boutari, Jannis Kountouras, Wael Ghaly, Athanasios D Anastasilakis, Asterios Karagiannis, Christos S Mantzoros
    The Journal of Clinical Endocrinology & Metabolism.2020; 105(3): e390.     CrossRef
  • Inflammatory Mechanisms of HCC Development
    Maria Grazia Refolo, Caterina Messa, Vito Guerra, Brian Irving Carr, Rosalba D’Alessandro
    Cancers.2020; 12(3): 641.     CrossRef
  • Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
    Robert F. Schwabe, Ira Tabas, Utpal B. Pajvani
    Gastroenterology.2020; 158(7): 1913.     CrossRef
  • Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis
    Chan-Hee Jung, Eun-Jung Rhee, Hyemi Kwon, Yoosoo Chang, Seungho Ryu, Won-Young Lee
    Endocrinology and Metabolism.2020; 35(1): 165.     CrossRef
  • Alpha-syntrophin deficiency protects against non-alcoholic steatohepatitis associated increase of macrophages, CD8+ T-cells and galectin-3 in the liver
    Lisa Rein-Fischboeck, Elisabeth M. Haberl, Ganimete Bajraktari, Susanne Feder, Rebekka Pohl, Elke Eggenhofer, Christa Buechler
    Experimental and Molecular Pathology.2020; 113: 104363.     CrossRef
  • Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
    Kyeongjin Kim, Kook Hwan Kim
    International Journal of Molecular Sciences.2020; 21(7): 2296.     CrossRef
  • Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block
    Vasilios G. Athyros, Stergios A. Polyzos, Jiannis Kountouras, Niki Katsiki, Panagiotis Anagnostis, Michael Doumas, Christos S. Mantzoros
    Current Vascular Pharmacology.2020; 18(2): 172.     CrossRef
  • High body mass index hinders fibrosis improvement in patients receiving long‐term tenofovir therapy in hepatitis B virus‐related cirrhosis
    Young Eun Chon, Kyu Sik Jung, Yeonjung Ha, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang, Sang Hoon Ahn, Do Young Kim, Kwang‐Hyub Han, Jun Yong Park
    Journal of Viral Hepatitis.2020; 27(11): 1119.     CrossRef
  • The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
    Nikolaos Perakakis, Konstantinos Stefanakis, Christos S. Mantzoros
    Metabolism.2020; 111: 154320.     CrossRef
  • The Selective Peroxisome Proliferator‐Activated Receptor Gamma Modulator CHS‐131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis
    Nikolaos Perakakis, Aditya Joshi, Natia Peradze, Konstantinos Stefanakis, Georgia Li, Michael Feigh, Sanne Skovgard Veidal, Glenn Rosen, Michael Fleming, Christos S. Mantzoros
    Hepatology Communications.2020; 4(9): 1302.     CrossRef
  • Osteocalcin and osteoprotegerin levels and their relationship with adipokines and proinflammatory cytokines in children with nonalcoholic fatty liver disease
    Doaa El Amrousy, Dalia El-Afify
    Cytokine.2020; 135: 155215.     CrossRef
  • The effect of saffron supplementation on some inflammatory and oxidative markers, leptin, adiponectin, and body composition in patients with nonalcoholic fatty liver disease: A double‐blind randomized clinical trial
    Farnaz Kavianipour, Naheed Aryaeian, Marjan Mokhtare, Reyhanesadat Mirnasrollahiparsa, Leila Jannani, Shahram Agah, Sodabeh Fallah, Nariman Moradi
    Phytotherapy Research.2020; 34(12): 3367.     CrossRef
  • Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms
    Ricardo Rodríguez-Calvo, Sara Samino, Josefa Girona, Neus Martínez-Micaelo, Pere Ràfols, María García-Altares, Sandra Guaita-Esteruelas, Alexandra Junza, Mercedes Heras, Oscar Yanes, Xavier Correig, Lluis Masana
    Biomolecules.2020; 10(9): 1275.     CrossRef
  • The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling
    Samukelisiwe C. Shabalala, Phiwayinkosi V. Dludla, Lawrence Mabasa, Abidemi P. Kappo, Albertus K. Basson, Carmen Pheiffer, Rabia Johnson
    Biomedicine & Pharmacotherapy.2020; 131: 110785.     CrossRef
  • NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
    Na Xie, Lu Zhang, Wei Gao, Canhua Huang, Peter Ernst Huber, Xiaobo Zhou, Changlong Li, Guobo Shen, Bingwen Zou
    Signal Transduction and Targeted Therapy.2020;[Epub]     CrossRef
  • Neurochemical Regulators of Food Behavior for Pharmacological Treatment of Obesity: Current Status and Future Prospects
    Gayane Sargis Vardanyan, Hasmik Samvel Harutyunyan, Michail Iosif Aghajanov, Ruben Sargis Vardanyan
    Future Medicinal Chemistry.2020; 12(20): 1865.     CrossRef
  • Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases
    Maite Martínez-Uña, Yaiza López-Mancheño, Carlos Diéguez, Manuel A. Fernández-Rojo, Marta G. Novelle
    International Journal of Molecular Sciences.2020; 21(24): 9368.     CrossRef
  • Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression
    Ming-Ling Chang, Zinger Yang, Sien-Sing Yang
    International Journal of Molecular Sciences.2020; 21(21): 8308.     CrossRef
  • CHANGES IN CARBOHYDRATE METABOLISM AND ADIPOCYTOKINES UNDER THE INFLUENCE OF TREATMENT OF PATIENTS WITH ALCOHOLIC CIRRHOSIS OF THE LIVER IN COMBINATION WITH OBESITY USING ADAMETHIONINUM AND ARGININE GLUTAMATE
    N. R. Matkovska
    Medical and Clinical Chemistry.2020; (3): 17.     CrossRef
  • Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
    Niki Katsiki, Nikolaos Perakakis, Christos Mantzoros
    Metabolism.2019; 98: iii.     CrossRef
  • Role of Soluble Adiponectin Receptor 2 in Non-Alcoholic Fatty Liver Disease in Children
    Gulsah Kaya Aksoy, Reha Artan, Cihat Aksoy, Sebahat Özdem, Atike Atalay, Aygen Yılmaz
    Pediatric Gastroenterology, Hepatology & Nutrition.2019; 22(5): 470.     CrossRef
  • Determinants of ectopic liver fat in metabolic disease
    Anja Bosy-Westphal, Wiebke Braun, Viktoria Albrecht, Manfred J. Müller
    European Journal of Clinical Nutrition.2019; 73(2): 209.     CrossRef
  • Involvement of the hepatic branch of the vagus nerve in the regulation of plasma adipokine levels in rats fed a high-fructose diet
    Naoto Hashimoto, Manabu Wakagi, Katsunari Ippoushi, Yuko Takano-Ishikawa
    The Journal of Nutritional Biochemistry.2019; 71: 90.     CrossRef
  • Fat and Sugar—A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease
    Ines C.M. Simoes, Justyna Janikiewicz, Judith Bauer, Agnieszka Karkucinska-Wieckowska, Piotr Kalinowski, Agnieszka Dobrzyń, Andrzej Wolski, Maciej Pronicki, Krzysztof Zieniewicz, Paweł Dobrzyń, Marcin Krawczyk, Hans Zischka, Mariusz R. Wieckowski, Yaiza P
    Nutrients.2019; 11(12): 2871.     CrossRef
  • Childhood obesity: increased risk for cardiometabolic disease and cancer in adulthood
    Susann Weihrauch-Blüher, Peter Schwarz, Jan-Henning Klusmann
    Metabolism.2019; 92: 147.     CrossRef
  • Effects of moderate-intensity continuous training and high-intensity interval training on serum levels of Resistin, Chemerin and liver enzymes in Streptozotocin-Nicotinamide induced Type-2 diabetic rats
    Parastesh Mohammad, Khosravi Zadeh Esfandiar, Saremi Abbas, Rekabtalae Ahoora
    Journal of Diabetes & Metabolic Disorders.2019; 18(2): 379.     CrossRef
  • Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
    Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
    Metabolism.2019; 92: 82.     CrossRef
  • The Latest Insights into Adipokines in Diabetes
    Won Kon Kim, Kwang-Hee Bae, Sang Chul Lee, Kyoung-Jin Oh
    Journal of Clinical Medicine.2019; 8(11): 1874.     CrossRef
  • Postprandial leptin and adiponectin in response to sugar and fat in obese and normal weight individuals
    M. A. Larsen, V. T. Isaksen, E. J. Paulssen, R. Goll, J. R. Florholmen
    Endocrine.2019; 66(3): 517.     CrossRef
  • First demonstration of protective effects of purified mushroom polysaccharide-peptides against fatty liver injury and the mechanisms involved
    Shuang Zhao, Shuman Zhang, Weiwei Zhang, Yi Gao, Chengbo Rong, Hexiang Wang, Yu Liu, Jack Ho Wong, Tzibun Ng
    Scientific Reports.2019;[Epub]     CrossRef
  • Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
    Somaya Albhaisi, Arun J. Sanyal
    Pharmaceutical Medicine.2019; 33(6): 451.     CrossRef
  • Adiponectin rs2241766 and rs266729 gene polymorphisms in non-alcoholic fatty liver disease
    Aida A. Mahmoud, Hoda M. Moghazy, Laila M. Yousef, Asmaa N. Mohammad
    Gene Reports.2019; 15: 100381.     CrossRef
  • Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study
    Nikolaos Perakakis, Stergios A. Polyzos, Alireza Yazdani, Aleix Sala-Vila, Jannis Kountouras, Athanasios D. Anastasilakis, Christos S. Mantzoros
    Metabolism.2019; 101: 154005.     CrossRef
  • Association between Helicobacter pylori infection and nonalcoholic fatty liver
    Rongqiang Liu, Qiuli Liu, Ying He, Wenqing Shi, Qianhui Xu, Qing Yuan, Qi Lin, Biao Li, Lei Ye, Youlan Min, Peiwen Zhu, Yi Shao
    Medicine.2019; 98(44): e17781.     CrossRef
  • CHANGES IN CARBOHYDRATE METABOLISM IN PATIENTS WITH ALCOHOLIC CIRRHOSIS OF THE LIVER ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE DEPENDING ON THE STAGE OF DECOMPENSATION
    Nataliia Matkovska, Nataliia Virstiuk, Uliana Balan
    International Academy Journal Web of Scholar.2019; (6(36)): 17.     CrossRef
  • Non-alcoholic fatty liver disease and colorectal cancer: A marker of risk or common causation?
    Niki Katsiki, Dimitri P. Mikhailidis, Christos Mantzoros
    Metabolism.2018; 87: A10.     CrossRef
  • Critical Roles of microRNAs in the Pathogenesis of Fatty Liver: New Advances, Challenges, and Potential Directions
    Chenggui Miao, Zhongwen Xie, Jun Chang
    Biochemical Genetics.2018; 56(5): 423.     CrossRef
  • Alpha-syntrophin dependent expression of tubulin alpha 8 protein in hepatocytes
    Lisa Rein-Fischboeck, Ganimete Bajraktari, Rebekka Pohl, Susanne Feder, Kristina Eisinger, Wolfgang Mages, Elisabeth M. Haberl, Christa Buechler
    Journal of Physiology and Biochemistry.2018; 74(4): 511.     CrossRef
  • Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
    Kook Hwan Kim, Myung-Shik Lee
    Frontiers in Endocrinology.2018;[Epub]     CrossRef
  • Helicobacter pyloriand extragastric diseases: A review
    Antonietta Gerarda Gravina, Rocco Maurizio Zagari, Cristiana De Musis, Lorenzo Romano, Carmelina Loguercio, Marco Romano
    World Journal of Gastroenterology.2018; 24(29): 3204.     CrossRef
  • Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl‑CoA desaturase‑1, lipase activity, leptin and resistin
    Hessah Al‑Muzafar, Kamal Amin
    Experimental and Therapeutic Medicine.2018;[Epub]     CrossRef
  • Impact of weight cycling on CTRP3 expression, adipose tissue inflammation and insulin sensitivity in C57BL/6J mice
    Xin Li, Li Jiang, Miao Yang, Yu‑Wen Wu, Jia‑Zhong Sun
    Experimental and Therapeutic Medicine.2018;[Epub]     CrossRef
  • Analysis of non‑alcoholic fatty liver disease microRNA expression spectra in rat liver tissues
    Jiao Nie, Chang‑Ping Li, Jue‑Hong Li, Xia Chen, Xiaoling Zhong
    Molecular Medicine Reports.2018;[Epub]     CrossRef
Close layer
The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis
Young-Ah Moon
Endocrinol Metab. 2017;32(1):6-10.   Published online January 19, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.1.6
  • 13,984 View
  • 263 Download
  • 92 Web of Science
  • 90 Crossref
AbstractAbstract PDFPubReader   

Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance, obesity, and dyslipidemia. NAFLD encompasses a wide range of states from the simple accumulation of triglycerides in the hepatocytes to serious states accompanied by inflammation and fibrosis in the liver. De novo lipogenesis has been shown to be a significant factor in the development of hepatic steatosis in insulin-resistant states. Sterol regulatory element binding protein-1c (SREBP-1c) is the main transcription factor that mediates the activation of lipogenesis, and SREBP cleavage activating protein (SCAP) is required for the activation of SREBPs. Here, recent animal studies that suggest SCAP as a therapeutic target for hepatic steatosis and hypertriglyceridemia are discussed.

Citations

Citations to this article as recorded by  
  • Revealing the biochemical regulations of L-PGDS in hepatic insulin-resistance using HepG2 cells
    Rhema Khairnar, Md Asrarul Islam, Kuljeet Singh, Divya K. Shetty, Anjali Yadav, Vikas V. Dukhande, Sunil Kumar
    Prostaglandins & Other Lipid Mediators.2026; 182: 107052.     CrossRef
  • Aster pekinensis Extract Mitigates High-Fat-Diet-Induced Obesity and Metabolic Dysfunction in Mice
    Hyeon Jeong Moon, Seon-Jin Lee, Geon Woo Kim, Yeong-Bin Baek, Sang-Ik Park
    Animals.2026; 16(2): 163.     CrossRef
  • Anti-Obesity Effect of Puffed Zingiber Officinale Ethanol Extract on 3T3-L1 Adipocytes and High-Fat Diet-Fed Mice
    Ye Jin Koo, Jeong Yoon Lee, Min Jeong Kim, Yoo-Hyun Lee
    Journal of Medicinal Food.2026; 29(1): 43.     CrossRef
  • Female C57BL/6 mice exhibit protection against nonalcoholic fatty liver disease and diabesity accompanied by differential regulation of hepatic lipocalin prostaglandin D2 synthase
    Md Asrarul Islam, Rhema Khairnar, Joshua Fleishman, Sandra E. Reznik, Louis Ragolia, Shruthi Gobbooru, Sunil Kumar
    Molecular and Cellular Endocrinology.2025; 595: 112404.     CrossRef
  • Cholesterol Depletion Activate Hepatic Stellate Cells Mediated Through SREBP‐2 Signaling
    Nivya Vijayan, Madan Kumar Perumal
    Journal of Cellular Physiology.2025;[Epub]     CrossRef
  • The mechanism of DEHP-induced lipid accumulation in liver of female zebrafish
    Yueyue Mi, Jiamin Shi, Xuan Ma, Dongqiong Wei, Rongjian Liu, Samra, Cong Yuan, Yongmei Qi, Dejun Huang
    Environmental Pollution.2025; 366: 125455.     CrossRef
  • Cepharanthine relieves nonalcoholic steatohepatitis through inhibiting STAT1/CXCL10 axis-mediated lipogenesis and inflammatory responses
    Pan Li, Ruoyu Zhang, Pingping Hu, Tingting Wang, Jianwei Wang
    Journal of Ethnopharmacology.2025; 341: 119358.     CrossRef
  • Ergosterol alleviates hepatic steatosis and insulin resistance via promoting fatty acid β-oxidation by activating mitochondrial ACSL1
    Zu-Guo Zheng, Yi-Ping Zhang, Xiao-Yu Zhang, Meng-Yao Qin, Yin-Yue Xu, He Wu, Run-Qing Liu, Qiu-Yi Wu, Ming-Su Wang, Chong Zhang, Yue-Qin Zheng, Jian-Ye Dai, Ping Li, Hua Yang
    Cell Reports.2025; 44(1): 115203.     CrossRef
  • Dietary Methionine Hydroxy Analog Regulates Hepatic Lipid Metabolism via SIRT1/AMPK Signaling Pathways in Largemouth Bass Micropterus salmodies
    Ju Zhao, Zhongjie Yang, Haifeng Liu, Chao Yang, Yujun Chen, Quanquan Cao, Jun Jiang
    Biology.2025; 14(3): 227.     CrossRef
  • PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD
    Amedeo Lonardo, Ralf Weiskirchen
    Exploration of Digestive Diseases.2025;[Epub]     CrossRef
  • Strength training promotes attenuation of fatty liver while improving insulin resistance and inflammatory biomarkers in obese rats induced by high-fat diet
    S. Torezani-Sales, A.P.L. Damiani, A.R. Madureira, J.P. Cordeiro, G.H. Taufner, B.V. Nogueira, M.C. Dias, M.M. Sugizaki, A.S. Leopoldo, A.P. Lima-Leopoldo
    Brazilian Journal of Medical and Biological Research.2025;[Epub]     CrossRef
  • Cranberry improves metabolic syndrome-related organ dysfunction in rats by modulating AMPK/SREBP1, ROCK1 and TGF-β1
    Sahar M. Elashmony, Yosra Alhindi, Dina H. Merzeban, Rehab A. Mohammed, Asmaa Mohamed Elsayed, Marwa A. Sofi, Rania H. Mahmoud, Hanan A. Shamardl, Dina Elsayed Shaker
    Scientific Reports.2025;[Epub]     CrossRef
  • Effect of dragon fruit dadih fortified with selenium on SREBP-1c expression and liver histopathology in obese rats
    Ulan Safitri, Ninik Rustanti, Adriyan Pramono
    Scripta Medica.2025; 56(6): 1119.     CrossRef
  • SREBPs as the potential target for solving the polypharmacy dilemma
    Xue Wang, Yanqiu Chen, Heyu Meng, Fanbo Meng
    Frontiers in Physiology.2024;[Epub]     CrossRef
  • The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis
    Preethi Chandrasekaran, Ralf Weiskirchen
    International Journal of Molecular Sciences.2024; 25(2): 1109.     CrossRef
  • Expression and correlation analysis of silent information regulator 1 (SIRT1), sterol regulatory element-binding protein-1 (SREBP1), and pyroptosis factor in gestational diabetes mellitus
    Ning Han, Xin-yuan Chang, Zi-li Yuan, Yi-zhan Wang
    The Journal of Maternal-Fetal & Neonatal Medicine.2024;[Epub]     CrossRef
  • Uxi (Endopleura uchi (Huber) Cuatrec) bark extract mitigates HFD-induced adiposity in rats via targeting oxidative stress, and lipogenic genes expression
    Eman A.R. Abdelghffar, Zuhair M. Mohammedsaleh, Raha Osailan, Aisha Elaimi, Wafae Ouchari, Mohamed A.O. Abdelfattah, Mona F. Mahmoud, Mansour Sobeh
    Journal of Functional Foods.2024; 114: 106034.     CrossRef
  • Robinetin Alleviates Metabolic Failure in Liver through Suppression of p300-CD38 Axis
    Ji-Hye Song, Hyo-Jin Kim, Jangho Lee, Seung-Pyo Hong, Min-Yu Chung, Yu-Geun Lee, Jae Ho Park, Hyo-Kyoung Choi, Jin-Taek Hwang
    Biomolecules & Therapeutics.2024; 32(2): 214.     CrossRef
  • Regeneration of Non-Alcoholic Fatty Liver Cells Using Chimeric FGF21/HGFR: A Novel Therapeutic Approach
    Sung-Jun Kim, So-Jung Kim, Jeongeun Hyun, Hae-Won Kim, Jun-Hyeog Jang
    International Journal of Molecular Sciences.2024; 25(6): 3092.     CrossRef
  • Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH
    Deqiang Zhang, Yuee Zhao, Gary Zhang, Daniel Lank, Sarah Cooke, Sujuan Wang, Alli Nuotio-Antar, Xin Tong, Lei Yin
    Molecular Metabolism.2024; 85: 101957.     CrossRef
  • Nutraceutical and dietary measures with potential for preventing/controlling non-alcoholic fatty liver disease and its complications
    Lidianys María Lewis Lujan, Mark F. McCarty, Juan Carlos Galvez Ruiz, Sergio Trujillo Lopez, Simon Bernard Iloki-Assanga
    Human Nutrition & Metabolism.2024; 37: 200281.     CrossRef
  • Ubiquitination and De-Ubiquitination in the Synthesis of Cow Milk Fat: Reality and Prospects
    Rui Gao, Yanni Wu, Yuhao Wang, Zhangping Yang, Yongjiang Mao, Yi Yang, Chunhua Yang, Zhi Chen
    Molecules.2024; 29(17): 4093.     CrossRef
  • Mitochondria-targeted hydrogen sulfide donor reduces fatty liver and obesity in mice fed a high fat diet by inhibiting de novo lipogenesis and inflammation via mTOR/SREBP-1 and NF-κB signaling pathways
    Aneta Stachowicz, Klaudia Czepiel, Anna Wiśniewska, Kamila Stachyra, Magdalena Ulatowska-Białas, Beata Kuśnierz-Cabala, Marcin Surmiak, Grzegorz Majka, Katarzyna Kuś, Mark E. Wood, Roberta Torregrossa, Matthew Whiteman, Rafał Olszanecki
    Pharmacological Research.2024; 209: 107428.     CrossRef
  • Zhimu-Huangbai herb-pair ameliorates hepatic steatosis in mice by regulating IRE1α/XBP1s pathway to inhibit SREBP-1c
    Wenjun Zhao, Xiaoying Wang, Wenlong Nie, Min Jiang, Yuan Zhao, Tong Zhang, Yue Ding
    Phytomedicine.2024; 134: 156017.     CrossRef
  • Evolutionary analysis of buffalo sterol regulatory element-binding factor (SREBF) family genes and their affection on milk traits
    Tingzhu Ye, Jing Yuan, Sayed Haidar Abbas Raza, Tingxian Deng, Lv Yang, Muhammad Jamil Ahmad, Seyed Mahdi Hosseini, Xinxin Zhang, Muna O Alamoudi, Qwait AlGabbani, Youssef S Alghamdi, Chao Chen, Aixin Liang, Nicola M. Schreurs, Liguo Yang
    Animal Biotechnology.2023; 34(7): 2082.     CrossRef
  • Hepatic Pin1 Expression, Particularly in Nuclei, Is Increased in NASH Patients in Accordance with Evidence of the Role of Pin1 in Lipid Accumulation Shown in Hepatoma Cell Lines
    Machi Kanna, Yusuke Nakatsu, Takeshi Yamamotoya, Akifumi Kushiyama, Midori Fujishiro, Hideyuki Sakoda, Hiraku Ono, Koji Arihiro, Tomoichiro Asano
    International Journal of Molecular Sciences.2023; 24(10): 8847.     CrossRef
  • Dietary acetate promotes growth and nutrients deposition in Nile tilapia (Oreochromis niloticus) through increasing acetyl-CoA-triggered energy production
    Wen-Hao Zhou, Samwel M. Limbu, Yuan Luo, Rui-Xin Li, Jiong Ren, Fang Qiao, Mei-Ling Zhang, Zhen-Yu Du
    Aquaculture.2023; 575: 739750.     CrossRef
  • Palmitate로 유발된 비알코올성 지방간 세포 모델에서 블랙커런트 초임계 추출물의 지방증 개선효과
    수정 이, 은숙 양, 영호 김, 혜연 김, 혜란 최, 석 김, 태호 류
    Korean Journal of Food and Cookery Science.2023; 39(3): 178.     CrossRef
  • PM2.5 induced liver lipid metabolic disorders in C57BL/6J mice
    Chenxiao Zhang, Tengfei Ma, Chang Liu, Ding Ma, Jian Wang, Meng Liu, Jinjun Ran, Xueting Wang, Xiaobei Deng
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • High Gamma-Aminobutyric Acid (GABA) Oolong Tea Alleviates High-Fat Diet-Induced Metabolic Disorders in Mice
    Monthana Weerawatanakorn, Sang He, Chun-Han Chang, Yen-Chun Koh, Meei-Ju Yang, Min-Hsiung Pan
    ACS Omega.2023; 8(37): 33997.     CrossRef
  • MicroRNA-19a regulates milk fat metabolism by targeting SYT1 in bovine mammary epithelial cells
    Baojun Yu, Jiamin Liu, Zhengyun Cai, Tong Mu, Di Zhang, Xiaofang Feng, Yaling Gu, Juan Zhang
    International Journal of Biological Macromolecules.2023; 253: 127096.     CrossRef
  • SREBP Regulation of Lipid Metabolism in Liver Disease, and Therapeutic Strategies
    Na Li, Xiaodan Li, Yifu Ding, Xiao Liu, Karin Diggle, Tatiana Kisseleva, David A. Brenner
    Biomedicines.2023; 11(12): 3280.     CrossRef
  • Daidzein stimulates fatty acid-induced fat deposition in C2C12 myoblast cells via the G protein-coupled receptor 30 pathway
    Chengjian Zhou, Ping Li, Meihong Han, Xuejun Gao
    Animal Biotechnology.2022; 33(5): 851.     CrossRef
  • Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress
    Qichuang Liu, Maoyuan Mu, Huan Chen, Guoyuan Zhang, Yanqing Yang, Jun Chu, Ying Li, Fangwan Yang, Shide Lin
    Molecular and Cellular Biochemistry.2022; 477(11): 2481.     CrossRef
  • The cholesterol pathway: impact on immunity and cancer
    Ryan J. King, Pankaj K. Singh, Kamiya Mehla
    Trends in Immunology.2022; 43(1): 78.     CrossRef
  • Hepatic retinaldehyde dehydrogenases are modulated by tocopherol supplementation in mice with hepatic steatosis
    Amanda D'Espessailles, Valeria Campos, Nevenka Juretić, Gladys S. Tapia, Paulina Pettinelli
    Nutrition.2022; 94: 111539.     CrossRef
  • CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing
    Han Zeng, Hong Qin, Meng Liao, Enze Zheng, Xiaoqing Luo, Anhua Xiao, Yiyu Li, Lin Chen, Li Wei, Lei Zhao, Xiong Z. Ruan, Ping Yang, Yaxi Chen
    Molecular Metabolism.2022; 57: 101428.     CrossRef
  • Biogenesis and Breakdown of Lipid Droplets in Pathological Conditions
    Claudio M. Fader Kaiser, Patricia S. Romano, M. Cristina Vanrell, Cristian A. Pocognoni, Julieta Jacob, Benjamín Caruso, Laura R. Delgui
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, pl
    Neeta B Amin, Amanda Darekar, Quentin M Anstee, Vincent Wai-Sun Wong, Frank Tacke, Manoli Vourvahis, Douglas S Lee, Michael Charlton, Naim Alkhouri, Atsushi Nakajima, Carla Yunis
    BMJ Open.2022; 12(3): e056159.     CrossRef
  • Identification of microRNA Transcriptome Involved in Bovine Intramuscular Fat Deposition
    Susan K. Duckett, Maslyn A. Greene
    Frontiers in Veterinary Science.2022;[Epub]     CrossRef
  • Camellia (Camellia oleifera bel.) seed oil reprograms gut microbiota and alleviates lipid accumulation in high fat-fed mice through the mTOR pathway
    Jing Gao, Li Ma, Jie Yin, Gang Liu, Jie Ma, SiTing Xia, SaiMing Gong, Qi Han, TieJun Li, YongZhong Chen, YuLong Yin
    Food & Function.2022; 13(9): 4977.     CrossRef
  • The Perirenal Fat Thickness Was Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Yuxian Yang, Shuting Li, Yuechao Xu, Jing Ke, Dong Zhao
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1505.     CrossRef
  • Vanadium(IV)-Chlorodipicolinate Protects against Hepatic Steatosis by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammation
    Yuanli Wang, Rulong Chen, Jingyi Li, Guodong Zeng, Juntao Yuan, Jingran Su, Chunyan Wu, Zhongbing Lu, Fang Zhang, Wenjun Ding
    Antioxidants.2022; 11(6): 1093.     CrossRef
  • Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis
    Satoshi Kawamura, Yuki Matsushita, Shigeyuki Kurosaki, Mizuki Tange, Naoto Fujiwara, Yuki Hayata, Yoku Hayakawa, Nobumi Suzuki, Masahiro Hata, Mayo Tsuboi, Takahiro Kishikawa, Hiroto Kinoshita, Takuma Nakatsuka, Masaya Sato, Yotaro Kudo, Yujin Hoshida, At
    Journal of Clinical Investigation.2022;[Epub]     CrossRef
  • Baicalein Prevents Fructose-Induced Hepatic Steatosis in Rats: In the Regulation of Fatty Acid De Novo Synthesis, Fatty Acid Elongation and Fatty Acid Oxidation
    Pan Li, Ruoyu Zhang, Meng Wang, Yuwei Chen, Zhiwei Chen, Xiumei Ke, Ling Zuo, Jianwei Wang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Identification and validation of immune related core transcription factors GTF2I in NAFLD
    Minbo Zhang, Yu Zhang, Xiaoxiao Jiao, Linying Lai, Yiting Qian, Bo Sun, Wenzhuo Yang
    PeerJ.2022; 10: e13735.     CrossRef
  • Lipid-lowering effect of microencapsulated peptides from brewer's spent grain in high-sucrose diet-fed rats
    M.R. Ferreira, A.G. Garzón, M.E. Oliva, R.E. Cian, S.R. Drago, M.E. D'Alessandro
    Food Bioscience.2022; 49: 101981.     CrossRef
  • The SREBP-dependent regulation of cyclin D1 coordinates cell proliferation and lipid synthesis
    Arwa Aldaalis, Maria T. Bengoechea-Alonso, Johan Ericsson
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Targets of statins intervention in LDL-C metabolism: Gut microbiota
    ChangXin Sun, ZePing Wang, LanQing Hu, XiaoNan Zhang, JiYe Chen, ZongLiang Yu, LongTao Liu, Min Wu
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Regulation of lipid droplet (LD) formation in hepatocytes via regulation of SREBP1c by non-coding RNAs
    Shereen A. El Sobky, Nourhan K. Aboud, Nihal M. El Assaly, Injie O. Fawzy, Nada El-Ekiaby, Ahmed I. Abdelaziz
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Aspalathin-rich green rooibos tea in combination with glyburide and atorvastatin enhances lipid metabolism in a db/db mouse model
    Oelfah Patel, Christo J. F. Muller, Elizabeth Joubert, Bernd Rosenkranz, Johan Louw, Charles Awortwe
    Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
  • Capparis spinosa improves non-alcoholic steatohepatitis through down-regulating SREBP-1c and a PPARα-independent pathway in high-fat diet-fed rats
    Rasoul Akbari, Hamid Yaghooti, Mohammad Taha Jalali, Laya Sadat Khorsandi, Narges Mohammadtaghvaei
    BMC Research Notes.2022;[Epub]     CrossRef
  • Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4/nuclear factor kappa B pathways
    Shuhua Shen, Kungen Wang, Yihui Zhi, Yue Dong
    Pharmaceutical Biology.2022; 60(1): 1949.     CrossRef
  • CYP51-mediated cholesterol biosynthesis is required for the proliferation of CD4+ T cells in Sjogren’s syndrome
    Junhao Yin, Jiayao Fu, Yanxiong Shao, Jiabao Xu, Hui Li, Changyu Chen, Yijie Zhao, Zhanglong Zheng, Chuangqi Yu, Lingyan Zheng, Baoli Wang
    Clinical and Experimental Medicine.2022; 23(5): 1691.     CrossRef
  • Differential TM4SF5‐mediated SIRT1 modulation and metabolic signaling in nonalcoholic steatohepatitis progression
    Jihye Ryu, Eunmi Kim, Min‐Kyung Kang, Dae‐Geun Song, Eun‐Ae Shin, Haesong Lee, Jae Woo Jung, Seo Hee Nam, Ji Eon Kim, Hye‐Jin Kim, Taekwon Son, Semi Kim, Hwi Young Kim, Jung Weon Lee
    The Journal of Pathology.2021; 253(1): 55.     CrossRef
  • Changes in Glutathione Content in Liver Diseases: An Update
    Mariapia Vairetti, Laura Giuseppina Di Pasqua, Marta Cagna, Plinio Richelmi, Andrea Ferrigno, Clarissa Berardo
    Antioxidants.2021; 10(3): 364.     CrossRef
  • Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings
    Baris Akinci, Angela Subauste, Nevin Ajluni, Nazanene H. Esfandiari, Rasimcan Meral, Adam H. Neidert, Akin Eraslan, Rita Hench, Diana Rus, Barbara Mckenna, Hero K. Hussain, Thomas L. Chenevert, Marwan K. Tayeh, Amit R. Rupani, Jeffrey W. Innis, Christos S
    Med.2021; 2(7): 814.     CrossRef
  • Prediction of Srebp-1 as a Key Target of Qing Gan San Against MAFLD in Rats via RNA-Sequencing Profile Analysis
    Bendong Yang, Jingyue Sun, Shufei Liang, Peixuan Wu, Rui Lv, Yanping He, Deqi Li, Wenlong Sun, Xinhua Song
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Structural insights into the mechanism of human NPC1L1-mediated cholesterol uptake
    Miaoqing Hu, Fan Yang, Yawen Huang, Xin You, Desheng Liu, Shan Sun, Sen-Fang Sui
    Science Advances.2021;[Epub]     CrossRef
  • Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease
    Justin K. Murray, Jason Long, Lei Liu, Shivani Singh, Danielle Pruitt, Michael Ollmann, Elissa Swearingen, Miki Hardy, Oliver Homann, Bin Wu, Jerry Ryan Holder, Kelvin Sham, Brad Herberich, Mei-Chu Lo, Hui Dou, Artem Shkumatov, Monica Florio, Ingrid C. Ru
    Nucleic Acid Therapeutics.2021; 31(5): 324.     CrossRef
  • Molecular mechanism of DLBS3733, a bioactive fraction of Lagerstroemia speciosa (L.) Pers., on ameliorating hepatic lipid accumulation in HepG2 cells
    Olivia M. Tandrasasmita, Guntur Berlian, Raymond R. Tjandrawinata
    Biomedicine & Pharmacotherapy.2021; 141: 111937.     CrossRef
  • The Role of Gut Microbiota on Cholesterol Metabolism in Atherosclerosis
    Margaret Vourakis, Gaétan Mayer, Guy Rousseau
    International Journal of Molecular Sciences.2021; 22(15): 8074.     CrossRef
  • Inhibition of Atherosclerosis and Liver Steatosis by Agmatine in Western Diet-Fed apoE-Knockout Mice Is Associated with Decrease in Hepatic De Novo Lipogenesis and Reduction in Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio
    Anna Wiśniewska, Aneta Stachowicz, Katarzyna Kuś, Magdalena Ulatowska-Białas, Justyna Totoń-Żurańska, Anna Kiepura, Kamila Stachyra, Maciej Suski, Mariusz Gajda, Jacek Jawień, Rafał Olszanecki
    International Journal of Molecular Sciences.2021; 22(19): 10688.     CrossRef
  • Therapeutic Targeting of Nonalcoholic Fatty Liver Disease by Downregulating SREBP-1C Expression via AMPK-KLF10 Axis
    Yu-Chi Chen, Rong-Jane Chen, Szu-Yuan Peng, Winston C. Y. Yu, Vincent Hung-Shu Chang
    Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
  • Regulation of Key Genes for Milk Fat Synthesis in Ruminants
    Tong Mu, Honghong Hu, Yanfen Ma, Xiaofang Feng, Juan Zhang, Yaling Gu
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis
    Chan-Hee Jung, Eun-Jung Rhee, Hyemi Kwon, Yoosoo Chang, Seungho Ryu, Won-Young Lee
    Endocrinology and Metabolism.2020; 35(1): 165.     CrossRef
  • Lipidomic profiling analysis of the phospholipid molecules in SCAP-induced lipid droplet formation in bovine mammary epithelial cells
    Liqiang Han, Kun Pang, Xiu ling Li, Juan J Loor, Guo yu Yang, Tengyun Gao
    Prostaglandins & Other Lipid Mediators.2020; 149: 106420.     CrossRef
  • Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research
    Amedeo Lonardo, Ayako Suzuki
    Journal of Clinical Medicine.2020; 9(5): 1278.     CrossRef
  • Smurf1 aggravates non‐alcoholic fatty liver disease by stabilizing SREBP‐1c in an E3 activity‐independent manner
    Xin Zhang, Yutao Zhan, Wenjun Lin, Fei Zhao, Chaojing Guo, Yujiao Chen, Mengge Du, Dongnian Li, Lingqiang Zhang, Wei An, Hong‐Rui Wang, Ping Xie
    The FASEB Journal.2020; 34(6): 7631.     CrossRef
  • Beneficial Effects of SREBP Decoy Oligodeoxynucleotide in an Animal Model of Hyperlipidemia
    Hyun-Jin An, Jung-Yeon Kim, Mi-Gyeong Gwon, Hyemin Gu, Hyun-Ju Kim, Jaechan Leem, Sung Won Youn, Kwan-Kyu Park
    International Journal of Molecular Sciences.2020; 21(2): 552.     CrossRef
  • Lack of Augmenter of Liver Regeneration Disrupts Cholesterol Homeostasis of Liver in Mice by Inhibiting the AMPK Pathway
    Xin Wang, Ling‐yue Dong, Qu‐jing Gai, Wei‐lun Ai, Yuan Wu, Wei‐chun Xiao, Jing Zhang, Wei An
    Hepatology Communications.2020; 4(8): 1149.     CrossRef
  • HESA-A Attenuates Hepatic Steatosis in NAFLD Rat Model Through the Suppression of SREBP-1c and NF-kβ
    M. Efati, M. Khorrami, Z. Jangravi, A. Z. Mahmoudabadi, M. Raeiszadeh, J. R. Sarshoori
    International Journal of Peptide Research and Therapeutics.2020; 26(3): 1283.     CrossRef
  • Prevention of Nonalcoholic Hepatic Steatosis by Shenling Baizhu Powder: Involvement of Adiponectin-Induced Inhibition of Hepatic SREBP-1c
    Kairui Tang, Yuanjun Deng, Chuiyang Zheng, Huan Nie, Maoxing Pan, Runsen Chen, Jiqian Xie, Qinhe Yang, Yupei Zhang
    Oxidative Medicine and Cellular Longevity.2020; 2020: 1.     CrossRef
  • (−)-Epicatechin and the comorbidities of obesity
    Eleonora Cremonini, Dario E. Iglesias, Jiye Kang, Giovanni E. Lombardo, Zahra Mostofinejad, Ziwei Wang, Wei Zhu, Patricia I. Oteiza
    Archives of Biochemistry and Biophysics.2020; 690: 108505.     CrossRef
  • microRNAs targeting cellular cholesterol: implications for combating anticancer drug resistance
    Bernice Monchusi, Mandeep Kaur
    Genes & Cancer.2020; 11(1-2): 20.     CrossRef
  • Cellular acidosis triggers human MondoA transcriptional activity by driving mitochondrial ATP production
    Blake R Wilde, Zhizhou Ye, Tian-Yeh Lim, Donald E Ayer
    eLife.2019;[Epub]     CrossRef
  • Differential Recovery Speed of Activity and Metabolic Rhythms in Rats After an Experimental Protocol of Shift-Work
    Nadia Saderi, Adrián Báez-Ruiz, Lucia E. Azuara-Álvarez, Carolina Escobar, Roberto C. Salgado-Delgado
    Journal of Biological Rhythms.2019; 34(2): 154.     CrossRef
  • Genetically modified mouse models to study hepatic neutral lipid mobilization
    Guenter Haemmerle, Achim Lass
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2019; 1865(5): 879.     CrossRef
  • Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism
    Elham Karimi-Sales, Abbas Ebrahimi-Kalan, Mohammad Reza Alipour
    Biomedicine & Pharmacotherapy.2019; 109: 1306.     CrossRef
  • A new pathway to eSCAPe lipotoxicity
    Fadila Benhamed, Catherine Postic
    Clinics and Research in Hepatology and Gastroenterology.2018; 42(1): 3.     CrossRef
  • Overexpression of SREBF chaperone (SCAP) enhances nuclear SREBP1 translocation to upregulate fatty acid synthase (FASN) gene expression in bovine mammary epithelial cells
    L.Q. Han, T.Y. Gao, G.Y. Yang, J.J. Loor
    Journal of Dairy Science.2018; 101(7): 6523.     CrossRef
  • Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study
    Gyuri Kim, Suk-Yong Jang, Chung Mo Nam, Eun Seok Kang
    Journal of Hepatology.2018; 68(3): 476.     CrossRef
  • Changes of the Fatty Acid Profile in Erythrocyte Membranes of Patients following 6-Month Dietary Intervention Aimed at the Regression of Nonalcoholic Fatty Liver Disease (NAFLD)
    Dominika Maciejewska, Wojciech Marlicz, Karina Ryterska, Marcin Banaszczak, Dominika Jamioł-Milc, Ewa Stachowska
    Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1.     CrossRef
  • Systems Analysis of the Liver Transcriptome in Adult Male Zebrafish Exposed to the Plasticizer (2-Ethylhexyl) Phthalate (DEHP)
    Matthew Huff, Willian A. da Silveira, Oliana Carnevali, Ludivine Renaud, Gary Hardiman
    Scientific Reports.2018;[Epub]     CrossRef
  • Inactivation of ceramide synthase 2 catalytic activity in mice affects transcription of genes involved in lipid metabolism and cell division
    Andreas Bickert, Paul Kern, Martina van Uelft, Stefanie Herresthal, Thomas Ulas, Katharina Gutbrod, Bernadette Breiden, Joachim Degen, Konrad Sandhoff, Joachim L. Schultze, Peter Dörmann, Dieter Hartmann, Reinhard Bauer, Klaus Willecke
    Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids.2018; 1863(7): 734.     CrossRef
  • Paradoxical Protective Effect of Perfluorooctanesulfonic Acid Against High-Fat Diet–Induced Hepatic Steatosis in Mice
    Ian Huck, Kevin Beggs, Udayan Apte
    International Journal of Toxicology.2018; 37(5): 383.     CrossRef
  • Developmental and extrahepatic physiological functions of SREBP pathway genes in mice
    Luke J. Engelking, Mary Jo Cantoria, Yanchao Xu, Guosheng Liang
    Seminars in Cell & Developmental Biology.2018; 81: 98.     CrossRef
  • Herbacetin, a flaxseed flavonoid, ameliorates high percent dietary fat induced insulin resistance and lipid accumulation through the regulation of hepatic lipid metabolizing and lipid-regulating enzymes
    Chinnadurai Veeramani, Mohammed A. Alsaif, Khalid S. Al-Numair
    Chemico-Biological Interactions.2018; 288: 49.     CrossRef
  • Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals
    Giuseppe Della Pepa, Claudia Vetrani, Gianluca Lombardi, Lutgarda Bozzetto, Giovanni Annuzzi, Angela Rivellese
    Nutrients.2017; 9(10): 1065.     CrossRef
  • MDG-1, a Potential Regulator of PPARα and PPARγ, Ameliorates Dyslipidemia in Mice
    Xu Wang, Linlin Shi, Sun Joyce, Yuan Wang, Yi Feng
    International Journal of Molecular Sciences.2017; 18(9): 1930.     CrossRef
Close layer
Obesity and Metabolism
Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease
Sun-Gi Kim, Byung-Kwon Kim, Kyumin Kim, Sungsoon Fang
Endocrinol Metab. 2016;31(4):500-504.   Published online December 20, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.4.500
  • 9,591 View
  • 80 Download
  • 36 Web of Science
  • 37 Crossref
AbstractAbstract PDFPubReader   

Nonalcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is accumulated in the liver without alcohol consumption. NAFLD is the most common liver disorder in advanced countries. NAFLD is a spectrum of pathology involving hepatic steatosis with/without inflammation and nonalcoholic steatohepatitis with accumulation of hepatocyte damage and hepatic fibrosis. Recent studies have revealed that NAFLD results in the progression of cryptogenic cirrhosis that leads to hepatocarcinoma and cardiovascular diseases such as heart failure. The main causes of NAFLD have not been revealed yet, metabolic syndromes including obesity and insulin resistance are widely accepted for the critical risk factors for the pathogenesis of NAFLD. Nuclear receptors (NRs) are transcriptional factors that sense environmental or hormonal signals and regulate expression of genes, involved in cellular growth, development, and metabolism. Several NRs have been reported to regulate genes involved in energy and xenobiotic metabolism and inflammation. Among various NRs, farnesoid X receptor (FXR) is abundantly expressed in the liver and a key regulator to control various metabolic processes in the liver. Recent studies have shown that NAFLD is associated with inappropriate function of FXR. The impact of FXR transcriptional activity in NAFLD is likely to be potential therapeutic strategy, but still requires to elucidate underlying potent therapeutic mechanisms of FXR for the treatment of NAFLD. This article will focus the physiological roles of FXR and establish the correlation between FXR transcriptional activity and the pathogenesis of NAFLD.

Citations

Citations to this article as recorded by  
  • Signaling pathways shaping the field of lipidomics
    Ehsan Pashay Ahi, Andrew H. House
    Prostaglandins & Other Lipid Mediators.2026; 182: 107053.     CrossRef
  • FXR activation remodels hepatic and intestinal transcriptional landscapes in metabolic dysfunction-associated steatohepatitis
    Ying-quan Wen, Zi-yuan Zou, Guan-guan Zhao, Meng-jiao Zhang, Yong-xin Zhang, Gai-hong Wang, Jing-jing Shi, Yuan-yang Wang, Ye-yu Song, Hui-xia Wang, Ru-ye Chen, Dong-xuan Zheng, Xiao-qun Duan, Ya-meng Liu, Frank J. Gonzalez, Jian-gao Fan, Cen Xie
    Acta Pharmacologica Sinica.2024; 45(11): 2313.     CrossRef
  • Total bile acids levels as a stratification tool for screening portopulmonary hypertension in patients with decompensated cirrhosis
    Kazuaki Tajima, Satoshi Miuma, Hisamitsu Miyaaki, Satoshi Matsuo, Akane Shimakura, Tomotaka Mori, Kosuke Takahashi, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Ryu Sasaki, Eisuke Ozawa, Kazuhiko Nakao
    Hepatology Research.2024; 54(11): 1049.     CrossRef
  • Role of Bile Acid Receptors in the Development and Function of Diabetic Nephropathy
    Yuanyuan Fang, Minjing Qin, Qitong Zheng, Kuilong Wang, Xin Han, Qiao Yang, Xia'nan Sang, Gang Cao
    Kidney International Reports.2024; 9(11): 3116.     CrossRef
  • Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo
    Hongshan Li, Yingfei Xi, Xin Xin, Qin Feng, Yiyang Hu
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • DOT1L Epigenetically Regulates Autophagy and Mitochondria Fusion in Cell Lines of Renal Cancer
    Yanguang Hou, Jiachen Liu, Shiyu Huang, Lei Wang, Juncheng Hu, Xiuheng Liu
    Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
  • Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
    Chander K. Negi, Pavel Babica, Lola Bajard, Julie Bienertova-Vasku, Giovanni Tarantino
    Metabolism.2022; 126: 154925.     CrossRef
  • FXR: structures, biology, and drug development for NASH and fibrosis diseases
    Si-yu Tian, Shu-ming Chen, Cheng-xi Pan, Yong Li
    Acta Pharmacologica Sinica.2022; 43(5): 1120.     CrossRef
  • Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena
    Aamir Bashir, Ajay Duseja, Arka De, Manu Mehta, Pramil Tiwari
    Liver Research.2022; 6(2): 72.     CrossRef
  • The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice
    Jamal Nasser Saleh Al-maamari, Mahardian Rahmadi, Sisca Melani Panggono, Devita Ardina Prameswari, Eka Dewi Pratiwi, Chrismawan Ardianto, Santhra Segaran Balan, Budi Suprapti
    Journal of Basic and Clinical Physiology and Pharmacology.2021; 32(4): 637.     CrossRef
  • Co‑administration of obeticholic acid and simvastatin protects against high‑fat diet‑induced non‑alcoholic steatohepatitis in mice
    Wen-Cong Li, Su-Xian Zhao, Wei-Guang Ren, Yu-Guo Zhang, Rong-Qi Wang, Ling-Bo Kong, Qing-Shan Zhang, Yue-Min Nan
    Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
  • Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis
    Hongshan Li, Yingfei Xi, Xin Xin, Huajie Tian, Yiyang Hu
    Nutrition & Metabolism.2020;[Epub]     CrossRef
  • Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
    Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen
    Pharmacological Research.2020; 159: 104984.     CrossRef
  • Farnesoid X Receptor Activation Protects Liver From Ischemia/Reperfusion Injury by Up‐Regulating Small Heterodimer Partner in Kupffer Cells
    Dan Jin, Tianfei Lu, Ming Ni, Han Wang, Jiang Zhang, Chenpeng Zhong, Chuan Shen, Jun Hao, Ronald W. Busuttil, Jerzy W. Kupiec‐Weglinski, Jianjun Zhang, Ning Xu, Yuan Zhai
    Hepatology Communications.2020; 4(4): 540.     CrossRef
  • Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota–bile acid–farnesoid X receptor axis
    Hongshan Li, Yingfei Xi, Xin Xin, Huajie Tian, Yiyang Hu
    Biomedicine & Pharmacotherapy.2020; 124: 109915.     CrossRef
  • An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
    Ke Pei, Ting Gui, Dongfang Kan, Huichao Feng, Yanqiang Jin, Ying Yang, Qian Zhang, Ziwei Du, Zhibo Gai, Jibiao Wu, Yunlun Li, Kusum Kharbanda
    BioMed Research International.2020;[Epub]     CrossRef
  • Intestinal Barrier Function–Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota
    Yizhe Cui, Qiuju Wang, Renxu Chang, Xiaocui Zhou, Chuang Xu
    Journal of Agricultural and Food Chemistry.2019; 67(10): 2754.     CrossRef
  • A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters
    Mao-xu Ge, Wei-xiao Niu, Jin-feng Ren, Shi-ying Cai, Dong-ke Yu, Hong-tao Liu, Na Zhang, Yi-xuan Zhang, Yu-cheng Wang, Rong-guang Shao, Ju-xian Wang, Hong-wei He
    Acta Pharmacologica Sinica.2019; 40(7): 895.     CrossRef
  • Consenso mexicano de la enfermedad por hígado graso no alcohólico
    R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrer
    Revista de Gastroenterología de México.2019; 84(1): 69.     CrossRef
  • Fish oil alleviates circadian bile composition dysregulation in male mice with NAFLD
    Yang Liu, Qi Li, Hualin Wang, Xiuju Zhao, Na Li, Hongyu Zhang, Guoxun Chen, Zhiguo Liu
    The Journal of Nutritional Biochemistry.2019; 69: 53.     CrossRef
  • RETRACTED ARTICLE: Effects of sanshoamides and capsaicinoids on plasma and liver lipid metabolism in hyperlipidemic rats
    Zhaojun Chen, Yongxiang Liu, Hui Wang, Zhongai Chen, Jia Liu, Hui Liu
    Food Science and Biotechnology.2019; 28(2): 519.     CrossRef
  • The Mexican consensus on nonalcoholic fatty liver disease
    R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrer
    Revista de Gastroenterología de México (English Edition).2019; 84(1): 69.     CrossRef
  • Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study
    Ning Liu, Jiao Feng, Yang Lv, Qing Liu, Jingfan Deng, Yujing Xia, Chuanyong Guo, Yingqun Zhou
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Essential role of nuclear receptors for the evaluation of the benefits of bioactive herbal extracts on liver function
    Fengling Wang, Yifan Wu, Xiaoting Xie, Jing Sun, Weidong Chen
    Biomedicine & Pharmacotherapy.2018; 99: 798.     CrossRef
  • Maternal obesity has sex‐dependent effects on insulin, glucose and lipid metabolism and the liver transcriptome in young adult rat offspring
    Consuelo Lomas‐Soria, Luis A. Reyes‐Castro, Guadalupe L. Rodríguez‐González, Carlos A. Ibáñez, Claudia J. Bautista, Laura A. Cox, Peter W. Nathanielsz, Elena Zambrano
    The Journal of Physiology.2018; 596(19): 4611.     CrossRef
  • Protective effect of dioscin against thioacetamide-induced acute liver injury via FXR/AMPK signaling pathway in vivo
    Lingli Zheng, Lianhong Yin, Lina Xu, Yan Qi, Hua Li, Youwei Xu, Xu Han, Kexin Liu, Jinyong Peng
    Biomedicine & Pharmacotherapy.2018; 97: 481.     CrossRef
  • New therapeutic perspectives in non-alcoholic steatohepatitis
    Javier Ampuero, Yolanda Sánchez-Torrijos, Virginia Aguilera, Francisco Bellido, Manuel Romero-Gómez
    Gastroenterología y Hepatología (English Edition).2018; 41(2): 128.     CrossRef
  • Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD
    Valerio Nobili, Anna Alisi, Antonella Mosca, Claudia Della Corte, Silvio Veraldi, Rita De Vito, Cristiano De Stefanis, Valentina D'Oria, Joerg Jahnel, Evelyn Zohrer, Eleonora Scorletti, Christopher D. Byrne
    Liver International.2018; 38(2): 342.     CrossRef
  • The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives
    Stefano Gitto, Valeria Guarneri, Alessandro Sartini, Pietro Andreone
    Expert Review of Gastroenterology & Hepatology.2018; 12(2): 165.     CrossRef
  • Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR
    Verena Hiebl, Angela Ladurner, Simone Latkolik, Verena M. Dirsch
    Biotechnology Advances.2018; 36(6): 1657.     CrossRef
  • Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica
    Javier Ampuero, Yolanda Sánchez-Torrijos, Virginia Aguilera, Francisco Bellido, Manuel Romero-Gómez
    Gastroenterología y Hepatología.2018; 41(2): 128.     CrossRef
  • Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease
    Qinwei Yu, Zhenzhou Jiang, Luyong Zhang
    Pharmacology & Therapeutics.2018; 190: 81.     CrossRef
  • Hippocampal FXR plays a role in the pathogenesis of depression: A preliminary study based on lentiviral gene modulation
    Wei-Guan Chen, Jia-Xuan Zheng, Xi Xu, Yu-Ming Hu, Yu-Min Ma
    Psychiatry Research.2018; 264: 374.     CrossRef
  • Bile acid receptors and the kidney
    Michal Herman-Edelstein, Talia Weinstein, Moshe Levi
    Current Opinion in Nephrology and Hypertension.2018; 27(1): 56.     CrossRef
  • Effects of resveratrol, exercises and their combination on Farnesoid X receptor, Liver X receptor and Sirtuin 1 gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver
    Amir Hajighasem, Parvin Farzanegi, Zohreh Mazaheri, Marjan Naghizadeh, Ghoncheh Salehi
    PeerJ.2018; 6: e5522.     CrossRef
  • Gut–Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease
    Marco Poeta, Luca Pierri, Pietro Vajro
    Children.2017; 4(8): 66.     CrossRef
  • Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review
    S Singh, KK Kharbanda
    Archives of Hepatitis Research.2017; 3(1): 029.     CrossRef
Close layer
Thyroid
Clinical Relevance of Environmental Factors in the Pathogenesis of Autoimmune Thyroid Disease
Wilmar M. Wiersinga
Endocrinol Metab. 2016;31(2):213-222.   Published online May 13, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.2.213
  • 21,845 View
  • 317 Download
  • 116 Web of Science
  • 118 Crossref
AbstractAbstract PDFPubReader   

Genetic factors contribute for about 70% to 80% and environmental factors for about 20% to 30% to the pathogenesis of autoimmune thyroid disease (AITD). Relatives of AITD patients carry a risk to contract AITD themselves. The 5-year risk can be quantified by the so-called Thyroid Events Amsterdam-score, based on serum thyroid-stimulating hormone, thyroid peroxidase (TPO)-antibodies and family history. Subjects at risk may ask what they can do to prevent development of AITD. This review summarizes what is known about modulation of exposure to environmental factors in terms of AITD prevention. To stop smoking decreases the risk on Graves disease but increases the risk on Hashimoto disease. Moderate alcohol intake provides some protection against both Graves and Hashimoto disease. Low selenium intake is associated with a higher prevalence of thyroid autoimmunity, but evidence that selenium supplementation may lower TPO antibodies and prevent subclinical hypothyroidism remains inconclusive. Low serum vitamin D levels are associated with a higher prevalence of TPO antibodies, but intervention studies with extra vitamin D have not been done yet. Stress may provoke Graves hyperthyroidism but not Hashimoto thyroiditis. Estrogen use have been linked to a lower prevalence of Graves disease. The postpartum period is associated with an increased risk of AITD. Taking together, preventive interventions to diminish the risk of AITD are few, not always feasible, and probably of limited efficacy.

Citations

Citations to this article as recorded by  
  • Association of IL17A rs4711998 and IL1B rs16944 Polymorphism with Anti-Thyroid Peroxidase Serum Level in Autoimmune Thyroid Diseases: A Case–Control Study in Iranian Population
    Aynaz Asgharvand-Hajeb, Alireza Hatami, Parvin Sarbakhsh, Sima Shahmohammadi Farid
    Genetic Testing and Molecular Biomarkers.2026; 30(1): 25.     CrossRef
  • The Role of Immunological Challenges, Oxidative Stress, and Dietary Interventions in Managing Hashimoto’s Thyroiditis: A Narrative Review
    Joanna Morasiewicz-Jeziorek, Angelika Buczyńska, Adam Jacek Krętowski, Agnieszka Adamska
    Nutrition Reviews.2026;[Epub]     CrossRef
  • Causal Association of Dietary Habits With Thyroid Diseases: Univariate and Multivariate Mendelian Randomization Studies
    Ningwei Wang, Yunyi Yang, Jiawen You, Xiaoxiao Qu, Weijin Huang, Yanming He, Hongjie Yang
    Food Science & Nutrition.2026;[Epub]     CrossRef
  • Thyroid Autoimmunity is Associated with Dietary Fat Consumption
    Lulian Xu, Zhenzhen Liu, Xu Xu, Qiwen Wan, Juanying Zhen, Li Jiang, Bernard Man Yung Cheung, Chao Li
    The Journal of Clinical Endocrinology & Metabolism.2025; 110(6): e1902.     CrossRef
  • The immune system in Hashimoto's thyroiditis: Updating the current state of knowledge on potential therapies and animal model construction
    Ruixi Li, Ting He, Zhichao Xing, Li Mi, Anping Su, Wenshuang Wu
    Autoimmunity Reviews.2025; 24(6): 103783.     CrossRef
  • The development of thyroid autoimmunity is potentially associated with the deficiency of vitamin D3 rather than vitamin D2 in euthyroid men
    Dongdong Luo, Chenxi Zhang, Bingrui Gao, Deping Wang, Zhaoying Chen, Kan Chen, Bojuan Li, Song Leng, Jing Li
    Thyroid Research.2025;[Epub]     CrossRef
  • The Percentage of Neutrophils is Independently Associated with Blood-Brain Barrier(BBB) Disruption in Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD)
    Xuan Cheng, Yidi Sun, Yaoyao Wang, Wenchao Cheng, Haifeng Zhang, Yan Jiang
    Journal of Inflammation Research.2025; Volume 18: 2823.     CrossRef
  • Commonalities between thyroid disease and systemic lupus erythematosus (SLE)
    Lin-Lin Li, Qiu-Rui Li, Lu Li, Hui-Xia Cao, Feng-Min Shao
    Lupus.2025; 34(8): 767.     CrossRef
  • The role of the T helper 17 and T regulatory cell ratio in the gut-thyroid axis
    Julia Williams, Anna Gruvstad Melén, Michelle Barrow
    Clinical Immunology Communications.2025; 8: 10.     CrossRef
  • Research Progress on the Association Between Life’s Essential 8 and Thyroid Diseases
    科 张
    Advances in Clinical Medicine.2025; 15(06): 2004.     CrossRef
  • Endocrine disruptive chemicals (EDCs) and autoimmune thyroid diseases (AITD): A systematic literature review
    Mathilda Monaghan, Sonia Rodrigues, Shiven Sharma, Angela M. Leung, Maaike van Gerwen
    Current Opinion in Endocrine and Metabolic Research.2025; 41: 100585.     CrossRef
  • COVID-19 vaccine-induced autoimmune hyperthyroidism: Graves’ disease
    Avaniyapuram Kannan Murugan, Ali S. Alzahrani
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Graves’ orbitopathy following Alemtuzumab treatment for multiple sclerosis: a systematic review and real-world insights
    Bohdan Patera, Andrea Zaffaroni, Sotiris Louka, Daniela Gallo, Eliana Piantanida, Maria Laura Tanda
    Thyroid Research.2025;[Epub]     CrossRef
  • Trends in Prevalence of Thyroid Dysfunction and its Associations With Mortality Among US Participants, 1988-2012
    Xiaowen Zhang, Yong Wang, Hongwei Wang, Xinlin Zhang
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(2): e657.     CrossRef
  • The role of medical and organizational measures in improving the quality of early detection and clinical examination of autoimmune thyroiditis among the population of the Republic of Belarus
    L. I. Danilova, V. A. Rozhko, I. V. Veyalkin, S. N. Nikanovich, T. M. Sharshakova
    Health and Ecology Issues.2024; 20(4): 129.     CrossRef
  • Hyperthyroidism
    Layal Chaker, David S Cooper, John P Walsh, Robin P Peeters
    The Lancet.2024; 403(10428): 768.     CrossRef
  • A Review of Thyroid Dysfunction Due to COVID-19
    Alireza Arefzadeh
    Mini-Reviews in Medicinal Chemistry.2024; 24(3): 265.     CrossRef
  • Alteration in kynurenine pathway metabolites in young women with autoimmune thyroiditis
    Anna Krupa, Agnieszka Łebkowska, Marcin Kondraciuk, Karol Adam Kaminski, Irina Kowalska
    Scientific Reports.2024;[Epub]     CrossRef
  • Association of autoimmune thyroid disease with type 1 diabetes mellitus and its ultrasonic diagnosis and management
    Jin Wang, Ke Wan, Xin Chang, Rui-Feng Mao
    World Journal of Diabetes.2024; 15(3): 348.     CrossRef
  • Assessment of Vitamin Concentrations in Patients with Hashimoto’s Thyroiditis and Their Relationships with Thyroid Function, Biochemical Status, and Anthropometric Parameters—A Preliminary Study
    Aniceta Ada Mikulska-Sauermann, Matylda Resztak, Marta Karaźniewicz-Łada, Dorota Filipowicz, Marek Ruchała, Franciszek K. Główka
    Nutrients.2024; 16(11): 1694.     CrossRef
  • Toenail and blood selenium mediated regulation of thyroid dysfunction through immune cells: a mediation Mendelian randomization analysis
    Yu-jia Jiang, Yi-quan Xiong, Tao Huang, Yun-xiao Xiao
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • The causal relationship between major depression disorder and thyroid diseases: A Mendelian randomization study and mediation analysis
    Xu Zhang, Qiao Lu, Yiping Luo, Luyao Wang, Yuan Tian, Xuemei Luo
    Journal of Affective Disorders.2024; 359: 287.     CrossRef
  • The Role of miRNA in Hyperthyroidism Induced by Excessive Iodine in Drinking Water
    Zhihan Yang, Yishan Dong, Shuo Wang, Jing He, Zheng Shen, Jin Cheng, Jinyu Li, Qiaoling Liu, Ziqi Xu, Dianjun Sun, Wei Zhang
    Biological Trace Element Research.2024; 203(5): 2478.     CrossRef
  • Causal effects of post-traumatic stress disorder on autoimmune thyroid disease: insights from mendelian randomization
    Zhaorong Chen, Yunfeng Yu, Jiayu Yao, Zirui Guo, Yanhui Cui, Fang Li, Changqi Li
    Frontiers in Psychiatry.2024;[Epub]     CrossRef
  • Causal relationship between antihypertensive drugs and Hashimoto’s thyroiditis: a drug-target Mendelian randomization study
    Bing Cui, Aqin Chen, Chengcheng Xu, Chaoming Mao, Yuehua Chen
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Comparison of Thyroid Size-Specific Radioiodine Dose and New Modified Dose Calculation in the Treatment of Graves’ Disease
    Alisara Wongsuttilert, Ruchirek Thamcharoen, Yoswanich Maiprasert, Sathapakorn Siriwong
    Endocrinology and Metabolism.2024; 39(5): 758.     CrossRef
  • Analysis of risk factors for autoimmune thyroid disease based on blood indicators and urinary iodine concentrations
    Jianning Liu, Zhuoying Feng, Ru Gao, Peng Liu, Fangang Meng, Lijun Fan, Lixiang Liu, Yang Du
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Genetic predisposition of MTHFR and TNFSF4 gene polymorphism related to hypothyroidism– A meta-analysis
    Iyshwarya Bhaskar Kalarani, Karpagavel Lakshmanan, Ramakrishnan Veerabathiran
    Gene Reports.2024; 37: 102091.     CrossRef
  • Autoimmune Thyroid Disease and Pregnancy: The Interaction Between Genetics, Epigenetics and Environmental Factors
    Tatjana Bogović Crnčić, Božena Ćurko-Cofek, Lara Batičić, Neva Girotto, Maja Ilić Tomaš, Antea Kršek, Ines Krištofić, Tea Štimac, Ivona Perić, Vlatka Sotošek, Sanja Klobučar
    Journal of Clinical Medicine.2024; 14(1): 190.     CrossRef
  • Hashimoto’s thyroiditis and coexisting disorders in correlation with HLA status—an overview
    Peter Mikosch, Adrian Aistleitner, Markus Oehrlein, Eva Trifina-Mikosch
    Wiener Medizinische Wochenschrift.2023; 173(1-2): 41.     CrossRef
  • The management and metabolic characterization: hyperthyroidism and hypothyroidism
    Yangyang Wang, YanPing Sun, Bingyou Yang, Qiuhong Wang, Haixue Kuang
    Neuropeptides.2023; 97: 102308.     CrossRef
  • Zn and Se abrogate heavy metal mixture induced ovarian and thyroid oxido-inflammatory effects mediated by activation of NRF2-HMOX-1 in female albino rats
    Boma F. Eddie-Amadi, Anthonet N. Ezejiofor, Chinna N. Orish, Orish E. Orisakwe
    Current Research in Toxicology.2023; 4: 100098.     CrossRef
  • Genetically predicted selenium concentrations and thyroid function: A two‐sample Mendelian randomization study
    Hui‐Jun Huang, Shan‐Shan Wang, Ming‐Min Jin, Bin‐Wei Cheng, Yu Liu, Xiao‐Chen Liu, Qiu‐Yan Yu, Xin‐Jun Yang
    Clinical Endocrinology.2023; 98(6): 813.     CrossRef
  • Identification of Smoking‐Associated Transcriptome Aberration in Blood with Machine Learning Methods
    FeiMing Huang, QingLan Ma, JingXin Ren, JiaRui Li, Fen Wang, Tao Huang, Yu-Dong Cai, Bilal Alatas
    BioMed Research International.2023;[Epub]     CrossRef
  • COVID-induced thyroid autoimmunity
    Alessandro Brancatella, Nicola Viola, Ferruccio Santini, Francesco Latrofa
    Best Practice & Research Clinical Endocrinology & Metabolism.2023; 37(2): 101742.     CrossRef
  • Associations between vitamin D levels and dietary patterns in patients with Hashimoto’s thyroiditis
    Dean Kaličanin, Maja Cvek, Ana Barić, Veselin Škrabić, Ante Punda, Vesna Boraska Perica
    Frontiers in Nutrition.2023;[Epub]     CrossRef
  • COMPARATIVE MORPHOLOGY OF THE THYROID GLAND
    L. O. Sviatotska
    Bulletin of Problems Biology and Medicine.2023; 1(2): 386.     CrossRef
  • Evaluation and epigenetic impact of B12, vitamin D, folic acid and anemia in Hashimoto's thyroiditis: a clinical and molecular docking study
    Elif Sibel ASLAN, Savaş GÜR
    Journal of Health Sciences and Medicine.2023; 6(4): 705.     CrossRef
  • Interactions between Polygenetic Variants and Lifestyle Factors in Hypothyroidism: A Hospital-Based Cohort Study
    Da Sol Kim, Sunmin Park
    Nutrients.2023; 15(17): 3850.     CrossRef
  • Do Dietary Supplements Affect Inflammation, Oxidative Stress, and Antioxidant Status in Adults with Hypothyroidism or Hashimoto’s Disease?—A Systematic Review of Controlled Trials
    Katarzyna Kubiak, Maria Karolina Szmidt, Joanna Kaluza, Agnieszka Zylka, Ewa Sicinska
    Antioxidants.2023; 12(10): 1798.     CrossRef
  • Identification and Preliminary Clinical Validation of Key Extracellular Proteins as the Potential Biomarkers in Hashimoto’s Thyroiditis by Comprehensive Analysis
    Zihan Xi, Tinglin Yang, Tao Huang, Jun Zhou, Peng Yang
    Biomedicines.2023; 11(12): 3127.     CrossRef
  • An examination of retinal findings with optical coherence tomography in hypothyroidism patients with vitamin D deficiency: A comparative study
    Samet Sayılan, Dila Kırağı, Mehmet Tayfun Arslan
    Journal of Clinical Medicine of Kazakhstan.2023; 20(6): 36.     CrossRef
  • The role of IL-4 −590 (C>T) Gene as diagnostic biomarker of Hashimoto thyroiditis disease patients in AL-Najaf provenance /Iraq
    Sarah Hasan Kadhum AL-Huchaimi, Mahdi Hussain AL-Ammar, Sabah N. AL-Fatlawi
    Al-Kufa University Journal for Biology.2023; 15(3): 14.     CrossRef
  • Early life stress in women with autoimmune thyroid disorders
    Alessia Corso, Hermann Engel, Fabienne Müller, Serena Fiacco, Laura Mernone, Elena Gardini, Ulrike Ehlert, Susanne Fischer
    Scientific Reports.2023;[Epub]     CrossRef
  • Protective Effects of Selenium and Zinc Against Nickel Chloride–Induced Hormonal Changes and Oxidative Damage in Thyroid of Pregnant Rats
    Imane Salah, Ounassa Adjroud, Awatef Elwej
    Biological Trace Element Research.2022; 200(5): 2183.     CrossRef
  • Effects of animal protein intake during pregnancy on autoimmune thyroiditis in pregnant women with mild iodine deficiency
    Zhengyuan Wang, Jiaying Shen, Qi Song, Xueying Cui, Zehuan Shi, Jin Su, Jiajie Zang
    Journal of Human Nutrition and Dietetics.2022; 35(3): 542.     CrossRef
  • Positive antithyroid antibody predicts severity of neuromyelitis optica spectrum disorder in children
    Liang Huo, Hua Wang, Yujun Yuan, Jian Gao, Xueyan Liu
    Multiple Sclerosis and Related Disorders.2022; 57: 103425.     CrossRef
  • Seasonality of month of birth in patients with autoimmune endocrine diseases: A systematic review
    Ana M. Ramos-Leví, Gloria Collado, Monica Marazuela
    Endocrinología, Diabetes y Nutrición.2022; 69(10): 779.     CrossRef
  • Are ethnic differences, urinary iodine status, lead and cadmium exposure associated with thyroid autoimmunity and hypothyroid status? A cross-sectional study
    Yi Chen, Qian Xiang, Ningjian Wang, Wen Zhang, Chunfang Zhu, Yuying Wang, Heng Wan, Jing Cheng, Kun Zhang, Yan Cai, Yingli Lu
    BMJ Open.2022; 12(2): e056909.     CrossRef
  • The Association of Thyroid Nodules With Blood Trace Elements Identified in a Cross-Section Study
    Huixian Zeng, Yuanyuan Hu, Yaosheng Luo, Yanshi Ye, Cheng Song, Genfeng Yu, Zhi Chen, Siyang Liu, Yongqian Liang, Lingling Liu, Heng Wan, Jie Shen
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Nutritional Management of Thyroiditis of Hashimoto
    Yana Danailova, Tsvetelina Velikova, Georgi Nikolaev, Zorka Mitova, Alexander Shinkov, Hristo Gagov, Rossitza Konakchieva
    International Journal of Molecular Sciences.2022; 23(9): 5144.     CrossRef
  • Association Between Vitamin D Deficiency and Autoimmune Thyroid Disorder: A Systematic Review
    Sabah A Khozam, Abdulhadi M Sumaili, Mohammed A Alflan, Rawan As'ad Salameh Shawabkeh
    Cureus.2022;[Epub]     CrossRef
  • Metabolic Characteristics of Hashimoto’s Thyroiditis Patients and the Role of Microelements and Diet in the Disease Management—An Overview
    Aniceta A. Mikulska, Marta Karaźniewicz-Łada, Dorota Filipowicz, Marek Ruchała, Franciszek K. Główka
    International Journal of Molecular Sciences.2022; 23(12): 6580.     CrossRef
  • Predictors of autoimmune thyroid disease
    Carol Cardona Attard, W. C. Candy Sze, Sandro Vella
    Baylor University Medical Center Proceedings.2022; 35(5): 608.     CrossRef
  • Selenium Status and Supplementation Effects in Pregnancy—A Study on Mother–Child Pairs from a Single-Center Cohort
    Dorota Filipowicz, Ewelina Szczepanek-Parulska, Małgorzata Kłobus, Krzysztof Szymanowski, Thilo Samson Chillon, Sabrina Asaad, Qian Sun, Aniceta A. Mikulska-Sauermann, Marta Karaźniewicz-Łada, Franciszek K. Główka, Dominika Wietrzyk, Lutz Schomburg, Marek
    Nutrients.2022; 14(15): 3082.     CrossRef
  • Inflammasome activation as a link between obesity and thyroid disorders: Implications for an integrated clinical management
    Rosario Le Moli, Veronica Vella, Dario Tumino, Tommaso Piticchio, Adriano Naselli, Antonino Belfiore, Francesco Frasca
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Seasonality of month of birth in patients with autoimmune endocrine diseases: A systematic review
    Ana M. Ramos-Leví, Gloria Collado, Monica Marazuela
    Endocrinología, Diabetes y Nutrición (English ed.).2022; 69(10): 779.     CrossRef
  • Impact of iodine intake on the pathogenesis of autoimmune thyroid disease in children and adults
    Iyshwarya Bhaskar Kalarani, Ramakrishnan Veerabathiran
    Annals of Pediatric Endocrinology & Metabolism.2022; 27(4): 256.     CrossRef
  • Morphological features of thyroid benign focal neoplasms in Graves’ disease
    Yu.V. Buldygina, A.V. Zelinskaya, L.Yu. Zurnadzhy, Yu.M. Tarashchenko, S.L. Shlyakhtych, M.D. Tronko
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2022; 18(4): 213.     CrossRef
  • Pathogenesis Markers of Hashimoto's Disease—A Mini Review
    Binghui Jin, Shuang Wang, Zhe Fan
    Frontiers in Bioscience-Landmark.2022;[Epub]     CrossRef
  • Experiences of Patients With Hashimoto Thyroiditis Through the Lens of Compassion
    Zoi Portokalidou, Anna Huysse-Gaytandjieva, Madelon L. Peters
    OBM Integrative and Complementary Medicine.2022; 07(03): 1.     CrossRef
  • Onset of Marine-Lenhart syndrome and Graves’ ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis
    Rosario Le Moli, Marco Russo, Pasqualino Malandrino, Veronica Vella, Antonino Belfiore, Francesco Frasca
    Hormones.2021; 20(1): 161.     CrossRef
  • Limited Genetic Overlap Between Overt Hashimoto’s Thyroiditis and Graves’ Disease in Twins: A Population-based Study
    Jakob Skov, Jan Calissendorff, Daniel Eriksson, Patrik Magnusson, Olle Kämpe, Sophie Bensing, Ralf Kuja-Halkola
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(4): e1101.     CrossRef
  • DNA Methylation Patterns in the HLA-DPB1 and PDCD1LG2 Gene Regions in Patients with Autoimmune Thyroiditis from Different Water Iodine Areas
    Siyuan Wan, Lixiang Liu, Bingxuan Ren, Mengying Qu, Huaiyong Wu, Wen Jiang, Xiaoming Wang, Hongmei Shen
    Thyroid.2021; 31(11): 1741.     CrossRef
  • Персоналізація лікування хвороби Грейвса на підставі клініко- імунологічних характеристик перебігу захворювання
    Yu.V. Buldygina, S.L. Shlyakhtych, H.M. Terekhova, T.V. Fed’ko, V.M. Klochkova, L.S. Strafun, Z.H. Lysova, I.I. Savos’ko
    Endokrynologia.2021; 26(4): 409.     CrossRef
  • Parity and Incidence of Thyroid Autoimmunity: A Population-Based Tehran Thyroid Study
    Miralireza Takyar, Maryam Rahmani, Atieh Amouzegar, Elham Madreseh, Maryam Tohidi, Ladan Mehran, Fereidoun Azizi
    Thyroid.2020; 30(8): 1186.     CrossRef
  • Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review
    D. Gallo, L. Mortara, M. B. Gariboldi, S. A. M. Cattaneo, S. Rosetti, L. Gentile, D. M. Noonan, P. Premoli, C. Cusini, M. L. Tanda, L. Bartalena, E. Piantanida
    Journal of Endocrinological Investigation.2020; 43(4): 413.     CrossRef
  • Hashimoto Thyreoiditis, therapeutische Optionen und extrathyreoidale Assoziationen – ein aktueller Überblick
    Eva Petnehazy, Wolfgang Buchinger
    Wiener Medizinische Wochenschrift.2020; 170(1-2): 26.     CrossRef
  • Pathophysiological Role and Therapeutic Implications of Vitamin D in Autoimmunity: Focus on Chronic Autoimmune Diseases
    Mattia Bellan, Laura Andreoli, Chiara Mele, Pier Paolo Sainaghi, Cristina Rigamonti, Silvia Piantoni, Carla De Benedittis, Gianluca Aimaretti, Mario Pirisi, Paolo Marzullo
    Nutrients.2020; 12(3): 789.     CrossRef
  • Thyroxine-binding globulin, peripheral deiodinase activity, and thyroid autoantibody status in association of phthalates and phenolic compounds with thyroid hormones in adult population
    Sohyeon Choi, Min Joo Kim, Young Joo Park, Sunmi Kim, Kyungho Choi, Gi Jeong Cheon, Yoon Hee Cho, Hye Li Jeon, Jiyoung Yoo, Jeongim Park
    Environment International.2020; 140: 105783.     CrossRef
  • Immunomodulatory Effects of Vitamin D in Thyroid Diseases
    Chiara Mele, Marina Caputo, Alessandro Bisceglia, Maria Teresa Samà, Marco Zavattaro, Gianluca Aimaretti, Loredana Pagano, Flavia Prodam, Paolo Marzullo
    Nutrients.2020; 12(5): 1444.     CrossRef
  • Significance of arsenic and lead in Hashimoto's thyroiditis demonstrated on thyroid tissue, blood, and urine samples
    Aleksandar Stojsavljević, Branislav Rovčanin, Jovana Jagodić, Danijela Drašković Radojković, Ivan Paunović, Marija Gavrović-Jankulović, Dragan Manojlović
    Environmental Research.2020; 186: 109538.     CrossRef
  • Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses
    Alessandro Antonelli, Silvia Martina Ferrari, Francesca Ragusa, Giusy Elia, Sabrina Rosaria Paparo, Ilaria Ruffilli, Armando Patrizio, Claudia Giusti, Debora Gonnella, Alfonso Cristaudo, Rudy Foddis, Yehuda Shoenfeld, Poupak Fallahi
    Best Practice & Research Clinical Endocrinology & Metabolism.2020; 34(1): 101387.     CrossRef
  • Vitamin D deficiency and thyroid autoantibody fluctuations in patients with Graves’ disease – A mere coincidence or a real relationship?
    Maria Teresa Płazińska, Agata Czarnywojtek, Nadia Sawicka-Gutaj, Małgorzata Zgorzalewicz-Stachowiak, Barbara Czarnocka, Paweł Gut, Maria Karlinska, Marta Fichna, Adam Stachowski, Marek Ruchała, Iwona Krela-Kaźmierczak, Leszek Królicki
    Advances in Medical Sciences.2020; 65(1): 39.     CrossRef
  • An eight-year-old girl with autoimmune polyglandular syndrome type3A that developed during the course of primary Epstein–Barr virus (EBV) infection: clinical implication of EBV in autoimmune thyroid disease
    Shizuka Kirino, Hisae Nakatani, Aoi Honma, Asami Shinbo, Keiko Onda, Mari Okada, Masako Imai, Natsuko Suzuki, Akihiro Oshiba, Masayuki Nagasawa
    Immunological Medicine.2020; 43(1): 57.     CrossRef
  • Exploring the role of copper and selenium in the maintenance of normal thyroid function among healthy Koreans
    Min Joo Kim, Soo Chin Kim, Soie Chung, Serim Kim, Ji Won Yoon, Young Joo Park
    Journal of Trace Elements in Medicine and Biology.2020; 61: 126558.     CrossRef
  • A comparison of serum zinc levels in melasma and non-melasma patients: a preliminary study of thyroid dysfunction
    Indina Sastrini Sekarnesia, Irma Bernadette S. Sitohang, Triana Agustin, Wismandari Wisnu, Aida S. D. Hoemardani
    Acta Dermatovenerologica Alpina Pannonica et Adriatica.2020;[Epub]     CrossRef
  • Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation
    Massimo Ralli, Diletta Angeletti, Marco Fiore, Vittorio D'Aguanno, Alessandro Lambiase, Marco Artico, Marco de Vincentiis, Antonio Greco
    Autoimmunity Reviews.2020; 19(10): 102649.     CrossRef
  • Vitamin D and Autoimmune Thyroid Disease—Cause, Consequence, or a Vicious Cycle?
    Inês Henriques Vieira, Dírcea Rodrigues, Isabel Paiva
    Nutrients.2020; 12(9): 2791.     CrossRef
  • New Insights into Mechanisms of Endocrine-Disrupting Chemicals in Thyroid Diseases: The Epigenetic Way
    Letizia Pitto, Francesca Gorini, Fabrizio Bianchi, Elena Guzzolino
    International Journal of Environmental Research and Public Health.2020; 17(21): 7787.     CrossRef
  • Genotype association of IP6K3 gene with Hashimoto’s thyroiditis in Algerian population (Aures region)
    Warda Kherrour, Dean Kalicanin, Luka Brčić, Leila Hambaba, Mouloud Yahia, Souheyla Benbia, Vesna Boraska Perica
    Egyptian Journal of Medical Human Genetics.2020;[Epub]     CrossRef
  • TOTAL ANTIOXIDANT ACTIVITY AND MANGANESE SUPEROXIDE DISMUTASE IN COMORBIDITY OF GASTROESOPHAGEAL REFLUX DISEASE AND AUTOIMMUNE THYROIDITIS IN STUDENT POPULATION
    Tamara M. Pasiieshvili, Natalia M. Zhelezniakova, Lyudmila M. Pasiyeshvili, Olga M. Kovalyova
    Wiadomości Lekarskie.2020; 73(12): 2644.     CrossRef
  • Vitamin B12 and Vitamin D Levels in Patients with Autoimmune Hypothyroidism and Their Correlation with Anti-Thyroid Peroxidase Antibodies
    Hanife Şerife Aktaş
    Medical Principles and Practice.2020; 29(4): 364.     CrossRef
  • Increased Risk of Thyroid Dysfunction Among Patients With Rheumatoid Arthritis
    Qian Li, Bin Wang, Kaida Mu, Jing Zhang, Yanping Yang, Wei Yao, Jie Zhu, Jin-an Zhang
    Frontiers in Endocrinology.2019;[Epub]     CrossRef
  • Association between thyroglobulin polymorphisms and autoimmune thyroid disease: a systematic review and meta-analysis of case–control studies
    Ming-Liang Zhang, Dong-ming Zhang, Cai-E. Wang, Xiao-Long Chen, Fang-Zhou Liu, Jian-Xue Yang
    Genes & Immunity.2019; 20(6): 484.     CrossRef
  • Changes in glucose‐lipid metabolism, insulin resistance, and inflammatory factors in patients with autoimmune thyroid disease
    Yi Lei, Jun Yang, Hua Li, Haihua Zhong, Qin Wan
    Journal of Clinical Laboratory Analysis.2019;[Epub]     CrossRef
  • Evaluation of Qualitative Dietary Protocol (Diet4Hashi) Application in Dietary Counseling in Hashimoto Thyroiditis: Study Protocol of a Randomized Controlled Trial
    Natalia Wojtas, Lidia Wadolowska, Elżbieta Bandurska-Stankiewicz
    International Journal of Environmental Research and Public Health.2019; 16(23): 4841.     CrossRef
  • Sjögren’s Syndrome and Autoimmune Thyroid Disease: Two Sides of the Same Coin
    Juan-Manuel Anaya, Paula Restrepo-Jiménez, Yhojan Rodríguez, Mónica Rodríguez-Jiménez, Yeny Acosta-Ampudia, Diana M. Monsalve, Yovana Pacheco, Carolina Ramírez-Santana, Nicolás Molano-González, Rubén D. Mantilla
    Clinical Reviews in Allergy & Immunology.2019; 56(3): 362.     CrossRef
  • Disease Presentation and Remission Rate in Graves Disease Treated With Antithyroid Drugs: is Gender Really A Factor?
    Talia Diker-Cohen, Hadar Duskin-Bitan, Ilan Shimon, Dania Hirsch, Amit Akirov, Gloria Tsvetov, Eyal Robenshtok
    Endocrine Practice.2019; 25(1): 43.     CrossRef
  • IRAK2 and TLR10 confer risk of Hashimoto’s disease: a genetic association study based on the Han Chinese population
    Miao Li, Wei Han, Li Zhu, Jue Jiang, Wei Qu, Lei Zhang, Liang Jia, Qi Zhou
    Journal of Human Genetics.2019; 64(7): 617.     CrossRef
  • Environmental exposure to pesticides and risk of thyroid diseases
    Mar Requena, Antonia López-Villén, Antonio F. Hernández, Tesifón Parrón, Ángela Navarro, Raquel Alarcón
    Toxicology Letters.2019; 315: 55.     CrossRef
  • Determining the Level of Knowledge about Graves’ Disease: Single-Center Results
    Hande Peynirci, Çiğdem Uzuntepe Aksu, Akif Doğan, Canan Ersoy
    Ankara Medical Journal.2019;[Epub]     CrossRef
  • Association between lifestyle and thyroid dysfunction: a cross-sectional epidemiologic study in the She ethnic minority group of Fujian Province in China
    Yanling Huang, Liangchun Cai, Yuanyuan Zheng, Jinxing Pan, Liantao Li, Liyao Zong, Wei Lin, Jixing Liang, Huibin Huang, Junping Wen, Gang Chen
    BMC Endocrine Disorders.2019;[Epub]     CrossRef
  • Vitamin D Receptor Gene Polymorphisms and Autoimmune Thyroiditis: Are They Associated with Disease Occurrence and Its Features?
    Adam Maciejewski, Michał J. Kowalczyk, Waldemar Herman, Adam Czyżyk, Marta Kowalska, Ryszard Żaba, Katarzyna Łącka
    BioMed Research International.2019; 2019: 1.     CrossRef
  • Diagnosis of Graves’ disease – laboratory tests and possible difficulties in interpretation
    Agata Maria Kalicka
    Diagnostyka Laboratoryjna.2019; 55(2): 121.     CrossRef
  • The influence of single-nucleotide polymorphisms of interleukin-1β -511 and +3954 on the susceptibility to Hashimoto’s thyroiditis in Egyptian women: immune-endocrine interactions
    Nearmeen M. Rashad, Manar H. Soliman, Mayada M. Mousa, Azza H. Abd El-Fatah
    The Egyptian Journal of Internal Medicine.2019; 31(1): 14.     CrossRef
  • Global epidemiology of hyperthyroidism and hypothyroidism
    Peter N. Taylor, Diana Albrecht, Anna Scholz, Gala Gutierrez-Buey, John H. Lazarus, Colin M. Dayan, Onyebuchi E. Okosieme
    Nature Reviews Endocrinology.2018; 14(5): 301.     CrossRef
  • Selenoproteins in human body: focus on thyroid pathophysiology
    Ana Valea, Carmen Emanuela Georgescu
    Hormones.2018; 17(2): 183.     CrossRef
  • Epidemiology of hyperthyroidism in Iran: a systematic review and meta-analysis
    Sayed Mahmoud Sajjadi-Jazi, Farshad Sharifi, Mehdi Varmaghani, Hamidreza Aghaei Meybodi, Farshad Farzadfar, Bagher Larijani
    Journal of Diabetes & Metabolic Disorders.2018; 17(2): 345.     CrossRef
  • The effect of vitamin D supplementation on thyroid autoantibody levels in the treatment of autoimmune thyroiditis: a systematic review and a meta-analysis
    Su Wang, Yaping Wu, Zhihua Zuo, Yijing Zhao, Kun Wang
    Endocrine.2018; 59(3): 499.     CrossRef
  • Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management
    Brigitte Decallonne, Emmanuel Bartholomé, Valérie Delvaux, Miguel D’haeseleer, Souraya El Sankari, Pierrette Seeldrayers, Bart Van Wijmeersch, Chantal Daumerie
    Acta Neurologica Belgica.2018; 118(2): 153.     CrossRef
  • Synergistic interactions of Angiotensin Converting Enzyme (ACE) gene and Apolipoprotein E (APOE) gene polymorphisms with T1DM susceptibility in south India
    Padma-Malini Ravi, Rathika Chinniah, Ramgopal Sivanadham, Murali Vijayan, Dharmarajan Pannerselvam, S. Pushkala, Balakrishnan Karuppiah
    Meta Gene.2018; 18: 39.     CrossRef
  • The effect of obesity and dietary habits on oxidative stress in Hashimoto’s thyroiditis
    Maria Giannakou, Katerina Saltiki, Emily Mantzou, Eleni Loukari, Georgios Philippou, Konstantinos Terzidis, Charalampos Stavrianos, Miltiades Kyprianou, Theodora Psaltopoulou, Kalliopi Karatzi, Maria Alevizaki
    Endocrine Connections.2018; 7(9): 990.     CrossRef
  • Interaction of HLA-DRB1* alleles and CTLA4 (+ 49 AG) gene polymorphism in Autoimmune Thyroid Disease
    Sivanadham Ramgopal, Chinniah Rathika, Malini Ravi Padma, Vijayan Murali, Kannan Arun, Mohamed Nainar Kamaludeen, Karuppiah Balakrishnan
    Gene.2018; 642: 430.     CrossRef
  • New insights into the etiopathogenesis of Hashimoto's Thyroiditis: The role of genetics and epigenetics
    Massimo Ralli, Armando De Virgilio, Marco Artico, Lucia Longo, Marco de Vincentiis, Antonio Greco
    Autoimmunity Reviews.2018; 17(10): 1065.     CrossRef
  • Comorbidity of autoimmune thyroid disorders and psychiatric disorders during the postpartum period: a Danish nationwide register-based cohort study
    V. Bergink, V. J. M. Pop, P. R. Nielsen, E. Agerbo, T. Munk-Olsen, X. Liu
    Psychological Medicine.2018; 48(8): 1291.     CrossRef
  • Spontaneous conversion from Graves’ disease to Hashimoto’s thyroiditis: a case report
    Muharrem Bayrak, Kenan Çadırcı, Emine Kartal Baykan, Ünsal Aydın, Ayşe Çarlıoğlu
    Ortadoğu Tıp Dergisi.2018; 10(1): 81.     CrossRef
  • Association of established hypothyroidism-associated genetic variants with Hashimoto’s thyroiditis
    A. Barić, L. Brčić, S. Gračan, V. Torlak Lovrić, I. Gunjača, M. Šimunac, M. Brekalo, M. Boban, O. Polašek, M. Barbalić, T. Zemunik, A. Punda, V. Boraska Perica
    Journal of Endocrinological Investigation.2017; 40(10): 1061.     CrossRef
  • Immune Response of Laying Hens Exposed to 30 ppm Ammonia for 25 Weeks
    H. Chen, F.F. Yan, J.Y. Hu, Yanan Wu, C.M. Tucker, A.R. Green, H.W. Cheng
    International Journal of Poultry Science.2017; 16(4): 139.     CrossRef
  • Dietary Factors Associated with Plasma Thyroid Peroxidase and Thyroglobulin Antibodies
    Antonela Matana, Vesela Torlak, Dubravka Brdar, Marijana Popović, Bernarda Lozić, Maja Barbalić, Vesna Boraska Perica, Ante Punda, Ozren Polašek, Caroline Hayward, Tatijana Zemunik
    Nutrients.2017; 9(11): 1186.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept
    Barbara Altieri, Giovanna Muscogiuri, Luigi Barrea, Chantal Mathieu, Carla V. Vallone, Luca Mascitelli, Giorgia Bizzaro, Vincenzo M. Altieri, Giacomo Tirabassi, Giancarlo Balercia, Silvia Savastano, Nicola Bizzaro, Cristina L. Ronchi, Annamaria Colao, Alf
    Reviews in Endocrine and Metabolic Disorders.2017; 18(3): 335.     CrossRef
  • A case‐control study of the association between ulcerative colitis and hyperthyroidism in an Asian population
    Ming‐Chieh Tsai, Herng‐Ching Lin, Cha‐Ze Lee
    Clinical Endocrinology.2017; 86(6): 825.     CrossRef
  • Hashimoto's thyroiditis: relative recurrence risk ratio and implications for screening of first‐degree relatives
    Nikita Bothra, Nalini Shah, Manjunath Goroshi, Swati Jadhav, Sheetal Padalkar, Hemangini Thakkar, Gurudayal Singh Toteja, Vyankatesh Shivane, Anurag Lila, Tushar Bandgar
    Clinical Endocrinology.2017; 87(2): 201.     CrossRef
  • Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature
    Dilia Giuggioli, M. Colaci, G. Cassone, P. Fallahi, F. Lumetti, A. Spinella, F. Campomori, A. Manfredi, C. U. Manzini, A. Antonelli, C. Ferri
    Clinical Rheumatology.2017; 36(3): 583.     CrossRef
  • Are Perinatal Events Risk Factors for Childhood Thyroid Autoimmunity
    Berglind Jonsdottir, Markus Lundgren, Sara Wallengren, Åke Lernmark, Ida Jönsson, Helena Elding Larsson
    European Thyroid Journal.2017; 6(6): 298.     CrossRef
  • Variants of Interleukin-22 Gene Confer Predisposition to Autoimmune Thyroid Disease
    Rong-hua Song, Qian Li, Wen Wang, Qiu-ming Yao, Xiao-qing Shao, Jin-an Zhang
    International Journal of Endocrinology.2017; 2017: 1.     CrossRef
  • Environmental Issues in Thyroid Diseases
    Silvia Martina Ferrari, Poupak Fallahi, Alessandro Antonelli, Salvatore Benvenga
    Frontiers in Endocrinology.2017;[Epub]     CrossRef
Close layer
Original Articles
Clinical Study
The Relationship between 10-Year Cardiovascular Risk Calculated Using the Pooled Cohort Equation and the Severity of Non-Alcoholic Fatty Liver Disease
Jeong In Lee, Min Chul Kim, Byung Sub Moon, Young Seok Song, Eun Na Han, Hyo Sun Lee, Yoonjeong Son, Jihyun Kim, Eun Jin Han, Hye-Jeong Park, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee
Endocrinol Metab. 2016;31(1):86-92.   Published online March 16, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.1.86
  • 8,111 View
  • 48 Download
  • 22 Web of Science
  • 24 Crossref
AbstractAbstract PDFPubReader   
Background

We investigated the association between the severity of non-alcoholic fatty liver disease (NAFLD) and the estimated 10-year risk of cardiovascular disease (CVD) calculated by Pooled Cohort Equation (PCE) and Framingham risk score (FRS).

Methods

A total of 15,913 participants (mean age, 46.3 years) in a health screening program were selected for analysis. The presence and severity of fatty liver was assessed by abdominal ultrasonogram. Subjects who drank alcohol more than three times a week were excluded from the study.

Results

Among the participants, 57.6% had no NAFLD, 35.4% had grade I, 6.5% had grade II, and 0.5% had grade III NAFLD. Mean estimated 10-year CVD risk was 2.59%, 3.93%, 4.68%, and 5.23% calculated using the PCE (P for trend <0.01) and 4.55%, 6.39%, 7.33%, and 7.13% calculated using FRS, according to NAFLD severity from none to severe (P for trend <0.01). The odds ratio for ≥7.5% estimated CVD risk calculated using the PCE showed a higher correlation with increasing severity of NAFLD even after adjustment for conventional CVD risk factors (1.52, 2.56, 3.35 vs. the no NAFLD group as a reference, P<0.01) compared with calculated risk using FRS (1.65, 1.62, 1.72 vs. no NAFLD group as a reference, P<0.01).

Conclusion

In our study of apparently healthy Korean adults, increasing severity of NAFLD showed a higher correlation with estimated 10-year CVD risk when calculated using the PCE than when calculated using FRS.

Citations

Citations to this article as recorded by  
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases
    Dana Kablawi, Faisal Aljohani, Chiara Saroli Palumbo, Sophie Restellini, Alain Bitton, Gary Wild, Waqqas Afif, Peter L Lakatos, Talat Bessissow, Giada Sebastiani
    Crohn's & Colitis 360.2023;[Epub]     CrossRef
  • Low Relative Handgrip Strength Is Associated with a High Risk of Non-Alcoholic Fatty Liver Disease in Italian Adults: A Retrospective Cohort Study
    Samantha Maurotti, Roberta Pujia, Elisa Mazza, Maria Francesca Pileggi, Franco Arturi, Maria Grazia Tarsitano, Tiziana Montalcini, Arturo Pujia, Yvelise Ferro
    Applied Sciences.2023; 13(22): 12489.     CrossRef
  • Fatty Liver Disease: Diagnosis and Stratification
    Yedidya Saiman, Andres Duarte-Rojo, Mary E. Rinella
    Annual Review of Medicine.2022; 73(1): 529.     CrossRef
  • “Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV”
    Adriana Cervo, Giada Sebastiani, Jovana Milic, Thomas Krahn, Sergio Mazzola, Salvatore Petta, Antonio Cascio, Giovanni Guaraldi, Giovanni Mazzola
    HIV Medicine.2022; 23(8): 911.     CrossRef
  • Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes
    Nong Li, Huiwen Tan, Aixia Xie, Cheng Li, Xuan Fu, Weiting Xang, Amina Kirim, Xuefang Huang
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • The Relation Between Non-alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease
    Seyed Moayed Alavian, Hosein Zadi
    Multidisciplinary Cardiovascular Annals.2022;[Epub]     CrossRef
  • Risk factors for cardiovascular disease among individuals with hepatic steatosis
    Julia Karády, Maros Ferencik, Thomas Mayrhofer, Nandini M. Meyersohn, Daniel O. Bittner, Pedro V. Staziaki, Balint Szilveszter, Travis R. Hallett, Michael T. Lu, Stefan B. Puchner, Tracey G. Simon, Borek Foldyna, Geoffrey S. Ginsburg, Robert W. McGarrah,
    Hepatology Communications.2022; 6(12): 3406.     CrossRef
  • Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity
    Mohammad E. Khamseh, Mojtaba Malek, Rowshanak Abbasi, Hoda Taheri, Maryam Lahouti, Fariba Alaei-Shahmiri
    Metabolic Syndrome and Related Disorders.2021; 19(3): 167.     CrossRef
  • Interplay between non‐alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population
    Grazia Pennisi, Vito Di Marco, Carola Buscemi, Giovanni Mazzola, Cristiana Randazzo, Federica Spatola, Antonio Craxì, Silvio Buscemi, Salvatore Petta
    Journal of Gastroenterology and Hepatology.2021; 36(9): 2389.     CrossRef
  • Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
    Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
    Endocrinology and Metabolism.2021; 36(4): 823.     CrossRef
  • Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver
    Toshihiro Niikura, Kento Imajo, Anna Ozaki, Takashi Kobayashi, Michihiro Iwaki, Yasushi Honda, Takaomi Kessoku, Yuji Ogawa, Masato Yoneda, Hiroyuki Kirikoshi, Satoru Saito, Atsushi Nakajima
    Diagnostics.2020; 10(3): 129.     CrossRef
  • Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management
    Hersh Shroff, Lisa B. VanWagner
    Current Hepatology Reports.2020; 19(3): 315.     CrossRef
  • Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults
    Sang Bae Lee, Min Kyung Kim, Shinae Kang, Kahui Park, Jung Hye Kim, Su Jung Baik, Ji Sun Nam, Chul Woo Ahn, Jong Suk Park
    Endocrinology and Metabolism.2019; 34(2): 179.     CrossRef
  • Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
    Pegah Golabi, Natsu Fukui, James Paik, Mehmet Sayiner, Alita Mishra, Zobair M. Younossi
    Hepatology Communications.2019; 3(8): 1050.     CrossRef
  • Lower hand grip strength in older adults with non-alcoholic fatty liver disease: a nationwide population-based study
    Beom-Jun Kim, Seong Hee Ahn, Seung Hun Lee, Seongbin Hong, Mark W. Hamrick, Carlos M. Isales, Jung-Min Koh
    Aging.2019; 11(13): 4547.     CrossRef
  • Implication of Nonalcoholic Fatty Liver Disease, Metabolic Syndrome, and Subclinical Inflammation on Mild Renal Insufficiency
    Ga Eun Nam, Soon Young Hwang, Hye Soo Chung, Ju Hee Choi, Hyun Jung Lee, Nam Hoon Kim, Hye Jin Yoo, Ji-A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi
    International Journal of Endocrinology.2018; 2018: 1.     CrossRef
  • Implication of liver enzymes on incident cardiovascular diseases and mortality: A nationwide population-based cohort study
    Kyung Mook Choi, Kyungdo Han, Sanghyun Park, Hye Soo Chung, Nam Hoon Kim, Hye Jin Yoo, Ji-A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Yong Gyu Park, Seon Mee Kim
    Scientific Reports.2018;[Epub]     CrossRef
  • Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance
    Mariana Verdelho Machado
    GE - Portuguese Journal of Gastroenterology.2017; 24(4): 157.     CrossRef
  • Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case‐control study
    Gyuri Kim, Suk‐Yong Jang, Eugene Han, Yong‐ho Lee, Se‐young Park, Chung Mo Nam, Eun Seok Kang
    International Journal of Cancer.2017; 140(4): 798.     CrossRef
  • Clinical Characteristics of Non-Alcoholic Fatty Liver Disease Based on Analyses from the Kangbuk Samsung Health Study
    Eun-Jung Rhee
    The Journal of Korean Diabetes.2017; 18(2): 81.     CrossRef
  • Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation
    Jihyun Kim, Da Young Lee, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee, Susanne Kaser
    PLOS ONE.2017; 12(7): e0180118.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases
    Eugene Han, Yong-ho Lee
    Diabetes & Metabolism Journal.2017; 41(6): 430.     CrossRef
Close layer
Clinical Study
Metabolic Health Is More Important than Obesity in the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Retrospective Study
Min-Kyung Lee, Eun-Jung Rhee, Min Chul Kim, Byung Sub Moon, Jeong In Lee, Young Seok Song, Eun Na Han, Hyo Sun Lee, Yoonjeong Son, Se Eun Park, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
Endocrinol Metab. 2015;30(4):522-530.   Published online December 31, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.4.522
  • 7,857 View
  • 69 Download
  • 29 Web of Science
  • 29 Crossref
AbstractAbstract PDFPubReader   
Background

The aim of this study is to compare the risk for future development of nonalcoholic fatty liver disease (NAFLD) according to different status of metabolic health and obesity.

Methods

A total of 3,045 subjects without NAFLD and diabetes at baseline were followed for 4 years. Subjects were categorized into four groups according to the following baseline metabolic health and obesity statuses: metabolically healthy, non-obese (MHNO); metabolically healthy, obese (MHO); metabolically unhealthy, non-obese (MUHNO); and metabolically unhealthy, obese (MUHO). Being metabolically healthy was defined as having fewer than two of the following five components: high blood pressure, high fasting blood glucose, high triglyceride, low high density lipoprotein cholesterol, and being in the highest decile of the homeostasis model assessment-insulin resistance index. Obesity was defined as a body mass index >25 kg/m2. The presence of NAFLD was assessed by ultrasonography.

Results

The proportions of subjects included in the MHNO, MHO, MUHNO, and MUHO groups were 71.4%, 9.8%, 13.0%, and 5.8%, respectively. The proportions of subjects who developed NAFLD were 10.5%, 31.4%, 23.2%, and 42% in the MHNO, MHO, MUHNO, and MUHO groups, respectively. The risk for developing NAFLD was highest in subjects who were metabolically unhealthy both at baseline and after 4 years compared with subjects who were consistently metabolically healthy during the follow-up period (odds ratio, 2.862). Using the MHNO group as reference, the odds ratios for the MHO, MUHNO, and MUHO groups were 1.731, 1.877, and 2.501, respectively.

Conclusion

The risk for NAFLD was lower in MHO subjects than in MUNO subjects.

Citations

Citations to this article as recorded by  
  • Metabolically Healthy Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Navigating the Controversies in Disease Development and Progression
    Chrysi Koliaki, Maria Dalamaga, Konstantinos Kakounis, Stavros Liatis
    Current Obesity Reports.2025;[Epub]     CrossRef
  • High prevalence of metabolic obesity in India: The ICMR-INDIAB national study (ICMR-INDIAB-23)
    Mohan Deepa, Rajendra Pradeepa, Ulagamadesan Venkatesan, Prabha Adhikari, Hiranya Kumar Das, Kalpana Dash, Jatinder Kumar Mokta, Somorjit Ningomban, Rosang Luaia, Richard O. Budnah, Anil Bhansali, Lobsang Jampa, Vizolie Suokhrie, Sunil M. Jain, Prashant P
    The Indian Journal of Medical Research.2025; 161: 461.     CrossRef
  • Metabolic Health Phenotypes Among Middle‐ to Older‐Aged Adults Living With and Without Obesity: Relationships With Hepatic Health Indicators
    Grainne Dolan, Seán R. Millar, Ivan J. Perry, Catherine M. Phillips
    Hepatology Research.2025;[Epub]     CrossRef
  • Increased metabolic variability in Korean patients with new onset bipolar disorder: a nationwide cohort study
    Ji Hyun Baek, Kyungdo Han, Hyewon Kim, Kyojin Yang, Hong Jin Jeon
    Frontiers in Psychiatry.2024;[Epub]     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight
    Ziyan Pan, Maryam Al Khatry, Ming-Lung Yu, Ashok Choudhury, Giada Sebastiani, Saleh A. Alqahtani, Mohammed Eslam
    Therapeutic Advances in Endocrinology and Metabolism.2024;[Epub]     CrossRef
  • Prevalence and factors associated with unhealthy metabolic status according to body mass index: analysis of a national nutritional survey
    Víctor Juan Vera-Ponce, Fiorella E. Zuzunaga-Montoya, Luisa Erika Milagros Vásquez-Romero, Joan A. Loayza-Castro, Cori Raquel Iturregui Paucar, Enrique Vigil-Ventura, Carmen Inés Gutiérrez De Carrillo
    Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
  • Increased risk of incident atrial fibrillation in young adults with mental disorders: A nationwide population-based study
    Hyun Jin Ahn, So-Ryoung Lee, Eue-Keun Choi, Nan Young Bae, Hyo-Jeong Ahn, Soonil Kwon, Seung-Woo Lee, Kyung-Do Han, Seil Oh, Gregory Y.H. Lip
    Heart Rhythm.2023; 20(3): 365.     CrossRef
  • Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis
    Wolhwa Song, Sung Hwan Yoo, Jinsun Jang, Su Jung Baik, Byoung Kwon Lee, Hyun Woong Lee, Jong Suk Park
    Gut and Liver.2023; 17(1): 130.     CrossRef
  • The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience
    Anna Boulouta, Ioanna Aggeletopoulou, Stavros Kanaloupitis, Efthymios P Tsounis, Vasileios Issaris, Konstantinos Papantoniou, Anastasios Apostolos, Paraskevas Tsaplaris, Ploutarchos Pastras, Christos Sotiropoulos, Aggeliki Tsintoni, Georgia Diamantopoulou
    Clinics and Research in Hepatology and Gastroenterology.2022; 46(5): 101896.     CrossRef
  • Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study
    Wenting Wang, Jianping Ren, Wenzhao Zhou, Jinyu Huang, Guomin Wu, Fenfang Yang, Shuang Yuan, Juan Fang, Jing Liu, Yao Jin, Haiyang Qi, Yuyang Miao, Yanna Le, Cenhong Ge, Xiantao Qiu, JinJing Wang, Ping Huang, Zixin Liu, Sheng Wang
    Scientific Reports.2022;[Epub]     CrossRef
  • Metabolically healthy obesity and risk of non‐alcoholic fatty liver disease severity independent of visceral fat
    Tsung‐Po Chen, Wen‐Yuan Lin, Chien‐Hsieh Chiang, Ting‐Hsin Shen, Kuo‐Chin Huang, Kuen‐Cheh Yang
    Journal of Gastroenterology and Hepatology.2021; 36(10): 2903.     CrossRef
  • Increased metabolic variability is associated with newly diagnosed depression: A nationwide cohort study
    Ji Hyun Baek, Dong Wook Shin, Maurizio Fava, David Mischoulon, Hyewon Kim, Mi Jin Park, Eun Ji Kim, Kyung-Do Han, Hong Jin Jeon
    Journal of Affective Disorders.2021; 294: 786.     CrossRef
  • The expression signatures in liver and adipose tissue from obese Göttingen Minipigs reveal a predisposition for healthy fat accumulation
    Susanna Cirera, Emirhan Taşöz, Mette Juul Jacobsen, Camilla Schumacher-Petersen, Berit Østergaard Christoffersen, Rikke Kaae Kirk, Trine Pagh Ludvigsen, Henning Hvid, Henrik Duelund Pedersen, Lisbeth Høier Olsen, Merete Fredholm
    Nutrition & Diabetes.2020;[Epub]     CrossRef
  • Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): A United Kingdom population-based cohort study using the health improvement network (THIN)
    A. Vusirikala, T. Thomas, N. Bhala, A. A. Tahrani, G. N. Thomas, K. Nirantharakumar
    BMC Endocrine Disorders.2020;[Epub]     CrossRef
  • Epidemiology of nonalcoholic fatty liver disease in non‐obese populations: Meta‐analytic assessment of its prevalence, genetic, metabolic, and histological profiles
    Zi Yuan Zou, Vincent Wai‐Sun Wong, Jian Gao Fan
    Journal of Digestive Diseases.2020; 21(7): 372.     CrossRef
  • Ultrasound-Diagnosed Nonalcoholic Fatty Liver Disease Independently Predicts a Higher Risk of Developing Diabetes Mellitus in Nonoverweight Individuals
    Liang Wang
    Academic Radiology.2019; 26(7): 863.     CrossRef
  • Blood Pressure and Development of Cardiovascular Disease in Koreans With Type 2 Diabetes Mellitus
    Mee Kyoung Kim, Kyungdo Han, Eun Sil Koh, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam, Hyuk-Sang Kwon
    Hypertension.2019; 73(2): 319.     CrossRef
  • Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease
    Nicolás Salva-Pastor, Norberto C. Chávez-Tapia, Misael Uribe, Natalia Nuño-Lámbarri
    The Journal of Steroid Biochemistry and Molecular Biology.2019; 194: 105445.     CrossRef
  • Weight change and mortality and cardiovascular outcomes in patients with new-onset diabetes mellitus: a nationwide cohort study
    Mee Kyoung Kim, Kyungdo Han, Eun Sil Koh, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam, Hyuk-Sang Kwon
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • Longitudinal analysis of risk of non‐alcoholic fatty liver disease in adulthood
    Daniel J. Cuthbertson, Emily Brown, Juha Koskinen, Costan G. Magnussen, Nina Hutri‐Kähönen, Matthew Sabin, Päivi Tossavainen, Eero Jokinen, Tomi Laitinen, Jorma Viikari, Olli T. Raitakari, Markus Juonala
    Liver International.2019; 39(6): 1147.     CrossRef
  • Associations of Variability in Blood Pressure, Glucose and Cholesterol Concentrations, and Body Mass Index With Mortality and Cardiovascular Outcomes in the General Population
    Mee Kyoung Kim, Kyungdo Han, Yong-Moon Park, Hyuk-Sang Kwon, Gunseog Kang, Kun-Ho Yoon, Seung-Hwan Lee
    Circulation.2018; 138(23): 2627.     CrossRef
  • The effects of metabolic status on non‐alcoholic fatty liver disease‐related outcomes, beyond the presence of obesity
    Javier Ampuero, Rocío Aller, Rocío Gallego‐Durán, Jesus M. Banales, Javier Crespo, Carmelo García‐Monzón, María Jesús Pareja, Eduardo Vilar‐Gómez, Juan Caballería, Desamparados Escudero‐García, Judith Gomez‐Camarero, José Luis Calleja, Mercedes Latorre, A
    Alimentary Pharmacology & Therapeutics.2018; 48(11-12): 1260.     CrossRef
  • Dissecting the relationship between obesity and hyperinsulinemia: Role of insulin secretion and insulin clearance
    Mee Kyoung Kim, Gerald M. Reaven, Sun H. Kim
    Obesity.2017; 25(2): 378.     CrossRef
  • The Effects of Exercise on Abdominal Fat and Liver Enzymes in Pediatric Obesity: A Systematic Review and Meta-Analysis
    Katherine González-Ruiz, Robinson Ramírez-Vélez, Jorge Enrique Correa-Bautista, Mark D. Peterson, Antonio García-Hermoso
    Childhood Obesity.2017; 13(4): 272.     CrossRef
  • Clinical Characteristics of Non-Alcoholic Fatty Liver Disease Based on Analyses from the Kangbuk Samsung Health Study
    Eun-Jung Rhee
    The Journal of Korean Diabetes.2017; 18(2): 81.     CrossRef
  • Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases
    Eugene Han, Yong-ho Lee
    Diabetes & Metabolism Journal.2017; 41(6): 430.     CrossRef
  • Predictive Value of Triglyceride Glucose Index for the Risk of Incident Diabetes: A 4-Year Retrospective Longitudinal Study
    Da Young Lee, Eun Seo Lee, Ji Hyun Kim, Se Eun Park, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee, Won-Young Lee, Fernando Guerrero-Romero
    PLOS ONE.2016; 11(9): e0163465.     CrossRef
  • Lean, but not healthy
    Cherlyn Ding, Zhiling Chan, Faidon Magkos
    Current Opinion in Clinical Nutrition & Metabolic Care.2016; 19(6): 408.     CrossRef
Close layer
Obesity and Metabolism
Comparison of Serum Ferritin and Vitamin D in Association with the Severity of Nonalcoholic Fatty Liver Disease in Korean Adults
Dong Wook Jeong, Hye Won Lee, Young Hye Cho, Dong Won Yi, Sang Yeoup Lee, Seok Man Son, Yang Ho Kang
Endocrinol Metab. 2014;29(4):479-488.   Published online December 29, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.4.479
  • 9,800 View
  • 45 Download
  • 14 Web of Science
  • 14 Crossref
AbstractAbstract PDFPubReader   
Background

Increased serum ferritin and decreased vitamin D levels associated with nonalcoholic fatty liver disease (NAFLD). However, their association with the severity of NAFLD has not been fully evaluated. The aim of this study was to compare the association of serum ferritin and 25(OH)D3 levels with the severity of ultrasonographically detected NAFLD (US-NAFLD) and hepatic steatosis defined by fatty liver index (FLI) in Korean adults.

Methods

A cross-sectional analysis of clinical and anthropometric data, including serum ferritin and 25(OH)D3, from men (n=295) and women (n=263) who underwent a routine health check-up in 2012.

Results

In men, with an increase in the quartile of serum ferritin level, the incidences of subjects with metabolic syndrome (P=0.002), US-NAFLD (P=0.041), and FLI ≥60 (P=0.010) were significantly elevated. In women, the incidence of subjects with US-NAFLD was also significantly elevated with increases in the serum ferritin quartile (P=0.012). Regarding 25(OH)D3, no statistical differences were observed among the different quartiles in either gender. Serum ferritin level significantly increased as the severity of US-NAFLD increased (P<0.001); however, no significant differences in 25(OH)D3 level were observed in men. No significant differences in either serum ferritin or 25(OH)D3 level were observed among women with different levels of severity of US-NAFLD.

Conclusion

Increased serum ferritin level showed a closer association with severity of NAFLD compared with level of serum vitamin D, suggesting that serum ferritin level may be a better marker than vitamin D level for predicting the severity of US-NAFLD and hepatic steatosis in a clinical setting.

Citations

Citations to this article as recorded by  
  • Maternal vitamin D intake correlates with serum 25-Hydroxyvitamin D, Interleukin-6, and ferritin in maternal and umbilical cord
    Yusrawati Yusrawati, Efrida Efrida, Nasrum Massi, Bahrul Fikri, Naoki Shimojo
    Scientific Reports.2025;[Epub]     CrossRef
  • Serum 25-hydroxyvitamin D levels and the risk of non-alcoholic fatty liver
    Qi Sheng, Huanchen Shi, Shousheng Liu, Likun Zhuang, Zhenzhen Zhao, Yongning Xin
    Saudi Journal of Gastroenterology.2023; 29(1): 39.     CrossRef
  • 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
    Michael H. Le, Yee Hui Yeo, Xiaohe Li, Jie Li, Biyao Zou, Yuankai Wu, Qing Ye, Daniel Q. Huang, Changqing Zhao, Jie Zhang, Chenxi Liu, Na Chang, Feng Xing, Shiping Yan, Zi Hui Wan, Natasha Sook Yee Tang, Maeda Mayumi, Xinting Liu, Chuanli Liu, Fajuan Rui,
    Clinical Gastroenterology and Hepatology.2022; 20(12): 2809.     CrossRef
  • Do Vitamin D Levels Affect Bone Mineral Density in Reproductive Women with Low Ferritin Levels?
    Hatice Hamarat, Göknur Yorulmaz, Ayşe Ekim Aydemir, Emel Örge Gönüllü, Ahmet Musmul, Sinem Gürcü
    Turkish Journal of Osteoporosis.2022; 28(1): 26.     CrossRef
  • Associations between Abnormal Iron Metabolism and Elevated Alanine Aminotransferase in Adults
    Xin Su, Danping Zhang, Zhe Chen, Xu Han, Peichen Xia, Minhao Yin, Hong Zhu
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • Ferritin as a key risk factor for nonalcoholic fatty liver disease in children with obesity
    Junfeng Zhang, Jiajia Cao, Hui Xu, Guanping Dong, Ke Huang, Wei Wu, Jingjing Ye, Junfen Fu
    Journal of Clinical Laboratory Analysis.2021;[Epub]     CrossRef
  • Serum ferritin level as a noninvasive marker for detection and staging of hepatocellular injury, liver fibrosis, and steatosis in children and adolescents with nonalcoholic fatty liver disease
    Ahmed A. Hassan, Mohiee E.-D.A. El-Aziz Awad, Hanan H. Soliman, Reda A.F. Usef, Dina S. Ata
    Alexandria Journal of Pediatrics.2021; 34(3): 253.     CrossRef
  • Low vitamin D level was associated with metabolic syndrome and high leptin level in subjects with nonalcoholic fatty liver disease: a community-based study
    Li-Wei Chen, Cheng-Hung Chien, Sheng-Fong Kuo, Chia-Ying Yu, Chih-Lang Lin, Rong-Nan Chien
    BMC Gastroenterology.2019;[Epub]     CrossRef
  • Association between Vitamin D Levels and Nonalcoholic Fatty Liver Disease: Potential Confounding Variables
    Lucia Pacifico, John F. Osborn, Enea Bonci, Pasquale Pierimarchi, Claudio Chiesa
    Mini-Reviews in Medicinal Chemistry.2019; 19(4): 310.     CrossRef
  • The association between serum ferritin and 25-hydroxyvitamin D and metabolic syndrome in Korean women: the Korea National Health and Nutrition Examination Survey 2010–2012
    Hyun Yoon, Nan Young Bae, Mi Young Gi, Bu Yeon Park, Jeong Min Seong
    Journal of Clinical Biochemistry and Nutrition.2017; 61(1): 60.     CrossRef
  • Gender difference in relationship between serum ferritin and 25-hydroxyvitamin D in Korean adults
    Jeong Min Seong, Yo Sang Yoon, Kyu Su Lee, Nan Young Bae, Mi Young Gi, Hyun Yoon, Andrzej T Slominski
    PLOS ONE.2017; 12(5): e0177722.     CrossRef
  • The Association of Serum Ferritin and Metabolic Syndrome and Metabolic Syndrome Score in Korean Adults
    Hyun Yoon, Jae Seong Go, Kang Uk Kim, Keon Woo Lee
    The Korean Journal of Clinical Laboratory Science.2016; 48(4): 287.     CrossRef
  • AMP-activated protein kinase suppresses the expression of LXR/SREBP-1 signaling-induced ANGPTL8 in HepG2 cells
    Jinmi Lee, Seok-Woo Hong, Se Eun Park, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
    Molecular and Cellular Endocrinology.2015; 414: 148.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
Close layer
Obesity and Metabolism
Association of Serum Adipocyte-Specific Fatty Acid Binding Protein with Fatty Liver Index as a Predictive Indicator of Nonalcoholic Fatty Liver Disease
Won Seon Jeon, Se Eun Park, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
Endocrinol Metab. 2013;28(4):283-287.   Published online December 12, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.4.283
  • 6,111 View
  • 37 Download
  • 16 Crossref
AbstractAbstract PDFPubReader   
Background

Adipocyte-specific fatty acid-binding protein (A-FABP) is a cytoplasmic protein expressed in macrophages and adipocytes and it plays a role in insulin resistance and metabolic syndrome. Recently, the fatty liver index (FLI) was introduced as an indicator of nonalcoholic fatty liver disease (NAFLD). In this study, we aimed to investigate the relationship between baseline serum A-FABP levels and FLI after 4 years in apparently healthy subjects.

Methods

A total of 238 subjects without a past history of alcoholism or hepatitis were recruited from a medical check-up program. The NAFLD state was evaluated 4 years later in the same subjects using FLI. Fatty liver disease was diagnosed as diffusely increased echogenicity of the hepatic parenchyma compared to the kidneys, vascular blurring, and deep-echo attenuation. NAFLD was defined as subjects with fatty liver and no history of alcohol consumption (>20 g/day).

Results

Baseline serum A-FABP levels were significantly associated with FLI after adjustment for age and sex (P<0.001). The subjects with higher A-FABP levels had a higher mean FLI (P for trend=0.006). After adjusting for age and sex, serum A-FABP levels at baseline were shown to be significantly associated with FLI as a marker of development of NAFLD after 4 years (odds ratio, 2.68; 95% confidence interval, 1.24 to 5.80 for highest tertile vs. lowest tertile; P=0.012).

Conclusion

This study demonstrated that higher baseline serum A-FABP levels were associated with FLI as a predictive indicator of NAFLD after 4 years of follow-up in healthy Korean adults.

Citations

Citations to this article as recorded by  
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • FABP4 Expression in Subcutaneous Adipose Tissue Is Independently Associated with Circulating Triglycerides in Obesity
    Óscar Osorio-Conles, Ainitze Ibarzabal, José María Balibrea, Josep Vidal, Emilio Ortega, Ana de Hollanda
    Journal of Clinical Medicine.2023; 12(3): 1013.     CrossRef
  • Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease
    Juan Moreno-Vedia, Josefa Girona, Daiana Ibarretxe, Lluís Masana, Ricardo Rodríguez-Calvo
    Biomedicines.2022; 10(1): 197.     CrossRef
  • Circulating level of fatty acid‐binding protein 4 is an independent predictor of metabolic dysfunction‐associated fatty liver disease in middle‐aged and elderly individuals
    Marenao Tanaka, Satoko Takahashi, Yukimura Higashiura, Akiko Sakai, Masayuki Koyama, Shigeyuki Saitoh, Kazuaki Shimamoto, Hirofumi Ohnishi, Masato Furuhashi
    Journal of Diabetes Investigation.2022; 13(5): 878.     CrossRef
  • New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis
    Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
    Life.2022; 12(8): 1189.     CrossRef
  • Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999–2016
    Chun-On Lee, Hang-Long Li, Man-Fung Tsoi, Ching-Lung Cheung, Bernard Man Yung Cheung
    Annals of Medicine.2021; 53(1): 1067.     CrossRef
  • Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk
    Ricardo Rodríguez-Calvo, Juan Moreno-Vedia, Josefa Girona, Daiana Ibarretxe, Neus Martínez-Micaelo, Jordi Merino, Nuria Plana, Lluis Masana
    Frontiers in Physiology.2021;[Epub]     CrossRef
  • Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
    Eun-Jung Rhee
    Endocrinology and Metabolism.2019; 34(3): 226.     CrossRef
  • Serum adipocyte fatty acid‐binding protein levels: An indicator of non‐alcoholic fatty liver disease in Chinese individuals
    Yiting Xu, Xiaojing Ma, Xiaoping Pan, Xingxing He, Yufei Wang, Yuqian Bao
    Liver International.2019; 39(3): 568.     CrossRef
  • Clinical Characteristics of Non-Alcoholic Fatty Liver Disease Based on Analyses from the Kangbuk Samsung Health Study
    Eun-Jung Rhee
    The Journal of Korean Diabetes.2017; 18(2): 81.     CrossRef
  • The relationship between serum fatty-acid binding protein 4 level and lung function in Korean subjects with normal ventilatory function
    Hye-Jeong Park, Se Eun Park, Cheol-Young Park, Seong Yong Lim, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee
    BMC Pulmonary Medicine.2016;[Epub]     CrossRef
  • Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease
    Erdem Akbal, Erdem Koçak, Ömer Akyürek, Seyfettin Köklü, Hikmetullah Batgi, Mehmet Şenes
    Wiener klinische Wochenschrift.2016; 128(1-2): 48.     CrossRef
  • High‐methionine diets accelerate atherosclerosis by HHcy‐mediated FABP4 gene demethylation pathway via DNMT1 in ApoE−/− mice
    An-Ning Yang, Hui-Ping Zhang, Yue Sun, Xiao-Ling Yang, Nan Wang, Guangrong Zhu, Hui Zhang, Hua Xu, Sheng-Chao Ma, Yue Zhang, Gui-Zhong Li, Yue-Xia Jia, Jun Cao, Yi-Deng Jiang
    FEBS Letters.2015; 589(24PartB): 3998.     CrossRef
  • Metabolic Health Is More Important than Obesity in the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Retrospective Study
    Min-Kyung Lee, Eun-Jung Rhee, Min Chul Kim, Byung Sub Moon, Jeong In Lee, Young Seok Song, Eun Na Han, Hyo Sun Lee, Yoonjeong Son, Se Eun Park, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
    Endocrinology and Metabolism.2015; 30(4): 522.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
  • Noninvasive Markers for the Diagnosis of Nonalcoholic Fatty Liver Disease
    Sang Yong Kim
    Endocrinology and Metabolism.2013; 28(4): 280.     CrossRef
Close layer
Obesity and Metabolism
Tumor Necrosis Factor-α as a Predictor for the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Follow-Up Study
Yun Yong Seo, Yong Kyun Cho, Ji-Cheol Bae, Mi Hae Seo, Se Eun Park, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
Endocrinol Metab. 2013;28(1):41-45.   Published online March 25, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.1.41
  • 8,477 View
  • 47 Download
  • 70 Crossref
AbstractAbstract PDFPubReader   
Background

Tumor necrosis factor (TNF)-α is associated with insulin resistance and systemic inflammatory responses. The aim of this study was to investigate the relationship between TNF-α and the development of nonalcoholic fatty liver disease (NAFLD) in a longitudinal study.

Methods

Three hundred and sixty-three apparently healthy subjects (mean age, 40.5±6.1 years; male, 57.6%) without NAFLD were enrolled in 2003. Anthropometric and laboratory measurements were performed. The participants were grouped into tertiles according to their serum TNF-α levels from samples taken in 2003. At a 4-year follow-up, we compared the odds ratios (ORs) of the development of NAFLD according to the tertiles of TNF-α levels measured in 2003.

Results

At the 4-year follow-up, the cumulative incidence of NAFLD was 29.2% (106/363). The group that developed NAFLD had higher levels of TNF-α than those in the group without NAFLD (3.65±1.79 pg/mL vs. 3.15±1.78 pg/mL; P=0.016). When the 2003 serum TNF-α levels were categorized into tertiles: incidence of NAFLD observed in 2007 was significantly higher with increasing tertiles (22.6%, 35.8%, and 41.5%, respectively; P<0.05). The risk of developing NAFLD was significantly greater in the highest tertile of TNF-α than in the lowest tertile after adjusting for age, smoking, and BMI (OR, 2.20; 95% confidence interval, 1.12 to 4.01; P<0.05).

Conclusion

Higher serum TNF-α levels in subjects without NAFLD were associated with the development of NAFLD. The results of study might suggest a pathologic role of inflammation in NAFLD.

Citations

Citations to this article as recorded by  
  • Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
    Pojsakorn Danpanichkul, Hanna Blaney, Javiera Perelli, Paula Huerta, Francisco Idalsoaga, Marco Arrese, Juan Pablo Arab, Rohit Loomba, Luis Antonio Díaz
    Metabolism and Target Organ Damage.2026;[Epub]     CrossRef
  • The Association Between Vitamin D Status With Inflammatory Markers and Clinical Features in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    Abbas Pishdadian, Farshad Amirkhizi, Zahra Zaersabet, Soudabeh Hamedi-Shahraki
    Topics in Clinical Nutrition.2025; 40(4): 267.     CrossRef
  • Inflammatory cytokines, soluble interleukin-6 receptors, and fragmented cytokeratin-18 as indicators of non-alcoholic steatohepatitis
    Anastasia A. Shipovskaya, Olga P. Dudanova, Irina V. Kurbatova
    Terapevticheskii arkhiv.2025; 97(2): 115.     CrossRef
  • Signature gene expression model for quantitative evaluation of MASH-like liver injury in mice
    Volodymyr P. Tryndyak, Rose A. Willett, Zhuolin Song, Kostiantyn Dreval, Jennifer M. Hughes Hanks, Mark I. Avigan, Fred A. Wright, Frederick A. Beland, Ivan Rusyn, Igor P. Pogribny
    Toxicology and Applied Pharmacology.2025; 502: 117442.     CrossRef
  • The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
    Ilias D. Vachliotis, Stergios A. Polyzos
    Current Obesity Reports.2025;[Epub]     CrossRef
  • NAFLD Is Associated With Quiescent Rather Than Active Crohn’s Disease
    Scott McHenry, Matthew Glover, Ali Ahmed, Quazim Alayo, Maria Zulfiqar, Daniel R Ludwig, Matthew A Ciorba, Nicholas O Davidson, Parakkal Deepak
    Inflammatory Bowel Diseases.2024; 30(5): 757.     CrossRef
  • Nigella sativa Efficacy in Non-alcoholic Fatty Liver Disease: Mechanisms and Clinical Effects
    A.A. Sangouni, A. Jamalzehi, M. Moradpour, H. Mozaffari-Khosravi
    Journal of Herbal Medicine.2024; 43: 100833.     CrossRef
  • Berberine prevents NAFLD and HCC by modulating metabolic disorders
    Xinyue Lin, Juanhong Zhang, Yajun Chu, Qiuying Nie, Junmin Zhang
    Pharmacology & Therapeutics.2024; 254: 108593.     CrossRef
  • Antitumor Mechanisms of Lycium barbarum Fruit: An Overview of In Vitro and In Vivo Potential
    Maria Rosaria Miranda, Vincenzo Vestuto, Giuseppina Amodio, Michele Manfra, Giacomo Pepe, Pietro Campiglia
    Life.2024; 14(3): 420.     CrossRef
  • Theabrownin alleviates nonalcoholic fatty liver disease by inhibiting the intestinal farnesoid X receptor–ceramide axis
    Jieyi Wang, Dan Zheng, Kun Ge, Fengjie Huang, Yang Li, Xiaojiao Zheng, Wei Jia, Aihua Zhao
    Food Frontiers.2024; 5(4): 1559.     CrossRef
  • Necroptosis contributes to non-alcoholic fatty liver disease pathoetiology with promising diagnostic and therapeutic functions
    Hong-Ju Sun, Bo Jiao, Yan Wang, Yue-Hua Zhang, Ge Chen, Zi-Xuan Wang, Hong Zhao, Qing Xie, Xiao-Hua Song
    World Journal of Gastroenterology.2024; 30(14): 1968.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment
    Gautam Maddineni, Sri J. Obulareddy, Ruchir D. Paladiya, Rohan R. Korsapati, Shika Jain, Herby Jeanty, Fnu Vikash, Nayanika C. Tummala, Samatha Shetty, Arezoo Ghazalgoo, Abinash Mahapatro, Viswanadh Polana, Dhruvan Patel
    Annals of Medicine & Surgery.2024; 86(8): 4714.     CrossRef
  • Caffeine mitigates tamoxifen-induced fatty liver in Wistar rats
    Yasin Sezgin, Ejder Saylav Bora, Duygu Burcu Arda, Yiğit Uyanikgil, Oytun Erbaş
    Acta Cirúrgica Brasileira.2024;[Epub]     CrossRef
  • RGS7-ATF3-Tip60 Complex Promotes Hepatic Steatosis and Fibrosis by Directly Inducing TNFα
    Madhuri Basak, Kiran Das, Tarun Mahata, Abhishek Singh Sengar, Sumit Kumar Verma, Sayan Biswas, Kakali Bhadra, Adele Stewart, Biswanath Maity
    Antioxidants & Redox Signaling.2023; 38(1-3): 137.     CrossRef
  • The capsaicinoid nonivamide suppresses the inflammatory response and attenuates the progression of steatosis in a NAFLD‐rat model
    Naruemon Wikan, Jiraporn Tocharus, Chio Oka, Sivanan Sivasinprasasn, Waraluck Chaichompoo, Apichart Suksamrarn, Chainarong Tocharus
    Journal of Biochemical and Molecular Toxicology.2023;[Epub]     CrossRef
  • Thermoneutral housing shapes hepatic inflammation and damage in mouse models of non-alcoholic fatty liver disease
    Jarren R. Oates, Keisuke Sawada, Daniel A. Giles, Pablo C. Alarcon, Michelle S.M.A. Damen, Sara Szabo, Traci E. Stankiewicz, Maria E. Moreno-Fernandez, Senad Divanovic
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • 1,25-Dihydroxycholecalciferol down-regulates 3-mercaptopyruvate sulfur transferase and caspase-3 in rat model of non-alcoholic fatty liver disease
    Maher N. Ibrahim, Abeer A. Khalifa, Dalia A. Hemead, Amira Ebrahim Alsemeh, Marwa A. Habib
    Journal of Molecular Histology.2023; 54(2): 119.     CrossRef
  • Effects of Resveratrol Supplementation on Nonalcoholic Fatty Liver Disease Management
    Arefe Nemati, Zeinab Nikniaz, Ali Mota
    Topics in Clinical Nutrition.2023; 38(2): 144.     CrossRef
  • The effects of chicory supplementation on liver enzymes and lipid profiles in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of clinical evidence
    Elham Maleki, Ali Sadeghpour, Erfan Taherifard, Bahareh Izadi, Mehdi Pasalar, Maryam Akbari
    Clinical Nutrition ESPEN.2023; 55: 447.     CrossRef
  • Using bioinformatics and systems biology methods to identify the mechanism of interaction between COVID-19 and nonalcoholic fatty liver disease
    Wenbo Dong, Yan Jin, Hongshuo Shi, Xuecheng Zhang, Jinshu Chen, Hongling Jia, Yongchen Zhang
    Medicine.2023; 102(23): e33912.     CrossRef
  • The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
    Ilias D. Vachliotis, Stergios A. Polyzos
    Current Obesity Reports.2023; 12(3): 191.     CrossRef
  • Gene-regulation modules in nonalcoholic fatty liver disease revealed by single-nucleus ATAC-seq
    Fumihiko Takeuchi, Yi-Qiang Liang, Hana Shimizu-Furusawa, Masato Isono, Mia Yang Ang, Kotaro Mori, Taizo Mori, Eiji Kakazu, Sachiyo Yoshio, Norihiro Kato
    Life Science Alliance.2023; 6(10): e202301988.     CrossRef
  • Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review
    Cristian Sandoval, Carolina Reyes, Pamela Rosas, Karina Godoy, Vanessa Souza-Mello, Jorge Farías
    International Journal of Molecular Sciences.2023; 24(21): 15728.     CrossRef
  • Maternal betaine supplementation ameliorates fatty liver disease in offspring mice by inhibiting hepatic NLRP3 inflammasome activation
    Lun Li, Liuqiao Sun, Xiaoping Liang, Qian Ou, Xuying Tan, Fangyuan Li, Zhiwei Lai, Chenghe Ding, Hangjun Chen, Xinxue Yu, Qiongmei Wu, Jun Wei, Feng Wu, Lijun Wang
    Nutrition Research and Practice.2023; 17(6): 1084.     CrossRef
  • Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease
    Yamei Duan, Xiongfeng Pan, Jiayou Luo, Xiang Xiao, Jingya Li, Prince L. Bestman, Miyang Luo
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • A potential link between plasma short‑chain fatty acids, TNF‑α level and disease progression in non‑alcoholic fatty liver disease: A retrospective study
    Jing Xiong, Xia Chen, Zhijing Zhao, Ying Liao, Ting Zhou, Qian Xiang
    Experimental and Therapeutic Medicine.2022;[Epub]     CrossRef
  • Update on Non-Alcoholic Fatty Liver Disease-Associated Single Nucleotide Polymorphisms and Their Involvement in Liver Steatosis, Inflammation, and Fibrosis: A Narrative Review
    Fajar Dwi Astarini, Neneng Ratnasari, Widya Wasityastuti
    Iranian Biomedical Journal.2022; 26(4): 252.     CrossRef
  • Clinical significance of epicardial fat assessment in hypertensive patients with non-alcoholic fatty liver disease
    M. Е. Statsenko, A. M. Streltsova
    "Arterial’naya Gipertenziya" ("Arterial Hypertension").2022; 28(3): 260.     CrossRef
  • The biological clock enhancer nobiletin ameliorates steatosis in genetically obese mice by restoring aberrant hepatic circadian rhythm
    Sebastian Larion, Caleb A. Padgett, Joshua T. Butcher, James D. Mintz, David J. Fulton, David W. Stepp
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2022; 323(4): G387.     CrossRef
  • Effect of Fiber Supplementation on Systemic Inflammation and Liver Steatosis in Mice Fed with High-Carbohydrate Diets
    Cacilda Rocha Hildebrand Budke, Débora Marchetti Chaves Thomaz, Rodrigo Juliano de Oliveira, Rita de Cássia Avellaneda Guimarães, Amariles Diniz Ramires, Doroty Mesquita Dourado, Elisvânia Freitas dos Santos, Adriana Conceicon Guercio Menezes, Andréia Con
    Metabolic Syndrome and Related Disorders.2022; 20(10): 558.     CrossRef
  • Association between inflammatory markers and non-alcoholic fatty liver disease in obese children
    Yamei Duan, Jiayou Luo, Xiongfeng Pan, Jia Wei, Xiang Xiao, Jingya Li, Miyang Luo
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials
    Sahar Rafiee, Hamed Mohammadi, Abed Ghavami, Erfan Sadeghi, Zahra Safari, Gholamreza Askari
    Complementary Therapies in Clinical Practice.2021; 42: 101281.     CrossRef
  • Association of xenobiotic-metabolizing enzymes (GSTM1 and GSTT 1), and pro-inflammatory cytokines (TNF-α and IL-6) genetic polymorphisms with non-alcoholic fatty liver disease
    Narges Damavandi, Sirous Zeinali
    Molecular Biology Reports.2021; 48(2): 1225.     CrossRef
  • Potential protective effect of curcumin in high-fat diet-induced nonalcoholic fatty liver disease in rats
    AhmedM M. Mahmouda, NohaA.-R A. El-Hagag, HusseinI El-Bitar, Abdel-HalimM Afifi
    Journal of Current Medical Research and Practice.2021; 6(1): 92.     CrossRef
  • Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease
    Mengyao Zhao, Shumin Chen, Xiaoguo Ji, Xin Shen, Jiangshan You, Xinyi Liang, Hao Yin, Liming Zhao
    Pharmacological Research.2021; 166: 105517.     CrossRef
  • Inflammation in Metabolic Diseases and Insulin Resistance
    Won-Young Lee
    Cardiovascular Prevention and Pharmacotherapy.2021; 3(2): 31.     CrossRef
  • Cellular Mechanisms of Liver Fibrosis
    Pragyan Acharya, Komal Chouhan, Sabine Weiskirchen, Ralf Weiskirchen
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • The role of insulin resistance and systemic inflammation in reducing the elasticity of the main arteries in patients with arterial hypertension and non-alcoholic fatty liver disease
    M.E. Statsenko, A.M. Streltsova, M.I. Turovets
    Profilakticheskaya meditsina.2021; 24(5): 60.     CrossRef
  • Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation
    Victoria L. Slaughter, John W. Rumsey, Rachel Boone, Duaa Malik, Yunqing Cai, Narasimhan Narasimhan Sriram, Christopher J. Long, Christopher W. McAleer, Stephen Lambert, Michael L. Shuler, J. J. Hickman
    Scientific Reports.2021;[Epub]     CrossRef
  • L-ergothioneine and metformin alleviates liver injury in experimental type-2 diabetic rats via reduction of oxidative stress, inflammation, and hypertriglyceridemia
    Ayobami Dare, Mahendra L. Channa, Anand Nadar
    Canadian Journal of Physiology and Pharmacology.2021; 99(11): 1137.     CrossRef
  • Patchouli alcohol ameliorates skeletal muscle insulin resistance and NAFLD via AMPK/SIRT1-mediated suppression of inflammation
    Do Hyeon Pyun, Tae Jin Kim, Seung Yeon Park, Hyun Jung Lee, A.M. Abd El-Aty, Ji Hoon Jeong, Tae Woo Jung
    Molecular and Cellular Endocrinology.2021; 538: 111464.     CrossRef
  • Low Vitamin D Level was Associated with Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Vahid Sheikhi, Zahra Heidari
    Shiraz E-Medical Journal.2021;[Epub]     CrossRef
  • Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System
    Pietro Torre, Benedetta Maria Motta, Roberta Sciorio, Mario Masarone, Marcello Persico
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Sarcopenia Is an Independent Risk Factor for NAFLD in COPD: A Nationwide Survey (KNHANES 2008–2011)


    Kyung Soo Hong, Min Cheol Kim, June Hong Ahn
    International Journal of Chronic Obstructive Pulmonary Disease.2020; Volume 15: 1005.     CrossRef
  • A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts
    Yen-Chun Koh, Yen-Cheng Lin, Pei-Sheng Lee, Ting-Jang Lu, Kai-Yi Lin, Min-Hsiung Pan
    Food & Function.2020; 11(9): 7545.     CrossRef
  • The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling
    Samukelisiwe C. Shabalala, Phiwayinkosi V. Dludla, Lawrence Mabasa, Abidemi P. Kappo, Albertus K. Basson, Carmen Pheiffer, Rabia Johnson
    Biomedicine & Pharmacotherapy.2020; 131: 110785.     CrossRef
  • Redox Regulation by Protein S-Glutathionylation: From Molecular Mechanisms to Implications in Health and Disease
    Aysenur Musaogullari, Yuh-Cherng Chai
    International Journal of Molecular Sciences.2020; 21(21): 8113.     CrossRef
  • Long-Term Soy Protein Isolate Consumption Reduces Liver Steatosis Through Changes in Global Transcriptomics in Obese Zucker Rats
    Melisa Kozaczek, Walter Bottje, Byungwhi Kong, Sami Dridi, Diyana Albataineh, Kentu Lassiter, Reza Hakkak
    Frontiers in Nutrition.2020;[Epub]     CrossRef
  • Lycopene Modulates Pathophysiological Processes of Non-Alcoholic Fatty Liver Disease in Obese Rats
    Mariane Róvero Costa, Jéssica Leite Garcia, Carol Cristina Vágula de Almeida Silva, Artur Junio Togneri Ferron, Fabiane Valentini Francisqueti-Ferron, Fabiana Kurokawa Hasimoto, Cristina Schmitt Gregolin, Dijon Henrique Salomé de Campos, Cleverton Roberto
    Antioxidants.2019; 8(8): 276.     CrossRef
  • A new method to induce nonalcoholic steatohepatitis (NASH) in mice
    Feryal Savari, Seyyed Ali Mard, Mohammad Badavi, Anahita Rezaie, Mohammad Kazem Gharib-Naseri
    BMC Gastroenterology.2019;[Epub]     CrossRef
  • Zeaxanthin Dipalmitate in the Treatment of Liver Disease
    Nisma Lena Bahaji Azami, Mingyu Sun
    Evidence-Based Complementary and Alternative Medicine.2019; 2019: 1.     CrossRef
  • A narrative review on effects of vitamin D on main risk factors and severity of Non-Alcoholic Fatty Liver Disease
    Abbas Ali Sangouni, Saeid Ghavamzadeh, Atena Jamalzehi
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(3): 2260.     CrossRef
  • ABO blood group and risk of newly diagnosed nonalcoholic fatty liver disease: A case-control study in Han Chinese population
    Guo-Chao Zhong, Shan Liu, Yi-Lin Wu, Mei Xia, Jin-Xian Zhu, Fa-Bao Hao, Lun Wan, Pavel Strnad
    PLOS ONE.2019; 14(12): e0225792.     CrossRef
  • Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
    Eun-Jung Rhee
    Endocrinology and Metabolism.2019; 34(3): 226.     CrossRef
  • Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study
    Marwan S.M. Al-Nimer, Vian A.W. Esmail, O. Mohammad
    Electronic Journal of General Medicine.2019; 16(3): em142.     CrossRef
  • TRUSS Exacerbates NAFLD Development by Promoting IκBα Degradation in Mice
    Chang‐Jiang Yu, Qiu‐Shi Wang, Ming‐Ming Wu, Bin‐Lin Song, Chen Liang, Jie Lou, Liang‐Liang Tang, Xiao‐Di Yu, Na Niu, Xu Yang, Bao‐Long Zhang, Yao Qu, Yang Liu, Zhi‐Chao Dong, Zhi‐Ren Zhang
    Hepatology.2018; 68(5): 1769.     CrossRef
  • Association Between Tumor Necrosis Factor-α and the Risk of Hepatic Events: A Median 3 Years Follow-Up Study
    Zhi Zhu, Shuofeng Li
    Hepatitis Monthly.2018;[Epub]     CrossRef
  • Erythrocyte membrane fatty acid profile & serum cytokine levels in patients with non-alcoholic fatty liver disease
    Bahareh Amirkalali, Masoud Reza Sohrabi, Ali Esrafily, Mahmoud Jalali, Ali Gholami, Payam Hosseinzadeh, Hossein Keyvani, Farzad Shidfar, Farhad Zamani
    Indian Journal of Medical Research.2018; 147(4): 352.     CrossRef
  • Changes in the immune system – the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease
    Marcin Kosmalski, Łukasz Mokros, Piotr Kuna, Andrzej Witusik, Tadeusz Pietras
    Central European Journal of Immunology.2018; 43(2): 231.     CrossRef
  • Clinical Characteristics of Non-Alcoholic Fatty Liver Disease Based on Analyses from the Kangbuk Samsung Health Study
    Eun-Jung Rhee
    The Journal of Korean Diabetes.2017; 18(2): 81.     CrossRef
  • Ezetimibe alleviates non-alcoholic fatty liver disease through the miR-16 inhibiting mTOR/p70S6K1 pathway
    Xiang Wang, Yunbing Meng, Junrong Zhang
    RSC Advances.2017; 7(60): 37967.     CrossRef
  • Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease
    Flavia A Cimini, Ilaria Barchetta, Simone Carotti, Laura Bertoccini, Marco G Baroni, Umberto Vespasiani-Gentilucci, Maria-Gisella Cavallo, Sergio Morini
    World Journal of Gastroenterology.2017; 23(19): 3407.     CrossRef
  • Omega-3 Fatty Acids Protect Fatty and Lean Mouse Livers After Major Hepatectomy
    Michael Linecker, Perparim Limani, Patryk Kambakamba, Philipp Kron, Christoph Tschuor, Nicolas Calo, Michelangelo Foti, Jean-François Dufour, Rolf Graf, Bostjan Humar, Pierre-Alain Clavien
    Annals of Surgery.2017; 266(2): 324.     CrossRef
  • Exogenous administration of DLK1 ameliorates hepatic steatosis and regulates gluconeogenesis via activation of AMPK
    Y-h Lee, M R Yun, H M Kim, B H Jeon, B-C Park, B-W Lee, E S Kang, H C Lee, Y W Park, B-S Cha
    International Journal of Obesity.2016; 40(2): 356.     CrossRef
  • Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets
    Feliciano Chanana Paquissi
    Frontiers in Immunology.2016;[Epub]     CrossRef
  • Comparison of Serum Adipocytokine Levels according to Metabolic Health and Obesity Status
    Tae Hoon Lee, Won Seon Jeon, Ki Joong Han, Shin Yeoung Lee, Nam Hee Kim, Hyun Beom Chae, Choel Min Jang, Kyung Mo Yoo, Hae Jung Park, Min Kyung Lee, Se Eun Park, Hyung Geun Oh, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee
    Endocrinology and Metabolism.2015; 30(2): 185.     CrossRef
  • Metabolic Health Is More Important than Obesity in the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Retrospective Study
    Min-Kyung Lee, Eun-Jung Rhee, Min Chul Kim, Byung Sub Moon, Jeong In Lee, Young Seok Song, Eun Na Han, Hyo Sun Lee, Yoonjeong Son, Se Eun Park, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
    Endocrinology and Metabolism.2015; 30(4): 522.     CrossRef
  • Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease
    Sanja Stojsavljević
    World Journal of Gastroenterology.2014; 20(48): 18070.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
Close layer
Free T4 is Negatively Correlated with Non-alcoholic Fatty Liver Disease in Euthyroid Women.
Eon Ju Jun, Hyun Sook Kim, Hyue Kyung Chung, Ji Hyun Lee, Sae Rom Kim, Eui Dal Jung
J Korean Endocr Soc. 2009;24(2):87-92.   Published online June 1, 2009
DOI: https://doi.org/10.3803/jkes.2009.24.2.87
  • 2,722 View
  • 21 Download
AbstractAbstract PDF
BACKGROUND
Thyroid hormones play an important role in the regulation of lipid and carbohydrate metabolism and the body mass index (BMI), which all affect non-alcoholic fatty liver disease (NAFLD). In a previous study, we demonstrated that free T4 was negatively associated with the BMI in euthyroid women. However, there is still uncertain as to whether the thyroid function within the normal range is associated with NAFLD and liver function abnormalities. We sought to evaluate the thyroid function (free T4, TSH) and its possible relationship with NAFLD in euthyroid women. METHODS: A total of 835 euthyroid, non heavy alcoholics women who visited the Daegu Catholic University University Medical Centre for primary health screening from January 1, 2006 to December 31, 2006 participated in this cross-sectional study. The women who were not euthyroid or heavy alcoholics (> 70 g/week in women according to the DSM-IV), there was no known history of diabetes mellitus, the fasting blood glucose was more than 5.55 mmol/L and those who had viral hepatitis were excluded. Hepatic ultrasonography scanning was performed in all the participants by a single experienced radiologist. The TSH, free T4, BP, fasting glucose, serum liver enzymes (AST, ALT, GGT, T-bilirubin), lipid profiles [total-cholesterol, triglyceride (TG), HDL-C, LDL-C] and NAFLD were evaluated. RESULTS: Euthyroid women with NAFLD had lower free T4 levels than did the euthyroid women without NAFLD. After adjustment for age and BMI, free T4 was negatively correlated with TG, but free T4 was positively correlated with the total serum bilirubin. Free T4 was not correlated with the serum AST, ALT and GGT. After adjustment for age, the BMI, the fasting glucose, the GGT and free T4, but not TSH, were significantly negatively correlated with NAFLD. CONCLUSION: We demonstrated a negative correlation between free T4 and NAFLD in euthyroid women. This finding suggests lower levels of free T4 is associated with NAFLD in euthyroid subjects.
Close layer
Effects of Alpha-lipoic Acid on SREBP-1c Expression in HepG2 Cells.
Tae Sung Yun, Ae Kyung Min, Nam Kyung Kim, Mi Kyung Kim, Ho Chan Cho, Hye Soon Kim, Jae Seok Hwang, Seong Yeol Ryu, Keun Gyu Park, In Kyu Lee
J Korean Endocr Soc. 2008;23(1):27-34.   Published online February 1, 2008
DOI: https://doi.org/10.3803/jkes.2008.23.1.27
  • 3,792 View
  • 52 Download
  • 2 Crossref
AbstractAbstract PDF
BACKGROUND
Non-alcoholic fatty liver disease is common in patients with insulin resistance. Sterol regulatory element binding protein-1c (SREBP-1c) is a member of a family of transcription factors that have been recognized as key regulators for lipid accumulation in the liver that activate enzymes involved in the fatty acid biosynthetic pathway. This study was designed to evaluate whether alpha-lipoic acid (ALA) inhibits insulin-stimulated SREBP-1c expression. METHODS: We investigated the effects of ALA on insulin-stimulated SREBP-1c expression in a human hepatoma cell line (HepG2 cells) using Northern and Western blot analysis. We also examined the effect of ALA on the promoter activity of the SREBP-1c gene to examine whether ALA can affect SREBP-1c expression at the transcriptional level. To discern the mechanism by which ALA inhibits SREBP-1c expression, we examined the role of AMP-activated protein kinase (AMPK). RESULTS: Insulin increased the expression of SREBP-1c mRNA and protein in HepG2 cells in a dose depended manner. Co-treatment with ALA inhibited the insulin increased SREBP-1c expression in a dose-dependent manner. ALA also inhibited insulin-stimulated activation of the SREBP-1c promoter activity, indicating that ALA inhibited SREBP-1c expression at the transcriptional level. ALA increased phosphorylation of AMPK in HepG2 cells. Inhibition of the AMPK activity by compound C markedly reversed the inhibitory effects of ALA for insulin-stimulated SREBP-1c expression. These results suggest that ALA-induced suppression of SREBP-1c expression is at least in part mediated via AMPK activation. CONCLUSION: The present study suggests that ALA has an inhibitory effect on insulin-stimulated SREBP-1c expression. Therefore, further studies on the effects of ALA on hepatic steatosis in an animal model need to be performed.

Citations

Citations to this article as recorded by  
  • Effects of an aqueous extract of purple sweet potato on nonalcoholic fatty liver in high fat/cholesterol-fed mice
    You Jin Lee, Yoon Kyoung Yang, You Jin Kim, Oran Kwon
    Journal of Nutrition and Health.2015; 48(1): 1.     CrossRef
  • Effects of an aqueous extract of purple sweet potato on nonalcoholic fatty liver in high fat/cholesterol-fed mice
    You Jin Lee, Yoon Kyoung Yang, You Jin Kim, Oran Kwon
    Journal of Nutrition and Health.2015; 48(1): 1.     CrossRef
Close layer
Case Report
A Case of Fetal Alcohol Syndrome with Secondary Amenorrhea.
Yoon Young Cho, Hyo Jin Oh, Seok Jae Han, Sang Hun Sung, Gyu Hwan Bae, Ho Sang Shon, Hyun Dae Yoon
J Korean Endocr Soc. 2005;20(5):524-530.   Published online October 1, 2005
DOI: https://doi.org/10.3803/jkes.2005.20.5.524
  • 2,861 View
  • 24 Download
  • 1 Crossref
AbstractAbstract PDF
Alcohol ingestion during pregnancy can be damaging to embryonic and fetal development. A specific pattern of malformation, identified as Fetal alcohol syndrome, has been documented in 1~2 of every 1,000 live infant births Fetal alcohol syndrome is characterized by growth deficiency, facial abnormalities, cardiac defects, minor joint and limb abnormalities, as well as central nervous system dysfunction, including microcephaly, mental retardation and abnormal neurobehavioral development. However, there are few reports of fetal alcohol syndrome associated with hormonal abnormality or amenorrhea. Recently, a case of secondary amenorrhea, which developed in a 19-year-old woman with fetal alcohol syndrome, was experienced at our institute, but the exact cause of the amenorrhea was difficulty to find. Herein, this case is reported, with a review of the literature.

Citations

Citations to this article as recorded by  
  • Alcohol Use during Pregnancy and Related Risk Factors in Korea
    So Hee Lee, Seung Ju Shin, Seong-Du Won, Eun-Ju Kim, Dong-Yul Oh
    Psychiatry Investigation.2010; 7(2): 86.     CrossRef
Close layer
Original Articles
Association between Non-alcoholic Fatty Liver and Metabolic Diseases.
Hong Kyu Kim, Chan Jong Suh, Hyo Joong Yoon, Yong Ha Hwang, Kee Young Lee, Hye Young Park, Kap Hwan Kim, Moon Ho Kang
J Korean Endocr Soc. 2002;17(4):526-534.   Published online August 1, 2002
  • 1,809 View
  • 25 Download
AbstractAbstract PDF
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) is known to be frequently associated with obesity, type 2 diabetes and dyslipidemia. Recently, the diagnosis of fatty liver disease, based on ultrasonographic findings, has increased. Therefore, we examined the association between NAFLD and various metabolic diseases, such as obesity, glucose intolerance, dyslipidemia, and hypertension or metabolic syndrome, and tried to find out whether NAFLD was independently related to insulin resistance. METHODS: From April to June 2000, 262 subjects, attending for routine physical check-ups, were screened. Of these, 115 one hundred fifteen subjects were studied, with the other 147 excluded due to significant alcohol consumption, evidence of viral or toxic hepatitis, significant liver or renal dysfunction, and overt thyroid disease. Fatty liver was diagnosed if the subject had a "bright" liver on ultrasonographic examination. All diagnoses were made by a single experienced radiologist. RESULTS: Of the 115 subjects. 30 (26%) showed NAFLD. 1. Systolic and diastolic blood pressures, body weight, serum total cholesterol, triglyceride, fasting insulin levels and HOMA IR (homeostasis model assessment insulin resistance index) were higher in the subjects with NAFLD than in the controls. 2. Multiple logistic regression analysis, including age, sex, BMI, waist to hip ratio, fasting serum glucose, lipids and insulin levels, HOMA IR, and hypertension showed that BMI, total cholesterol and HOMA IR were independently related with NAFLD. 3. 27% of the subjects with NAFLD showed metabolic syndrome, and 53% of subjects with metabolic syndrome had NAFLD. 4. The percentage of subjects who had more than two factors of metabolic syndrome was three times higher in the subjects with NAFLD compared to the controls. CONCLUSION: These results suggest that NAFLD may be independently related with insulin resistance. Metabolic diseases, such as glucose intolerance, obesity, dyslipidemia and hypertension, were more prevalent in the subjects with NAFLD than in the controls. Therefore, we should try to assess the status of the metabolic diseases, and treat them in patients with NAFLD.
Close layer
Metabolic Abnormalities according to Severity of Non-alcoholic Fatty Liver Disease in Korean Adults.
H J Kim, D J Kim, S K Kim, S H Kim, Y M Rhee, C W Ahn, B S Cha, Y D Song, S K Lim, K R Kim, H C Lee, K B Huh
J Korean Endocr Soc. 2002;17(4):514-525.   Published online August 1, 2002
  • 1,687 View
  • 21 Download
AbstractAbstract PDF
BACKGROUND
We evaluated the frequency of non-alcoholic fatty liver diseases, and the associations between the metabolic abnormalities and severity of non-alcoholic fatty liver disease in Korean adults using ultrasonography. METHODS: We examined 1074 Korean adults above the age of 30 years, comprising of 502 men and 572 women, participating in medical check-ups at the Health Promotion Center. Hepatitis B and C serologies were negative, and the average weekly alcohol intake was < or = 2 standard drinks. A standard interview, physical exam and biochemical study, were conducted, and an experienced operator carried out ultrasound liver studies. RESULTS: 522 of the subjects had non-alcoholic fatty liver disease, and the remaining 552 did not. The frequency in the men was higher than that in the women (57 vs 42%, p<0.05). The frequency of non-alcoholic fatty liver disease in the subjects without diabetes, obesity or dyslipidemia was 20%. We classified subjects into 4 groups: the controls (n=552) and those with mild (n=218), moderate (n=273) or severe fatty liver disease (n=31), according to their ultrasonographic findings. BMI, waist circumference, body fat, systolic blood pressure, aspartate aminotransferase, alanine aminotransferase, total cholesterol, triglyceride, the total- to HDL-cholesterol ratio, impaired fasting glucose, hypertension and insulin resistance, were all significantly increased with the increased severity of non-alcoholic fatty liver disease (p<0.05). Following the multiple regression analyses, waist, alanine aminotransferase, HOMAIR, the total- to HDL-cholesterol ratio, aspartate aminotransferase and systolic blood pressure, were all associated with the severity of non-alcoholic fatty liver disease. Odd ratios of insulin resistance in the mild, moderate and severe non-alcoholic fatty liver disease were 14.7 (CI: 6.8~32.0), 6.9 (CI: 4.6~10.3) and 5.7 (CI3.6~8.8), respectively. The percentages of subjects with insulin resistance in each group were 7.6, 32.0, 36.0 and 55.0% (p<0.05), respectively. The percentages of subjects with risk of non-alcoholic steatohepatitis in each groups were 5.0, 21.6, 27.8 and 58.1% (p<0.05) respectively. CONCLUSION: The frequency of non-alcoholic fatty liver disease was relatively high in Korean adults. Proportional differences in metabolic abnormalities, relation to the severity of non-alcoholic fatty liver disease, were found by ultrasonography.
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP